<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for heart failure in people with chronic kidney disease - Lunney, M - 2020 | Cochrane Library</title> <meta content="Pharmacological interventions for heart failure in people with chronic kidney disease - Lunney, M - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012466.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for heart failure in people with chronic kidney disease - Lunney, M - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012466.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012466.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for heart failure in people with chronic kidney disease" name="citation_title"/> <meta content="Meaghan Lunney" name="citation_author"/> <meta content="University of Calgary" name="citation_author_institution"/> <meta content="Marinella Ruospo" name="citation_author"/> <meta content="Patrizia Natale" name="citation_author"/> <meta content="Robert R Quinn" name="citation_author"/> <meta content="Paul E Ronksley" name="citation_author"/> <meta content="University of Calgary" name="citation_author_institution"/> <meta content="Ioannis Konstantinidis" name="citation_author"/> <meta content="University of Pittsburgh Medical Center" name="citation_author_institution"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="Christchurch Hospital, University of Otago" name="citation_author_institution"/> <meta content="Marcello Tonelli" name="citation_author"/> <meta content="Cumming School of Medicine, University of Calgary" name="citation_author_institution"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="Pietro Ravani" name="citation_author"/> <meta content="pravani@ucalgary.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD012466.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/02/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012466.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012466.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012466.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta‐Antagonists [therapeutic use]; Antidiuretic Hormone Receptor Antagonists [therapeutic use]; Antihypertensive Agents [*therapeutic use]; Heart Failure [*drug therapy, mortality]; Hospitalization; Mineralocorticoid Receptor Antagonists [therapeutic use]; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic [*complications, drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012466.pub2&amp;doi=10.1002/14651858.CD012466.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Nio3SV1W";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012466\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012466\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","zh_HANS","zh_HANT","fa","ko","th","pl","de"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012466.pub2",title:"Pharmacological interventions for heart failure in people with chronic kidney disease",firstPublishedDate:"Feb 27, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012466.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012466.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012466.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012466.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012466.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012466.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012466.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012466.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012466.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012466.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7291 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012466.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-sec-0128"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-sec-0050"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-sec-0051"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-sec-0059"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-sec-0060"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-sec-0086"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-sec-0122"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/appendices#CD012466-sec-0133"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/table_n/CD012466StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/table_n/CD012466StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for heart failure in people with chronic kidney disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#CD012466-cr-0002">Meaghan Lunney</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#CD012466-cr-0003">Marinella Ruospo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#CD012466-cr-0004">Patrizia Natale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#CD012466-cr-0005">Robert R Quinn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#CD012466-cr-0006">Paul E Ronksley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#CD012466-cr-0007">Ioannis Konstantinidis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#CD012466-cr-0008">Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#CD012466-cr-0009">Marcello Tonelli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#CD012466-cr-0010">Giovanni FM Strippoli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information#CD012466-cr-0011"><i class="icon corresponding-author fa fa-envelope"></i>Pietro Ravani</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information/en#CD012466-sec-0137">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 February 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012466.pub2">https://doi.org/10.1002/14651858.CD012466.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012466-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012466-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012466-abs-0019">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012466-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012466-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012466-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012466-abs-0014">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD012466-abs-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012466-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012466-abs-0001" lang="en"> <section id="CD012466-sec-0001"> <h3 class="title" id="CD012466-sec-0001">Background</h3> <p>Approximately half of people with heart failure have chronic kidney disease (CKD). Pharmacological interventions for heart failure in people with CKD have the potential to reduce death (any cause) or hospitalisations for decompensated heart failure. However, these interventions are of uncertain benefit and may increase the risk of harm, such as hypotension and electrolyte abnormalities, in those with CKD. </p> </section> <section id="CD012466-sec-0002"> <h3 class="title" id="CD012466-sec-0002">Objectives</h3> <p>This review aims to look at the benefits and harms of pharmacological interventions for HF (i.e., antihypertensive agents, inotropes, and agents that may improve the heart performance indirectly) in people with HF and CKD. </p> </section> <section id="CD012466-sec-0003"> <h3 class="title" id="CD012466-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies through 12 September 2019 in consultation with an Information Specialist and using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD012466-sec-0004"> <h3 class="title" id="CD012466-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials of any pharmacological intervention for acute or chronic heart failure, among people of any age with chronic kidney disease of at least three months duration. </p> </section> <section id="CD012466-sec-0005"> <h3 class="title" id="CD012466-sec-0005">Data collection and analysis</h3> <p>Two authors independently screened the records to identify eligible studies and extracted data on the following dichotomous outcomes: death, hospitalisations, worsening heart failure, worsening kidney function, hyperkalaemia, and hypotension. We used random effects meta‐analysis to estimate treatment effects, which we expressed as a risk ratio (RR) with 95% confidence intervals (CI). We assessed the risk of bias using the Cochrane tool. We applied the GRADE methodology to rate the certainty of evidence. </p> </section> <section id="CD012466-sec-0006"> <h3 class="title" id="CD012466-sec-0006">Main results</h3> <p>One hundred and twelve studies met our selection criteria: 15 were studies of adults with CKD; 16 studies were conducted in the general population but provided subgroup data for people with CKD; and 81 studies included individuals with CKD, however, data for this subgroup were not provided. The risk of bias in all 112 studies was frequently high or unclear. Of the 31 studies (23,762 participants) with data on CKD patients, follow‐up ranged from three months to five years, and study size ranged from 16 to 2916 participants. In total, 26 studies (19,612 participants) reported disaggregated and extractable data on at least one outcome of interest for our review and were included in our meta‐analyses. </p> <p>In acute heart failure, the effects of adenosine A1‐receptor antagonists, dopamine, nesiritide, or serelaxin on death, hospitalisations, worsening heart failure or kidney function, hyperkalaemia, hypotension or quality of life were uncertain due to sparse data or were not reported. </p> <p>In chronic heart failure, the effects of angiotensin‐converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) (4 studies, 5003 participants: RR 0.85, 95% CI 0.70 to 1.02; I<sup>2</sup> = 78%; low certainty evidence), aldosterone antagonists (2 studies, 34 participants: RR 0.61 95% CI 0.06 to 6.59; very low certainty evidence), and vasopressin receptor antagonists (RR 1.26, 95% CI 0.55 to 2.89; 2 studies, 1840 participants; low certainty evidence) on death (any cause) were uncertain. Treatment with beta‐blockers may reduce the risk of death (any cause) (4 studies, 3136 participants: RR 0.69, 95% CI 0.60 to 0.79; I<sup>2</sup> = 0%; moderate certainty evidence). </p> <p>Treatment with ACEi or ARB (2 studies, 1368 participants: RR 0.90, 95% CI 0.43 to 1.90; I<sup>2</sup> = 97%; very low certainty evidence) had uncertain effects on hospitalisation for heart failure, as treatment estimates were consistent with either benefit or harm. Treatment with beta‐blockers may decrease hospitalisation for heart failure (3 studies, 2287 participants: RR 0.67, 95% CI 0.43 to 1.05; I<sup>2</sup> = 87%; low certainty evidence). </p> <p>Aldosterone antagonists may increase the risk of hyperkalaemia compared to placebo or no treatment (3 studies, 826 participants: RR 2.91, 95% CI 2.03 to 4.17; I<sup>2</sup> = 0%; low certainty evidence). Renin inhibitors had uncertain risks of hyperkalaemia (2 studies, 142 participants: RR 0.86, 95% CI 0.49 to 1.49; I<sup>2</sup> = 0%; very low certainty). We were unable to estimate whether treatment with sinus node inhibitors affects the risk of hyperkalaemia, as there were few studies and meta‐analysis was not possible. Hyperkalaemia was not reported for the CKD subgroup in studies investigating other therapies. </p> <p>The effects of ACEi or ARB, or aldosterone antagonists on worsening heart failure or kidney function, hypotension, or quality of life were uncertain due to sparse data or were not reported. </p> <p>Effects of anti‐arrhythmic agents, digoxin, phosphodiesterase inhibitors, renin inhibitors, sinus node inhibitors, vasodilators, and vasopressin receptor antagonists were very uncertain due to the paucity of studies. </p> </section> <section id="CD012466-sec-0007"> <h3 class="title" id="CD012466-sec-0007">Authors' conclusions</h3> <p>The effects of pharmacological interventions for heart failure in people with CKD are uncertain and there is insufficient evidence to inform clinical practice. Study data for treatment outcomes in patients with heart failure and CKD are sparse despite the potential impact of kidney impairment on the benefits and harms of treatment. Future research aimed at analysing existing data in general population HF studies to explore the effect in subgroups of patients with CKD, considering stage of disease, may yield valuable insights for the management of people with HF and CKD. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012466-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012466-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012466-abs-0020">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012466-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012466-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012466-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012466-abs-0015">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012466-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012466-abs-0018">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012466-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012466-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012466-abs-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012466-abs-0011">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012466-abs-0004" lang="en"> <h3>Heart failure drugs in people with chronic kidney disease</h3> <p><b>What is the issue?</b> </p> <p>People with heart failure (when the heart doesn't pump blood properly) often need medicine to help with symptoms like fatigue, swelling, and breathing problems. Studies have looked at whether these medicines are harmful or helpful. However, but they do not clarify whether these treatments may help people with heart failure that also have kidney problems (when the kidneys don't remove waste and fluid from the body properly). </p> <p><b>What did we do?</b> </p> <p>We searched for all research studies that assessed the different treatments for heart failure up to September 2019. We evaluated whether medicines prevent death or hospital admissions, or increase risk of harm, for people with kidney disease. We also measured how certain we could be about the effects of these medicines on the body using a system called "GRADE". </p> <p><b>What did we find?</b> </p> <p>We found 31 studies involving 23,762 people with heart failure and chronic kidney disease. Patients were given either a heart failure medicine compared to standard care or a placebo. The treatment they received was decided by random chance. Although there were many different treatments studied, unfortunately, few of them looked at the same type of medicine. As well, there were many different ways that researchers measured what happened when patients took these medicines. As a result, we could not combine the studies together and clarify the benefits and harms of each treatment. Existing studies cannot really tell us whether medicines used to treat heart failure in the general population are effective or safe for people who have both heart failure and chronic kidney disease. </p> <p><b>Conclusions</b> </p> <p>We are not able to recommend which heart failure medicines are best for people with heart failure and chronic kidney disease. We need more information from large clinical studies. Most of the heart failure studies did not report treatment effects separately based on levels of kidney function. Obtaining this information from existing studies may be helpful to learn more about how to treat heart failure in people with chronic kidney disease. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012466-sec-0128" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012466-sec-0128"></div> <h3 class="title" id="CD012466-sec-0129">Implications for practice</h3> <section id="CD012466-sec-0129"> <p> <ul id="CD012466-list-0024"> <li> <p>In accordance with current guidelines, pharmacological interventions for HF should be used in caution in patients with comorbid renal insufficiency. Systematic review of the existing literature didn't change the certainty of evidence around the using interventions for HF in people with CKD. </p> </li> <li> <p>While most analyses did not suggest a reduced risk of death or hospitalisation, the limited certainty of this evidence suggests a lack of evidence, not a lack of benefit, on these interventions. No changes to clinical practice are advised at this time until further information becomes available. </p> </li> <li> <p>Evidence on the appropriateness of the use of HF therapies is limited by: (1) the relatively small number of studies from which CKD data could be extracted to inform each comparison:outcome combination; and (2) the fact that people with advanced CKD are often under‐represented in general HF studies. </p> </li> <li> <p>Available data suggest beta‐blockers may reduce risk of death. However, high‐quality studies enrolling patients with CKD are needed to increase the level of certainty for this effect. </p> </li> <li> <p>There is low certainty that anti‐aldosterone interventions lead to hyperkalaemia. Information on the risk of other harms for most therapies is limited. </p> </li> <li> <p>Studies assessing interventions for acute decompensated HF compared outcomes within the first six months only. </p> </li> </ul> </p> </section> <h3 class="title" id="CD012466-sec-0130">Implications for research</h3> <section id="CD012466-sec-0130"> <p> <ul id="CD012466-list-0025"> <li> <p>A better understanding of the risks of harms associated with HF interventions in people with CKD is needed. </p> </li> <li> <p>While the evidence surrounding the efficacy and safety of HF interventions is strong in the general population, exploring whether the same applies to people with CKD is important because these people may potentially gain more benefits from these interventions but also suffer from more harms. Future studies comparing risk between non‐CKD patients with those with CKD will help guide this knowledge. </p> </li> <li> <p>The stage of CKD should be considered when exploring the impact of kidney disease on the efficacy or safety of HF interventions. Including patients with a very low baseline eGFR (including those receiving kidney replacement therapy) will help inform practice for patients with advanced CKD and HF. </p> </li> <li> <p>Although the majority of HF studies did not exclude participants with CKD, subgroup analyses by CKD were not available in most studies. </p> </li> <li> <p>Future research aimed at analysing existing data in general population HF studies to explore the effect in sub‐groups of patients with CKD may yield valuable insights for the management of people with HF and CKD. </p> </li> <li> <p>One of the limitations of this systematic review is the inability to access the data generated by RCTs of pharmacological interventions for HF that included people with CKD. Removing existing barriers to study data would promote more rapid advancement of new knowledge, improve patient care, and the use of resources in health systems. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012466-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012466-sec-0050"></div> <div class="table" id="CD012466-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ACUTE: Serelaxin versus placebo in patients with heart failure and chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ACUTE: Serelaxin versus placebo in patients with heart failure and chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> heart failure with chronic kidney disease </p> <p><b>Settings:</b> acute, inpatient </p> <p><b>Intervention:</b> serelaxin </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Serelaxin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death (any cause)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> <p>(14 to 43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> </p> <p>(0.34 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1395 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>97 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> </p> <p>(20 to 105)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b> (0.21 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1395 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation (any cause)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heart failure hospitalisation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening heart failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>162 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>115 per 1000</b> </p> <p>(87 to 149)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.71</b> (0.54 to 0.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1395 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening kidney function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>86 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>74 per 1000</b> </p> <p>(32 to 170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.86</b> (0.37 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1395 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> <p>(39 to 94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> (0.81 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1395 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hyperkalaemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>48 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>52 per 1000</p> <p>(15 to 187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.08 (0.30 to 3.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Important study limitations due to risks of bias </p> <p><sup>2</sup> The confidence intervals include potential for important benefits and harms </p> <p><sup>3</sup> Important and unexplained heterogeneity present (or insufficient data observations to evaluate) </p> <p><sup>4</sup> Insufficient data observations to evaluate </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012466-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CHRONIC: ACEi or ARB versus placebo in patients with heart failure and chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CHRONIC: ACEi or ARB versus placebo in patients with heart failure and chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> heart failure with chronic kidney disease </p> <p><b>Settings:</b> chronic, outpatient </p> <p><b>Intervention:</b> ACEi or ARB </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ACEi or ARB</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death (any cause)</b> </p> <p>(follow‐up 2 to 3.5 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>320 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b><br/> (224 to 326) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> (0.70 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5003 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> <p>(follow‐up 3 to 4 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>411 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b><br/> (263 to 415) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.81</b> (0.64 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1368 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation (any cause)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heart failure hospitalisation</b> </p> <p>(follow‐up 2 to 3.5 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>546 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>491 per 1000</b><br/> (235 to 1037) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> (0.43 to 1.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1368 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2</sup> </b><sup>,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Worsening heart failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Worsening kidney function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension (ARB; withdrawn from study)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> </p> <p>(47 to 254</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.60</b> (1.12 to 6.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>332 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hyperkalaemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The <b>assumed risk</b> (e.g. the median control group risk across studies) was calculated by dividing the number of participants in the control group that experienced an event by the total number of participants in the control group. The <b>corresponding risk</b> was calculated by multiplying the assumed risk with the <b>relative effect</b> from the meta‐analysis. The 95% CI for the corresponding risk was calculated by multiplying the assumed risk with the lower and upper CI of the risk ratio estimate from the meta‐analysis. </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>ACEi</b> : angiotensin‐converting enzyme inhibitor; <b>ARB</b>: angiotensin receptor blocker </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Important study limitations due to risks of bias </p> <p><sup>2</sup> The confidence intervals include potential for important benefits and harms </p> <p><sup>3</sup> Important and unexplained heterogeneity present (or insufficient data observations to evaluate) </p> <p><sup>4</sup> Insufficient data observations to evaluate </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012466-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CHRONIC: Beta‐blockers versus placebo in patients with heart failure and chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CHRONIC: Beta‐blockers versus placebo in patients with heart failure and chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> heart failure with chronic kidney disease </p> <p><b>Settings:</b> chronic, outpatient </p> <p><b>Intervention:</b> beta‐blockers </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Beta‐blockers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death (any cause)</b> </p> <p>(follow‐up 1 to 2.5 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>215 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b><br/> (129to 170) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b> </p> <p>(0.60 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3136 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> <p>(follow‐up 1 to 2.5 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><br/> (43 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b> (0.35 to 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2287 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation (any cause)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>432 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>324 per 1000</b><br/> (225 to 467) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.75</b> (0.52 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1583 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heart failure hospitalisation</b> </p> <p>(follow‐up 1 to 2.5 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>318 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>213 per 1000</b><br/> (137 to 334) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.67</b> (0.43 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2287 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening heart failure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> </p> <p>(0.58 to 3.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>704 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening kidney function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>no events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>no events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>704 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>no events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2/356**</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.11</b> </p> <p>(0.25 to 106.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>704 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hyperkalaemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The <b>assumed risk</b> (e.g. the median control group risk across studies) was calculated by dividing the number of participants in the control group that experienced an event by the total number of participants in the control group. The <b>corresponding risk</b> was calculated by multiplying the assumed risk with the <b>relative effect</b> from the meta‐analysis. The 95% CI for the corresponding risk was calculated by multiplying the assumed risk with the lower and upper CI of the risk ratio estimate from the meta‐analysis. </p> <p>** Event rate derived from the raw data. A 'per thousand' rate is non‐informative in view of the scarcity of evidence and zero events in the control group </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Important study limitations due to risks of bias </p> <p><sup>2</sup> The confidence intervals include potential for important benefits and harms </p> <p><sup>3</sup> Important and unexplained heterogeneity present (or insufficient data observations to evaluate) </p> <p><sup>4</sup> Insufficient data observations to evaluate </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012466-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">CHRONIC: Aldosterone antagonists versus placebo in patients with heart failure and chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CHRONIC: Aldosterone antagonists versus placebo in patients with heart failure and chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> heart failure with chronic kidney disease </p> <p><b>Settings:</b> chronic, outpatient </p> <p><b>Intervention:</b> aldosterone antagonists </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐aldosterone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death (any cause)</b> </p> <p>(follow‐up 6 to 21 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b><br/> (17 to 1,938) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.61</b> (0.06 to 6.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation (any cause)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heart failure hospitalisation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening heart failure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening kidney function</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypotension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hyperkalaemia</b> </p> <p>follow‐up 6‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>243 per 1000</b><br/> (170 to 350) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.91</b> (2.03 to 4.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>826 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The <b>assumed risk</b> (e.g. the median control group risk across studies) was calculated by dividing the number of participants in the control group that experienced an event by the total number of participants in the control group. The <b>corresponding risk</b> was calculated by multiplying the assumed risk with the <b>relative effect</b> from the meta‐analysis. The 95% CI for the corresponding risk was calculated by multiplying the assumed risk with the lower and upper CI of the risk ratio estimate from the meta‐analysis. </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Important study limitations due to risks of bias </p> <p><sup>2</sup> The confidence intervals include potential for important benefits and harms </p> <p><sup>3</sup> Important and unexplained heterogeneity present (or insufficient data observations to evaluate) </p> <p><sup>4</sup> Insufficient data observations to evaluate </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012466-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012466-sec-0051"></div> <section id="CD012466-sec-0052"> <h3 class="title" id="CD012466-sec-0052">Description of the condition</h3> <p>Chronic kidney disease (CKD) is defined by structural (presence of albuminuria) or functional (persistently reduced kidney function) alterations of the kidney that persists for three or more months. CKD is classified according to estimated glomerular filtration rate (eGFR) and albumin:creatinine ratio (ACR), using 'G' to denote the GFR category (G1 to G5, with cut‐offs at 90, 60, 30 and 15 mL/min/1.73 m<sup>2</sup>) and 'A' for the ACR category (A1 to A3, with cut‐offs at 3 and 30 mg/mol) (<a href="./references#CD012466-bbs2-0193" title="LeveyAS , deJongPE , CoreshJ , ElNahasM , AstorBC , MatsushitaK , et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.[Erratum appears in Kidney Int. 2011 Nov;80(9):1000]. Kidney International2011;80(1):17‐28. [MEDLINE: 21150873] ">Levey 2011</a>). CKD is usually clinically silent until end‐stage kidney disease (ESKD) requiring dialysis or kidney transplantation, although complications including fluid retention, hypertension or anaemia are often identified in earlier CKD stages. </p> <p>Heart failure (HF) results from any structural or functional cardiac disorder that impairs the ability of the heart to function as a pump to support the circulation of blood. People with HF have symptoms of fatigue and breathlessness and signs of fluid retention such as ankle swelling, elevated jugular venous pressure, and pulmonary crackles. Guidelines (<a href="./references#CD012466-bbs2-0195" title="McKelvieRS , MoeGW , EzekowitzJA , HeckmanGA , CostiganJ , DucharmeA , et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Canadian Journal of Cardiology2013;29(2):168‐81. [MEDLINE: 23201056] ">McKelvie 2012</a>; <a href="./references#CD012466-bbs2-0199" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , atal . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure2016;18(8):891‐975. [MEDLINE: 27207191] ">Ponikowski 2016</a>; <a href="./references#CD012466-bbs2-0207" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDEJr , ColvinMM , et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology2016;68(13):1476‐88. [MEDLINE: 27216111] ">Yancy 2016</a>) restrict HF definition and management recommendations to stages at which symptoms are apparent. </p> <p>HF can be classified by symptoms or based on measurement of the left ventricular ejection fraction (EF) as below: </p> <section id="CD012466-sec-0053"> <h4 class="title">Based on symptoms (Yancy 2016)</h4> <p> <ul id="CD012466-list-0001"> <li> <p>Stage I: no limitation of physical activity; ordinary physical activity does not cause symptoms of HF </p> </li> <li> <p>Stage II: slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in symptoms of HF </p> </li> <li> <p>Stage III: marked limitation of physical activity; comfortable at rest, but less than ordinary activity causes symptoms of HF </p> </li> <li> <p>Stage IV: unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest. </p> </li> </ul> </p> </section> <section id="CD012466-sec-0054"> <h4 class="title">Based on left ventricular EF (Ponikowski 2016)</h4> <p> <ul id="CD012466-list-0002"> <li> <p>HF with preserved EF (≥ 50%; HFpEF)</p> </li> <li> <p>HF with reduced EF (&lt; 40%; HFrEF or systolic HF)</p> </li> <li> <p>HF with mid‐range EF (40% to 49%; HFmrEF).</p> </li> </ul> </p> <p>According to current guidelines (<a href="./references#CD012466-bbs2-0195" title="McKelvieRS , MoeGW , EzekowitzJA , HeckmanGA , CostiganJ , DucharmeA , et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Canadian Journal of Cardiology2013;29(2):168‐81. [MEDLINE: 23201056] ">McKelvie 2012</a>; <a href="./references#CD012466-bbs2-0199" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , atal . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure2016;18(8):891‐975. [MEDLINE: 27207191] ">Ponikowski 2016</a>; <a href="./references#CD012466-bbs2-0207" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDEJr , ColvinMM , et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology2016;68(13):1476‐88. [MEDLINE: 27216111] ">Yancy 2016</a>) most studies of pharmacological interventions for HF included people with HFrEF, partly because HFrEF is felt to be more severe and possibly because HFpEF is more difficult to diagnose. Because most people with HFrEF also have diastolic dysfunction, and subtle systolic abnormalities are present in people with HFpEF, the terminology based on left ventricle EF (HFrEF/HFpEF) is preferred over the terminology of preserved or reduced ‘systolic function’ (<a href="./references#CD012466-bbs2-0199" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , atal . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure2016;18(8):891‐975. [MEDLINE: 27207191] ">Ponikowski 2016</a>). </p> </section> <section id="CD012466-sec-0055"> <h4 class="title">Based on time course and clinical presentation (Ponikowski 2016)</h4> <p> <ul id="CD012466-list-0003"> <li> <p>Chronic HF identifies HF for some time; unchanged symptoms and signs for at least one month define ‘stable HF’ </p> </li> <li> <p>Acute HF could present as decompensation of chronic stable HF, occurrence of de novo HF (e.g. due to a myocardial infarction (MI)), or progression of HF in a subacute (gradual) fashion (e.g. due to progressive dilated cardiomyopathy) </p> </li> <li> <p>Congestive HF is a term sometimes used to describe acute or chronic HF with significant evidence of volume overload. </p> </li> </ul> </p> <p>CKD and HF are highly prevalent in the general population. In population‐based studies, the prevalence of HF ranges from 0.2% in those aged 18 to 44 years, to 24% in patients 85 years and older (<a href="./references#CD012466-bbs2-0185" title="HemmelgarnBR , JamesMT , MannsBJ , O'HareAM , MuntnerP , RavaniP , et al. Rates of treated and untreated kidney failure in older vs younger adults. JAMA2012;307(23):2507‐15. [MEDLINE: 22797451] ">Hemmelgarn 2012</a>). The prevalence of CKD ranges from 1% to 33% in individuals 18 to 44 years and over age 60, respectively (<a href="./references#CD012466-bbs2-0185" title="HemmelgarnBR , JamesMT , MannsBJ , O'HareAM , MuntnerP , RavaniP , et al. Rates of treated and untreated kidney failure in older vs younger adults. JAMA2012;307(23):2507‐15. [MEDLINE: 22797451] ">Hemmelgarn 2012</a>). The two conditions often co‐exist and 40% to 60% of patients with HF will have evidence of CKD (<a href="./references#CD012466-bbs2-0205" title="ShibaN , ShimokawaH . Chronic kidney disease and heart failure‐‐Bidirectional close link and common therapeutic goal. Journal of Cardiology2011;57(1):8‐17. [MEDLINE: 21030212] ">Shiba 2011</a>). Furthermore, people with both HF and CKD have a greater risk of cardiovascular morbidity and death than people with HF alone (<a href="./references#CD012466-bbs2-0202" title="SantoroA , MandreoliM . Chronic renal disease and risk of cardiovascular morbidity‐mortality. Kidney &amp; Blood Pressure Research2014;39(2‐3):142‐6. [MEDLINE: 25117863] ">Santoro 2014</a>). As compared to people with either condition alone, those with both HF and CKD have worse quality of life (QoL), a higher risk of morbidity and death, and often require complex multidisciplinary management (<a href="./references#CD012466-bbs2-0205" title="ShibaN , ShimokawaH . Chronic kidney disease and heart failure‐‐Bidirectional close link and common therapeutic goal. Journal of Cardiology2011;57(1):8‐17. [MEDLINE: 21030212] ">Shiba 2011</a>). Criteria to classify cardio‐renal syndromes, according to the direction of the organ damage or whether the clinical manifestations are acute or chronic, have been defined by the Acute Dialysis Quality Initiative consensus group (<a href="./references#CD012466-bbs2-0201" title="RoncoC , McCulloughP , AnkerSD , AnandI , AspromonteN , BagshawSM , et al. Cardio‐renal syndromes: report from the consensus conference of the acute dialysis quality initiative. European Heart Journal2010;31(6):703‐11. [MEDLINE: 20037146] ">Ronco 2010</a>). </p> <p>The prevalence of HF and concomitant CKD is increasing. Additionally, CKD may increase the risk of harms associated with HF medication (e.g. spironolactone (<a href="./references#CD012466-bbs2-0200" title="QuachK , LvtvynL , BaigentC , BuetiJ , GargAX , HawleyC , et al. The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta‐analysis. American Journal of Kidney Diseases2016;68(4):591‐8. [MEDLINE: 27265777] ">Quach 2016</a>)). Therefore, a better understanding of appropriate pharmacological management of HF in this patient population is particularly important. </p> </section> </section> <section id="CD012466-sec-0056"> <h3 class="title" id="CD012466-sec-0056">Description of the intervention</h3> <p>Several pharmacological interventions are used to treat HF. These include:</p> <p> <ol id="CD012466-list-0004"> <li> <p>Direct agents</p> <ul id="CD012466-list-0005"> <li> <p>Those that reduce peripheral resistance, heart rate or blood volume (anti‐hypertensive agents) </p> </li> <li> <p>Those that increase the strength of the heart contraction (positive inotropes)</p> </li> </ul> </li> <li> <p>Indirect agents</p> <ul id="CD012466-list-0006"> <li> <p>Those that may improve the heart performance indirectly (lipid lowering agents, antiplatelet agents and nutritional supplements) </p> </li> </ul> </li> </ol> </p> <p>Guidelines for the general population (<a href="./references#CD012466-bbs2-0199" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , atal . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure2016;18(8):891‐975. [MEDLINE: 27207191] ">Ponikowski 2016</a>; <a href="./references#CD012466-bbs2-0207" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDEJr , ColvinMM , et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology2016;68(13):1476‐88. [MEDLINE: 27216111] ">Yancy 2016</a>) make a distinction between: </p> <p> <ol id="CD012466-list-0007"> <li> <p>Interventions that are recommended for HFrEF: angiotensin‐converting enzyme inhibitors (ACEi), beta‐blockers and mineralocorticoid receptor antagonists </p> </li> <li> <p>Interventions that may be beneficial in HFrEF: diuretics, angiotensin receptor neprilysin inhibitor (a single molecule that combines the moieties of valsartan and sacubitril), sinus node I<sub>f</sub> channel inhibitors (ivabradine), angiotensin receptor blockers (ARB), hydralazine and isosorbide dinitrate </p> </li> <li> <p>Interventions with uncertain benefits in HFrEF: digoxin and other digitalis glycosides, and n‐3 polyunsaturated fatty acids </p> </li> <li> <p>Interventions with unproven benefits in HFrEF: statins, oral anticoagulants and antiplatelet therapy, renin inhibitors </p> </li> <li> <p>Interventions potentially harmful in HFrEF: calcium‐channel blockers.</p> </li> </ol> </p> <p>The same guidelines specify that no treatment has yet been shown, convincingly, to reduce morbidity or death in patients with HFpEF (<a href="./references#CD012466-bbs2-0199" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , atal . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure2016;18(8):891‐975. [MEDLINE: 27207191] ">Ponikowski 2016</a>). </p> <p>Interventions for acute HF are supported by a lower level of evidence, according to these guidelines (<a href="./references#CD012466-bbs2-0195" title="McKelvieRS , MoeGW , EzekowitzJA , HeckmanGA , CostiganJ , DucharmeA , et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Canadian Journal of Cardiology2013;29(2):168‐81. [MEDLINE: 23201056] ">McKelvie 2012</a>; <a href="./references#CD012466-bbs2-0199" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , atal . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure2016;18(8):891‐975. [MEDLINE: 27207191] ">Ponikowski 2016</a>; <a href="./references#CD012466-bbs2-0207" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDEJr , ColvinMM , et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology2016;68(13):1476‐88. [MEDLINE: 27216111] ">Yancy 2016</a>). These interventions include diuretics for congestive HF (loop diuretics, thiazides and mineral‐corticoid antagonists), vasodilators for hypertensive HF (nitroglycerin, isosorbide dinitrate, nitroprusside, nesiritide), inotropic agents for hypotensive HF (dopamine, dobutamine, levosimendan, milrinone, enoximone), vasopressors for hypotensive HF (norepinephrine, epinephrine), and digoxin, beta‐blockers or amiodarone for atrial fibrillation with high ventricular rate. </p> </section> <section id="CD012466-sec-0057"> <h3 class="title" id="CD012466-sec-0057">How the intervention might work</h3> <p>Pharmacological interventions improve the heart performance by reducing how quickly the heart beats, reducing its workload, or by increasing the strength of the cardiac muscle directly or indirectly. In the general population, there is strong evidence to support the use of renin‐angiotensin‐aldosterone system (RAAS) blockers, beta‐blockers and their combination, and moderate levels of evidence for diuretics and inotropes. In the CKD population, these agents are thought to work in the same way. However, most studies of interventions for HF excluded people with CKD because it was felt that these interventions may not have the same benefits in a CKD population, and they may be potentially harmful (<a href="./references#CD012466-bbs2-0176" title="CocaSG , KrumholzHM , GargAX , ParikhCR . Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA2006;296(11):1377‐84. [MEDLINE: 16985230] ">Coca 2006</a>; <a href="./references#CD012466-bbs2-0190" title="KonstantinidisI , NadkarniGN , YacoubR , SahaA , SimoesP , ParikhCR , et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Internal Medicine2015;176(1):121‐4. [MEDLINE: 26619332] ">Konstantinidis 2016</a>). For example, RAAS blockers may increase the risk of hyperkalaemia, excessive volume depletion with diuretics may worsen kidney function, and some inotropes may accumulate in CKD and adversely affect cardiac rhythm. </p> </section> <section id="CD012466-sec-0058"> <h3 class="title" id="CD012466-sec-0058">Why it is important to do this review</h3> <p>People with CKD and HF require coordinated care from CKD and HF specialists. Individuals with CKD are at high risk of cardiovascular morbidity and death. A narrative review including 1,076,104 patients found a significantly higher risk of death among HF patients with comorbid CKD, compared to those without baseline CKD (<a href="./references#CD012466-bbs2-0178" title="DammanK , ValenteMA , VoorsAE , O'ConnorCM , vanVeldhuisenDJ , HillegeHL . Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta‐analysis. European Heart Journal2014;35(7):455‐69. [MEDLINE: 24164864] ">Damman 2014a</a>). They may have the potential for significant benefit more from interventions for HF, but they may also be more vulnerable to the potential harms of these interventions. We do not know if benefits and harms of interventions for HF vary with the severity of CKD. For example, people with more advanced stages of CKD benefit less from interventions for ischaemic heart disease (e.g. statins (<a href="./references#CD012466-bbs2-0197" title="PalmerSC , CraigJC , NavaneethanSD , TonelliM , PellegriniF , StrippoliGF . Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta‐analysis. Annals of Internal Medicine2012;157(4):263‐75. [MEDLINE: 22910937] ">Palmer 2012</a>)), and complications from HF dominate as the leading cause of hospitalisation. A systematic review of studies addressing questions about pharmacological interventions for HF in people with CKD is not available. Given the increasing prevalence of HF as eGFR declines, the complex and costly management of people affected by both conditions, and the uncertain benefits and harms of available therapies to treat HF in people who also have CKD, this information is important for patients, healthcare providers and policy makers. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012466-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012466-sec-0059"></div> <p>This review aims to look at the benefits and harms of pharmacological interventions for HF (i.e., antihypertensive agents, inotropes, and agents that may improve the heart performance indirectly) in people with HF and CKD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012466-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012466-sec-0060"></div> <section id="CD012466-sec-0061"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012466-sec-0062"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) evaluating the benefits and harms attributable to any pharmacological interventions for HF in people with CKD. </p> </section> <section id="CD012466-sec-0063"> <h4 class="title">Types of participants</h4> <p>We included studies in people with HF as defined by the authors. For example, people with HF or people with symptoms of HF in case the term HF or the NYHA classification were not explicitly stated. These included breathlessness, ankle swelling and fatigue that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles and peripheral oedema) caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress (<a href="./references#CD012466-bbs2-0199" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , atal . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure2016;18(8):891‐975. [MEDLINE: 27207191] ">Ponikowski 2016</a>). Eligible studies included those in any population age, sex, race, educational status or disease type/severity, and could be conducted in any setting (e.g. community, hospital, nursing home, chronic care institution, or outpatient setting). We included individuals with CKD of any stage (from persistent albuminuria without diminished eGFR to ESKD treated with dialysis or kidney transplantation). </p> <section id="CD012466-sec-0064"> <h5 class="title">Inclusion criteria</h5> <p>CKD is defined based on the presence of urinary albumin excretion of ≥ 30 mg/mol, or equivalent (marker of kidney damage), or as eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> (marker of decreased kidney function) for three months or longer regardless of the primary cause of kidney injury. We considered studies that included people with any CKD stage (including stage V treated with dialysis or transplantation); however, we considered definitions used by study authors. HF is a common clinical syndrome resulting from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with (diastolic dysfunction) or eject blood (systolic dysfunction). Therefore, we considered studies of HF due to left ventricular dysfunction (left‐sided HF), with reduced ejection fraction (EF≤ 40%; systolic left‐sided HF (HFrEF)) or preserved ejection fraction (EF &gt; 40%; diastolic left‐sided HF (HFpEF or HFmrEF)); or due to right ventricular dysfunction (right‐sided HF). We considered studies including people with stable HF or acute HF as described above, similarly, as defined by study authors. We only included studies of at least three months in duration, without publication year or language restriction. </p> </section> <section id="CD012466-sec-0065"> <h5 class="title">Exclusion criteria</h5> <p>We excluded studies shorter than three months.</p> </section> </section> <section id="CD012466-sec-0066"> <h4 class="title">Types of interventions</h4> <p>Based on existing recommendations (<a href="./references#CD012466-bbs2-0195" title="McKelvieRS , MoeGW , EzekowitzJA , HeckmanGA , CostiganJ , DucharmeA , et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Canadian Journal of Cardiology2013;29(2):168‐81. [MEDLINE: 23201056] ">McKelvie 2012</a>; <a href="./references#CD012466-bbs2-0199" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , atal . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure2016;18(8):891‐975. [MEDLINE: 27207191] ">Ponikowski 2016</a>; <a href="./references#CD012466-bbs2-0207" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDEJr , ColvinMM , et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology2016;68(13):1476‐88. [MEDLINE: 27216111] ">Yancy 2016</a>), we considered the following pharmacological intervention for either acute or chronic HF. </p> <p>Interventions for acute HF</p> <p> <ul id="CD012466-list-0008"> <li> <p>Diuretics for congestive HF: loop diuretics, thiazides and mineral‐corticoid antagonists</p> </li> <li> <p>Vasodilators for hypertensive HF: nitroglycerin, isosorbide dinitrate, nitroprusside, nesiritide </p> </li> <li> <p>Inotropic agents for hypotensive HF: dopamine, dobutamine, levosimendan, milrinone, enoximone </p> </li> <li> <p>Vasopressors for hypotensive HF: norepinephrine, epinephrine</p> </li> <li> <p>Digoxin, beta‐blockers or amiodarone for atrial fibrillation with high ventricular rate. </p> </li> </ul> </p> <p>Interventions for chronic HF</p> <p> <ul id="CD012466-list-0009"> <li> <p>The combination of ACEi and beta‐blockers with and without mineral‐corticoid receptor antagonists </p> </li> <li> <p>Diuretics, angiotensin receptor neprilysin inhibitor, sinus node I<sub>f</sub> channel inhibitors, ARB, hydralazine and isosorbide dinitrate </p> </li> <li> <p>Digoxin and other digitalis glycosides, n‐3 polyunsaturated fatty acids, coenzyme Q10, creatine analogues, L‐carnitine, thiamine, vitamin D supplementation </p> </li> <li> <p>Statins, fibrates, ezetimibe, oral anticoagulants and antiplatelet therapy (cyclooxygenase inhibitors, ADP receptor blockers, PDE inhibitors, PAR‐1 antagonists, thromboxane inhibitors, adenosine re‐uptake inhibitors, others), renin inhibitors </p> </li> <li> <p>Calcium‐channel blockers.</p> </li> </ul> </p> <p>For all interventions, we considered any preparation, route of administration, dose, duration, frequency, and combinations. </p> <p>Given the large number of research questions that this review could potentially address, we focused on the following interventions that are recommended in the non‐CKD population. </p> <p> <ul id="CD012466-list-0010"> <li> <p>Use of ACEi or ARB, and beta‐blockers</p> </li> <li> <p>Mineralocorticoid receptor antagonists</p> </li> <li> <p>Use of diuretics in congestive HF.</p> </li> </ul> </p> <p>The primary focus of this review was to assess whether there is evidence that these treatments for HF are effective and safe in people with concomitant CKD when compared to an active control, placebo or no intervention. </p> </section> <section id="CD012466-sec-0067"> <h4 class="title">Types of outcome measures</h4> <section id="CD012466-sec-0068"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012466-list-0011"> <li> <p>Death (any cause)</p> </li> <li> <p>Hospitalisation for decompensated HF</p> </li> </ul> </p> </section> <section id="CD012466-sec-0069"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012466-list-0012"> <li> <p>Cardiovascular death</p> </li> <li> <p>Hospitalisation (any cause)</p> </li> <li> <p>Worsening HF (reported as a dichotomous outcome by authors)</p> </li> <li> <p>Worsening kidney function, including acute kidney injury (reported as a dichotomous outcome by authors) </p> </li> <li> <p>Hyperkalaemia</p> </li> <li> <p>Hypotension</p> </li> <li> <p>Other adverse events due to treatment, worsening of the disease course (syncope/pre‐syncope, shortness of breath, and peripheral oedema), and measures of quality of life (QoL) as reported by authors </p> </li> </ul> </p> </section> </section> </section> <section id="CD012466-sec-0070"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012466-sec-0071"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 12 September 2019 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources. </p> <p> <ol id="CD012466-list-0013"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Hand‐searching of kidney‐related journals and the proceedings of major kidney and transplant conferences </p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available on the <a href="https://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant website</a>. </p> <p>See <a href="./appendices#CD012466-sec-0134">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD012466-sec-0072"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of review articles, relevant studies and clinical practice guidelines. </p> </section> </section> <section id="CD012466-sec-0073"> <h3 class="title" id="CD012466-sec-0073">Data collection and analysis</h3> <section id="CD012466-sec-0074"> <h4 class="title">Selection of studies</h4> <p>We used the search strategy to identify studies relevant to this review. Two authors screened the titles and abstracts independently and selected studies based on whether they met the patient, intervention, comparator, and design criteria. When necessary, two authors (ML, PR) independently assessed full texts to determine which studies satisfied the full inclusion criteria. </p> </section> <section id="CD012466-sec-0075"> <h4 class="title">Data extraction and management</h4> <p>Four authors extracted data independently using standard forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of a study existed, reports were grouped together and the publication with the most complete data was used in the analyses. </p> </section> <section id="CD012466-sec-0076"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Four authors independently assessed the following items using the risk of bias assessment tool (<a href="./references#CD012466-bbs2-0188" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD012466-sec-0135">Appendix 2</a>). </p> <p> <ul id="CD012466-list-0014"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (blinding)? </p> <ul id="CD012466-list-0015"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias (registration, funding, etc.)? </p> </li> </ul> </p> </section> <section id="CD012466-sec-0077"> <h4 class="title">Measures of treatment effect</h4> <p>We used risk ratios (RR) with 95% confidence intervals (CI) to summarize dichotomous outcomes (e.g. death, hospitalisation, kidney failure). Where continuous scales of measurement were reported (e.g. QoL, symptom burden), we assessed the effects of treatment using the mean difference (MD) or the standardised mean difference (SMD) for different scales. We referred to the Cochrane Handbook for Systematic Reviews of Interventions to deal with specific issues (e.g. change scores or time‐to‐event data) (<a href="./references#CD012466-bbs2-0188" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Summary intervention effect measures were estimated in comparisons with at least two studies. </p> </section> <section id="CD012466-sec-0078"> <h4 class="title">Unit of analysis issues</h4> <p>We referred to the Cochrane Handbook for Systematic Reviews of Interventions to deal with non‐standard designs (e.g. as cross‐over studies or cluster‐randomised studies) (<a href="./references#CD012466-bbs2-0188" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD012466-sec-0079"> <h4 class="title">Dealing with missing data</h4> <p>We requested any further information required from the original author by written correspondence (e.g. emailing corresponding authors) and included any relevant information obtained in this manner in the review. We also investigated attrition rates, for example drop‐outs, losses to follow‐up and withdrawals and critically appraised issues of missing data and imputation methods (for example, last‐observation‐carried‐forward) (<a href="./references#CD012466-bbs2-0188" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD012466-sec-0080"> <h4 class="title">Assessment of heterogeneity</h4> <p>In analyses with at least two studies, we assessed heterogeneity by visual inspection of the forest plot. We then quantified statistical heterogeneity using the I<sup>2</sup> statistic, which described the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<a href="./references#CD012466-bbs2-0187" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). We followed this guide to interpret I<sup>2</sup> values. </p> <p> <ul id="CD012466-list-0016"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I<sup>2</sup> depended on both its magnitude and the strength of evidence for heterogeneity (e.g. P‐value from the chi‐squared test or a confidence interval for I<sup>2</sup>) (<a href="./references#CD012466-bbs2-0188" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD012466-sec-0081"> <h4 class="title">Assessment of reporting biases</h4> <p>In analyses with at least 10 studies, we planned to use funnel plots to assess for the potential existence of small study bias (<a href="./references#CD012466-bbs2-0188" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD012466-sec-0082"> <h4 class="title">Data synthesis</h4> <p>We summarized data using random‐effects models.</p> </section> <section id="CD012466-sec-0083"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In analyses with at least three studies, we investigated potential sources of heterogeneity. We considered participant factors, including demographics (age, sex, race), comorbidity (diabetes, coronary heart disease), type of HF, and stage of CKD. Where possible, we considered agent subclasses (ACEi versus ARB) and dose and duration of therapy, as well as the following pre‐specified indicators for subgroup analyses (defining different types of cardiac disease or stages of CKD). </p> <p> <ol id="CD012466-list-0017"> <li> <p>The type of HF (right‐ versus left‐sided HF)</p> </li> <li> <p>The nature of the functional impairment of the left ventricle (HFrEF versus HFmrEF or HFpEF) </p> </li> <li> <p>Congestive versus non‐congestive acute HF</p> </li> <li> <p>Cardio‐renal (acute versus chronic) versus reno‐cardiac (acute versus chronic) HF</p> </li> <li> <p>The severity of CKD (defined by levels of urine albumin:creatinine ratio and eGFR; CKD stages 1‐5). </p> </li> </ol> </p> </section> <section id="CD012466-sec-0084"> <h4 class="title">Sensitivity analysis</h4> <p>Where possible, we planned to perform sensitivity analyses to explore the influence of the following factors on effect size. </p> <p> <ul id="CD012466-list-0018"> <li> <p>Repeating the analysis excluding unpublished studies</p> </li> <li> <p>Repeating the analysis taking into account of the risk of bias, as specified</p> </li> <li> <p>Repeating the analysis excluding studies of short duration or small studies (using the median as a cut‐off) </p> </li> <li> <p>Repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), and country. </p> </li> </ul> </p> <section id="CD012466-sec-0085"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD012466-bbs2-0203" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schunemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD012466-bbs2-0181" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>; <a href="./references#CD012466-bbs2-0182" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [MEDLINE: 21195583] ">GRADE 2011</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD012466-bbs2-0204" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schunemann 2011b</a>). Assumed risk was calculated by dividing the number of participants in the control group that experienced an event by the total number of participants in the control group. Corresponding risk was calculated by multiplying the assumed risk with the risk ratio estimate from the meta‐analysis. The 95% CI for the corresponding risk was calculated by multiplying the assumed risk with the lower and upper CI of the risk ratio estimate from the meta‐analysis. </p> <p>We included the following outcomes in the 'Summary of findings' tables.</p> <p> <ul id="CD012466-list-0019"> <li> <p>Death (any cause)</p> </li> <li> <p>Cardiovascular death</p> </li> <li> <p>Hospitalisation (any cause)</p> </li> <li> <p>Hospitalisation for decompensated HF</p> </li> <li> <p>Worsening HF</p> </li> <li> <p>Worsening kidney function</p> </li> <li> <p>Hyperkalaemia</p> </li> <li> <p>Hypotension</p> </li> <li> <p>Quality of Life</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012466-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012466-sec-0086"></div> <section id="CD012466-sec-0087"> <h3 class="title">Description of studies</h3> <section id="CD012466-sec-0088"> <h4 class="title">Results of the search</h4> <p>Our search of the Cochrane Kidney and Transplant specialised register identified 869 records. We identified an additional 78 records using other sources (reference lists of review articles, relevant studies, and clinical practice guidelines) ‐ therefore a total of 947 records (176 studies) were identified. We excluded 61 studies (252 records), either due to a population other than HF (38 studies), a non‐pharmacological intervention (5), follow‐up shorter than three months (16), or a study design other than a RCT (2) (see <a href="./references#CD012466-sec-0141" title="">Characteristics of excluded studies</a>). </p> <p>Overall, 115 studies were eligible. Of these, three are ongoing and awaiting publication of primary data (<a href="./references#CD012466-bbs2-0172" title="SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON‐HF Trial. JACC Heart Failure2017;5(7):471‐82. [MEDLINE: 28662936] SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON‐HF trial. Circulation: Heart Failure2018;11(7):e004962. [MEDLINE: 29980595] ">PARAGON‐HF 2018</a>; <a href="./references#CD012466-bbs2-0173" title="TeerlinkJR , VoorsAA , PonikowskiP , PangPS , GreenbergBH , FilippatosG , et al. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study. European Journal of Heart Failure2017;19(6):800‐9. [MEDLINE: 28452195] ">RELAX‐AHF‐2 2017</a>; <a href="./references#CD012466-bbs2-0174" title="MehraMR , McCluskeyT , BarrM , BourgeRC , JessupML , ManciniD , et al. Rationale, design, and methods for the Transplant‐Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC. American Heart Journal2007;153(6):932‐40. [MEDLINE: 17540193] ">TMAC 2007</a>) and will be included in a future update of this review. As a result, 112 studies were included in this review (<a href="#CD012466-fig-0001">Figure 1</a>) and are categorised as follows. </p> <div class="figure" id="CD012466-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012466-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>CKD population studies:</p> <p> <ul id="CD012466-list-0020"> <li> <p>Reported data on CKD patients only (15): <a href="./references#CD012466-bbs2-0008" title='MatsueY , SuzukiM , NagahoriW , YoshidaK , OnishiY , SatohY , et al. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. Cardiovascular Drugs &amp; Therapy2014;28(1):73‐7. [MEDLINE: 24048511] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction.[Erratum appears in J Card Fail. 2016 Nov;22(11):941; PMID: 27481596]. Journal of Cardiac Failure2016;22(6):423‐32. [MEDLINE: 26915749] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423‐432.[Erratum for J Card Fail. 2016 Jun;22(6):423‐32; PMID: 26915749]. Journal of Cardiac Failure2016;22(11):941. [MEDLINE: 27481596] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. International Journal of Cardiology2016;221:188‐93. [MEDLINE: 27404673] MatsueY , Ter MaatenJM , SuzukiM , ToriiS , YamaguchiS , FukamizuS , et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology2017;106(10):802‐12. [MEDLINE: 28540483] '>AQUAMARINE 2014</a>; <a href="./references#CD012466-bbs2-0009" title="SchrotenNF , DammanK , HemmelderMH , VoorsAA , NavisG , GaillardCA , et al. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). American Heart Journal2015;169(5):693‐701. [MEDLINE: 25965717] ">ARIANA‐CHF‐RD 2016</a>; <a href="./references#CD012466-bbs2-0031" title="CiceG , TagliamonteE , FerraraL , DiBenedettoA , SoriceP , IaconoA . Efficacy of diltiazem in uremic hemodialyzed patients with isolated diastolic dysfunction and dialysis hypotensive crisis [Efficacia del diltiazem in pazienti uremici emodializzati con disfunzione diastolica isolata e crisi ipotensive intradialitiche]. Cardiologia1999;44(3):289‐94. [MEDLINE: 10327731] ">Cice 1999a</a>; <a href="./references#CD012466-bbs2-0032" title="CiceG , FerraraL , D'AndreaA , D'IsaS , DiBenedettoA , CittadiniA , et al. Carvedilol increases two‐year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo‐controlled trial. Journal of the American College of Cardiology2003;41(9):1438‐44. [MEDLINE: 12742278] CiceG , FerraraL , DiBenedettoA , RussoPE , MarinelliG , PaveseF , et al. Dilated cardiomyopathy in dialysis patients‐‐beneficial effects of carvedilol: a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2001;37(2):407‐11. [MEDLINE: 11216954] ">Cice 2001</a>; <a href="./references#CD012466-bbs2-0033" title="CiceG , DiBenedettoA , D'AndreaA , D'IsaS , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on left ventricular structure and function in hemodialyzed patients with chronic heart failure: a double‐blind placebo‐controlled multicenter study [abstract no: MP434]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv446. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on mortality and morbidity in haemodialysis patients with chronic heart failure: a double‐blind placebo‐controlled trial [abstract no: MO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v187. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , DeGregoriaP , CalabroR . Effect of telmisartan added to angiotensin converting enzyme inhibitors in reducing morbidity and mortality in haemodialysis patients with chronic heart failure [abstract no: P1.19]. Journal of Hypertension ‐ Supplement2006;24(Suppl):S56. [CENTRAL: CN‐00793137] CiceG , DiBenedettoA , D'IsaS , D'AndreaA , MarcelliD , GattiE , et al. Effects of telmisartan added to angiotensin‐converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2010;56(21):1701‐8. [MEDLINE: 21070920] ">Cice 2010</a>; <a href="./references#CD012466-bbs2-0050" title="O'ConnorCM , FiuzatM , LindenfeldJ , MillerA , LombardiC , CarsonP , et al. Mode of death and hospitalization from the Second Follow‐up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. American Journal of Cardiology2011;108(10):1449‐57. [MEDLINE: 21890092] YancyCW , KrumH , MassieBM , SilverMA , StevensonLW , ChengM , et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow‐Up Serial Infusions of Nesiritide (FUSION II) trial. Circulation: Heart Failure2008;1(1):9‐16. [MEDLINE: 19808265] YancyCW , KrumH , MassieBM , SilverMA , StevensonLW , ChengM , et al. The Second Follow‐up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. American Heart Journal2007;153(4):478‐84. [MEDLINE: 17383282] ">FUSION II 2008</a>; <a href="./references#CD012466-bbs2-0067" title="PalazzuoliA , PellegriniM , FranciB , BeltramiM , RuoccoG , GonnelliS , et al. Short and long‐term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction. Internal &amp; Emergency Medicine2015;10(1):41‐49. [MEDLINE: 25087085] PalazzuoliA , PellegriniM , RuoccoG , MartiniG , FranciB , CampagnaMS , et al. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Critical Care (London, England)2014;18(3):R132. [MEDLINE: 24974232] ">Palazzuoli 2014</a>; <a href="./references#CD012466-bbs2-0070" title="Pita‐FernandezS , Choucino‐FernandezT , Juega‐PuigJ , Seoane‐PilladoT , Lopez‐CalvinoB , Pertega‐DiazS , et al. A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia. International Journal of Clinical Practice2014;68(10):1231‐8. [MEDLINE: 25040146] ">Pita‐Fernandez 2015</a>; <a href="./references#CD012466-bbs2-0072" title="DavisonBA , CotterG , SunH , ChenL , TeerlinkJR , MetraM , et al. Permutation criteria to evaluate multiple clinical endpoints in a proof‐of‐concept study: lessons from Pre‐RELAX‐AHF. Clinical Research in Cardiology2011;100(9):745‐53. [MEDLINE: 21416190] MetraM , TeerlinkJR , FelkerGM , GreenbergBH , FilippatosG , PonikowskiP , et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre‐RELAX‐AHF study. European Journal of Heart Failure2010;12(10):1130‐9. [MEDLINE: 20732868] Milo‐CotterO , TeerlinkJR , MetraM , FelkerGM , PonikowskiP , VoorsAA , et al. Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre‐RELAX‐AHF study. Cardiology2010;117(3):190‐6. [MEDLINE: 21088400] TeerlinkJR , MetraM , FelkerGM , PonikowskiP , VoorsAA , WeatherleyBD , et al. Relaxin for the treatment of patients with acute heart failure (Pre‐RELAX‐AHF): a multicentre, randomised, placebo‐controlled, parallel‐group, dose‐finding phase IIb study. Lancet2009;373(9673):1429‐39. [MEDLINE: 19329178] VoorsAA , DavisonBA , FelkerGM , PonikowskiP , UnemoriE , CotterG , et al. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre‐RELAX‐AHF. European Journal of Heart Failure2011;13(9):961‐7. [MEDLINE: 21622980] ">Pre‐RELAX‐AHF 2009</a>; <a href="./references#CD012466-bbs2-0076" title="ClelandJG , ChiswellK , TeerlinkJR , StevensS , FiuzatM , GivertzMM , et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo‐Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Circulation: Heart Failure2014;7(1):76‐87. [MEDLINE: 24281134] CotterG , DittrichHC , WeatherleyBD , BloomfieldDM , O'ConnorCM , MetraM , et al. The PROTECT pilot study: a randomized, placebo‐controlled, dose‐finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. Journal of Cardiac Failure2008;14(8):631‐40. [MEDLINE: 18926433] GivertzMM , PostmusD , HillegeHL , MansoorGA , MassieBM , DavisonBA , et al. Renal function trajectories and clinical outcomes in acute heart failure. Circulation: Heart Failure2014;7(1):59‐67. [MEDLINE: 24281137] MassieBM , O'ConnorCM , MetraM , PonikowskiP , TeerlinkJR , CotterG , et al. Rolofylline, an adenosine A1‐receptor antagonist, in acute heart failure. New England Journal of Medicine2010;363(15):1419‐28. [MEDLINE: 20925544] MetraM , ClelandJG , WeatherleyBD , DittrichHC , GivertzMM , MassieBM , et al. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60‐day outcomes in the PROTECT pilot study. European Journal of Heart Failure2010;12(5):499‐507. [MEDLINE: 20228387] MetraM , O'ConnorCM , DavisonBA , ClelandJG , PonikowskiP , TeerlinkJR , et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. European Heart Journal2011;32(12):1519‐34. [MEDLINE: 21388992] TeerlinkJR , IraguiVJ , MohrJP , CarsonPE , HauptmanPJ , LovettDH , et al. The safety of an adenosine A(1)‐receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Safety2012;35(3):233‐44. [MEDLINE: 22339573] VoorsAA , DittrichHC , MassieBM , DeLuccaP , MansoorGA , MetraM , et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo‐Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). Journal of the American College of Cardiology2011;57(19):1899‐907. [MEDLINE: 21545947] WeatherleyBD , CotterG , DittrichHC , DeLuccaP , MansoorGA , BloomfieldDM , et al. Design and rationale of the PROTECT study: a placebo‐controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. Journal of Cardiac Failure2010;16(1):25‐35. [MEDLINE: 20123315] ">PROTECT 2008</a>; <a href="./references#CD012466-bbs2-0079" title="LiuLC , VoorsAA , TeerlinkJR , CotterG , DavisonBA , FelkerGM , et al. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX‐AHF. Clinical Research in Cardiology2016;105(9):727‐37. [MEDLINE: 27017514] MetraM , CotterG , DavisonBA , FelkerGM , FilippatosG , GreenbergBH , et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX‐AHF) development program: correlation with outcomes. Journal of the American College of Cardiology2013;61(2):196‐206. [MEDLINE: 23273292] MetraM , PonikowskiP , CotterG , DavisonBA , FelkerGM , FilippatosG , et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX‐AHF. European Heart Journal2013;34(40):3128‐36. [MEDLINE: 23999454] PangPS , TeerlinkJR , VoorsAA , PonikowskiP , GreenbergBH , FilippatosG , et al. Use of high‐sensitivity troponin t to identify patients with acute heart failure at lower risk for adverse outcomes: an exploratory analysis from the RELAX‐AHF trial. JACC Heart Failure2016;4(7):591‐9. [MEDLINE: 27039129] PonikowskiP , MetraM , TeerlinkJR , UnemoriE , FelkerGM , VoorsAA , et al. Design of the RELAXin in acute heart failure study. American Heart Journal2012;163(2):149‐55. [MEDLINE: 22305830] TeerlinkJR , CotterG , DavisonBA , FelkerGM , FilippatosG , GreenbergBH , et al. Serelaxin, recombinant human relaxin‐2, for treatment of acute heart failure (RELAX‐AHF): a randomised, placebo‐controlled trial. Lancet2013;381(9860):29‐39. [MEDLINE: 23141816] ">RELAX‐AHF 2012</a>; <a href="./references#CD012466-bbs2-0080" title="PangPS , MehraM , MaggioniAP , FilippatosG , MiddlebrooksJ , TurlapatyP , et al. Rationale, design, and results from RENO‐DEFEND 1: a randomized, dose‐finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. American Heart Journal2011;161(6):1012‐23. [MEDLINE: 21641345] ">RENO‐DEFEND 1 2011</a>; <a href="./references#CD012466-bbs2-0082" title="ChenHH , AbouEzzeddineOF , AnstromKJ , GivertzMM , BartBA , FelkerGM , et al. Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circulation: Heart Failure2013;6(5):1087‐94. [MEDLINE: 24046475] ChenHH , AnstromKJ , GivertzMM , StevensonLW , SemigranMJ , GoldsmithSR , et al. Low‐dose dopamine or low‐dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA2013;310(23):2533‐43. [MEDLINE: 24247300] GrodinJL , LalaA , StevensSR , DeVoreAD , CooperLB , AbouEzzeddineOF , et al. Clinical Implications of serum albumin levels in acute heart failure: insights from DOSE‐AHF and ROSE‐AHF. Journal of Cardiac Failure2016;22(11):884‐90. [MEDLINE: 26844764] GrodinJL , SunJL , AnstromKJ , ChenHH , StarlingRC , TestaniJM , et al. Implications of serum chloride homeostasis in acute heart failure (from ROSE‐AHF). American Journal of Cardiology2017;119(1):78‐83. [MEDLINE: 27816115] WanSH , StevensSR , BorlaugBA , AnstromKJ , DeswalA , FelkerGM , et al. Differential response to low‐dose dopamine or low‐dose nesiritide in acute heart failure with reduced or preserved ejection fraction: results from the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circulation: Heart Failure2016;9(8):1. [MEDLINE: 27512103] ">ROSE AHF 2013</a>; <a href="./references#CD012466-bbs2-0094" title="MortazaviM , TaheriS , ShahidiS , PourmoghaddasA , YaraghiMG , SeyrafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: FP379]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi145. [CENTRAL: CN‐00716090] TaheriS , MortazaviM , ShahidiS , PourmoghadasA , GarakyaraghiM , SeirafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):392‐7. [MEDLINE: 19414940] TaheriS , MortazaviM , ShahidiS , PourmoghadasA , GarakyaraghiM , SeirafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: S‐PO‐0370]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:148. ">Taheri HD 2009</a>; <a href="./references#CD012466-bbs2-0093" title="NajafabadiMM , TaheriS , SeyrafianS , AlipoorZ , KarimiS , PoormodhadasA , et al. Spironolactone in continuous ambulatory peritoneal dialysis patients, improves cardiac function [abstract no: SU475]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. TaheriS , MortazaviM , PourmoghadasA , SeyrafianS , AlipourZ , KarimiS . A prospective double‐blind randomized placebo‐controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi Journal of Kidney Diseases &amp; Transplantation2012;23(3):507‐12. [MEDLINE: 22569436] ">Taheri CAPD 2012</a>. </p> </li> </ul> </p> <p>General population studies, including people with CKD:</p> <p> <ul id="CD012466-list-0021"> <li> <p>Reported data on general population, including both people with and without CKD, and provided stratified data for CKD patients (16): <a href="./references#CD012466-bbs2-0006" title="JacksonCE , MacDonaldMR , PetrieMC , SolomonSD , PittB , LatiniR , et al. Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure2011;13(7):746‐54. [MEDLINE: 21459891] MaggioniAP , McMurrayJJ , LatiniR , SolomonSD , SmithBA , BushC , et al. Safety and tolerability profile of aliskiren added to optimized therapy in patients with heart failure and renal impairment [abstract no: SA‐PO2247]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):616A. [CENTRAL: CN‐00776176] McMurrayJJ , PittB , LatiniR , MaggioniAP , SolomonSD , KeefeDL , et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure2008;1(1):17‐24. [MEDLINE: 19808266] ">ALOFT 2008</a>; <a href="./references#CD012466-bbs2-0003" title="AnandIS , TamSW , RectorTS , TaylorAL , SabolinskiML , ArchambaultWT , et al. Influence of blood pressure on the effectiveness of a fixed‐dose combination of isosorbide dinitrate and hydralazine in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2007;49(1):32‐9. [MEDLINE: 17207719] AnandIS , WinS , RectorTS , CohnJN , TaylorAL . Effect of fixed‐dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30‐day readmission rates in patients with heart failure: results from the African‐American Heart Failure Trial. Circulation: Heart Failure2014;7(5):759‐65. [MEDLINE: 24970468] CarsonP , TamSW , GhaliJK , ArchambaultWT , TaylorA , CohnJN , et al. Relationship of quality of life scores with baseline characteristics and outcomes in the African‐American heart failure trial. Journal of Cardiac Failure2009;15(10):835‐42. [MEDLINE: 19944359] ChangKW , BeriN , NguyenNH , ArbitB , FoxS , MojaverS , et al. Heart failure with recovered ejection fraction in African Americans: results from the African‐American Heart Failure Trial. Journal of Cardiac Failure2018;24(5):303‐9. [MEDLINE: 28918108] CohnJN , TamSW , AnandIS , TaylorAL , SabolinskiML , WorcelM , et al. Isosorbide dinitrate and hydralazine in a fixed‐dose combination produces further regression of left ventricular remodeling in a well‐treated black population with heart failure: results from A‐HeFT. Journal of Cardiac Failure2007;13(5):331‐9. [MEDLINE: 17602978] FranciosaJA , TaylorAL , CohnJN , YancyCW , ZiescheS , OlukotunA , et al. African‐American Heart Failure Trial (A‐HeFT): rationale, design, and methodology. Journal of Cardiac Failure2002;8(3):128‐35. [MEDLINE: 12140804] GhaliJK , TamSW , FerdinandKC , LindenfeldJ , SabolinskiML , TaylorAL , et al. Effects of ACE inhibitors or beta‐blockers in patients treated with the fixed‐dose combination of isosorbide dinitrate/hydralazine in the African‐American Heart Failure Trial. American Journal of Cardiovascular Drugs2007;7(5):373‐80. [MEDLINE: 18041162] GhaliJK , TamSW , SabolinskiML , TaylorAL , LindenfeldJ , CohnJN , et al. Exploring the potential synergistic action of spironolactone on nitric oxide‐enhancing therapy: insights from the African‐American Heart Failure Trial. Journal of Cardiac Failure2008;14(9):718‐23. [MEDLINE: 18995175] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , TaylorAL , et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A‐HeFT Trial. Journal of the American College of Cardiology2006;48(6):1277‐82. [MEDLINE: 16979018] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , VenkitachalamL , et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A‐HeFT trial. Journal of Cardiac Failure2009;15(3):191‐8. [MEDLINE: 19327620] McNamaraDM , TaylorAL , TamSW , WorcelM , YancyCW , Hanley‐YanezK , et al. G‐protein beta‐3 subunit genotype predicts enhanced benefit of fixed‐dose isosorbide dinitrate and hydralazine: results of A‐HeFT. JACC Heart Failure2014;2(6):551‐7. [MEDLINE: 25306451] MitchellJE , TamSW , TrivediK , TaylorAL , O'NealW , CohnJN , et al. Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A‐HeFT). American Heart Journal2011;162(1):154‐9. [MEDLINE: 21742102] TaylorAL . The African‐American Heart Failure Trial (A‐HeFT): rationale and methodology.[Erratum appears in J Card Fail. 2003 Dec;9(6):481 Note: Dosage error in article text]. Journal of Cardiac Failure2003;9(5 Suppl Nitric Oxide):S216‐9. [MEDLINE: 14583892] TaylorAL , CohnJN , WorcelM , FranciosaJA , A‐HeFT Investigators.African‐American Heart Failure Trial. The African‐American Heart Failure Trial: background, rationale and significance. Journal of the National Medical Association2002;94(9):762‐9. [MEDLINE: 12392039] TaylorAL , LindenfeldJ , ZiescheS , WalshMN , MitchellJE , AdamsK , et al. Outcomes by gender in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2006;48(11):2263‐7. [MEDLINE: 17161257] TaylorAL , SabolinskiML , TamSW , ZiescheS , GhaliJK , ArchambaultWT , et al. Effect of fixed‐dose combined isosorbide dinitrate/hydralazine in elderly patients in the African‐American heart failure trial. Journal of Cardiac Failure2012;18(8):600‐6. [MEDLINE: 22858074] TaylorAL , ZiescheS , YancyC , CarsonP , D'AgostinoRJr , FerdinandK , et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.[Erratum appears in N Engl J Med. 2005 Mar 24;352(12):1276]. New England Journal of Medicine2004;351(20):2049‐57. [MEDLINE: 15533851] TaylorAL , ZiescheS , YancyCW , CarsonP , FerdinandK , TaylorM , et al. Early and sustained benefit on event‐free survival and heart failure hospitalization from fixed‐dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African‐American Heart Failure Trial. Circulation2007;115(13):1747‐53. [MEDLINE: 17372175] YancyCW , GhaliJK , BramanVM , SabolinskiML , WorcelM , ArchambaultWT , et al. Evidence for the continued safety and tolerability of fixed‐dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African‐American Heart Failure Trial). American Journal of Cardiology2007;100(4):684‐9. [MEDLINE: 17697829] ">A‐HeFT 2002</a>; <a href="./references#CD012466-bbs2-0029" title='Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. Fundamental &amp; Clinical Pharmacology1997;11(2):138‐42. [MEDLINE: 9107560] Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS‐II). European Heart Journal2001;22(12):1021‐31. [MEDLINE: 11428837] The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): a randomised trial. Lancet1999;353(9146):9‐13. [MEDLINE: 10023943] BohmM , MaackC , Wehrlen‐GrandjeanM , ErdmannE . Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardiac Insufficiency Bisoprolol Study II (CIBIS II)). Zeitschrift fur Kardiologie2003;92(8):668‐76. [MEDLINE: 12955414] CastagnoD , JhundPS , McMurrayJJ , LewseyJD , ErdmannE , ZannadF , et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS‐II) trial. European Journal of Heart Failure2010;12(6):607‐16. [MEDLINE: 20354032] EkmanM , ZethraeusN , JonssonB . Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics2001;19(9):901‐16. [MEDLINE: 11700777] ErdmannE , LechatP , VerkenneP , WiemannH . Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure. European Journal of Heart Failure2001;3(4):469‐79. [MEDLINE: 11511434] GallanaghS , CastagnoD , WilsonB , ErdmannE , ZannadF , RemmeWJ , et al. Evaluation of the functional status questionnaire in heart failure: a sub‐study of the second cardiac insufficiency bisoprolol survival study (CIBIS‐II). Cardiovascular Drugs &amp; Therapy2011;25(1):77‐85. [MEDLINE: 21287410] KrumH , BaileyM , MeyerW , VerkenneP , DargieH , LechatP , et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta‐blocker use: results of CIBIS II. Cardiology2007;108(1):28‐34. [MEDLINE: 16960445] KrumH , HareD . "Bisoprolol dose‐response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II)," by Simon T. European Heart Journal2004;25(3):277. [MEDLINE: 14972430] LechatP , HulotJS , EscolanoS , MalletA , LeizoroviczA , Werhlen‐GrandjeanM , et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation2001;103(10):1428‐33. [MEDLINE: 11245648] SimonT , Mary‐KrauseM , Funck‐BrentanoC , JaillonP . Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation2001;103(3):375‐80. [MEDLINE: 11157688] SimonT , Mary‐KrauseM , Funck‐BrentanoC , LechatP , JaillonP . Bisoprolol dose‐response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). European Heart Journal2003;24(6):552‐9. [MEDLINE: 12643888] '>CIBIS II 1997</a>; <a href="./references#CD012466-bbs2-0040" title="BrendorpB , ElmingH , JunL , KoberL , MalikM , JensenGB , et al. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation2001;103(10):1422‐7. [MEDLINE: 11245647] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group.Danish Investigations Of Arrhythmia and Mortality On Dofetilide. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. European Journal of Heart Failure2002;4(2):201‐6. [MEDLINE: 11959050] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group. The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide. Clinical Cardiology2003;26(5):219‐25. [MEDLINE: 12769249] MollerM , Torp‐PedersenCT , KoberL . Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congestive Heart Failure2001;7(3):146‐50. [MEDLINE: 11828153] PedersenHS , ElmingH , SeibaekM , BurchardtH , BrendorpB , Torp‐PedersenC , et al. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. American Journal of Cardiology2007;100(5):876‐80. [MEDLINE: 17719337] Torp‐PedersenC , MollerM , Bloch‐ThomsenPE , KoberL , SandoeE , EgstrupK , et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. New England Journal of Medicine1999;341(12):857‐65. [MEDLINE: 10486417] ">DIAMOND 1999</a>; <a href="./references#CD012466-bbs2-0041" title="Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long‐term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clinical Trials1996;17(1):77‐97. [MEDLINE: 8721804] AhmedA . Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. Journals of Gerontology Series A‐Biological Sciences &amp; Medical Sciences2007;62(3):323‐9. [MEDLINE: 17389731] AhmedA , AronowWS , FlegJL . Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. American Journal of Therapeutics2006;13(4):325‐31. [MEDLINE: 16858168] AhmedA , LoveTE , SuiX , RichMW . Effects of angiotensin‐converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. Journal of Cardiac Failure2006;12(7):499‐506. [MEDLINE: 16952782] AhmedA , RichMW , SandersPW , PerryGJ , BakrisGL , ZileMR , et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. American Journal of Cardiology2007;99(3):393‐8. [MEDLINE: 17261405] BowlingCB , PittB , AhmedMI , AbanIB , SandersPW , MujibM , et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity‐matched studies. Circulation: Heart Failure2010;3(2):353‐60. [MEDLINE: 20103777] CampbellRC , SuiX , FilippatosG , LoveTE , WahleC , SandersPW , et al. Association of chronic kidney disease with outcomes in chronic heart failure: a propensity‐matched study. Nephrology Dialysis Transplantation2009;24(1):186‐93. [MEDLINE: 18711222] Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine1997;336(8):525‐33. [MEDLINE: 9036306] EkundayoOJ , MuchimbaM , AbanIB , RitchieC , CampbellRC , AhmedA . Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. American Journal of Cardiology2009;103(1):88‐92. [MEDLINE: 19101236] RitchieC , EkundayoOJ , MuchimbaM , CampbellRC , FrankSJ , LiuB , et al. Effects of diabetes mellitus in patients with heart failure and chronic kidney disease: a propensity‐matched study of multimorbidity in chronic heart failure.[Erratum appears in Int J Cardiol. 2010 Jan 7;138(1):106]. International Journal of Cardiology2009;134(3):330‐5. [MEDLINE: 19178965] ShlipakMG , SmithGL , RathoreSS , MassieBM , KrumholzHM . Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. Journal of the American Society of Nephrology2004;15(8):2195‐203. [MEDLINE: 15284305] TestaniJM , BriscoMA , TangWH , KimmelSE , Tiku‐OwensA , ForfiaPR , et al. Potential effects of digoxin on long‐term renal and clinical outcomes in chronic heart failure. Journal of Cardiac Failure2013;19(5):295‐302. [MEDLINE: 23663810] ">DIG 1996</a>; <a href="./references#CD012466-bbs2-0044" title="EschalierR , McMurrayJJ , SwedbergK , vanVeldhuisenDJ , KrumH , PocockSJ , et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS‐HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Journal of the American College of Cardiology2013;62(17):1585‐93. [MEDLINE: 23810881] KrumH , ShiH , PittB , McMurrayJ , SwedbergK , vanVeldhuisenDJ , et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS‐HF study. Circulation: Heart Failure2013;6(4):711‐8. [MEDLINE: 23625945] RogersJK , McMurrayJJ , PocockSJ , ZannadF , KrumH , vanVeldhuisenDJ , et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation2012;126(19):2317‐23. [MEDLINE: 23042980] RossignolP , DobreD , McMurrayJJ , SwedbergK , KrumH , vanVeldhuisenDJ , et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF). Circulation: Heart Failure2014;7(1):51‐8. [MEDLINE: 24297687] ZannadF , McMurrayJJ , DrexlerH , KrumH , vanVeldhuisenDJ , SwedbergK , et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF). European Journal of Heart Failure2010;12(6):617‐22. [MEDLINE: 20388647] ZannadF , McMurrayJJ , KrumH , vanVeldhuisenDJ , SwedbergK , ShiH , et al. Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine2011;364(1):11‐21. [MEDLINE: 21073363] ">EMPHASIS‐HF 2010</a>; <a href="./references#CD012466-bbs2-0046" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJC , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJC , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD012466-bbs2-0053" title="HuDY , HuangJ , CaiNS , ZhuWL , LiYS , MassaadR , et al. A multi‐center, double‐blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment. Chinese Medical Journal2012;125(21):3868‐74. [MEDLINE: 23106890] KiernanMS , GregoryD , SarnakMJ , RossignolP , MassaroJ , KociolR , et al. Early and late effects of high‐ versus low‐dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.[Erratum appears in JACC Heart Fail. 2015 Jun;3(6):510‐1]. JACC Heart Failure2015;3(3):214‐23. [MEDLINE: 25742759] KiernanMS , WentworthD , FrancisG , MartinezFA , DicksteinK , KomajdaM , et al. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. European Journal of Heart Failure2012;14(12):1401‐9. [MEDLINE: 23187648] KonstamMA , NeatonJD , DicksteinK , DrexlerH , KomajdaM , MartinezFA , et al. Effects of high‐dose versus low‐dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double‐blind trial.[Erratum appears in Lancet. 2009 Dec 5;374(9705):1888]. Lancet2009;374(9704):1840‐8. [MEDLINE: 19922995] KonstamMA , Poole‐WilsonPA , DicksteinK , DrexlerH , JusticeSJ , KomajdaM , et al. Design of the heart failure endpoint evaluation of AII‐antagonist losartan (HEAAL) study in patients intolerant to ACE‐inhibitor. European Journal of Heart Failure2008;10(9):899‐906. [MEDLINE: 18768350] RossignolP , DobreD , GregoryD , MassaroJ , KiernanM , KonstamMA , et al. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2014;173(3):380‐7. [MEDLINE: 24726210] RossignolP , GirerdN , GregoryD , MassaroJ , KonstamMA , ZannadF . Increased visit‐to‐visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2015;187:183‐9. [MEDLINE: 25828348] UpshawJN , KonstamMA , KlaverenD , NoubaryF , HugginsGS , KentDM . Multistate model to predict heart failure hospitalizations and all‐cause mortality in outpatients with heart failure with reduced ejection fraction: model derivation and external validation. Circulation: Heart Failure2016;9(8):e003146. [MEDLINE: 27514751] ">HEAAL 2008</a>; <a href="./references#CD012466-bbs2-0059" title="Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Lancet1999;353(9169):2001‐7. [MEDLINE: 10376614] Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT‐HF). The International Steering Committee. American Journal of Cardiology1997;80(9B):54‐8J. [MEDLINE: 9375952] BattyJA , HallAS , WhiteHL , WikstrandJ , deBoerRA , vanVeldhuisenDJ , et al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT‐HF substudy. Clinical Pharmacology &amp; Therapeutics2014;95(3):321‐30. [MEDLINE: 24193112] CaroJJ , Migliaccio‐WalleK , O'BrienJA , NovaW , KimJ , HauchO , et al. Economic implications of extended‐release metoprolol succinate for heart failure in the MERIT‐HF trial: a US perspective of the MERIT‐HF trial. Journal of Cardiac Failure2005;11(9):647‐56. [MEDLINE: 16360958] DeedwaniaPC , GilesTD , KlibanerM , GhaliJK , HerlitzJ , HildebrandtP , et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT‐HF. American Heart Journal2005;149(1):159‐67. [MEDLINE: 15660048] FagerbergB . Screening, endpoint classification, and safety monitoring in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). European Journal of Heart Failure2000;2(3):315‐24. [MEDLINE: 10938494] GhaliJK , PinaIL , GottliebSS , DeedwaniaPC , WikstrandJC , MERIT‐HF Study Group. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended‐Release Randomized Intervention Trial in Heart Failure (MERIT‐HF). Circulation2002;105(13):1585‐91. [MEDLINE: 11927527] GhaliJK , WikstrandJ , vanVeldhuisenDJ , FagerbergB , GoldsteinS , HjalmarsonA , et al. The influence of renal function on clinical outcome and response to beta‐blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT‐HF). Journal of Cardiac Failure2009;15(4):310‐8. [MEDLINE: 19398079] GoldsteinS , HjalmarsonA . The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT‐HF Trial. Clinical Cardiology1999;22(Suppl 5):V30‐5. [MEDLINE: 10526701] GottliebSS , FisherML , KjekshusJ , DeedwaniaP , GullestadL , VitovecJ , et al. Tolerability of beta‐blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT‐HF). Circulation2002;105(10):1182‐8. [MEDLINE: 11889011] GullestadL , ManhenkeC , AarslandT , SkardalR , FagertunH , WikstrandJ , et al. Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure ‐ a substudy to the MERIT‐HF trial. European Journal of Heart Failure2001;3(4):463‐8. [MEDLINE: 11511433] GullestadL , UelandT , BrunsvigA , KjekshusJ , SimonsenS , FrolandSS , et al. Effect of metoprolol on cytokine levels in chronic heart failure‐‐a substudy in the Metoprolol Controlled‐Release Randomised Intervention Trial in Heart Failure (MERIT‐HF). American Heart Journal2001;141(3):418‐21. [MEDLINE: 11231439] GullestadL , WikstrandJ , DeedwaniaP , HjalmarsonA , EgstrupK , ElkayamU , et al. What resting heart rate should one aim for when treating patients with heart failure with a beta‐blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT‐HF). Journal of the American College of Cardiology2005;45(2):252‐9. [MEDLINE: 15653024] HjalmarsonA , GoldsteinS , FagerbergB , WedelH , WaagsteinF , KjekshusJ , et al. Effects of controlled‐release metoprolol on total mortality, hospitalizations, and well‐being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT‐HF). MERIT‐HF Study Group. JAMA2000;283(10):1295‐302. [MEDLINE: 10714728] SavvaJ , MaqboolA , WhiteHL , GallowaySL , YuldashevaNY , BallSG , et al. Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT‐HF substudy. Journal of Cardiac Failure2009;15(5):435‐41. [MEDLINE: 19477404] TepperD . Frontiers in congestive heart failure: effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Congestive Heart Failure1999;5(4):184‐5. [MEDLINE: 12189311] WhiteHL , deBoerRA , MaqboolA , GreenwoodD , vanVeldhuisenDJ , CuthbertR , et al. An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study. European Journal of Heart Failure2003;5(4):463‐8. [MEDLINE: 12921807] WikstrandJ , HjalmarsonA , WaagsteinF , FagerbergB , GoldsteinS , KjekshusJ , et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT‐HF). Journal of the American College of Cardiology2002;40(3):491‐8. [MEDLINE: 12142116] vanVeldhuisenDJ , AassH , ElAllafD , DunselmanPH , GullestadL , HalinenM , et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT‐HF Study. European Journal of Heart Failure2006;8(5):539‐46. [MEDLINE: 16567126] van derMeerP , DeBoerRA , WhiteHL , van derSteegeG , HallAS , VoorsAA , et al. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT‐HF substudy. Journal of Cardiac Failure2005;11(4):279‐84. [MEDLINE: 15880336] ">MERIT‐HF 1997</a>; <a href="./references#CD012466-bbs2-0075" title="EichhornEJ , TandonPK , DiBiancoR , TimmisGC , FensterPE , ShannonJ , et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. Journal of the American College of Cardiology1993;21(3):634‐40. [MEDLINE: 8436744] PackerM . Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. American Journal of Cardiology1989;63(2):41‐5A. [MEDLINE: 2642629] PackerM , CarverJR , RodehefferRJ , IvanhoeRJ , DiBiancoR , ZeldisSM , et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. New England Journal of Medicine1991;325(21):1468‐75. [MEDLINE: 1944425] TeerlinkJR , JalaluddinM , AndersonS , KukinML , EichhornEJ , FrancisG , et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation2000;101(1):40‐6. [MEDLINE: 10618302] ">PROMISE 1989</a>; <a href="./references#CD012466-bbs2-0077" title="Effectiveness of spironolactone added to an angiotensin‐converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). American Journal of Cardiology1996;78(8):902‐7. [MEDLINE: 8888663] GlickHA , OrzolSM , TooleyJF , RemmeWJ , SasayamaS , PittB . Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovascular Drugs &amp; Therapy2002;16(1):53‐9. [MEDLINE: 12085979] HaubenM , ReichL , GerritsCM , MadiganD . Detection of spironolactone‐associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Safety2007;30(12):1143‐9. [MEDLINE: 18035866] PittB , ZannadF , RemmeWJ , CodyR , CastaigneA , PerezA , et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine1999;341(10):709‐17. [MEDLINE: 10471456] PittD . ACE inhibitor co‐therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). European Heart Journal1995;16 Suppl N:107‐10. [MEDLINE: 8682055] RousseauMF , GurneO , DuprezD , VanMieghemW , RobertA , AhnS , et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.[Erratum appears in J Am Coll Cardiol. 2003 Nov 19;42(10):1865]. Journal of the American College of Cardiology2002;40(9):1596‐601. [MEDLINE: 12427411] SchwingerRH . The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study [Der Aldosteronantagonist Spironolacton verlangert das Uberleben chronisch herzinsuffizienter Patienten. Ergebnisse der RALES‐Studie]. Deutsche Medizinische Wochenschrift1999;124(34‐5):987‐8. [MEDLINE: 10488324] VardenyO , WuDH , DesaiA , RossignolP , ZannadF , PittB , et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure. Journal of the American College of Cardiology2012;60(20):2082‐9. [MEDLINE: 23083787] WittesJ , PalenskyJ , AsnerD , JulianD , BoisselJP , FurbergCD , et al. Experience collecting interim data on mortality: an example from the RALES study. Current Controlled Trials in Cardiovascular Medicine2001;2(1):59‐62. [MEDLINE: 11806773] ZannadF , AllaF , DoussetB , PerezA , PittB . Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.[Erratum appears in Circulation 2001 Jan 23;103(3):476]. Circulation2000;102(22):2700‐6. [MEDLINE: 11094035] ">RALES 1995</a>; <a href="./references#CD012466-bbs2-0084" title="HagerWD , DavisBR , RibaA , MoyeLA , WunCC , RouleauJL , et al. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. American Heart Journal1998;135(3):406‐13. [MEDLINE: 9506325] JoseP , SkaliH , AnavekarN , TomsonC , KrumholzHM , RouleauJL , et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. Journal of the American Society of Nephrology2006;17(10):2886‐91. [MEDLINE: 16928807] LamasGA , PfefferMA , HammP , WertheimerJ , RouleauJL , BraunwaldE . Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? the SAVE Investigators. New England Journal of Medicine1992;327(4):241‐7. [MEDLINE: 1535419] MitchellGF , MoyeLA , BraunwaldE , RouleauJL , BernsteinV , GeltmanEM , et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation1997;96(12):4254‐60. [MEDLINE: 9416890] MoyeLA , PfefferMA , BraunwaldE . Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. SAVE Investigators. American Journal of Cardiology1991;68(14):70‐9D. [MEDLINE: 1836100] PfefferMA , BraunwaldE , MoyeLA , BastaL , BrownEJJr , CuddyTE , et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. New England Journal of Medicine1992;327(10):669‐77. [MEDLINE: 1386652] PfefferMA , MoyeLA , BraunwaldE , BastaL , BrownEJJr , CuddyTE , et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA1991;266(4):528‐32. [MEDLINE: 2061979] RouleauJL , MoyeLA , PfefferMA , ArnoldJM , BernsteinV , CuddyTE , et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. New England Journal of Medicine1993;328(11):779‐84. [MEDLINE: 8123063] RutherfordJD , PfefferMA , MoyeLA , DavisBR , FlakerGC , KoweyPR , et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation1994;90(4):1731‐8. [MEDLINE: 7923656] TokmakovaMP , SkaliH , KenchaiahS , BraunwaldE , RouleauJL , PackerM , et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin‐converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation2004;110(24):3667‐73. [MEDLINE: 15569840] UrenaPE , LamasGA , MitchellG , FlakerGC , SmithSCJr , WackersFJ , et al. Ejection fraction by radionuclide ventriculography and contrast left ventriculogram. A tale of two techniques. SAVE Investigators. Survival and Ventricular Enlargement. Journal of the American College of Cardiology1999;33(1):180‐5. [MEDLINE: 9935027] VantrimpontP , RouleauJL , WunCC , CiampiA , KleinM , SussexB , et al. Additive beneficial effects of beta‐blockers to angiotensin‐converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. Journal of the American College of Cardiology1997;29(2):229‐36. [MEDLINE: 9014971] ">SAVE 1991</a>; <a href="./references#CD012466-bbs2-0085" title="Cohen‐SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872‐80. [MEDLINE: 19648605] FlatherMD , ShibataMC , CoatsAJ , VanVeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomised trial to determine the effect of nebivolol on mortality and hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26(3):215‐25. [MEDLINE: 15642700] ShibataMC , FlatherMD , BöhmM , BorbolaJ , Cohen‐SolalA , DumitrascuD , et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisations in Seniors with Heart Failure (SENIORS): rationale and design. International Journal of Cardiology2002;86(1):77‐85. [MEDLINE: 12243852] vanVeldhuisenDJ , Cohen‐SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta‐blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150‐8. [MEDLINE: 19497441] ">SENIORS 2002</a>; <a href="./references#CD012466-bbs2-0086" title="BocchiEA , BohmM , BorerJS , FordI , KomajdaM , SwedbergK , et al. Effect of combining ivabradine and beta‐blockers: focus on the use of carvedilol in the SHIFT population. Cardiology2015;131(4):218‐24. [MEDLINE: 25968495] BohmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20(2):373‐81. [MEDLINE: 29027329] BohmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost‐BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo‐controlled trial. Lancet2010;376(9744):886‐94. [MEDLINE: 20801495] BorerJS , BohmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33(22):2813‐20. [MEDLINE: 22927555] BorerJS , BohmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497‐503. [MEDLINE: 24332674] FordI , RobertsonM , KomajdaM , BohmM , BorerJS , TavazziL , et al. Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: the SHIFT risk model. International Journal of Cardiology2015;184:163‐9. [MEDLINE: 25703424] KomajdaM , BohmM , BorerJS , FordI , RobertsonM , ManolisAJ , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. European Journal of Heart Failure2014;16(7):810‐6. [MEDLINE: 24961493] KomajdaM , TavazziL , FrancqBG , BohmM , BorerJS , FordI , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. European Journal of Heart Failure2015;17(12):1294‐301. [MEDLINE: 26377342] KomajdaM , TavazziL , SwedbergK , BohmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of SHIFT. European Journal of Heart Failure2016;18(9):1182‐9. [MEDLINE: 27210035] SwedbergK , KomajdaM , BohmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta‐blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. Journal of the American College of Cardiology2012;59(22):1938‐45. [MEDLINE: 22617188] SwedbergK , KomajdaM , BohmM , BorerJS , FordI , Dubost‐BramaA , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo‐controlled study.[Erratum appears in Lancet. 2010 Dec 11;376(9757):1988 Note: Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadan, I Roldan]; Leva, M [corrected to Ieva, M]]. Lancet2010;376(9744):875‐85. [MEDLINE: 20801500] SwedbergK , KomajdaM , BöhmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). European Journal of Heart Failure2010;12(1):75‐81. [MEDLINE: 19892778] TardifJC , O'MearaE , KomajdaM , BohmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507‐15. [MEDLINE: 21875858] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182‐8. [MEDLINE: 24225201] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. European Journal of Heart Failure2013;15(11):1296‐303. [MEDLINE: 23803951] VoorsAA , vanVeldhuisenDJ , RobertsonM , FordI , BorerJS , BohmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure2014;16(4):426‐34. [MEDLINE: 24504937] ">SHIFT 2010</a>; <a href="./references#CD012466-bbs2-0089" title="Al‐AhmadA , LeveyA , RandW , MajunathG , SalemD , GregoryD , et al. Anemia and renal insufficiency as risk factors for mortality in patients with left ventricular dysfunction [abstract no: A0739]. Journal of the American Society of Nephrology2000;11(Sept):137A. [CENTRAL: CN‐00550523] Al‐AhmadAM , SarnakMJ , RandW , GregoryD , KonstamMA , SalemDN , et al. Level of renal function as an independent predictor of mortality in patients with left ventricular dysfunction [abstract no: A0783]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):152A. [CENTRAL: CN‐00550524] Alsheikh‐AliAA , TrikalinosTA , RuthazerR , TerrinN , WongJB , SarnakMJ , et al. Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease. American Heart Journal2011;161(1):204‐9. [MEDLINE: 21167355] BansalN , TighiouartH , WeinerD , GriffithJ , VlagopoulosP , SalemD , et al. Anemia as a risk factor for kidney function decline in heart failure [abstract no: TH‐PO928]. Journal of the American Society of Nephrology2005;16(Oct):322A. [CENTRAL: CN‐01658120] BansalN , TighiouartH , WeinerD , GriffithJ , VlagopoulosP , SalemD , et al. Anemia as a risk factor for kidney function decline in individuals with heart failure. American Journal of Cardiology2007;99(8):1137‐42. [MEDLINE: 17437743] BowlingCB , SandersPW , AllmanRM , RogersWJ , PatelK , AbanIB , et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. International Journal of Cardiology2013;167(1):151‐6. [MEDLINE: 22257685] CapesSE , GersteinHC , NegassaA , YusufS . Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care2000;23(3):377‐80. [MEDLINE: 10868869] GregoryDD , SarnakMJ , KonstamMA , PereiraB , SalemD . Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction. American Journal of Cardiology2003;92(11):1300‐5. [MEDLINE: 14636907] KnightEL , GlynnRJ , McIntyreKM , MogunH , AvornJ . Predictors of decreased renal function in patients with heart failure during angiotensin‐converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). American Heart Journal1999;138(5 (Pt 1)):849‐55. [MEDLINE: 10539815] RiedingerMS , DracupKA , BrechtML , SOLVD Investigators. Studies of Left Ventricular Dysfunction. Quality of life in women with heart failure, normative groups, and patients with other chronic conditions. American Journal of Critical Care2002;11(3):211‐9. [MEDLINE: 12022484] SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New England Journal of Medicine1991;325(5):293‐302. [MEDLINE: 2057034] SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD)‐‐rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction.[Erratum appears in Am J Cardiol 1990 Oct 15;66(12):1026]. American Journal of Cardiology1990;66(3):315‐22. [MEDLINE: 2195865] TestaniJM , KimmelSE , DriesDL , CocaSG . Prognostic importance of early worsening renal function after initiation of angiotensin‐converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circulation: Heart Failure2011;4(6):685‐91. [MEDLINE: 21903907] ">SOLVD (Treatment) 1992</a>; <a href="./references#CD012466-bbs2-0100" title="AnandIS , BishuK , RectorTS , IshaniA , KuskowskiMA , CohnJN . Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin‐converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation2009;120(16):1577‐84. [MEDLINE: 19805651] AnandIS , RectorTS , KuskowskiM , AdourianA , MuntendamP , CohnJN . Baseline and serial measurements of galectin‐3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val‐HeFT. European Journal of Heart Failure2013;15(5):511‐8. [MEDLINE: 23291728] CohnJN . Improving outcomes in congestive heart failure: Val‐HeFT. Valsartan in Heart Failure Trial. Cardiology1999;91 Suppl 1:19‐22. [MEDLINE: 10449891] CohnJN , TognoniG , Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure.[Summary for patients in J Card Fail. 2002 Apr;8(2):56‐8; PMID: 12016625]. New England Journal of Medicine2001;345(23):1667‐75. [MEDLINE: 11759645] LesogorA , CohnJN , LatiniR , TognoniG , KrumH , MassieB , et al. Interaction between baseline and early worsening of renal function and efficacy of renin‐angiotensin‐aldosterone system blockade in patients with heart failure: insights from the Val‐HeFT study. European Journal of Heart Failure2013;15(11):1236‐44. [MEDLINE: 23787721] WongM , StaszewskyL , VolpiA , LatiniR , BarleraS , HoglundC . Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val‐HeFT). Journal of the American Society of Echocardiography2002;15(4):293‐301. [MEDLINE: 11944005] ">Val‐HeFT 1999</a> </p> </li> </ul> </p> <p>General population studies, potentially including people with CKD:</p> <p> <ul id="CD012466-list-0022"> <li> <p>Reported data on general population, including both people with and without CKD, but did not provide stratified data for CKD patients (81): <a href="./references#CD012466-bbs2-0001" title="ChowSL , O'BarrSA , ChewE , PakF , PatelP , PattersonJH , et al. Response of cystatin‐C and IL‐6 is sustained following nesiritide or nitroglycerin infusion [abstract no: 078]. Journal of Cardiac Failure2012;18(8 Suppl 1):S25‐6. [EMBASE: 70836720] ChowSL , O'BarrSA , PengJ , ChewE , PakF , QuistR , et al. Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study. Circulation: Heart Failure2011;4(4):450‐5. [MEDLINE: 21576282] ChowSL , O'BarrSA , PengJ , ChewE , PakF , QuistR , et al. Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure. Journal of Cardiac Failure2011;17(3):181‐7. [MEDLINE: 21362524] ChowSL , O'BarrSA , RietdorfE , PatelP , HeywoodJT . Smokers paradox: Reduction of inflammation from smoking may benefit acute decompensated heart failure [abstract no: 158]. Journal of Cardiac Failure2013;19(8 Suppl 1):S55. [EMBASE: 71142526] ">ABC‐HFT 2011</a>; <a href="./references#CD012466-bbs2-0002" title="FilippatosG , RossiJ , Lloyd‐JonesDM , StoughWG , OuyangJ , ShinDD , et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. Journal of Cardiac Failure2007;13(5):360‐4. [MEDLINE: 17602982] GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKF , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] PayvarS , OrlandiC , StoughWG , ElkayamU , OuyangJ , CasscellsSW , et al. Comparison of 60‐day mortality in hospitalized heart failure patients with versus without hypothermia. American Journal of Cardiology2006;98(11):1485‐8. [MEDLINE: 17126655] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD012466-bbs2-0004" title="Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet1993;342(8875):821‐8. [MEDLINE: 8104270] BallSG , HallAS , MurrayGD . ACE inhibition, atherosclerosis and myocardial infarction‐‐the AIRE Study in practice. Acute Infarction Ramipril Efficacy Study. European Heart Journal1994;15 Suppl B:20‐5. [MEDLINE: 8076659] ClelandJG , ErhardtL , HallAS , WinterC , BallSG . Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: a report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Journal of Cardiovascular Pharmacology1993;22 Suppl 9:S22‐7. [MEDLINE: 7514237] ErhardtL , BallS , AnderssonF , BergentoftP , MartinezC . Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy. Pharmacoeconomics1997;12(2 Pt 2):256‐66. [MEDLINE: 10170450] HallAS , MurrayGD , BallSG . Follow‐up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet1997;349(9064):1493‐7. [MEDLINE: 9167457] HallAS , WinterC , BogleSM , MackintoshAF , MurrayGD , BallSG . The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions. Journal of Cardiovascular Pharmacology1991;18 Suppl 2:S105‐9. [MEDLINE: 1725016] SchadlichPK , HuppertzE , BrechtJG . Cost‐effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance. Pharmacoeconomics1998;14(6):653‐69. [MEDLINE: 10346417] SpargiasK , BallS , HallA . The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy. Journal of Human Hypertension1999;13(8):511‐6. [MEDLINE: 10455471] ">AIRE 1991</a>; <a href="./references#CD012466-bbs2-0005" title="CammAJ , KaramR , PrattCM . The azimilide post‐infarct survival evaluation (ALIVE) trial. American Journal of Cardiology1998;81(6A):35‐9D. [MEDLINE: 9537221] CammAJ , PrattCM , SchwartzPJ , Al‐KhalidiHR , SpytMJ , HolroydeMJ , et al. Mortality in patients after a recent myocardial infarction: a randomized, placebo‐controlled trial of azimilide using heart rate variability for risk stratification. Circulation2004;109(8):990‐6. [MEDLINE: 14967728] PrattCM , SinghSN , Al‐KhalidiHR , BrumJM , HolroydeMJ , MarcelloSR , et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. Journal of the American College of Cardiology2004;43(7):1211‐6. [MEDLINE: 15063432] ">ALIVE 1998</a>; <a href="./references#CD012466-bbs2-0007" title="Effects of carvedilol, a vasodilator‐beta‐blocker, in patients with congestive heart failure due to ischemic heart disease. Australia‐New Zealand Heart Failure Research Collaborative Group. Circulation1995;92(2):212‐8. [MEDLINE: 7600653] ">ANZ 1995</a>; <a href="./references#CD012466-bbs2-0010" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105‐14. [MEDLINE: 27130705] PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224‐32. [MEDLINE: 25678098] SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113‐22. [MEDLINE: 27074824] ">ARTS‐HF 2015</a>; <a href="./references#CD012466-bbs2-0011" title="AbualnajaS , PodderM , HernandezAF , McMurrayJJ , StarlingRC , O'ConnorCM , et al. Acute heart failure and atrial fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND‐HF) Trial. Journal of the American Heart Association2015;4(8):e002092. [MEDLINE: 26304935] DandamudiS , ChenHH . The ASCEND‐HF trial: an acute study of clinical effectiveness of nesiritide and decompensated heart failure. Expert Review of Cardiovascular Therapy2012;10(5):557‐63. [MEDLINE: 22651831] EzekowitzJA , HernandezAF , O'ConnorCM , StarlingRC , ProulxG , WeissMH , et al. Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. Journal of the American College of Cardiology2012;59(16):1441‐8. [MEDLINE: 22497823] GreeneSJ , HernandezAF , SunJL , MetraM , ButlerJ , AmbrosyAP , et al. Influence of clinical trial site enrollment on patient characteristics, protocol completion, and end points: insights from the ASCEND‐HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Circulation: Heart Failure2016;9(9):e002986. [MEDLINE: 27623769] GrodinJL , PerezAL , WuY , HernandezAF , ButlerJ , MetraM , et al. Circulating kidney injury molecule‐1 levels in acute heart failure: insights from the ASCEND‐HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). JACC Heart Failure2015;3(10):777‐85. [MEDLINE: 26449997] HernandezAF , O'ConnorCM , StarlingRC , ReistCJ , ArmstrongPW , DicksteinK , et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND‐HF). American Heart Journal2009;157(2):271‐7. [MEDLINE: 19185633] HowlettJG , EzekowitzJA , PodderM , HernandezAF , DiazR , DicksteinK , et al. Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND‐HF). Circulation. Cardiovascular Quality &amp; Outcomes2013;6(5):534‐42. [MEDLINE: 23899930] KaulP , ReedSD , HernandezAF , HowlettJG , EzekowitzJA , LiY , et al. Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States. JACC Heart Failure2013;1(6):523‐30. [MEDLINE: 24622005] KellyJP , MentzRJ , HasselbladV , EzekowitzJA , ArmstrongPW , ZannadF , et al. Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND‐HF). American Heart Journal2015;170(2):298‐305. [MEDLINE: 26299227] KhazanieP , HeizerGM , HasselbladV , ArmstrongPW , CaliffRM , EzekowitzJ , et al. Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. American Heart Journal2015;170(2):290‐7. [MEDLINE: 26299226] MentzRJ , HasselbladV , DeVoreAD , MetraM , VoorsAA , ArmstrongPW , et al. Torsemide versus furosemide in patients with acute heart failure (from the ASCEND‐HF Trial). American Journal of Cardiology2016;117(3):404‐11. [MEDLINE: 26704029] MetraM , MentzRJ , HernandezAF , HeizerGM , ArmstrongPW , ClausellN , et al. Geographic differences in patients in a global acute heart failure clinical trial (from the ASCEND‐HF Trial). American Journal of Cardiology2016;117(11):1771‐8. [MEDLINE: 27108685] PatelPA , HeizerG , O'ConnorCM , SchultePJ , DicksteinK , EzekowitzJA , et al. Hypotension during hospitalization for acute heart failure is independently associated with 30‐day mortality: findings from ASCEND‐HF. Circulation: Heart Failure2014;7(6):918‐25. [MEDLINE: 25281655] PleisterAP , BaligaRR , HaasGJ . Acute study of clinical effectiveness of nesiritide in decompensated heart failure: nesiritide redux. Current Heart Failure Reports2011;8(3):226‐32. [MEDLINE: 21695395] ReedSD , KaulP , LiY , EapenZJ , Davidson‐RayL , SchulmanKA , et al. Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND‐HF. Journal of Cardiac Failure2013;19(9):611‐20. [MEDLINE: 24054337] SamskyMD , DunningA , DeVoreAD , SchultePJ , StarlingRC , TangWH , et al. Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND‐HF. European Journal of Heart Failure2016;18(4):424‐32. [MEDLINE: 26707029] TangWH , DupontM , HernandezAF , VoorsAA , HsuAP , FelkerGM , et al. Comparative assessment of short‐term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND‐HF trial. JACC Heart Failure2015;3(1):40‐9. [MEDLINE: 25453534] TangWH , WuY , GrodinJL , HsuAP , HernandezAF , ButlerJ , et al. Prognostic value of baseline and changes in circulating soluble ST2 levels and the effects of nesiritide in acute decompensated heart failure. JACC Heart Failure2016;4(1):68‐77. [MEDLINE: 26656144] vanDiepenS , PodderM , HernandezAF , WesterhoutCM , ArmstongPW , McMurrayJJ , et al. Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND‐HF. International Journal of Cardiology2014;177(3):840‐6. [MEDLINE: 25465830] ">ASCEND‐HF 2009</a>; <a href="./references#CD012466-bbs2-0012" title="ClelandJG , ClarkAL , CostanzoP , FrancisDP . Diabetes, aliskiren, and heart failure: let's bring ASTRONAUT down to earth. European Heart Journal2013;34(40):3097‐9. [MEDLINE: 23999453] GheorghiadeM , AlbaghdadiM , ZannadF , FonarowGC , BohmM , GimpelewiczC , et al. Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure2011;13(1):100‐6. [MEDLINE: 21123186] GheorghiadeM , BöhmM , GreeneSJ , FonarowGC , LewisEF , ZannadF , et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.[Erratum appears in JAMA. 2013 Apr 10;309(14):1461]. JAMA2013;309(11):1125‐35. [MEDLINE: 23478743] GreeneSJ , ButlerJ , FonarowGC , SubaciusHP , AmbrosyAP , VaduganathanM , et al. Pre‐discharge and early post‐discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. European Journal of Heart Failure2018;20(2):281‐91. [MEDLINE: 29044915] GreeneSJ , FonarowGC , SolomonSD , SubaciusH , MaggioniAP , BohmM , et al. Global variation in clinical profile, management, and post‐discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. European Journal of Heart Failure2015;17(6):591‐600. [MEDLINE: 25930208] GreeneSJ , FonarowGC , SolomonSD , SubaciusHP , AmbrosyAP , VaduganathanM , et al. Influence of atrial fibrillation on post‐discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. European Journal of Heart Failure2017;19(4):552‐62. [MEDLINE: 27748006] GreeneSJ , MaggioniAP , FonarowGC , SolomonSD , BohmM , KandraA , et al. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. European Journal of Heart Failure2015;17(1):98‐108. [MEDLINE: 25597870] MaggioniAP , GreeneSJ , FonarowGC , BohmM , ZannadF , SolomonSD , et al. Effect of aliskiren on post‐discharge outcomes among diabetic and non‐diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. European Heart Journal2013;34(40):3117‐27. [MEDLINE: 23999456] VaduganathanM , CheemaB , ClevelandE , SankarK , SubaciusH , FonarowGC , et al. Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. European Journal of Heart Failure2018;20(4):677‐86. [MEDLINE: 29143416] ">ASTRONAUT 2011</a>; <a href="./references#CD012466-bbs2-0013" title="ClelandJG , ArmstrongP , HorowitzJD , MassieB , PackerM , Poole‐WilsonPA , et al. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. European Journal of Heart Failure1999;1(1):73‐9. [MEDLINE: 10937983] ClelandJG , ThygesenK , UretskyBF , ArmstrongP , HorowitzJD , MassieB , et al. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. European Heart Journal2001;22(17):1601‐12. [MEDLINE: 11492990] EssSM , LuscherTF , SzucsTD . High dose lisinopril in heart failure: economic considerations. Cardiovascular Drugs &amp; Therapy2002;16(4):365‐71. [MEDLINE: 12652106] HorowitzJD . The ATLAS study: low‐dose versus high‐dose lisinopril in heart failure. International Journal of Clinical Practice. Supplement1999;100:15‐6. [MEDLINE: 10658293] MajumdarSR , McAlisterFA , CreeM , ChangWC , PackerM , ArmstrongPW , et al. Do evidence‐based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin‐converting enzyme inhibitors? A secondary analysis of one‐year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. Clinical Therapeutics2004;26(5):694‐703. [MEDLINE: 15220013] PackerM . Implications of the ATLAS study for clinical practice. International Journal of Clinical Practice. Supplement1999;100:21‐3. [MEDLINE: 10658296] PackerM , Poole‐WilsonPA , ArmstrongPW , ClelandJG , HorowitzJD , MassieBM , et al. Comparative effects of low and high doses of the angiotensin‐converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation1999;100(23):2312‐18. [MEDLINE: 10587334] Poole‐WilsonPA , UretskyBF , ThygesenK , ClelandJG , MassieBM , RydenL , et al. Mode of death in heart failure: findings from the ATLAS trial. Heart2003;89(1):42‐8. [MEDLINE: 12482789] RydenL , ArmstrongPW , ClelandJG , HorowitzJD , MassieBM , PackerM , et al. Efficacy and safety of high‐dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. European Heart Journal2000;21(23):1967‐78. [MEDLINE: 11071803] SculpherMJ , PooleL , ClelandJ , DrummondM , ArmstrongPW , HorowitzJD , et al. Low doses vs. high doses of the angiotensin converting‐enzyme inhibitor lisinopril in chronic heart failure: a cost‐effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. European Journal of Heart Failure2000;2(4):447‐54. [MEDLINE: 11113723] ">ATLAS 1999</a>; <a href="./references#CD012466-bbs2-0014" title="KristensenSL , MogensenUM , TarnesbyG , GimpelewiczCR , AliMA , ShaoQ , et al. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. European Journal of Heart Failure2018;20(1):136‐47. [MEDLINE: 28948656] KrumH , MassieB , AbrahamWT , DicksteinK , KoberL , McMurrayJJ , et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. European Journal of Heart Failure2011;13(1):107‐14. [MEDLINE: 21169387] KrumH , McMurrayJJ , AbrahamWT , DicksteinK , KoberL , DesaiAS , et al. The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. European Journal of Heart Failure2015;17(10):1075‐83. [MEDLINE: 26511146] McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KoberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521‐32. [MEDLINE: 27043774] ">ATMOSPHERE 2011</a>; <a href="./references#CD012466-bbs2-0015" title="BarrCS , LangCC , HansonJ , ArnottM , KennedyN , StruthersAD . Effects of adding spironolactone to an angiotensin‐converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology1995;76(17):1259‐65. [MEDLINE: 7503007] ">Barr 1995</a>; <a href="./references#CD012466-bbs2-0016" title="BarrCS , NaasAA , FenwickM , StruthersAD . Enalapril reduces QTc dispersion in mild congestive heart failure secondary to coronary artery disease. American Journal of Cardiology1997;79(3):328‐33. [MEDLINE: 9036753] ">Barr 1997</a>; <a href="./references#CD012466-bbs2-0017" title="Beautiful Study Group, FerrariR , FordI , FoxK , StegPG , TenderaM . The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction ‐ baseline characteristics of the study population. Cardiology2008;110(4):271‐82. [MEDLINE: 18595216] CeconiC , FreedmanSB , TardifJC , HildebrandtP , McDonaghT , GueretP , et al. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. International Journal of Cardiology2011;146(3):408‐14. [MEDLINE: 21112101] DanchinN . Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial. Therapie2009;64(2):111‐4. [MEDLINE: 19664404] FilipovskyJ . Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study [Ivabradin u nemocnych se stabilni ischemickou chorobou srdecni a systolickou dysfunkci leve srdecni komory: vysledky studie BEAUTIFUL]. Vnitrni Lekarstvi2009;55(5):513‐6. [MEDLINE: 19514618] FoxK , FerrariR , TenderaM , StegPG , FordI , BEAUTIFUL Steering Committee. Rationale and design of a randomized, double‐blind, placebo‐controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity‐mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. American Heart Journal2006;152(5):860‐6. [MEDLINE: 17070146] FoxK , FordI , StegPG , TenderaM , FerrariR , BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left‐ventricular systolic dysfunction (BEAUTIFUL): a randomised, double‐blind, placebo‐controlled trial. Lancet2008;372(9641):807‐16. [MEDLINE: 18757088] FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left‐ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817‐21. [MEDLINE: 18757091] FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. European Heart Journal2009;30(19):2337‐45. [MEDLINE: 19720635] TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). American Journal of Cardiology2011;107(6):805‐11. [MEDLINE: 21247517] ">BEAUTIFUL 2006</a>; <a href="./references#CD012466-bbs2-0018" title="BerryC , MurphyNF , DeVitoG , GallowayS , SeedA , FisherC , et al. Effects of aldosterone receptor blockade in patients with mild‐moderate heart failure taking a beta‐blocker.[Erratum appears in Eur J Heart Fail. 2007 Oct;9(10):1074 Note: Murphy, Niamh [corrected to Murphy, Niamh F]]. European Journal of Heart Failure2007;9(4):429–34. [MEDLINE: 17126073] ">Berry 2007</a>; <a href="./references#CD012466-bbs2-0019" title="Design of the Beta‐Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. American Journal of Cardiology1995;75(17):1220‐3. [MEDLINE: 7778543] AleongRG , SauerWH , DavisG , MurphyGA , PortJD , AnandIS , et al. Prevention of atrial fibrillation by bucindolol is dependent on the beta1389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Failure2013;1(4):338‐44. [MEDLINE: 24159564] BristowMR , Krause‐SteinraufH , NuzzoR , LiangCS , LindenfeldJ , LowesBD , et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta‐blocker evaluation of survival trial. Circulation2004;110(11):1437‐42. [MEDLINE: 15337700] CarsonP , FiuzatM , O'ConnorC , AnandI , PlehnJ , LindenfeldJA , et al. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (beta‐Blocker Evaluation of Survival Trial [BEST]). American Heart Journal2010;160(4):649‐54. [MEDLINE: 20934558] DesaiRV , BanachM , AhmedMI , MujibM , AbanI , LoveTE , et al. Impact of baseline systolic blood pressure on long‐term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). American Journal of Cardiology2010;106(2):221‐7. [MEDLINE: 20599007] DesaiRV , GuichardJL , MujibM , AhmedMI , FellerMA , FonarowGC , et al. Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving beta‐blockers: insights from the BEST trial. International Journal of Cardiology2013;163(1):61‐7. [MEDLINE: 21704392] DesaiRV , MeyerP , AhmedMI , MujibM , AdamopoulosC , WhiteM , et al. Relationship between left and right ventricular ejection fractions in chronic advanced systolic heart failure: insights from the BEST trial. European Journal of Heart Failure2011;13(4):392‐7. [MEDLINE: 21097899] DomanskiM , CoadyS , FlegJ , TianX , SachdevV . Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta‐blocker Evaluation of Survival Trial [BEST]). American Journal of Cardiology2007;99(10):1448‐50. [MEDLINE: 17493477] DomanskiM , Krause‐SteinraufH , DeedwaniaP , FollmannD , GhaliJK , GilbertE , et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. Journal of the American College of Cardiology2003;42(5):914‐22. [MEDLINE: 12957443] EichhornEJ , GrayburnPA , MayerSA , StJohn SuttonM , AppletonC , PlehnJ , et al. Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta‐blockade in patients with heart failure: the Beta‐Blocker Evaluation of Survival Trial (BEST). Circulation2003;108(19):2336‐41. [MEDLINE: 14597587] FrantzRP , LowesBD , GrayburnPA , WhiteM , Krause‐SteinraufH , KrishnanV , et al. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta‐Blocker Evaluation of Survival Study (BEST). Journal of Cardiac Failure2007;13(6):437‐44. [MEDLINE: 17675057] GhaliJK , Krause‐SteinraufHJ , AdamsKF , KhanSS , RosenbergYD , YancyCW , et al. Gender differences in advanced heart failure: insights from the BEST study. Journal of the American College of Cardiology2003;42(12):2128‐34. [MEDLINE: 14680739] GrayburnPA , AppletonCP , DeMariaAN , GreenbergB , LowesB , OhJ , et al. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the Beta‐blocker Evaluation of Survival Trial (BEST). Journal of the American College of Cardiology2005;45(7):1064‐71. [MEDLINE: 15808765] JonesLG , SinMK , HageFG , KheirbekRE , MorganCJ , ZileMR , et al. Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta‐blocker Evaluation of Survival Trial (BEST). Circulation: Heart Failure2015;8(1):17‐24. [MEDLINE: 25480782] KaoDP , DavisG , AleongR , O'ConnorCM , FiuzatM , CarsonPE , et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. European Journal of Heart Failure2013;15(3):324‐33. [MEDLINE: 23223178] KaoDP , WagnerBD , RobertsonAD , BristowMR , LowesBD . A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PLoS ONE [Electronic Resource]2012;7(11):e48184. [MEDLINE: 23144856] KristensenSL , RorthR , JhundPS , ShenL , LeeMM , PetrieMC , et al. Microvascular complications in diabetes patients with heart failure and reduced ejection fraction‐insights from the Beta‐blocker Evaluation of Survival Trial. European Journal of Heart Failure2018;20(11):1549‐56. [MEDLINE: 29727039] LindenfeldJ , GhaliJK , Krause‐SteinraufHJ , KhanS , AdamsK , GoldmanS , et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. Journal of the American College of Cardiology2003;42(7):1238‐45. [MEDLINE: 14522488] MeyerP , DesaiRV , MujibM , FellerMA , AdamopoulosC , BanachM , et al. Right ventricular ejection fraction &lt;20% is an independent predictor of mortality but not of hospitalization in older systolic heart failure patients. International Journal of Cardiology2012;155(1):120‐5. [MEDLINE: 21664707] MeyerP , FilippatosGS , AhmedMI , IskandrianAE , BittnerV , PerryGJ , et al. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation2010;121(2):252‐8. [MEDLINE: 20048206] O'ConnorCM , GottliebS , BourqueJM , Krause‐SteinraufH , AnandI , AndersonJL , et al. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. American Journal of Cardiology2005;95(5):558‐64. [MEDLINE: 15721091] PressmanA , AvinsAL , NeuhausJ , AckersonL , RuddP . Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST). Contemporary Clinical Trials2012;33(3):492‐8. [MEDLINE: 22265975] ShenL , JhundPS , MogensenUM , KoberL , ClaggettB , RogersJK , et al. Re‐Examination of the BEST trial using composite outcomes, including Emergency Department visits. JACC Heart Failure2017;5(8):591‐9. [MEDLINE: 28774394] TateCW3rd , RobertsonAD , ZoltyR , ShakarSF , LindenfeldJ , WolfelEE , et al. Quality of life and prognosis in heart failure: results of the Beta‐Blocker Evaluation of Survival Trial (BEST). Journal of Cardiac Failure2007;13(9):732‐7. [MEDLINE: 17996821] The Beta‐Blocker Evaluation of Survival Trial Investigators, EichhornEJ , DomanskiMJ , Krause‐SteinraufH , BristowMR , LavoriPW . A trial of the beta‐blocker bucindolol in patients with advanced chronic heart failure. New England Journal of Medicine2001;344(22):1659‐67. [MEDLINE: 11386264] WhiteM , DesaiRV , GuichardJL , MujibM , AbanIB , AhmedMI , et al. Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified post hoc analysis of BEST. Canadian Journal of Cardiology2012;28(3):354‐9. [MEDLINE: 21982425] WhiteM , PatelK , CaldenteyG , DeedwaniaP , KheirbekR , FletcherRD , et al. Racial differences in mortality in patients with advanced systolic heart failure: potential role of right ventricular ejection fraction. International Journal of Cardiology2014;177(1):255‐60. [MEDLINE: 25499389] ">BEST 1995</a>; <a href="./references#CD012466-bbs2-0020" title="BohlerS , SaubaduS , ScheldewaertR , FigullaHR . Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design. Arzneimittel‐Forschung1999;49(4):311‐7. [MEDLINE: 10337449] FigullaHR , Krzeminska‐PakulaM , WrabecK , ChocholaJ , KalmbachC , FridlP . Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial). International Journal of Cardiology2006;113(2):153‐60. [MEDLINE: 16157399] ">BETACAR 1999</a>; <a href="./references#CD012466-bbs2-0021" title="CotterG , DavisonBA , ButlerJ , CollinsSP , EzekowitzJA , FelkerGM , et al. Relationship between baseline systolic blood pressure and long‐term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST‐AHF. Clinical Research in Cardiology2018;107(2):170‐81. [MEDLINE: 28986703] FelkerGM , ButlerJ , CollinsSP , CotterG , DavisonBA , EzekowitzJA , et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin‐2 type 1 receptor. Rationale and design of the BLAST‐AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Failure2015;3(3):193‐201. [MEDLINE: 25650371] PangPS , ButlerJ , CollinsSP , CotterG , DavisonBA , EzekowitzJA , et al. Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double‐blind, placebo‐controlled, phase IIB, dose ranging trial (BLAST‐AHF). European Heart Journal2017;38(30):2364–73. [MEDLINE: 28459958] ">BLAST‐AHF 2015</a>; <a href="./references#CD012466-bbs2-0022" title="ColucciWS . Landmark study: the Carvedilol Post‐Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). American Journal of Cardiology2004;93(9A):13‐6B. [MEDLINE: 15144931] CostalungaA , GavazziA . Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial [Effetti del carvedilolo sulla prognosi dopo infarto miocardico in pazienti con disfunzione ventricolare sinistra: lo studio CAPRICORN]. Italian Heart Journal Supplement2001;2(11):1246‐7. [MEDLINE: 11775420] DargieHJ . Design and methodology of the CAPRICORN trial ‐ a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. European Journal of Heart Failure2000;2(3):325‐32. [MEDLINE: 10938495] DargieHJ . Effect of carvedilol on outcome after myocardial infarction in patients with left‐ventricular dysfunction: the CAPRICORN randomised trial. Lancet2001;357(9266):1385‐90. [MEDLINE: 11356434] DoughtyRN , WhalleyGA , WalshHA , GambleGD , Lopez‐SendonJ , SharpeN , et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation2004;109(2):201‐6. [MEDLINE: 14707020] FonarowGC , LukasMA , RobertsonM , ColucciWS , DargieHJ . Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post‐Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). American Heart Journal2007;154(4):637‐44. [MEDLINE: 17892984] McMurrayJ , KoberL , RobertsonM , DargieH , ColucciW , Lopez‐SendonJ , et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post‐Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. Journal of the American College of Cardiology2005;45(4):525‐30. [MEDLINE: 15708698] OtterstadJE , FordI . The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta‐blocker trials?. European Journal of Heart Failure2002;4(4):501‐6. [MEDLINE: 12167391] ">CAPRICORN 2001</a>; <a href="./references#CD012466-bbs2-0023" title="KomajdaM , LutigerB , MadeiraH , ThygesenK , BobbioM , HildebrandtP , et al. Tolerability of carvedilol and ACE‐Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE‐Inhibitor Remodelling Mild CHF EvaluatioN). European Journal of Heart Failure2004;6(4):467–75. [MEDLINE: 15182773] RemmeWJ , CARMEN Steering Committee and Investigators. The Carvedilol and ACE‐Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN)‐‐rationale and design. Cardiovascular Drugs &amp; Therapy2001;15(1):69‐77. [MEDLINE: 11504166] ">CARMEN 2001</a>; <a href="./references#CD012466-bbs2-0024" title="ZairisMN , ApostolatosC , AnastasiadisF , MytasD , KopurisN , GrassosH , et al. The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: Results from the CAlcium Sensitizer or Inotrope or None in low Output heart failure study (CASINO) [abstract no: 835‐6]. Journal of the American College of Cardiology2004;43(5 Suppl 1):206‐7A. [CENTRAL: CN‐00870514] ZairisMN , ApostolatosC , AnastassiadisF , KourisN , GrassosH , SifakiM , et al. Comparison of the effect of levosimendan,or dobutamine or placebo in chronic low output decompensated heart failure. CAlcium Sensitizer or Inotrope or NOne in low output heart failure (CASINO) study [abstract no: 273]. European Journal of Heart Failure. Supplements2004;3(1):66. ">CASINO 2004</a>; <a href="./references#CD012466-bbs2-0025" title="AritiCA , ClelandJG , PocockSJ , PfefferMA , SwedbergK , GrangerCB , et al. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. American Heart Journal2011;162(5):900‐6. [MEDLINE: 22093207] BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation: Heart Failure2014;7(4):590‐5. [MEDLINE: 24874200] ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health &amp; Risk Management2008;4(1):223‐34. [MEDLINE: 18629370] DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation: Heart Failure2014;7(6):895‐902. [MEDLINE: 25326006] HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510‐7. [MEDLINE: 17317308] HillegeHL , NitschD , PfefferMA , SwedbergK , McMurrayJJ , YusufS , et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation2006;113(5):671‐8. [MEDLINE: 16461840] LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20(8):1230‐9. [MEDLINE: 29431256] McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure‐Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261‐70. [MEDLINE: 12798823] McMurrayJJ , AnderssonFL , StewartS , SvenssonK , SolalAC , DietzR , et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2006;27(12):1447‐58. [MEDLINE: 16754631] McMurrayJJ , OstergrenJ , OlofssonB , GrangerCB , MichelsonE , YoungJB , et al. Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: results of the Candesartan in Heart Failure‐Assessment of Reduction in Mortality and Morbidity programme (CHARM) [abstract no: 835‐5]. Journal of the American College of Cardiology2004;43(5 Suppl 1):206A. McMurrayJJ , OstergrenJ , SwedbergK , GrangerCB , HeldP , MichelsonEL , et al. Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function taking angiotensin‐converting‐enzyme inhibitors: the CHARM‐Added trial. Lancet2003;362(9386):767‐71. [MEDLINE: 13678869] McMurrayJJ , YoungJB , DunlapME , GrangerCB , HainerJ , MichelsonEL , et al. Relationship of dose of background angiotensin‐converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)‐Added trial. American Heart Journal2006;151(5):985‐91. [MEDLINE: 16644319] OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure‐‐assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension ‐ Supplement2006;24(1):S3‐7. [MEDLINE: 16601570] PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , MichelsonEL , et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM‐Overall programme.[Erratum appears in Lancet. 2009 Nov 21‐2009 Nov 27;(9703):1744]. Lancet2003;362(9386):759‐66. [MEDLINE: 13678868] PreissD , ZetterstrandS , McMurrayJJ , OstergrenJ , MichelsonEL , GrangerCB , et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Diabetes Care2009;32(5):915‐20. [MEDLINE: 19196892] SolomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause‐specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180‐3. [MEDLINE: 15466644] WeirRA , McMurrayJJ , PuuM , SolomonSD , OlofssonB , GrangerCB , et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin‐converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)‐Added trial. European Journal of Heart Failure2008;10(2):157‐63. [MEDLINE: 18242128] YoungJB , DunlapME , PfefferMA , ProbstfieldJL , Cohen‐SolalA , DietzR , et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low‐left ventricular ejection fraction trials. Circulation2004;110(17):2618‐26. [MEDLINE: 15492298] ">CHARM‐Added 2003</a>; <a href="./references#CD012466-bbs2-0026" title="AritiCA , ClelandJG , PocockSJ , PfefferMA , SwedbergK , GrangerCB , et al. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. American Heart Journal2011;162(5):900‐6. [MEDLINE: 22093207] BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation: Heart Failure2014;7(4):590‐5. [MEDLINE: 24874200] ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health &amp; Risk Management2008;4(1):223‐34. [MEDLINE: 18629370] DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme. European Journal of Heart Failure2016;18(12):1508‐17. [MEDLINE: 27427441] DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation: Heart Failure2014;7(6):895‐902. [MEDLINE: 25326006] GrangerCB , McMurrayJJ , YusufS , HeldP , MichelsonEL , OlofssonB , et al. Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function intolerant to angiotensin‐converting‐enzyme inhibitors: the CHARM‐Alternative trial. Lancet2003;362(9386):772‐6. [MEDLINE: 13678870] HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510‐7. [MEDLINE: 17317308] HillegeHL , NitschD , PfefferMA , SwedbergK , McMurrayJJ , YusufS , et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation2006;113(5):671‐8. [MEDLINE: 16461840] LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20(8):1230‐9. [MEDLINE: 29431256] McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure‐Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261‐70. [MEDLINE: 12798823] McMurrayJJ , AnderssonFL , StewartS , SvenssonK , SolalAC , DietzR , et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2006;27(12):1447‐58. [MEDLINE: 16754631] McMurrayJJ , OstergrenJ , OlofssonB , GrangerCB , MichelsonE , YoungJB , et al. Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: results of the Candesartan in Heart Failure‐Assessment of Reduction in Mortality and Morbidity programme (CHARM) [abstract no: 835‐5]. Journal of the American College of Cardiology2004;43(5 Suppl 1):206A. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure‐‐assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension ‐ Supplement2006;24(1):S3‐7. [MEDLINE: 16601570] PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , MichelsonEL , et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM‐Overall programme.[Erratum appears in Lancet. 2009 Nov 21‐2009 Nov 27;(9703):1744]. Lancet2003;362(9386):759‐66. [MEDLINE: 13678868] PreissD , ZetterstrandS , McMurrayJJ , OstergrenJ , MichelsonEL , GrangerCB , et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Diabetes Care2009;32(5):915‐20. [MEDLINE: 19196892] SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160‐4. [MEDLINE: 15184734] SolomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause‐specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180‐3. [MEDLINE: 15466644] YoungJB , DunlapME , PfefferMA , ProbstfieldJL , Cohen‐SolalA , DietzR , et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low‐left ventricular ejection fraction trials. Circulation2004;110(17):2618‐26. [MEDLINE: 15492298] ">CHARM‐Alternative 2003</a>; <a href="./references#CD012466-bbs2-0027" title="AritiCA , ClelandJG , PocockSJ , PfefferMA , SwedbergK , GrangerCB , et al. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. American Heart Journal2011;162(5):900‐6. [MEDLINE: 22093207] BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation: Heart Failure2014;7(4):590‐5. [MEDLINE: 24874200] ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health &amp; Risk Management2008;4(1):223‐34. [MEDLINE: 18629370] DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation: Heart Failure2014;7(6):895‐902. [MEDLINE: 25326006] HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510‐7. [MEDLINE: 17317308] HillegeHL , NitschD , PfefferMA , SwedbergK , McMurrayJJ , YusufS , et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation2006;113(5):671‐8. [MEDLINE: 16461840] LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20(8):1230‐9. [MEDLINE: 29431256] McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure‐Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261‐70. [MEDLINE: 12798823] McMurrayJJ , AnderssonFL , StewartS , SvenssonK , SolalAC , DietzR , et al. Resource utilization and costs in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2006;27(12):1447‐58. [MEDLINE: 16754631] McMurrayJJ , OstergrenJ , OlofssonB , GrangerCB , MichelsonE , YoungJB , et al. Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: results of the Candesartan in Heart Failure‐Assessment of Reduction in Mortality and Morbidity programme (CHARM) [abstract no: 835‐5]. Journal of the American College of Cardiology2004;43(5 Suppl 1):206A. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure‐‐assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension ‐ Supplement2006;24(1):S3‐7. [MEDLINE: 16601570] PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy‐CHARMES. Journal of the American College of Cardiology2007;49(6):687‐94. [MEDLINE: 17291934] PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , MichelsonEL , et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM‐Overall programme.[Erratum appears in Lancet. 2009 Nov 21‐2009 Nov 27;(9703):1744]. Lancet2003;362(9386):759‐66. [MEDLINE: 13678868] PreissD , ZetterstrandS , McMurrayJJ , OstergrenJ , MichelsonEL , GrangerCB , et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Diabetes Care2009;32(5):915‐20. [MEDLINE: 19196892] RogersJK , PocockSJ , McMurrayJJ , GrangerCB , MichelsonEL , OstergrenJ , et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved.[Erratum appears in Eur J Heart Fail. 2014 May;16(5):592]. European Journal of Heart Failure2014;16(1):33‐40. [MEDLINE: 24453096] SolomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause‐specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180‐3. [MEDLINE: 15466644] YoungJB , DunlapME , PfefferMA , ProbstfieldJL , Cohen‐SolalA , DietzR , et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low‐left ventricular ejection fraction trials. Circulation2004;110(17):2618‐26. [MEDLINE: 15492298] YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left‐ventricular ejection fraction: the CHARM‐Preserved Trial. Lancet2003;362(9386):777‐81. [MEDLINE: 13678871] ">CHARM‐Preserved 2003</a>; <a href="./references#CD012466-bbs2-0028" title="A randomized trial of beta‐blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS).CIBIS Investigators and Committees. Circulation1994;90(4):1765‐73. [MEDLINE: 7923660] LevyP , LechatP , LeizoroviczA , LevyE . A cost‐minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovascular Drugs &amp; Therapy1998;12(3):301‐5. [MEDLINE: 9784910] ">CIBIS I 1994</a>; <a href="./references#CD012466-bbs2-0030" title="CIBIS III trial: Bisoprolol treatment for CHF leads to 46% reduction in sudden death after one year. Cardiovascular Journal of Southern Africa2006;17(5):278. [MEDLINE: 17117242] Trend towards prolonged survival in bisoprolol‐first (Concor) for heart‐failure trial (CIBIS III).[Erratum appears in Cardiovasc J S Afr. 2006 Jan‐Feb;17(1):38]. Cardiovascular Journal of Southern Africa2005;16(5):276‐9. [MEDLINE: 16307161] DobreD , vanVeldhuisenDJ , GoulderMA , KrumH , WillenheimerR . Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial. Cardiovascular Drugs &amp; Therapy2008;22(5):399‐405. [MEDLINE: 18528751] Funck‐BrentanoC , vanVeldhuisenDJ , van deVenLL , FollathF , GoulderM , WillenheimerR , et al. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS‐III trial. European Journal of Heart Failure2011;13(7):765‐72. [MEDLINE: 21551161] KrumH , vanVeldhuisenDJ , Funck‐BrentanoC , VanoliE , SilkeB , ErdmannE , et al. Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial. Cardiovascular Therapeutics2011;29(2):89‐98. [MEDLINE: 20528880] WillenheimerR . How to begin treatment in chronic heart failure? Results of CIBIS III. European Heart Journal2006;8(Suppl C):C43‐50. [EMBASE: 44594442] WillenheimerR , ErdmannE , FollathF , KrumH , PonikowskiP , SilkeB , et al. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS‐III. European Journal of Heart Failure2004;6(4):493‐500. [MEDLINE: 15182776] WillenheimerR , SilkeB . Possible clinical implications of the Cardiac Insufficiency Bisoprolol (CIBIS) III trial. British Journal of Cardiology2005;12(6):448‐54. [EMBASE: 43023774] WillenheimerR , vanVeldhuisenDJ , SilkeB , ErdmannE , FollathF , KrumH , et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation2005;112(16):2426‐35. [MEDLINE: 16143696] van deVenLL , vanVeldhuisenDJ , GoulderM , ZilahiZ , MeyerWR , WillenheimerR . The effect of treatment with bisoprolol‐first versus enalapril‐first on cardiac structure and function in heart failure. International Journal of Cardiology2010;144(1):59‐63. [MEDLINE: 19481278] ">CIBIS III 2006</a>; <a href="./references#CD012466-bbs2-0034" title='ClelandJG , CharlesworthA , LubsenJ , SwedbergK , RemmeWJ , ErhardtL , et al. A comparison of the effects of carvedilol and metoprolol on well‐being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). Journal of the American College of Cardiology2006;47(8):1603‐11. [MEDLINE: 16630997] ClelandJG , GoodeK , ErhardtL , RemmeWJ , CharlesworthA , Poole‐WilsonPA , et al. A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovascular Drugs &amp; Therapy2004;18(2):139‐52. [MEDLINE: 15162076] DiLenardaA , RemmeWJ , CharlesworthA , ClelandJG , LutigerB , MetraM , et al. Exchange of beta‐blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). European Journal of Heart Failure2005;7(4):640‐9. [MEDLINE: 15921806] LevyWC , MozaffarianD , LinkerDT , KenyonKW , ClelandJG , KomajdaM , et al. Years‐needed‐to‐treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. European Journal of Heart Failure2009;11(3):256‐63. [MEDLINE: 19164422] MetraM , Torp‐PedersenC , ClelandJG , DiLenardaA , KomajdaM , RemmeWJ , et al. Should beta‐blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. European Journal of Heart Failure2007;9(9):901‐9. [MEDLINE: 17581778] OlssonLG , SwedbergK , ClelandJG , SparkPA , KomajdaM , MetraM , et al. Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a beta‐blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. European Journal of Heart Failure2007;9(8):795‐801. [MEDLINE: 17693380] Poole‐WilsonPA , ClelandJG , DiLenardaA , HanrathP , KomajdaM , MetraM , et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. European Journal of Heart Failure2002;4(3):321‐9. [MEDLINE: 12034158] Poole‐WilsonPA , SwedbergK , ClelandJG , DiLenardaA , HanrathP , KomajdaM , et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet2003;362(9377):7‐13. [MEDLINE: 12853193] Torp‐PedersenC , MetraM , CharlesworthA , SparkP , LukasMA , Poole‐WilsonPA , et al. Effects of metoprolol and carvedilol on pre‐existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart2007;93(8):968‐73. [MEDLINE: 17237130] Torp‐PedersenC , MetraM , SparkP , LukasMA , MoulletC , ScherhagA , et al. The safety of amiodarone in patients with heart failure. Journal of Cardiac Failure2007;13(5):340‐5. [MEDLINE: 17602979] Torp‐PedersenC , Poole‐WilsonPA , SwedbergK , ClelandJG , DiLenardaA , HanrathP , et al. Effects of metoprolol and carvedilol on cause‐specific mortality and morbidity in patients with chronic heart failure‐‐COMET. American Heart Journal2005;149(2):370‐6. [MEDLINE: 15846279] Torp‐PedersenCT , Carvedilol Or Metoprolol European Trial. A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) [En randomiseret sammenligning af carvedilol og metoprolol hos patienter med kronisk hjerteinsufficiens]. Ugeskrift for Laeger2004;166(32):2671‐4. [MEDLINE: 15347171] '>COMET 2003</a>; <a href="./references#CD012466-bbs2-0035" title="CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine1987;316(23):1429‐35. [MEDLINE: 2883575] SwedbergK , KjekshusJ . Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). American Journal of Cardiology1988;62(2):60‐6A. [MEDLINE: 2839019] ">CONSENSUS 1987</a>; <a href="./references#CD012466-bbs2-0036" title="ClarkAL , CoatsAJ , KrumH , KatusHA , MohacsiP , SalekinD , et al. Effect of beta‐adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. Journal of Cachexia, Sarcopenia and Muscle2017;8(4):549‐56. [MEDLINE: 28244261] FowlerMB . Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure. American Journal of Cardiology2004;93(9A):35‐9B. [MEDLINE: 15144935] HartmannF , PackerM , CoatsAJ , FowlerMB , KrumH , MohacsiP , et al. NT‐proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT‐proBNP substudy. European Journal of Heart Failure2004;6(3):343‐50. [MEDLINE: 14987586] HartmannF , PackerM , CoatsAJ , FowlerMB , KrumH , MohacsiP , et al. Prognostic impact of plasma N‐terminal pro‐brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation2004;110(13):1780‐6. [MEDLINE: 15381643] KrumH , MohacsiP , KatusHA , TenderaM , RouleauJL , FowlerMB , et al. Are beta‐blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. American Heart Journal2006;151(1):55‐61. [MEDLINE: 16368292] KrumH , RoeckerEB , MohacsiP , RouleauJL , TenderaM , CoatsAJ , et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA2003;289(6):712‐8. [MEDLINE: 12585949] PackerM , CoatsAJ , FowlerMB , KatusHA , KrumH , MohacsiP , et al. Effect of carvedilol on survival in severe chronic heart failure. New England Journal of Medicine2001;344(22):1651‐8. [MEDLINE: 11386263] PackerM , FowlerMB , RoeckerEB , CoatsAJ , KatusHA , KrumH , et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation2002;106(17):2194‐9. [MEDLINE: 12390947] RouleauJL , RoeckerEB , TenderaM , MohacsiP , KrumH , KatusHA , et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Journal of the American College of Cardiology2004;43(8):1423‐9. [MEDLINE: 15093878] StewartS , McMurrayJJ , HebbornA , CoatsAJ , PackerM , COPERNICUS Study Group. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. International Journal of Cardiology2005;100(1):143‐9. [MEDLINE: 15820297] ">COPERNICUS 2001</a>; <a href="./references#CD012466-bbs2-0037" title="Erratum: Effects of statin therapy according to plasma high‐sensitivity C‐reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis (Circulation (2009)). Circulation2010;121(25):e461. [EMBASE: 359110247] Abdul‐RahimAH , PerezAC , FultonRL , JhundPS , LatiniR , TognoniG , et al. Response to Letter Regarding Article, &quot;Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca‐Heart Failure (GISSI‐HF) Trials.&quot;. Circulation2015;132(22):e358. [MEDLINE: 26621661] Abdul‐RahimAH , PerezAC , FultonRL , JhundPS , LatiniR , TognoniG , et al. Risk of stroke in chronic heart failure patients without atrial fibrillation: analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca‐Heart Failure (GISSI‐HF) Trials. Circulation2015;131(17):1486‐94. [MEDLINE: 25810334] ArainF , GullestadL , NymoS , KjekshusJ , ClelandJG , MichelsenA , et al. Low YKL‐40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Biomarkers2017;22(3‐4):261‐7. [MEDLINE: 27325138] ArainFK , GullestadL , NymoSH , KjekshusJ , ClelandJG , WikstrandJ , et al. YKL‐40 In chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA) [abstract]. European Heart Journal2015;36(Suppl 1):1174. [EMBASE: 72023129] AskevoldET , GullestadL , NymoS , KjekshusJ , YndestadA , LatiniR , et al. Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). PLoS ONE [Electronic Resource]2015;10(8):e0133970. [MEDLINE: 26288364] AskevoldET , GullestadL , NymoS , MichelsenAE , YndestadA , KjekshusJ , et al. Secreted frizzled related protein 3 predicts outcomes in chronic heart failure: A controlled rosuvastatin multinational trial in heart failure (CORONA) substudy. European Journal of Heart Failure Supplement2012;11(Suppl 1):S116‐7. [EMBASE: 71191045] AskevoldET , NymoS , UelandT , GravningJ , WergelandR , KjekshusJ , et al. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circulation: Heart Failure2013;6(1):91‐8. [MEDLINE: 23230311] AskevoldET , NymoS , UelandT , KjekshusJ , HultheJ , ClelandJG , et al. Soluble gp130 predicts outcome in chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA) [abstract]. European Heart Journal2011;32(Suppl 1):19. [EMBASE: 70533109] BadarAA , Perez‐MorenoAC , JhundPS , WongCM , HawkinsNM , ClelandJG , et al. Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal2014;35(48):3426‐33. [MEDLINE: 25265976] ClelandJG , McMurrayJJ , KjekshusJ , CornelJH , DunselmanP , FonsecaC , et al. Plasma concentration of amino‐terminal pro‐brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). Journal of the American College of Cardiology2009;54(20):1850‐9. [MEDLINE: 19892235] GravningJ , AskevoldET , NymoSH , UelandT , WikstrandJ , McMurrayJJ , et al. Prognostic effect of high‐sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circulation: Heart Failure2014;7(1):96‐103. [MEDLINE: 24284025] GullestadL , UelandT , KjekshusJ , NymoSH , HultheJ , MuntendamP , et al. Galectin‐3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal2012;33(18):2290‐6. [MEDLINE: 22513778] GullestadL , UelandT , KjekshusJ , NymoSH , HultheJ , MuntendamP , et al. The predictive value of galectin‐3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). American Heart Journal2012;164(6):878‐83. [MEDLINE: 23194488] HaverVG , Mateo LeachI , KjekshusJ , FoxJC , WedelH , WikstrandJ , et al. Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA). European Journal of Heart Failure2015;17(3):313‐9. [MEDLINE: 25639660] HaverVG , VerweijN , KjekshusJ , FoxJC , WedelH , WikstrandJ , et al. The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA). BMC Medical Genetics2014;15:140. [MEDLINE: 25528061] InglisS , McMurrayJJV , WedelH , DunselmanP , KjekshusJ , HjalmarsonA , et al. Intermittent claudication as a new predictor of outcome in heart failure: Evidence from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) [abstract]. European Journal of Heart Failure Supplement2009;8(Suppl 2):ii470. [EMBASE: 70298406] InglisSC , McMurrayJJ , BohmM , SchaufelbergerM , vanVeldhuisenDJ , LindbergM , et al. Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). European Journal of Heart Failure2010;12(7):698‐705. [MEDLINE: 20501489] KjekshusJ , ApetreiE , BarriosV , BohmM , ClelandJG , CornelJH , et al. Rosuvastatin in older patients with systolic heart failure. New England Journal of Medicine2007;357(22):2248‐61. [MEDLINE: 17984166] KjekshusJ , DunselmanP , BlideskogM , EskilsonC , HjalmarsonA , McMurrayJV , et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. European Journal of Heart Failure2005;7(6):1059‐69. [MEDLINE: 16227145] LinGM , HungY , LiYH . Letter by Lin et al Regarding Article, &quot;Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca‐Heart Failure (GISSI‐HF) Trials.&quot;. Circulation2015;132(22):e357. [MEDLINE: 26621660] LorgellyPK , BriggsAH , WedelH , DunselmanP , HjalmarsonA , KjekshusJ , et al. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. European Journal of Heart Failure2010;12(1):66‐74. [MEDLINE: 20023047] McMurrayJJ , DunselmanP , WedelH , ClelandJG , LindbergM , HjalmarsonA , et al. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre‐specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). Journal of the American College of Cardiology2010;56(15):1196‐204. [MEDLINE: 20883926] McMurrayJJ , DunselmanP , WikstrandJ , LindbergM , WedelH , WaagsteinF , et al. Intermittent claudication as a new predictor of outcome in heart failure: Evidence from the controlled rosuvastatin multinational trial in heart failure (CORONA) [abstract]. Journal of the American College of Cardiology2009;53(10):A165. [EMBASE: 70064578] McMurrayJJ , KjekshusJ , DunselmanP , HjalmarsonA , WedelH , LindbergM , et al. Effects of statin therapy according to plasma high sensitivity C‐reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA) [abstract]. European Heart Journal2009;30(Suppl 1):1032. [EMBASE: 70357125] McMurrayJJ , KjekshusJ , DunselmanP , HjalmarsonA , WedelH , LindbergM , et al. Prognostic importance of co‐enzyme Q10 in heart failure and interaction with statin therapy in the controlled rosuvastatin multinational trial in heart failure trial (CORONA) [abstract]. European Heart Journal2009;30(Suppl 1):1027. [EMBASE: 70357109] McMurrayJJ , KjekshusJ , GullestadL , DunselmanP , HjalmarsonA , WedelH , et al. Effects of statin therapy according to plasma high‐sensitivity C‐reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.[Erratum appears in Circulation. 2010 Jun 29;121(25):e461]. Circulation2009;120(22):2188‐96. [MEDLINE: 19917888] PerezAC , JhundP , PreissD , KjekshusJ , McMurrayJJ . Effect of rosuvastatin on fatigue in patients with heart failure. Journal of the American College of Cardiology2013;61(10):1121‐2. [MEDLINE: 23473415] PerezAC , JhundPS , StottDJ , GullestadL , ClelandJG , vanVeldhuisenDJ , et al. Thyroid‐stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure). JACC Heart Failure2014;2(1):35‐40. [MEDLINE: 24622117] Perez‐MorenoAC , JhundPS , MacdonaldMR , ClelandJG , BohmM , vanVeldhuisenDJ , et al. Symptoms as predictors of outcome in patients with heart failure in the controlled rosuvastatin multinational trial in heart failure (CORONA) [abstract]. Circulation2013;128(22 Suppl 1):NA. [EMBASE: 71339381] Perez‐MorenoAC , JhundPS , MacdonaldMR , PetrieMC , ClelandJG , BohmM , et al. Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Failure2014;2(2):187‐97. [MEDLINE: 24720928] RogersJK , JhundPS , PerezAC , BohmM , ClelandJG , GullestadL , et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Failure2014;2(3):289‐97. [MEDLINE: 24952697] UelandT , DahlCP , KjekshusJ , HultheJ , BohmM , MachF , et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circulation: Heart Failure2011;4(2):145‐52. [MEDLINE: 21216833] WaagsteinF , DunselmanP , HjalmarsonA , KjekshusJ , McMurrayJJ , WedelH , et al. Occurrence of hopitalization in relation to time of follow‐up in older patients with advanced systolic heart failure treated with rosuvastatin: experiences from the CORONA trial [abstract]. Journal of the American College of Cardiology2009;53(10):A153. [EMBASE: 70064528] WedelH , McMurrayJJ , LindbergM , WikstrandJ , ClelandJG , CornelJH , et al. Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide. European Journal of Heart Failure2009;11(3):281‐91. [MEDLINE: 19168876] ZhangJ , ClelandJG , McMurrayJ , LewseyJ , GullestadL , VeldhuisenDV , et al. Mortality risk stratification in chronic heart failure patients: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) [abstract]. European Heart Journal2012;33(Suppl 1):644. [EMBASE: 70884837] van derHarstP , SlartRH , TioRA , DunselmanPH , WillemsenAT , van denHeuvelAF , et al. Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study). American Journal of Cardiology2010;105(4):517‐21. [MEDLINE: 20152247] ">CORONA 2005</a>; <a href="./references#CD012466-bbs2-0038" title="TriposkiadisFK , ButlerJ , KarayannisG , StarlingRC , FilippatosG , WolskiK , et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD‐HF II) Trial. International Journal of Cardiology2014;172(1):115–21. [MEDLINE: 24485633] ">DAD‐HF II 2014</a>; <a href="./references#CD012466-bbs2-0039" title="deGraeffPA , KingmaJH , ViersmaJW , WesselingH , LieKI . Acute and chronic effects of ramipril and captopril in congestive heart failure. International Journal of Cardiology1989;23(1):59‐67. [MEDLINE: 2523870] ">de Graeff 1989</a>; <a href="./references#CD012466-bbs2-0042" title="CowleyAJ , WiensBL , SegalR , RichMW , SantanelloNC , DasbachEJ , et al. Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy. Quality of Life Research2000;9(4):377‐84. [MEDLINE: 11131930] PittB , ChangP , TimmermansPB . Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovascular Drugs &amp; Therapy1995;9(5):693‐700. [MEDLINE: 8573552] PittB , SegalR , MartinezFA , MeurersG , CowleyAJ , ThomasI , et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet1997;349(9054):747‐52. [MEDLINE: 9074572] ShielsP , NaasA , LimP , LearyA , MacDonaldT . The ELITE study. Evaluation of Losartan in the Elderly Study. British Journal of Clinical Pharmacology1998;45(6):613‐4. [MEDLINE: 9663821] ">ELITE 1995</a>; <a href="./references#CD012466-bbs2-0043" title="GangY , OnoT , HnatkovaK , HashimotoK , CammAJ , PittB , et al. QT dispersion has no prognostic value in patients with symptomatic heart failure: an ELITE II substudy. Pacing &amp; Clinical Electrophysiology2003;26(1P2):394‐400. [MEDLINE: 12687853] KonstamMA , NeatonJD , Poole‐WilsonPA , PittB , SegalR , SharmaD , et al. Comparison of losartan and captopril on heart failure‐related outcomes and symptoms from the losartan heart failure survival study (ELITE II). American Heart Journal2005;150(1):123‐31. [MEDLINE: 16084158] PittB , Poole‐WilsonP , SegalR , MartinezFA , DicksteinK , CammAJ , et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study‐‐ELITE II. Journal of Cardiac Failure1999;5(2):146‐54. [MEDLINE: 10404354] PittB , Poole‐WilsonPA , SegalR , MartinezFA , DicksteinK , CammAJ , et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial‐‐the Losartan Heart Failure Survival Study ELITE II. Lancet2000;355(9215):1582‐7. [MEDLINE: 10821361] SharmaR , FrancisDP , PittB , Poole‐WilsonPA , CoatsAJ , AnkerSD . Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. European Heart Journal2004;25(12):1021‐8. [MEDLINE: 15191772] ">ELITE II 2000</a>; <a href="./references#CD012466-bbs2-0045" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42(3):750–64. [MEDLINE: 24781725] ">Erb 2014</a>; <a href="./references#CD012466-bbs2-0047" title="GivertzMM , AnstromKJ , RedfieldMM , DeswalA , HaddadH , ButlerJ , et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT‐HF) study. Circulation2015;131(20):1763‐71. [MEDLINE: 25986447] GivertzMM , MannDL , LeeKL , IbarraJC , VelazquezEJ , HernandezAF , et al. Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT‐HF study. Circulation: Heart Failure2013;6(4):862‐8. [MEDLINE: 23861505] ">EXACT‐HF 2013</a>; <a href="./references#CD012466-bbs2-0048" title="FuchsW . Comparison of the safety and efficacy of delapril with captopril in outpatients with congestive heart failure. American Journal of Cardiology1995;75(16 Suppl 1):29‐36F. [MEDLINE: 7778531] ">Fuchs 1995</a>; <a href="./references#CD012466-bbs2-0049" title="SinghAK , YancyCW . Nesiritide is safe for CHF patients with renal insufficiency: retrospective results from the follow up serial infusions of nesiritide (FUSION) trial [abstract no: SA‐PO070]. Journal of the American Society of Nephrology2004;15(Oct):314A. [CENTRAL: CN‐00550458] YancyCW , SaltzbergMT , BerkowitzRL , BertoletB , VijayaraghavanK , BurnhamK , et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). American Journal of Cardiology2004;94(5):595‐601. [MEDLINE: 15342289] YancyCW , SinghA . Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow‐Up Serial Infusions of Nesiritide [FUSION I] trial). American Journal of Cardiology2006;98(2):226‐9. [MEDLINE: 16828598] ">FUSION I 2004</a>; <a href="./references#CD012466-bbs2-0051" title="GilesTD , KatzR , SullivanJM , WolfsonP , HauglandM , KirlinP , et al. Short‐ and long‐acting angiotensin‐converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril‐Captopril Congestive Heart Failure Study Group. Journal of the American College of Cardiology1989;13(6):1240‐7. [MEDLINE: 2539403] ">Giles 1989</a>; <a href="./references#CD012466-bbs2-0052" title="AleksovaA , MassonS , MaggioniAP , LucciD , FabbriG , BerettaL , et al. n‐3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI‐HF trial. European Journal of Heart Failure2013;15(11):1289‐95. [MEDLINE: 23839902] AskevoldET , AukrustP , NymoSH , LundeIG , KaasbollOJ , AakhusS , et al. The cardiokine secreted Frizzled‐related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure. Journal of Internal Medicine2014;275(6):621‐30. [MEDLINE: 24330105] BalconiG , LehmannR , FiordalisoF , AssmusB , DimmelerS , SartoP , et al. Levels of circulating pro‐angiogenic cells predict cardiovascular outcomes in patients with chronic heart failure. Journal of Cardiac Failure2009;15(9):747‐55. [MEDLINE: 19879460] BarleraS , TavazziL , FranzosiMG , MarchioliR , RaimondiE , MassonS , et al. Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico‐Heart Failure trial: proposal for a nomogram. Circulation: Heart Failure2013;6(1):31‐9. [MEDLINE: 23152490] CanepaM , TemporelliPL , RossiA , RossiA , GonziniL , NicolosiGL , et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure: data from the GISSI‐HF Trial. Cardiology2017;136(2):128‐37. [MEDLINE: 27618363] CannoneV , BarleraS , PileggiS , MassonS , FranzosiMG , LatiniR , et al. The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failure. International Journal of Cardiology2014;176(3):1249‐51. [MEDLINE: 25129277] CosmiF , DiGiulioP , MassonS , FinziA , MarfisiRM , CosmiD , et al. Regular wine consumption in chronic heart failure: impact on outcomes, quality of life, and circulating biomarkers. Circulation: Heart Failure2015;8(3):428‐37. [MEDLINE: 25925415] DammanK , MassonS , LucciD , GoriniM , UrsoR , MaggioniAP , et al. Progression of renal impairment and chronic kidney disease in chronic heart failure: an analysis from GISSI‐HF. Journal of Cardiac Failure2017;23(1):2‐9. [MEDLINE: 27638233] DaurizM , TargherG , TemporelliPL , LucciD , GonziniL , NicolosiGL , et al. Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: a post‐hoc analysis of the GISSI‐HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure) Trial. Journal of the American Heart Association2017;6(7):e005156. [MEDLINE: 28679559] DobsonCP , LaRovereMT , OlsenC , BerardinangeliM , VenianiM , MidiP , et al. 24‐hour QT variability in heart failure. Journal of Electrocardiology2009;42(6):500‐4. [MEDLINE: 19647268] DobsonCP , LaRovereMT , PinnaGD , GoldsteinR , OlsenC , BernardinangeliM , et al. QT variability index on 24‐hour Holter independently predicts mortality in patients with heart failure: analysis of Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) trial. Heart Rhythm2011;8(8):1237‐42. [MEDLINE: 21457791] GhioS , ScelsiL , LatiniR , MassonS , EleuteriE , PalvariniM , et al. Effects of n‐3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI‐HF trial.[Erratum appears in Eur J Heart Fail. 2011 Sep;13(9):1042]. European Journal of Heart Failure2010;12(12):1345‐53. [MEDLINE: 20952767] HarrisWS , MassonS , BarleraS , MilaniV , PileggiS , FranzosiMG , et al. Red blood cell oleic acid levels reflect olive oil intake while omega‐3 levels reflect fish intake and the use of omega‐3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico‐Heart Failure trial. Nutrition Research2016;36(9):989‐94. [MEDLINE: 27632919] LaRovereMT , PinnaGD , MaestriR , BarleraS , BernardinangeliM , VenianiM , et al. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI‐HF trial. European Journal of Heart Failure2012;14(12):1410‐9. [MEDLINE: 22851700] LaRovereMT , StaszewskyL , BarleraS , MaestriR , MezzaniA , MidiP , et al. n‐3PUFA and Holter‐derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) Holter substudy. Heart Rhythm2013;10(2):226‐32. [MEDLINE: 23107655] MaggioniAP , FabbriG , LucciD , MarchioliR , FranzosiMG , LatiniR , et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI‐HF trial. European Heart Journal2009;30(19):2327‐36. [MEDLINE: 19717850] MantovaniA , TargherG , TemporelliPL , LucciD , GonziniL , NicolosiGL , et al. Prognostic impact of elevated serum uric acid levels on long‐term outcomes in patients with chronic heart failure: A post‐hoc analysis of the GISSI‐HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure) trial. Metabolism: Clinical &amp; Experimental2018;83:205‐15. [MEDLINE: 29477817] MarchioliR , LevantesiG , SillettaMG , BarleraS , BernardinangeliM , CarbonieriE , et al. Effect of n‐3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI‐HF trial. Expert Review of Cardiovascular Therapy2009;7(7):735‐48. [MEDLINE: 19589110] MassonS , BarleraS , ColottaF , MagnoliM , BonelliF , MoroM , et al. A low plasma 1,25(OH)2 vitamin D/PTH (1‐84) ratio predicts worsening of renal function in patients with chronic heart failure. International Journal of Cardiology2016;224:220‐5. [MEDLINE: 27657477] MassonS , GoriF , LatiniR , MilaniV , FlyvbjergA , FrystykJ , et al. Adiponectin in chronic heart failure: influence of diabetes and genetic variants. European Journal of Clinical Investigation2011;41(12):1330‐8. [MEDLINE: 21623778] MassonS , LatiniR , CarbonieriE , MorettiL , RossiMG , CiricugnoS , et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial. European Journal of Heart Failure2010;12(4):338‐47. [MEDLINE: 20097683] MassonS , LatiniR , MilaniV , MorettiL , RossiMG , CarbonieriE , et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI‐Heart Failure trial. Circulation: Heart Failure2010;3(1):65‐72. [MEDLINE: 19850697] RosjoH , MassonS , LatiniR , FlyvbjergA , MilaniV , LaRovereMT , et al. Prognostic value of chromogranin A in chronic heart failure: data from the GISSI‐Heart Failure trial. European Journal of Heart Failure2010;12(6):549‐56. [MEDLINE: 20388648] RossiA , InciardiRM , RossiA , TemporelliPL , LucciD , GonziniL , et al. Prognostic effects of rosuvastatin in patients with co‐existing chronic obstructive pulmonary disease and chronic heart failure: a sub‐analysis of GISSI‐HF trial. Pulmonary Pharmacology &amp; Therapeutics2017;44:16‐23. [MEDLINE: 28263812] RoyslandR , MassonS , OmlandT , MilaniV , BjerreM , FlyvbjergA , et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI‐HF trial. American Heart Journal2010;160(2):286‐93. [MEDLINE: 20691834] TavazziL , MaggioniAP , MarchioliR , BarleraS , FranzosiMG , LatiniR , et al. Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial. Lancet2008;372(9645):1223–30. [MEDLINE: 18757090] TavazziL , MaggioniAP , MarchioliR , BarleraS , FranzosiMG , LatiniR , et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial. Lancet2008;372(9645):1231‐9. [MEDLINE: 18757089] TavazziL , TognoniG , FranzosiMG , LatiniR , MaggioniAP , MarchioliR , et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure2004;6(5):635‐41. [MEDLINE: 15302013] ">GISSI‐HF 2004</a>; <a href="./references#CD012466-bbs2-0054" title="BlairJE , MacarieC , RuzylloW , BacchieriA , ValentiniG , BianchettiM , et al. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON‐HF) trial. American Journal of Therapeutics2008;15(3):231‐40. [MEDLINE: 18496261] GheorghiadeM , BlairJE , FilippatosGS , MacarieC , RuzylloW , KorewickiJ , et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. Journal of the American College of Cardiology2008;51(23):2276–85. [MEDLINE: 18534276] ShahSJ , BlairJE , FilippatosGS , MacarieC , RuzylloW , KorewickiJ , et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON‐HF) trial. American Heart Journal2009;157(6):1035‐41. [MEDLINE: 19464414] ">HORIZON‐HF 2008</a>; <a href="./references#CD012466-bbs2-0055" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175‐82. [MEDLINE: 25302657] AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino‐terminal pro‐brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I‐PRESERVE trial. Circulation: Heart Failure2011;4(5):569‐77. [MEDLINE: 21715583] BadarAA , Perez‐MorenoAC , HawkinsNM , JhundPS , BruntonAP , AnandIS , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. Circulation: Heart Failure2015;8(4):717‐24. [MEDLINE: 26067854] BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I‐Preserve). European Journal of Heart Failure2014;16(7):778‐87. [MEDLINE: 24864045] CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I‐PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021‐31. [MEDLINE: 27194023] CarsonPE , AnandIS , WinS , RectorT , HaassM , Lopez‐SendonJ , et al. The hospitalization burden and post‐hospitalization mortality risk in heart failure with preserved ejection fraction: results from the I‐PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). JACC Heart Failure2015;3(6):429‐41. [MEDLINE: 25982110] DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106‐13. [MEDLINE: 25212644] GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin‐like growth factor‐binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20‐8. [MEDLINE: 27317843] HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I‐PRESERVE) trial. Circulation: Heart Failure2011;4(3):324‐31. [MEDLINE: 21350053] JhundPS , AnandIS , KomajdaM , ClaggettBL , McKelvieRS , ZileMR , et al. Changes in N‐terminal pro‐B‐type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I‐Preserve study. European Journal of Heart Failure2015;17(8):809‐17. [MEDLINE: 25921853] KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925‐35. [MEDLINE: 26250359] KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I‐PRESERVE). Circulation: Heart Failure2011;4(1):27‐35. [MEDLINE: 21068341] KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N‐terminal Pro‐B‐type natriuretic peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478‐86. [MEDLINE: 26046842] KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169‐76. [MEDLINE: 25756844] KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43‐53. [MEDLINE: 25406306] KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I‐Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724‐35. [MEDLINE: 28052977] KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I‐PRESERVE collagen substudy. Circulation: Heart Failure2011;4(5):561‐8. [MEDLINE: 21750125] LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I‐PRESERVE) trial. Circulation: Heart Failure2012;5(5):571‐8. [MEDLINE: 22887722] MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileMR , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456‐67. [MEDLINE: 19001508] McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I‐PRESERVE trial. European Journal of Heart Failure2008;10(2):149‐56. [MEDLINE: 18279770] RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long‐term effects of irbesartan on heart failure with preserved ejection fraction as measured by the Minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I‐PRESERVE) trial. Circulation: Heart Failure2012;5(2):217‐25. [MEDLINE: 22267751] ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I‐Preserve) trial. Circulation2010;121(12):1393‐405. [MEDLINE: 20231531] ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491‐501. [MEDLINE: 22064591] ">I‐PRESERVE 2008</a>; <a href="./references#CD012466-bbs2-0056" title="JiaZ , GuoM , ZhangLY , ZhangYQ , LiangHQ , SongY . Levosimendan and nesiritide as a combination therapy in patients with acute heart failure. American Journal of the Medical Sciences2015;349(5):398–405. [MEDLINE: 25853935] ">Jia 2015</a>; <a href="./references#CD012466-bbs2-0057" title="KumLC , YipGW , LeePW , LamYY , WuEB , ChanAK , et al. Comparison of angiotensin‐converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure. International Journal of Cardiology2008;125(1):16–21. [MEDLINE: 17433840] ">Kum 2008</a>; <a href="./references#CD012466-bbs2-0058" title="3‐year follow‐up of patients randomised in the metoprolol in dilated cardiomyopathy trial. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet1998;351(9110):1180‐1. [MEDLINE: 9643698] AnderssonB , CaidahlK , diLenardaA , WarrenSE , GossF , WaldenstromA , et al. Changes in early and late diastolic filling patterns induced by long‐term adrenergic beta‐blockade in patients with idiopathic dilated cardiomyopathy. Circulation1996;94(4):673‐82. [MEDLINE: 8772687] AnderssonB , HammC , PerssonS , WikstromG , SinagraG , HjalmarsonA , et al. Improved exercise hemodynamic status in dilated cardiomyopathy after beta‐adrenergic blockade treatment. Journal of the American College of Cardiology1994;23(6):1397‐404. [MEDLINE: 8176099] WaagsteinF , BristowMR , SwedbergK , CameriniF , FowlerMB , SilverMA , et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet1993;342(8885):1441‐6. [MEDLINE: 7902479] WiklundI , WaagsteinF , SwedbergK , HjalmarssonA . Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial. Cardiovascular Drugs &amp; Therapy1996;10(3):361‐8. [MEDLINE: 8877080] ">MDC 1993</a>; <a href="./references#CD012466-bbs2-0060" title="KleberFX , NiemollerL . Long‐term survival in the Munich Mild Heart Failure Trial (MHFT). American Journal of Cardiology1993;71(13):1237‐9. [MEDLINE: 8480657] KleberFX , NiemollerL , DoeringW . Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. British Heart Journal1992;67(4):289‐96. [MEDLINE: 1389702] KleberFX , NiemollerL , FischerM , DoeringW . Influence of severity of heart failure on the efficacy of angiotensin‐converting enzyme inhibition. American Journal of Cardiology1991;68(14):121‐6D. [MEDLINE: 1746416] ">MMHFT 1992</a>; <a href="./references#CD012466-bbs2-0061" title="CohnJN , PfefferMA , RouleauJ , SharpeN , SwedbergK , StraubM , et al. Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON). European Journal of Heart Failure2003;5(5):659–67. [MEDLINE: 14607206] PocockS , WilhelmsenL , DicksteinK , FrancisG , WittesJ . The data monitoring experience in the MOXCON trial. European Heart Journal2004;25(22):1974‐8. [MEDLINE: 15541832] ">MOXCON 2003</a>; <a href="./references#CD012466-bbs2-0062" title="HeJ , WintersteinAG , BeaverTM . Projecting the effect of nesiritide on dialysis and hospital mortality in cardiac surgery patients. Value in Health2010;13(5):643‐8. [MEDLINE: 20345547] MentzerRMJr , OzMC , SladenRN , GraeveAH , HebelerRF , LuberJM , et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. Journal of the American College of Cardiology2007;49(6):716–26. [MEDLINE: 17291938] ">NAPA 2007</a>; <a href="./references#CD012466-bbs2-0063" title="AnkerSD , VoorsA , OkonkoD , ClarkAL , JamesMK , vonHaehlingS , et al. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. European Heart Journal2009;30(11):1331‐9. [MEDLINE: 19383732] BogaleN , OrnS , JamesM , McCarrollK , deLunaAB , DicksteinK , et al. Usefulness of either or both left and right bundle branch block at baseline or during follow‐up for predicting death in patients following acute myocardial infarction. American Journal of Cardiology2007;99(5):647‐50. [MEDLINE: 17317365] BonarjeeVV , RosengrenA , SnapinnSM , JamesMK , DicksteinK , OPTIMAAL study group. Sex‐based short‐ and long‐term survival in patients following complicated myocardial infarction. European Heart Journal2006;27(18):2177‐83. [MEDLINE: 16882677] Brugger‐AndersenT , PonitzV , SnapinnS , DicksteinK , OPTIMAAL study group. Moderate alcohol consumption is associated with reduced long‐term cardiovascular risk in patients following a complicated acute myocardial infarction. International Journal of Cardiology2009;133(2):229‐32. [MEDLINE: 18372063] DicksteinK , GleimGW , SnapinnS , JamesMK , KjekshusJ , OPTIMAAL study group. The impact of morbid events on survival following hospitalization for complicated myocardial infarction. European Journal of Heart Failure2006;8(1):74‐80. [MEDLINE: 16081319] DicksteinK , KjekshusJ , OPTIMAAL Trial Steering Committee and Investigators.Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. American Journal of Cardiology2001;87(6):766‐71. [MEDLINE: 11249900] DicksteinK , KjekshusJ , OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high‐risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet2002;360(9335):752‐60. [MEDLINE: 12241832] GustafssonI , KistorpCN , JamesMK , FaberJO , DicksteinK , HildebrandtPR , et al. Unrecognized glycometabolic disturbance as measured by hemoglobin A1c is associated with a poor outcome after acute myocardial infarction. American Heart Journal2007;154(3):470‐6. [MEDLINE: 17719292] JaatunHJ , SutradharSC , DicksteinK , OPTIMAAL study group. Comparison of mortality rates after acute myocardial infarction in smokers versus nonsmokers. American Journal of Cardiology2004;94(5):632‐6. [MEDLINE: 15342296] KennedyLM , DicksteinK , AnkerSD , KristiansonK , WillenheimerR , OPTIMAAL study group. The prognostic importance of body mass index after complicated myocardial infarction. Journal of the American College of Cardiology2005;45(1):156‐8. [MEDLINE: 15629390] KlipIT , VoorsAA , AnkerSD , HillegeHL , StruckJ , SquireI , et al. Prognostic value of mid‐regional pro‐adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart2011;97(11):892‐8. [MEDLINE: 21415071] LehtoM , SnapinnS , DicksteinK , SwedbergK , NieminenMS , OPTIMAAL investigators. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. European Heart Journal2005;26(4):350‐6. [MEDLINE: 15618041] MollerJE , DahlstromU , GotzscheO , LahiriA , SkagenK , AndersenGS , et al. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy. American Heart Journal2004;147(3):494‐501. [MEDLINE: 14999200] VoorsAA , vonHaehlingS , AnkerSD , HillegeHL , StruckJ , HartmannO , et al. C‐terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal2009;30(10):1187‐94. [MEDLINE: 19346228] ">OPTIMAAL 2002</a>; <a href="./references#CD012466-bbs2-0064" title="OzdemirM , ArslanU , TurkogluS , BalciogluS , CengelA . Losartan improves heart rate variability and heart rate turbulence in heart failure due to ischemic cardiomyopathy. Journal of Cardiac Failure2007;13(10):812‐7. [MEDLINE: 18068613] ">Ozdemir 2007</a>; <a href="./references#CD012466-bbs2-0065" title="PacherR , StanekB , GlobitsS , BergerR , HulsmannM , WutteM , et al. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure. European Heart Journal1996;17(8):1223‐32. [MEDLINE: 8869864] ">Pacher 1996</a>; <a href="./references#CD012466-bbs2-0066" title="PackerM , LeeWH , YushakM , MedinaN . Comparison of captopril and enalapril in patients with severe chronic heart failure.[Erratum appears in N Engl J Med 1986 Oct 23;315(17):1105]. New England Journal of Medicine1986;315(14):847‐53. [MEDLINE: 3018566] ">Packer 1986</a>; <a href="./references#CD012466-bbs2-0068" title="ChandraA , LewisEF , ClaggettBL , DesaiAS , PackerM , ZileMR , et al. Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM‐HF trial. JAMA Cardiology2018;3(6):498‐505. [MEDLINE: 29617523] DesaiAS , McMurrayJJ , PackerM , SwedbergK , RouleauJL , ChenF , et al. Effect of the angiotensin‐receptor‐neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal2015;36(30):1990‐7. [MEDLINE: 26022006] DesaiAS , SolomonS , ClaggettB , McMurrayJJ , RouleauJ , SwedbergK , et al. Factors associated with noncompletion during the run‐in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM‐HF Trial. Circulation: Heart Failure2016;9(6):e002735. [MEDLINE: 27296397] DesaiAS , VardenyO , ClaggettB , McMurrayJJ , PackerM , SwedbergK , et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM‐HF trial. JAMA Cardiology2017;2(1):79‐85. [MEDLINE: 27842179] JhundPS , FuM , BayramE , ChenCH , Negrusz‐KaweckaM , RosenthalA , et al. Efficacy and safety of LCZ696 (sacubitril‐valsartan) according to age: insights from PARADIGM‐HF. European Heart Journal2015;36(38):2576‐84. [MEDLINE: 26231885] KristensenSL , MartinezF , JhundPS , ArangoJL , BelohlavekJ , BoytsovS , et al. Geographic variations in the PARADIGM‐HF heart failure trial. European Heart Journal2016;37(41):3167‐74. [MEDLINE: 27354044] KristensenSL , PreissD , JhundPS , SquireI , CardosoJS , MerkelyB , et al. Risk related to pre‐diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure2016;9(1):e002560. [MEDLINE: 26754626] LewisEF , ClaggettBL , McMurrayJJ , PackerM , LefkowitzMP , RouleauJL , et al. Health‐related quality of life outcomes in PARADIGM‐HF. Circulation: Heart Failure2017;10(8):e003430. [MEDLINE: 28784687] McMurrayJ , PackerM , DesaiA , GongJ , GreenlawN , LefkowitzM , et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal2015;36(7):434‐9. [MEDLINE: 25416329] McMurrayJJ , PackerM , DesaiAS , GongJ , LefkowitzMP , RizkalaAR , et al. Angiotensin‐neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine2014;371(11):993‐1004. [MEDLINE: 25176015] McMurrayJJ , PackerM , DesaiAS , GongJ , LefkowitzMP , RizkalaAR , et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF). European Journal of Heart Failure2013;15(9):1062‐73. [MEDLINE: 23563576] NadruzWJr , ClaggettBL , McMurrayJJ , PackerM , ZileMR , RouleauJL , et al. Impact of body mass index on the accuracy of n‐terminal pro‐brain natriuretic peptide and brain natriuretic peptide for predicting outcomes in patients with chronic heart failure and reduced ejection fraction: insights from the PARADIGM‐HF study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation2016;134(22):1785‐7. [MEDLINE: 27895026] O'MearaE , PrescottMF , ClaggettB , RouleauJL , ChiangLM , SolomonSD , et al. Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM‐HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circulation: Heart Failure2018;11(5):e004446. [MEDLINE: 29748349] OkumuraN , JhundPS , GongJ , LefkowitzMP , RizkalaAR , RouleauJL , et al. Effects of sacubitril/valsartan in the PARADIGM‐HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy. Circulation: Heart Failure2016;9(9):e003212. [MEDLINE: 27618854] OkumuraN , JhundPS , GongJ , LefkowitzMP , RizkalaAR , RouleauJL , et al. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM‐HF). Circulation2016;133(23):2254‐62. [MEDLINE: 27143684] PackerM , ClaggettB , LefkowitzMP , McMurrayJJV , RouleauJL , SolomonSD , et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin‐angiotensin system: a secondary analysis of the PARADIGM‐HF trial. Lancet Diabetes &amp; Endocrinology2018;6(7):547‐54. [MEDLINE: 29661699] PackerM , McMurrayJJ , DesaiAS , GongJ , LefkowitzMP , RizkalaAR , et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation2015;131(1):54‐61. [MEDLINE: 25403646] SabeMA , JacobMS , TaylorDO . A new class of drugs for systolic heart failure: The PARADIGM‐HF study. Cleveland Clinic Journal of Medicine2015;82(10):693‐701. [MEDLINE: 26469827] SimpsonJ , JhundPS , Silva CardosoJ , MartinezF , MosterdA , RamiresF , et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS‐HF risk scores: an analysis of mortality and morbidity in PARADIGM‐HF. Journal of the American College of Cardiology2015;66(19):2059‐71. [MEDLINE: 26541915] SolomonSD , ClaggettB , DesaiAS , PackerM , ZileM , SwedbergK , et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM‐HF) trial. Circulation: Heart Failure2016;9(3):e002744. [MEDLINE: 26915374] SolomonSD , ClaggettB , PackerM , DesaiA , ZileMR , SwedbergK , et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM‐HF trial. JACC Heart Failure2016;4(10):816‐22. [MEDLINE: 27395349] ZileMR , ClaggettBL , PrescottMF , McMurrayJJ , PackerM , RouleauJL , et al. Prognostic implications of changes in N‐terminal pro‐B‐type natriuretic peptide in patients with heart failure. Journal of the American College of Cardiology2016;68(22):2425‐36. [MEDLINE: 27908347] ">PARADIGM‐HF 2013</a>; <a href="./references#CD012466-bbs2-0069" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N‐terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP‐CHF study. European Journal of Heart Failure2012;14(5):487‐94. [MEDLINE: 22505395] ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP‐CHF study. The PEP investigators. European Journal of Heart Failure1999;1(3):211‐7. [MEDLINE: 10935667] ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ , et al. The perindopril in elderly people with chronic heart failure (PEP‐CHF) study. European Heart Journal2006;27(19):2338–45. [MEDLINE: 16963472] ">PEP‐CHF 1999</a>; <a href="./references#CD012466-bbs2-0071" title="CabellCH , TrichonBH , VelazquezEJ , DumesnilJG , AnstromKJ , RyanT , et al. Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE‐2) echocardiographic study. American Heart Journal2004;147(1):151‐7. [MEDLINE: 14691434] PackerM , CarsonP , ElkayamU , KonstamMA , MoeG , O'ConnorC , et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE‐2 study (prospective randomized amlodipine survival evaluation 2). JACC Heart Failure2013;1(4):308–14. [MEDLINE: 24621933] StantonE , HansenM , WijeysunderaHC , KupchakP , HallC , RouleauJL , et al. A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non‐ischaemic origin. European Journal of Heart Failure2005;7(4):557‐65. [MEDLINE: 15921795] WeinbergEO , ShimpoM , HurwitzS , TominagaS , RouleauJL , LeeRT . Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation2003;107(5):721‐6. [MEDLINE: 12578875] WijeysunderaHC , HansenMS , StantonE , CroppAS , HallC , DhallaNS , et al. Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. American Heart Journal2003;146(2):291‐7. [MEDLINE: 12891198] ">PRAISE‐II 2003</a>; <a href="./references#CD012466-bbs2-0073" title="GirbesAR , ZijlstraJG . Ibopamine and survival in severe congestive heart failure: PRIME II. Lancet1997;350(9071):147‐8. [MEDLINE: 9228993] HamptonJR , vanVeldhuisenDJ , CowleyAJ , KleberFX , CharlesworthA . Achieving appropriate endpoints in heart failure trials: the PRIME‐II protocol. The Second Perspective Randomised study of Ibopamine on Mortality and Efficacy. European Journal of Heart Failure1999;1(1):89‐93. [MEDLINE: 10937985] HamptonJR , vanVeldhuisenDJ , KleberFX , CowleyAJ , ArdiaA , et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet1997;349(9057):971‐7. [MEDLINE: 9100622] MasselD . Ibopamine and survival in severe congestive heart failure: PRIME II. Lancet1997;350(9071):147. [MEDLINE: 9228992] ">PRIME‐II 1997</a>; <a href="./references#CD012466-bbs2-0074" title="HansenMS , StantonEB , GawadY , PackerM , PittB , SwedbergK , et al. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. American Journal of Cardiology2002;90(9):969–73. [MEDLINE: 12398964] PackerM , PittB , RouleauJL , SwedbergK , DeMetsDL , FisherL . Long‐ term effects of flosequinan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the PROFILE trial after 24 years. JACC Heart Failure2017;5(6):399‐407. [MEDLINE: 28501522] StantonEB , HansenMS , SoleMJ , GawadY , PackerM , PittB , et al. Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. Canadian Journal of Cardiology2005;21(1):39‐43. [MEDLINE: 15685301] ">PROFILE 2002</a>; <a href="./references#CD012466-bbs2-0078" title="GottliebSS , GivertzMM , MetraM , GergichK , BirdS , Jones‐BurtonC , et al. The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study. Journal of Cardiac Failure2010;16(9):714‐9. [MEDLINE: 20797594] ">REACH UP 2010</a>; <a href="./references#CD012466-bbs2-0081" title="RislerT , BraunU , KlarnerHG , Muller‐SchauenburgW , HeitkampHC , BrillaGG , et al. Comparison of lisinopril and captopril in treatment of severe heart failure (NYHA III‐IV) in high risk patients. Preliminary results of the trial [Vergleich von Lisinopril und Captopril zur Behandlung der schweren Herzinsuffizienz (NYHA III‐IV) bei Hochrisikopatienten]. Zeitschrift fur Kardiologie1991;80 Suppl 2:40‐3. [MEDLINE: 1850942] ">Risler 1991</a>; <a href="./references#CD012466-bbs2-0083" title="SkvortsovAA , MareevVIu , NasonovaSN , SychevAV , ArbolishviliGN , BaklanovaNA , et al. Is triple combination of different neurohormonal modulators recommended for treatment of mild‐to‐moderate congestive heart failure patients? (Results of SADKO‐CHF study). Part 2. Terapevticheskii Arkhiv2006;78(9):61‐71. [MEDLINE: 17076227] SkvortsovAA , MareevVIu , NasonovaSN , SychevAV , ArbolishviliGN , BaklanovaNA , et al. Is triple combination of different neurohormonal modulators recommended for treatment of mild‐to‐moderate congestive heart failure patients? (Results of Sadko‐CHF study). Terapevticheskii Arkhiv2006;78(8):14‐20. [MEDLINE: 17078211] SkvortsovAA , NasonovaSN , SychevAV , ArbolishviliGN , BaklanovaNA , MareevVIu , et al. Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24‐h heart rate variability compared to the effect of monotherapy (data from the trial SADKO‐CHF). Terapevticheskii Arkhiv2005;77(8):34‐43. [MEDLINE: 16206603] SkvortsovAA , NasonovaSN , SychevAV , OrlovaIaA , BaklanovaNA , MasenkoVP , et al. Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO‐CHF study. Kardiologiia2006;46(7):33‐51. [MEDLINE: 16883264] ">SADKO‐CHF 2005</a>; <a href="./references#CD012466-bbs2-0087" title="SkvortsovAA , MareyevVY , ChelmakinaSM , BaklanovaNA , BelenkovYN . Efficacy and safety of long‐term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy. Kardiologiia2007;47(10):12‐23. [MEDLINE: 18260939] ">Skvortsov 2007</a>; <a href="./references#CD012466-bbs2-0088" title="SOLVD Investigators, YusufS , PittB , DavisCE , HoodWBJr , CohnJN . Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.[Erratum appears in N Engl J Med 1992 Dec 10;327(24):1768]. New England Journal of Medicine1992;327(10):685‐91. [MEDLINE: 1463530] ">SOLVD (Prevention) 1992</a>; <a href="./references#CD012466-bbs2-0090" title="GrangerCB , ErtlG , KuchJ , MaggioniAP , McMurrayJ , RouleauJL , et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin‐converting enzyme inhibitors. American Heart Journal2000;139(4):609‐17. [MEDLINE: 10740141] ">SPICE 2000</a>; <a href="./references#CD012466-bbs2-0091" title="StatsenkoME , BelenkovaSV , SporovaOE , ShilinaNN . The use of mildronate in combined therapy of postinfarction chronic heart failure in patients with type 2 diabetes mellitus. Klinicheskaia Meditsina2007;85(7):39‐42. [MEDLINE: 17882808] ">Statsenko 2007</a>; <a href="./references#CD012466-bbs2-0092" title="GhaliJK . SWORD trial of d‐sotalol. Lancet1996;348(9030):827. [MEDLINE: 8814008] PrattCM , CammAJ , CooperW , FriedmanPL , MacNeilDJ , MoultonKM , et al. Mortality in the Survival With ORal D‐sotalol (SWORD) trial: why did patients die?. American Journal of Cardiology1998;81(7):869‐76. [MEDLINE: 9555777] SchwartzPJ . Prevention of sudden death in myocardial infarct: do experimental results help to understand the clinical reality? The case of the clinical trial SWORD (Survival With ORal D‐sotalol) [Prevenzione della morte improvvisa nell'infarto miocardico: i risultati sperimentali aiutano a comprendere la realta clinica? Il caso del trial clinico SWORD]. Cardiologia1996;41(8):739‐45. [MEDLINE: 8925528] WaldoAL , CammAJ , deRuyterH , FreidmanPL , MacNeilDJ , PittB , et al. Survival with oral d‐sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). American Journal of Cardiology1995;75(15):1023‐7. [MEDLINE: 7747682] WaldoAL , CammAJ , deRuyterH , FriedmanPL , MacNeilDJ , PaulsJF , et al. Effect of d‐sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d‐Sotalol.[Erratum appears in Lancet 1996 Aug 10;348(9024):416]. Lancet1996;348(9019):7‐12. [MEDLINE: 8691967] ">SWORD 1995</a>; <a href="./references#CD012466-bbs2-0095" title="ToblliJ , LombranaA , DiGennaroF , DuarteP . NT‐proBNP reduction in elderly anemic patients with cardio‐renal anemia syndrome treated by IV iron without EPO [abstract no: SaO048]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi230. ToblliJE , DiGennaroF , RivasC . Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Heart, Lung &amp; Circulation2015;24(7):686‐95. [MEDLINE: 25666998] ToblliJE , DiGennaroFP . Hospitalization and mortality in elderly cardio‐renal patients with iron deficiency anemia receiving intravenous iron therapy: a five year follow‐up from a pilot study [abstract no: 16763]. Circulation2012;126(21 Suppl 1):NA. [EMBASE: 70956977] ToblliJE , LombranaA , DuarteP , DiGennaroF . Intravenous iron reduces NT‐pro‐brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. Journal of the American College of Cardiology2007;50(17):1657‐65. [MEDLINE: 17950147] ">Toblli 2007</a>; <a href="./references#CD012466-bbs2-0096" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Failure2017;5(4):241‐52. [MEDLINE: 28359411] BristowMR , SharmaK , AssmannSF , LinasS , GershBJ , GradyC , et al. Data and safety monitoring board evaluation and management of a renal adverse event signal in TOPCAT. European Journal of Heart Failure2017;19(4):457‐65. [MEDLINE: 27873428] DalzellJR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):179. [MEDLINE: 25006727] EfthimiadisGK , ZegkosT , KarvounisH . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):179‐80. [MEDLINE: 25006728] KumarN , GargN . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):180. [MEDLINE: 25006729] MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. [MEDLINE: 25006730] PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34‐42. [MEDLINE: 25406305] PfefferMA , PittB , McKinlaySM . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181‐2. [MEDLINE: 25006726] PittB , PfefferMA , AssmannSF , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383‐92. [MEDLINE: 24716680] ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circulation Heart Failure2014;7(5):740‐51. [MEDLINE: 25122186] ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation: Heart Failure2013;6(2):184‐92. [MEDLINE: 23258572] ">TOPCAT 2014</a>; <a href="./references#CD012466-bbs2-0097" title="AbdullaJ , BrendorpB , Torp‐PedersenC , KoberL , TRACE study group (TRAndolapril Cardiac Evaluation). Does the electrocardiographic presence of Q waves influence the survival of patients with acute myocardial infarction?. European Heart Journal2001;22(12):1008‐14. [MEDLINE: 11469214] AbdullaJ , BurchardtH , AbildstromZ , KoberL , Torp‐PedersenC , TRACE Study Group. The angiotensin converting enzyme inhibitor trandolapril has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function. European Heart Journal2003;24(23):2116‐22. [MEDLINE: 14643272] AbildstromSZ , Rask‐MadsenC , OttesenMM , AndersenPK , RosthojS , Torp‐PedersenC , et al. Impact of age and sex on sudden cardiovascular death following myocardial infarction. Heart2002;88(6):573‐8. [MEDLINE: 12433881] BallingL , KoberL , SchouM , Torp‐PedersenC , GustafssonF . Efficacy and safety of angiotensin‐converting enzyme inhibitors in patients with left ventricular systolic dysfunction and hyponatremia. Journal of Cardiac Failure2013;19(11):725‐30. [MEDLINE: 24263115] GustafssonF , KoberL , Torp‐PedersenC , PerHildebrandt . Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study. Journal of Hypertension ‐ Supplement1998;16(1):S65‐70. [MEDLINE: 9534100] KjollerE , KoberL , IversenK , Torp‐PedersenC , TRACE Study Group. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. European Journal of Heart Failure2004;6(1):71‐7. [MEDLINE: 15012921] KjollerE , KoberL , JorgensenS , Torp‐PedersenC , TRACE Study Group. Short and long term prognostic importance of regional dyskinesia versus akinesia in acute myocardial infarction. Heart2002;87(5):410‐4. [MEDLINE: 11997405] KoberL , Torp‐PedersenC , CarlsenJ , VidebaekR , EgebladH . An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi‐centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. European Heart Journal1994;15(12):1616‐20. [MEDLINE: 7698130] KoberL , Torp‐PedersenC , CarlsenJE , BaggerH , EliasenP , LyngborgK , et al. A clinical trial of the angiotensin‐converting‐enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. New England Journal of Medicine1995;333(25):1670‐6. [MEDLINE: 7477219] KoberL , Torp‐PedersenC , PedersenOD , HoibergS , CammAJ . Importance of congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction. American Journal of Cardiology1996;78(10):1124‐8. [MEDLINE: 8914875] KragelundC , HassagerC , HildebrandtP , Torp‐PedersenC , KoberL , TRACE study group. Impact of obesity on long‐term prognosis following acute myocardial infarction. International Journal of Cardiology2005;98(1):123‐31. [MEDLINE: 15676176] KragelundC , SnorgaardO , KoberL , BengtssonB , OttesenM , HojbergS , et al. Hyperinsulinaemia is associated with increased long‐term mortality following acute myocardial infarction in non‐diabetic patients. European Heart Journal2004;25(21):1891‐7. [MEDLINE: 15522467] MelchiorT , KoberL , MadsenCR , SeibaekM , JensenGV , HildebrandtP , et al. Accelerating impact of diabetes mellitus on mortality in the years following an acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. European Heart Journal1999;20(13):973‐8. [MEDLINE: 10361050] PedersenOD , AbildstromSZ , OttesenMM , Rask‐MadsenC , BaggerH , KoberL , et al. Increased risk of sudden and non‐sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. European Heart Journal2006;27(3):290‐5. [MEDLINE: 16267070] PedersenOD , BaggerH , KoberL , Torp‐PedersenC , TRACE Study Group. Impact of congestive heart failure and left ventricular systolic function on the prognostic significance of atrial fibrillation and atrial flutter following acute myocardial infarction. International Journal of Cardiology2005;100(1):65‐71. [MEDLINE: 15820287] Torp‐PedersenC , KoberL , CarlsenJ . Angiotensin‐converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. American Heart Journal1996;132(1 Pt 2 Su):235‐43. [MEDLINE: 8677862] ValeurN , NielsenOW , McMurrayJJ , Torp‐PedersenC , KoberL , TRACE Study Group. Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction. European Journal of Heart Failure2006;8(6):577‐84. [MEDLINE: 16678485] ">TRACE 1994</a>; <a href="./references#CD012466-bbs2-0098" title="KimKH , KimHK , HwangIC , ChoHJ , JeN , KwonOM , et al. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12‐week, randomized, double‐blind, placebo‐controlled trial. American Heart Journal2015;169(6):813‐22. [MEDLINE: 26027619] KimKH , KimHK , HwangIC , LeeSP , ChoHJ , KangHJ , et al. ULTIMATE‐SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo‐controlled, double‐blind trial. Trials [Electronic Resource]2013;14:188. [MEDLINE: 23799908] ">ULTIMATE‐HFrEF 2013</a>; <a href="./references#CD012466-bbs2-0099" title="CohnJN , FowlerMB , BristowMR , ColucciWS , GilbertEM , KinhalV , et al. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. Journal of Cardiac Failure1997;3(3):173‐9. [MEDLINE: 9330125] ColucciWS , PackerM , BristowMR , GilbertEM , CohnJN , FowlerMB , et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation1996;94(11):2800‐6. [MEDLINE: 8941105] FowlerMB , Vera‐LlonchM , OsterG , BristowMR , CohnJN , ColucciWS , et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. Journal of the American College of Cardiology2001;37(6):1692‐9. [MEDLINE: 11345386] JoglarJA , AcustaAP , ShustermanNH , RamaswamyK , KowalRC , BarberaSJ , et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. American Heart Journal2001;142(3):498‐501. [MEDLINE: 11526364] PackerM , BristowMR , CohnJN , ColucciWS , FowlerMB , GilbertEM , et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. New England Journal of Medicine1996;334(21):1349‐55. [MEDLINE: 8614419] Vera‐LlonchM , MenzinJ , RichnerRE , OsterG . Cost‐effectiveness results from the US Carvedilol Heart Failure Trials Program. Annals of Pharmacotherapy2001;35(7‐8):846‐51. [MEDLINE: 11485131] ">US‐Carvedilol 1996</a>; <a href="./references#CD012466-bbs2-0101" title="AnavekarNS , McMurrayJJ , VelazquezEJ , SolomonSD , KoberL , RouleauJL , et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New England Journal of Medicine2004;351(13):1285‐95. [MEDLINE: 15385655] AnavekarNS , SolomonSD , McMurrayJJ , MaggioniA , RouleauJL , CaliffR , et al. Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. American Journal of Cardiology2008;101(7):925–9. [MEDLINE: 18359309] BerryC , PieperKS , WhiteHD , SolomonSD , Van deWerfF , VelazquezEJ , et al. Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). European Heart Journal2009;30(12):1450‐6. [MEDLINE: 19346225] HawkinsNM , HuangZ , PieperKS , SolomonSD , KoberL , VelazquezEJ , et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure2009;11(3):292‐8. [MEDLINE: 19176539] HungCL , VermaA , UnoH , ShinSH , BourgounM , HassaneinAH , et al. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. Journal of the American College of Cardiology2010;56(22):1812‐22. [MEDLINE: 21087709] LamCS , McEntegartM , ClaggettB , LiuJ , SkaliH , LewisE , et al. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure2015;17(3):301‐12. [MEDLINE: 25655011] LewisEF , LiY , PfefferMA , SolomonSD , WeinfurtKP , VelazquezEJ , et al. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). JACC Heart Failure2014;2(2):159‐65. [MEDLINE: 24720924] MaggioniAP , FabbriG . VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert Opinion on Pharmacotherapy2005;6(3):507‐12. [MEDLINE: 15794740] McMurrayJ , SolomonS , PieperK , ReedS , RouleauJ , VelazquezE , et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal of the American College of Cardiology2006;47(4):726‐33. [MEDLINE: 16487836] MoukarbelGV , SignorovitchJE , PfefferMA , McMurrayJJ , WhiteHD , MaggioniAP , et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. European Heart Journal2009;30(18):2226‐32. [MEDLINE: 19556260] NilssonKRJr , Al‐KhatibSM , ZhouY , PieperK , WhiteHD , MaggioniAP , et al. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart2010;96(11):838‐42. [MEDLINE: 20406769] PfefferMA , McMurrayJ , LeizoroviczA , MaggioniAP , RouleauJL , Van deWerfF , et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. American Heart Journal2000;140(5):727‐50. [MEDLINE: 11054617] PfefferMA , McMurrayJJ , VelazquezEJ , RouleauJL , KoberL , MaggioniAP , et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.[Erratum appears in N Engl J Med. 2004 Jan 8;350(2):203]. New England Journal of Medicine2003;349(20):1893–906. [MEDLINE: 14610160] PicciniJP , HranitzkyPM , KilaruR , RouleauJL , WhiteHD , AylwardPE , et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). American Journal of Cardiology2008;102(11):1427‐32. [MEDLINE: 19026290] PouleurAC , BarkoudahE , UnoH , SkaliH , FinnPV , ZelenkofskeSL , et al. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation2010;122(6):597‐602. [MEDLINE: 20660803] PrisantLM , ThomasKL , LewisEF , HuangZ , FrancisGS , WeaverWD , et al. Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. Journal of the American College of Cardiology2008;51(19):1865‐71. [MEDLINE: 18466801] ReedSD , RadevaJI , WeinfurtKP , McMurrayJJ , PfefferMA , VelazquezEJ , et al. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal2005;150(2):323‐9. [MEDLINE: 16086938] ShahAM , UnoH , KoberL , VelazquezEJ , MaggioniAP , MacDonaldMR , et al. The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction. European Journal of Heart Failure2010;12(11):1229‐37. [MEDLINE: 20965879] ShamshadF , KenchaiahS , FinnPV , Soler‐SolerJ , McMurrayJJ , VelazquezEJ , et al. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American Heart Journal2010;160(1):145‐51. [MEDLINE: 20598985] ThuneJJ , SignorovitchJE , KoberL , McMurrayJJ , SwedbergK , RouleauJ , et al. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. European Journal of Heart Failure2011;13(2):148‐53. [MEDLINE: 21037250] VelazquezEJ , PfefferMA , McMurrayJV , MaggioniAP , RouleauJL , Van deWerfF , et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European Journal of Heart Failure2003;5(4):537‐44. [MEDLINE: 12921816] WhiteHD , AylwardPE , HuangZ , DalbyAJ , WeaverWD , BarvikS , et al. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation2005;112(22):3391‐9. [MEDLINE: 16301343] YeS , GrunnertM , ThuneJJ , StephensonKM , UnoH , FinnPV , et al. Circumstances and outcomes of sudden unexpected death in patients with high‐risk myocardial infarction: implications for prevention. Circulation2011;123(23):2674‐80. [MEDLINE: 21606398] ">VALIANT 2000</a>; <a href="./references#CD012466-bbs2-0102" title="van denBroekSA , deGraeffPA , SmitAJ , GirbesAR , JourneeL , vanGilstWH , et al. Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure: a comparison between a short‐ and a long‐acting angiotensin‐converting enzyme inhibitor. Journal of Cardiovascular Pharmacology1995;25(1):105‐12. [MEDLINE: 7723338] ">van den Broek 1995</a>; <a href="./references#CD012466-bbs2-0103" title="ClelandJG , TeerlinkJR , DavisonBA , ShoaibA , MetraM , SengerS , et al. Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure‐does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). European Journal of Heart Failure2017;19(6):739‐47. [MEDLINE: 28296139] CotterG , DavisonBA , MiloO , BourgeRC , ClelandJG , JondeauG , et al. Predictors and associations with outcomes of length of hospital stay in patients with acute heart failure: results from VERITAS. Journal of Cardiac Failure2016;22(10):815‐22. [MEDLINE: 26721775] CotterG , MetraM , DavisonBA , JondeauG , ClelandJG , BourgeRC , et al. Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?. European Journal of Heart Failure2018;20(2):317‐22. [MEDLINE: 28871621] CotterG , MetraM , DavisonBA , SengerS , BourgeRC , ClelandJG , et al. Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. European Journal of Heart Failure2014;16(12):1362‐71. [MEDLINE: 25371147] McMurrayJJ , TeerlinkJR , CotterG , BourgeRC , ClelandJG , JondeauG , et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA2007;298(17):2009‐19. [MEDLINE: 17986694] Milo‐CotterO , Cotter‐DavisonB , LombardiC , SunH , BettariL , BugattiS , et al. Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology2011;119(2):96‐105. [MEDLINE: 21912122] TeerlinkJR , McMurrayJJ , BourgeRC , ClelandJG , CotterG , JondeauG , et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). American Heart Journal2005;150(1):46‐53. [MEDLINE: 16084150] ">VERITAS 1 2005</a>; <a href="./references#CD012466-bbs2-0104" title="ClelandJG , TeerlinkJR , DavisonBA , ShoaibA , MetraM , SengerS , et al. Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure‐does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). European Journal of Heart Failure2017;19(6):739‐47. [MEDLINE: 28296139] CotterG , DavisonBA , MiloO , BourgeRC , ClelandJG , JondeauG , et al. Predictors and associations with outcomes of length of hospital stay in patients with acute heart failure: results from VERITAS. Journal of Cardiac Failure2016;22(10):815‐22. [MEDLINE: 26721775] CotterG , MetraM , DavisonBA , JondeauG , ClelandJG , BourgeRC , et al. Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?. European Journal of Heart Failure2018;20(2):317‐22. [MEDLINE: 28871621] CotterG , MetraM , DavisonBA , SengerS , BourgeRC , ClelandJG , et al. Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. European Journal of Heart Failure2014;16(12):1362‐71. [MEDLINE: 25371147] McMurrayJJ , TeerlinkJR , CotterG , BourgeRC , ClelandJG , JondeauG , et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA2007;298(17):2009‐19. [MEDLINE: 17986694] Milo‐CotterO , Cotter‐DavisonB , LombardiC , SunH , BettariL , BugattiS , et al. Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology2011;119(2):96‐105. [MEDLINE: 21912122] TeerlinkJR , McMurrayJJ , BourgeRC , ClelandJG , CotterG , JondeauG , et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). American Heart Journal2005;150(1):46‐53. [MEDLINE: 16084150] ">VERITAS 2 2005</a>; <a href="./references#CD012466-bbs2-0105" title="CarsonP , JohnsonG , FletcherR , CohnJ . Mild systolic dysfunction in heart failure (left ventricular ejection fraction &gt;35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V‐HeFT).[Erratum appears in: J Am Coll Cardiol 1996 May;27(6):1554]. Journal of the American College of Cardiology1996;27(3):642‐9. [MEDLINE: 8606276] CarsonP , ZiescheS , JohnsonG , CohnJN . Racial differences in response to therapy for heart failure: analysis of the vasodilator‐heart failure trials. Vasodilator‐Heart Failure Trial Study Group. Journal of Cardiac Failure1999;5(3):178‐87. [MEDLINE: 10496190] CarsonPE , JohnsonGR , DunkmanWB , FletcherRD , FarrellL , CohnJN . The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V‐HeFT Studies. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI102‐10. [MEDLINE: 8500233] CintronG , JohnsonG , FrancisG , CobbF , CohnJN . Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI17‐23. [MEDLINE: 8500235] CohnJN , ArchibaldDG , ZiescheS , FranciosaJA , HarstonWE , TristaniFE , et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. New England Journal of Medicine1986;314(24):1547‐52. [MEDLINE: 3520315] CohnJN , JohnsonGR , ShabetaiR , LoebH , TristaniF , RectorT , et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI5‐16. [MEDLINE: 8500240] DunkmanWB , JohnsonGR , CarsonPE , BhatG , FarrellL , CohnJN . Incidence of thromboembolic events in congestive heart failure. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI94‐101. [MEDLINE: 8500246] GoldmanS , JohnsonG , CohnJN , CintronG , SmithR , FrancisG . Mechanism of death in heart failure. The Vasodilator‐Heart Failure Trials. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI24‐31. [MEDLINE: 8500236] HughesCV , WongM , JohnsonG , CohnJN . Influence of age on mechanisms and prognosis of heart failure. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI111‐7. [MEDLINE: 8500234] LoebHS , JohnsonG , HenrickA , SmithR , WilsonJ , CremoR , et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI78‐87. [MEDLINE: 8500244] TamSW , SabolinskiML , WorcelM , PackerM , CohnJN . Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed‐dose combination of isosorbide dinitrate/hydralazine: the V‐HeFT paradox. Clinical Pharmacokinetics2007;46(10):885‐95. [MEDLINE: 17854237] WongM , JohnsonG , ShabetaiR , HughesV , BhatG , LopezB , et al. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V‐HeFT I and II. V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI65‐70. [MEDLINE: 8500242] ZiescheS , CobbFR , CohnJN , JohnsonG , TristaniF . Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V‐HeFT I and V‐HeFT II. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI56‐64. [MEDLINE: 8500241] ">V‐HEFT I 1986</a>; <a href="./references#CD012466-bbs2-0106" title="CarsonP , JohnsonG , FletcherR , CohnJ . Mild systolic dysfunction in heart failure (left ventricular ejection fraction &gt;35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V‐HeFT).[Erratum appears in: J Am Coll Cardiol 1996 May;27(6):1554]. Journal of the American College of Cardiology1996;27(3):642‐9. [MEDLINE: 8606276] CarsonP , ZiescheS , JohnsonG , CohnJN . Racial differences in response to therapy for heart failure: analysis of the vasodilator‐heart failure trials. Vasodilator‐Heart Failure Trial Study Group. Journal of Cardiac Failure1999;5(3):178‐87. [MEDLINE: 10496190] CarsonPE , JohnsonGR , DunkmanWB , FletcherRD , FarrellL , CohnJN . The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V‐HeFT Studies. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI102‐10. [MEDLINE: 8500233] CintronG , JohnsonG , FrancisG , CobbF , CohnJN . Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI17‐23. [MEDLINE: 8500235] CohnJN , JohnsonG , ZiescheS , CobbF , FrancisG , TristaniF , et al. A comparison of enalapril with hydralazine‐isosorbide dinitrate in the treatment of chronic congestive heart failure. New England Journal of Medicine1991;325(5):303‐10. [MEDLINE: 2057035] CohnJN , JohnsonGR , ShabetaiR , LoebH , TristaniF , RectorT , et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI5‐16. [MEDLINE: 8500240] DunkmanWB , JohnsonGR , CarsonPE , BhatG , FarrellL , CohnJN . Incidence of thromboembolic events in congestive heart failure. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI94‐101. [MEDLINE: 8500246] FletcherRD , CintronGB , JohnsonG , OrndorffJ , CarsonP , CohnJN . Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V‐HeFT II VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI49‐55. [MEDLINE: 8500239] FrancisGS , CohnJN , JohnsonG , RectorTS , GoldmanS , SimonA . Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V‐HeFT II. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI40‐8. [MEDLINE: 8500238] GoldmanS , JohnsonG , CohnJN , CintronG , SmithR , FrancisG . Mechanism of death in heart failure. The Vasodilator‐Heart Failure Trials. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI24‐31. [MEDLINE: 8500236] HughesCV , WongM , JohnsonG , CohnJN . Influence of age on mechanisms and prognosis of heart failure. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI111‐7. [MEDLINE: 8500234] JohnsonG , CarsonP , FrancisGS , CohnJN . Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V‐HeFT II). V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI32‐9. [MEDLINE: 8500237] LoebHS , JohnsonG , HenrickA , SmithR , WilsonJ , CremoR , et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI78‐87. [MEDLINE: 8500244] RectorTS , JohnsonG , DunkmanWB , DanielsG , FarrellL , HenrickA , et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V‐HeFT II. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI71‐7. [MEDLINE: 8500243] TamSW , SabolinskiML , WorcelM , PackerM , CohnJN . Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed‐dose combination of isosorbide dinitrate/hydralazine: the V‐HeFT paradox. Clinical Pharmacokinetics2007;46(10):885‐95. [MEDLINE: 17854237] WongM , JohnsonG , ShabetaiR , HughesV , BhatG , LopezB , et al. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V‐HeFT I and II. V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI65‐70. [MEDLINE: 8500242] ZiescheS , CobbFR , CohnJN , JohnsonG , TristaniF . Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V‐HeFT I and V‐HeFT II. The V‐HeFT VA Cooperative Studies Group. Circulation1993;87(6 Suppl):VI56‐64. [MEDLINE: 8500241] ">V‐HEFT II 1991</a>; <a href="./references#CD012466-bbs2-0107" title="BodenWE , ZiescheS , CarsonPE , ConradCH , SyatD , CohnJN . Rationale and design of the third vasodilator‐heart failure trial (V‐HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V‐HeFT III investigators. American Journal of Cardiology1996;77(12):1078‐82. [MEDLINE: 8644661] CohnJN , ZiescheS , SmithR , AnandI , DunkmanWB , LoebH , et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V‐HeFT III. Vasodilator‐Heart Failure Trial (V‐HeFT) Study Group. Circulation1997;96(3):856‐63. [MEDLINE: 9264493] ">V‐HEFT III 1996</a>; <a href="./references#CD012466-bbs2-0108" title="VizzardiE , NodariS , CarettaG , D'AloiaA , PezzalIN , FadenG , atal . Effects of spironolactone on long‐term mortality and morbidity in patients with heart failure and mild or no symptoms. American Journal of the Medical Sciences2014;347(4):271–6. [MEDLINE: 24196866] ">Vizzardi 2014</a>; <a href="./references#CD012466-bbs2-0109" title="Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.[Erratum appears in Lancet 1990 Sep 15;336(8716):698]. Lancet1990;336(8706):1‐6. [MEDLINE: 1694945] Bergler‐KleinJ , SochorH , PouleurH , PacherR , PorentaG , GlogarD . Safety of concomitant potassium‐sparing diuretics in angiotensin‐converting enzyme inhibitor therapy in severe congestive heart failure. Xamoterol in Severe Heart Failure Study Group. Journal of Cardiovascular Pharmacology1994;24(2):194‐8. [MEDLINE: 7526050] PouleurH , RousseauMF , OakleyC , RydenL . Difference in mortality between patients treated with captopril or enalapril in the Xamoterol in Severe Heart Failure Study. American Journal of Cardiology1991;68(1):71‐4. [MEDLINE: 1676239] ">Xamoterol in SHF 1990</a>; <a href="./references#CD012466-bbs2-0110" title="YamadaT , MoritaT , FurukawaY , IwasakiY , KawasakiM , KikuchiA , et al. Atorvastatin would prevent chronic kidney injury in patients with chronic heart failure‐a prospective randomized‐controlled study [abstract no: A14706]. Circulation2013;128(22 Suppl 1):NA. [EMBASE: 71339165] ">Yamada 2013</a>; <a href="./references#CD012466-bbs2-0111" title="YangW , ZhouYJ , FUY , QinJ , QinS , ChenXM , et al. A multicenter, randomized, trial comparing urapidil and nitroglycerin in multifactor heart failure in the elderly. American Journal of the Medical Sciences2015;350(2):109–15. [MEDLINE: 26164864] ">Yang 2015a</a>; <a href="./references#CD012466-bbs2-0112" title="ZhaoQ , WuTG , LinY , LiB , LuoJY , WangLX . Low‐dose nesiritide improves renal function in heart failure patients following acute myocardial infarction. Heart Vessels2010;25(2):97–103. [MEDLINE: 20339970] ">Zhao 2010</a>. </p> </li> </ul> </p> <p>Detailed information on the design, participants, intervention, comparator and outcomes of these included studies are summarised in <a href="./references#CD012466-sec-0140" title="">Characteristics of included studies</a>. </p> </section> <section id="CD012466-sec-0089"> <h4 class="title">Included studies</h4> <p>In total, 31 studies reported data for CKD patients and the characteristics of these 31 studies are reported here. Full details for all studies are summarised in the <a href="./references#CD012466-sec-0140" title="">Characteristics of included studies</a> table. </p> <section id="CD012466-sec-0090"> <h5 class="title">Study size, country and year</h5> <p>A total of 23,762 adult CKD participants were randomised; six studies (3892) were in the setting of acute HF and 25 (19,870) were in the setting of chronic HF. The number of CKD participants per group was not provided in two studies (<a href="./references#CD012466-bbs2-0003" title="AnandIS , TamSW , RectorTS , TaylorAL , SabolinskiML , ArchambaultWT , et al. Influence of blood pressure on the effectiveness of a fixed‐dose combination of isosorbide dinitrate and hydralazine in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2007;49(1):32‐9. [MEDLINE: 17207719] AnandIS , WinS , RectorTS , CohnJN , TaylorAL . Effect of fixed‐dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30‐day readmission rates in patients with heart failure: results from the African‐American Heart Failure Trial. Circulation: Heart Failure2014;7(5):759‐65. [MEDLINE: 24970468] CarsonP , TamSW , GhaliJK , ArchambaultWT , TaylorA , CohnJN , et al. Relationship of quality of life scores with baseline characteristics and outcomes in the African‐American heart failure trial. Journal of Cardiac Failure2009;15(10):835‐42. [MEDLINE: 19944359] ChangKW , BeriN , NguyenNH , ArbitB , FoxS , MojaverS , et al. Heart failure with recovered ejection fraction in African Americans: results from the African‐American Heart Failure Trial. Journal of Cardiac Failure2018;24(5):303‐9. [MEDLINE: 28918108] CohnJN , TamSW , AnandIS , TaylorAL , SabolinskiML , WorcelM , et al. Isosorbide dinitrate and hydralazine in a fixed‐dose combination produces further regression of left ventricular remodeling in a well‐treated black population with heart failure: results from A‐HeFT. Journal of Cardiac Failure2007;13(5):331‐9. [MEDLINE: 17602978] FranciosaJA , TaylorAL , CohnJN , YancyCW , ZiescheS , OlukotunA , et al. African‐American Heart Failure Trial (A‐HeFT): rationale, design, and methodology. Journal of Cardiac Failure2002;8(3):128‐35. [MEDLINE: 12140804] GhaliJK , TamSW , FerdinandKC , LindenfeldJ , SabolinskiML , TaylorAL , et al. Effects of ACE inhibitors or beta‐blockers in patients treated with the fixed‐dose combination of isosorbide dinitrate/hydralazine in the African‐American Heart Failure Trial. American Journal of Cardiovascular Drugs2007;7(5):373‐80. [MEDLINE: 18041162] GhaliJK , TamSW , SabolinskiML , TaylorAL , LindenfeldJ , CohnJN , et al. Exploring the potential synergistic action of spironolactone on nitric oxide‐enhancing therapy: insights from the African‐American Heart Failure Trial. Journal of Cardiac Failure2008;14(9):718‐23. [MEDLINE: 18995175] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , TaylorAL , et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A‐HeFT Trial. Journal of the American College of Cardiology2006;48(6):1277‐82. [MEDLINE: 16979018] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , VenkitachalamL , et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A‐HeFT trial. Journal of Cardiac Failure2009;15(3):191‐8. [MEDLINE: 19327620] McNamaraDM , TaylorAL , TamSW , WorcelM , YancyCW , Hanley‐YanezK , et al. G‐protein beta‐3 subunit genotype predicts enhanced benefit of fixed‐dose isosorbide dinitrate and hydralazine: results of A‐HeFT. JACC Heart Failure2014;2(6):551‐7. [MEDLINE: 25306451] MitchellJE , TamSW , TrivediK , TaylorAL , O'NealW , CohnJN , et al. Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A‐HeFT). American Heart Journal2011;162(1):154‐9. [MEDLINE: 21742102] TaylorAL . The African‐American Heart Failure Trial (A‐HeFT): rationale and methodology.[Erratum appears in J Card Fail. 2003 Dec;9(6):481 Note: Dosage error in article text]. Journal of Cardiac Failure2003;9(5 Suppl Nitric Oxide):S216‐9. [MEDLINE: 14583892] TaylorAL , CohnJN , WorcelM , FranciosaJA , A‐HeFT Investigators.African‐American Heart Failure Trial. The African‐American Heart Failure Trial: background, rationale and significance. Journal of the National Medical Association2002;94(9):762‐9. [MEDLINE: 12392039] TaylorAL , LindenfeldJ , ZiescheS , WalshMN , MitchellJE , AdamsK , et al. Outcomes by gender in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2006;48(11):2263‐7. [MEDLINE: 17161257] TaylorAL , SabolinskiML , TamSW , ZiescheS , GhaliJK , ArchambaultWT , et al. Effect of fixed‐dose combined isosorbide dinitrate/hydralazine in elderly patients in the African‐American heart failure trial. Journal of Cardiac Failure2012;18(8):600‐6. [MEDLINE: 22858074] TaylorAL , ZiescheS , YancyC , CarsonP , D'AgostinoRJr , FerdinandK , et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.[Erratum appears in N Engl J Med. 2005 Mar 24;352(12):1276]. New England Journal of Medicine2004;351(20):2049‐57. [MEDLINE: 15533851] TaylorAL , ZiescheS , YancyCW , CarsonP , FerdinandK , TaylorM , et al. Early and sustained benefit on event‐free survival and heart failure hospitalization from fixed‐dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African‐American Heart Failure Trial. Circulation2007;115(13):1747‐53. [MEDLINE: 17372175] YancyCW , GhaliJK , BramanVM , SabolinskiML , WorcelM , ArchambaultWT , et al. Evidence for the continued safety and tolerability of fixed‐dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African‐American Heart Failure Trial). American Journal of Cardiology2007;100(4):684‐9. [MEDLINE: 17697829] ">A‐HeFT 2002</a>; <a href="./references#CD012466-bbs2-0041" title="Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long‐term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clinical Trials1996;17(1):77‐97. [MEDLINE: 8721804] AhmedA . Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. Journals of Gerontology Series A‐Biological Sciences &amp; Medical Sciences2007;62(3):323‐9. [MEDLINE: 17389731] AhmedA , AronowWS , FlegJL . Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. American Journal of Therapeutics2006;13(4):325‐31. [MEDLINE: 16858168] AhmedA , LoveTE , SuiX , RichMW . Effects of angiotensin‐converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. Journal of Cardiac Failure2006;12(7):499‐506. [MEDLINE: 16952782] AhmedA , RichMW , SandersPW , PerryGJ , BakrisGL , ZileMR , et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. American Journal of Cardiology2007;99(3):393‐8. [MEDLINE: 17261405] BowlingCB , PittB , AhmedMI , AbanIB , SandersPW , MujibM , et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity‐matched studies. Circulation: Heart Failure2010;3(2):353‐60. [MEDLINE: 20103777] CampbellRC , SuiX , FilippatosG , LoveTE , WahleC , SandersPW , et al. Association of chronic kidney disease with outcomes in chronic heart failure: a propensity‐matched study. Nephrology Dialysis Transplantation2009;24(1):186‐93. [MEDLINE: 18711222] Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine1997;336(8):525‐33. [MEDLINE: 9036306] EkundayoOJ , MuchimbaM , AbanIB , RitchieC , CampbellRC , AhmedA . Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. American Journal of Cardiology2009;103(1):88‐92. [MEDLINE: 19101236] RitchieC , EkundayoOJ , MuchimbaM , CampbellRC , FrankSJ , LiuB , et al. Effects of diabetes mellitus in patients with heart failure and chronic kidney disease: a propensity‐matched study of multimorbidity in chronic heart failure.[Erratum appears in Int J Cardiol. 2010 Jan 7;138(1):106]. International Journal of Cardiology2009;134(3):330‐5. [MEDLINE: 19178965] ShlipakMG , SmithGL , RathoreSS , MassieBM , KrumholzHM . Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. Journal of the American Society of Nephrology2004;15(8):2195‐203. [MEDLINE: 15284305] TestaniJM , BriscoMA , TangWH , KimmelSE , Tiku‐OwensA , ForfiaPR , et al. Potential effects of digoxin on long‐term renal and clinical outcomes in chronic heart failure. Journal of Cardiac Failure2013;19(5):295‐302. [MEDLINE: 23663810] ">DIG 1996</a>). Sample sizes ranged from 16 to 3157 participants and the reported follow‐up ranged from 12 weeks to five years. </p> <p>Ten of 31 studies (32%) were conducted in single‐country settings. Three (10%) in Canada or the USA only, and 16 (52%) were in at least three countries. Two studies (6%) did not report this information. Study initiation ranged from 1986 to 2015. </p> <p>Participants’ mean age was reported in 24 (77%) of the 31 studies. The proportion of men ranged between 64.9% and 82.1% and the proportion of people with diabetes ranged between 14.5% and 62.5%. Demographic data for CKD participants (age, sex, diabetes status) were not reported in seven studies (<a href="./references#CD012466-bbs2-0003" title="AnandIS , TamSW , RectorTS , TaylorAL , SabolinskiML , ArchambaultWT , et al. Influence of blood pressure on the effectiveness of a fixed‐dose combination of isosorbide dinitrate and hydralazine in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2007;49(1):32‐9. [MEDLINE: 17207719] AnandIS , WinS , RectorTS , CohnJN , TaylorAL . Effect of fixed‐dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30‐day readmission rates in patients with heart failure: results from the African‐American Heart Failure Trial. Circulation: Heart Failure2014;7(5):759‐65. [MEDLINE: 24970468] CarsonP , TamSW , GhaliJK , ArchambaultWT , TaylorA , CohnJN , et al. Relationship of quality of life scores with baseline characteristics and outcomes in the African‐American heart failure trial. Journal of Cardiac Failure2009;15(10):835‐42. [MEDLINE: 19944359] ChangKW , BeriN , NguyenNH , ArbitB , FoxS , MojaverS , et al. Heart failure with recovered ejection fraction in African Americans: results from the African‐American Heart Failure Trial. Journal of Cardiac Failure2018;24(5):303‐9. [MEDLINE: 28918108] CohnJN , TamSW , AnandIS , TaylorAL , SabolinskiML , WorcelM , et al. Isosorbide dinitrate and hydralazine in a fixed‐dose combination produces further regression of left ventricular remodeling in a well‐treated black population with heart failure: results from A‐HeFT. Journal of Cardiac Failure2007;13(5):331‐9. [MEDLINE: 17602978] FranciosaJA , TaylorAL , CohnJN , YancyCW , ZiescheS , OlukotunA , et al. African‐American Heart Failure Trial (A‐HeFT): rationale, design, and methodology. Journal of Cardiac Failure2002;8(3):128‐35. [MEDLINE: 12140804] GhaliJK , TamSW , FerdinandKC , LindenfeldJ , SabolinskiML , TaylorAL , et al. Effects of ACE inhibitors or beta‐blockers in patients treated with the fixed‐dose combination of isosorbide dinitrate/hydralazine in the African‐American Heart Failure Trial. American Journal of Cardiovascular Drugs2007;7(5):373‐80. [MEDLINE: 18041162] GhaliJK , TamSW , SabolinskiML , TaylorAL , LindenfeldJ , CohnJN , et al. Exploring the potential synergistic action of spironolactone on nitric oxide‐enhancing therapy: insights from the African‐American Heart Failure Trial. Journal of Cardiac Failure2008;14(9):718‐23. [MEDLINE: 18995175] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , TaylorAL , et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A‐HeFT Trial. Journal of the American College of Cardiology2006;48(6):1277‐82. [MEDLINE: 16979018] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , VenkitachalamL , et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A‐HeFT trial. Journal of Cardiac Failure2009;15(3):191‐8. [MEDLINE: 19327620] McNamaraDM , TaylorAL , TamSW , WorcelM , YancyCW , Hanley‐YanezK , et al. G‐protein beta‐3 subunit genotype predicts enhanced benefit of fixed‐dose isosorbide dinitrate and hydralazine: results of A‐HeFT. JACC Heart Failure2014;2(6):551‐7. [MEDLINE: 25306451] MitchellJE , TamSW , TrivediK , TaylorAL , O'NealW , CohnJN , et al. Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A‐HeFT). American Heart Journal2011;162(1):154‐9. [MEDLINE: 21742102] TaylorAL . The African‐American Heart Failure Trial (A‐HeFT): rationale and methodology.[Erratum appears in J Card Fail. 2003 Dec;9(6):481 Note: Dosage error in article text]. Journal of Cardiac Failure2003;9(5 Suppl Nitric Oxide):S216‐9. [MEDLINE: 14583892] TaylorAL , CohnJN , WorcelM , FranciosaJA , A‐HeFT Investigators.African‐American Heart Failure Trial. The African‐American Heart Failure Trial: background, rationale and significance. Journal of the National Medical Association2002;94(9):762‐9. [MEDLINE: 12392039] TaylorAL , LindenfeldJ , ZiescheS , WalshMN , MitchellJE , AdamsK , et al. Outcomes by gender in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2006;48(11):2263‐7. [MEDLINE: 17161257] TaylorAL , SabolinskiML , TamSW , ZiescheS , GhaliJK , ArchambaultWT , et al. Effect of fixed‐dose combined isosorbide dinitrate/hydralazine in elderly patients in the African‐American heart failure trial. Journal of Cardiac Failure2012;18(8):600‐6. [MEDLINE: 22858074] TaylorAL , ZiescheS , YancyC , CarsonP , D'AgostinoRJr , FerdinandK , et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.[Erratum appears in N Engl J Med. 2005 Mar 24;352(12):1276]. New England Journal of Medicine2004;351(20):2049‐57. [MEDLINE: 15533851] TaylorAL , ZiescheS , YancyCW , CarsonP , FerdinandK , TaylorM , et al. Early and sustained benefit on event‐free survival and heart failure hospitalization from fixed‐dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African‐American Heart Failure Trial. Circulation2007;115(13):1747‐53. [MEDLINE: 17372175] YancyCW , GhaliJK , BramanVM , SabolinskiML , WorcelM , ArchambaultWT , et al. Evidence for the continued safety and tolerability of fixed‐dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African‐American Heart Failure Trial). American Journal of Cardiology2007;100(4):684‐9. [MEDLINE: 17697829] ">A‐HeFT 2002</a>; <a href="./references#CD012466-bbs2-0006" title="JacksonCE , MacDonaldMR , PetrieMC , SolomonSD , PittB , LatiniR , et al. Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure2011;13(7):746‐54. [MEDLINE: 21459891] MaggioniAP , McMurrayJJ , LatiniR , SolomonSD , SmithBA , BushC , et al. Safety and tolerability profile of aliskiren added to optimized therapy in patients with heart failure and renal impairment [abstract no: SA‐PO2247]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):616A. [CENTRAL: CN‐00776176] McMurrayJJ , PittB , LatiniR , MaggioniAP , SolomonSD , KeefeDL , et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure2008;1(1):17‐24. [MEDLINE: 19808266] ">ALOFT 2008</a>; <a href="./references#CD012466-bbs2-0040" title="BrendorpB , ElmingH , JunL , KoberL , MalikM , JensenGB , et al. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation2001;103(10):1422‐7. [MEDLINE: 11245647] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group.Danish Investigations Of Arrhythmia and Mortality On Dofetilide. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. European Journal of Heart Failure2002;4(2):201‐6. [MEDLINE: 11959050] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group. The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide. Clinical Cardiology2003;26(5):219‐25. [MEDLINE: 12769249] MollerM , Torp‐PedersenCT , KoberL . Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congestive Heart Failure2001;7(3):146‐50. [MEDLINE: 11828153] PedersenHS , ElmingH , SeibaekM , BurchardtH , BrendorpB , Torp‐PedersenC , et al. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. American Journal of Cardiology2007;100(5):876‐80. [MEDLINE: 17719337] Torp‐PedersenC , MollerM , Bloch‐ThomsenPE , KoberL , SandoeE , EgstrupK , et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. New England Journal of Medicine1999;341(12):857‐65. [MEDLINE: 10486417] ">DIAMOND 1999</a>; <a href="./references#CD012466-bbs2-0044" title="EschalierR , McMurrayJJ , SwedbergK , vanVeldhuisenDJ , KrumH , PocockSJ , et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS‐HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Journal of the American College of Cardiology2013;62(17):1585‐93. [MEDLINE: 23810881] KrumH , ShiH , PittB , McMurrayJ , SwedbergK , vanVeldhuisenDJ , et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS‐HF study. Circulation: Heart Failure2013;6(4):711‐8. [MEDLINE: 23625945] RogersJK , McMurrayJJ , PocockSJ , ZannadF , KrumH , vanVeldhuisenDJ , et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation2012;126(19):2317‐23. [MEDLINE: 23042980] RossignolP , DobreD , McMurrayJJ , SwedbergK , KrumH , vanVeldhuisenDJ , et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF). Circulation: Heart Failure2014;7(1):51‐8. [MEDLINE: 24297687] ZannadF , McMurrayJJ , DrexlerH , KrumH , vanVeldhuisenDJ , SwedbergK , et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF). European Journal of Heart Failure2010;12(6):617‐22. [MEDLINE: 20388647] ZannadF , McMurrayJJ , KrumH , vanVeldhuisenDJ , SwedbergK , ShiH , et al. Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine2011;364(1):11‐21. [MEDLINE: 21073363] ">EMPHASIS‐HF 2010</a>; <a href="./references#CD012466-bbs2-0046" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJC , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJC , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD012466-bbs2-0053" title="HuDY , HuangJ , CaiNS , ZhuWL , LiYS , MassaadR , et al. A multi‐center, double‐blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment. Chinese Medical Journal2012;125(21):3868‐74. [MEDLINE: 23106890] KiernanMS , GregoryD , SarnakMJ , RossignolP , MassaroJ , KociolR , et al. Early and late effects of high‐ versus low‐dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.[Erratum appears in JACC Heart Fail. 2015 Jun;3(6):510‐1]. JACC Heart Failure2015;3(3):214‐23. [MEDLINE: 25742759] KiernanMS , WentworthD , FrancisG , MartinezFA , DicksteinK , KomajdaM , et al. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. European Journal of Heart Failure2012;14(12):1401‐9. [MEDLINE: 23187648] KonstamMA , NeatonJD , DicksteinK , DrexlerH , KomajdaM , MartinezFA , et al. Effects of high‐dose versus low‐dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double‐blind trial.[Erratum appears in Lancet. 2009 Dec 5;374(9705):1888]. Lancet2009;374(9704):1840‐8. [MEDLINE: 19922995] KonstamMA , Poole‐WilsonPA , DicksteinK , DrexlerH , JusticeSJ , KomajdaM , et al. Design of the heart failure endpoint evaluation of AII‐antagonist losartan (HEAAL) study in patients intolerant to ACE‐inhibitor. European Journal of Heart Failure2008;10(9):899‐906. [MEDLINE: 18768350] RossignolP , DobreD , GregoryD , MassaroJ , KiernanM , KonstamMA , et al. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2014;173(3):380‐7. [MEDLINE: 24726210] RossignolP , GirerdN , GregoryD , MassaroJ , KonstamMA , ZannadF . Increased visit‐to‐visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2015;187:183‐9. [MEDLINE: 25828348] UpshawJN , KonstamMA , KlaverenD , NoubaryF , HugginsGS , KentDM . Multistate model to predict heart failure hospitalizations and all‐cause mortality in outpatients with heart failure with reduced ejection fraction: model derivation and external validation. Circulation: Heart Failure2016;9(8):e003146. [MEDLINE: 27514751] ">HEAAL 2008</a>; <a href="./references#CD012466-bbs2-0075" title="EichhornEJ , TandonPK , DiBiancoR , TimmisGC , FensterPE , ShannonJ , et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. Journal of the American College of Cardiology1993;21(3):634‐40. [MEDLINE: 8436744] PackerM . Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. American Journal of Cardiology1989;63(2):41‐5A. [MEDLINE: 2642629] PackerM , CarverJR , RodehefferRJ , IvanhoeRJ , DiBiancoR , ZeldisSM , et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. New England Journal of Medicine1991;325(21):1468‐75. [MEDLINE: 1944425] TeerlinkJR , JalaluddinM , AndersonS , KukinML , EichhornEJ , FrancisG , et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation2000;101(1):40‐6. [MEDLINE: 10618302] ">PROMISE 1989</a>). </p> <p>Studies in acute HF (6) included patients who had been admitted for acute decompensated HF (<a href="./references#CD012466-bbs2-0067" title="PalazzuoliA , PellegriniM , FranciB , BeltramiM , RuoccoG , GonnelliS , et al. Short and long‐term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction. Internal &amp; Emergency Medicine2015;10(1):41‐49. [MEDLINE: 25087085] PalazzuoliA , PellegriniM , RuoccoG , MartiniG , FranciB , CampagnaMS , et al. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Critical Care (London, England)2014;18(3):R132. [MEDLINE: 24974232] ">Palazzuoli 2014</a>; <a href="./references#CD012466-bbs2-0072" title="DavisonBA , CotterG , SunH , ChenL , TeerlinkJR , MetraM , et al. Permutation criteria to evaluate multiple clinical endpoints in a proof‐of‐concept study: lessons from Pre‐RELAX‐AHF. Clinical Research in Cardiology2011;100(9):745‐53. [MEDLINE: 21416190] MetraM , TeerlinkJR , FelkerGM , GreenbergBH , FilippatosG , PonikowskiP , et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre‐RELAX‐AHF study. European Journal of Heart Failure2010;12(10):1130‐9. [MEDLINE: 20732868] Milo‐CotterO , TeerlinkJR , MetraM , FelkerGM , PonikowskiP , VoorsAA , et al. Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre‐RELAX‐AHF study. Cardiology2010;117(3):190‐6. [MEDLINE: 21088400] TeerlinkJR , MetraM , FelkerGM , PonikowskiP , VoorsAA , WeatherleyBD , et al. Relaxin for the treatment of patients with acute heart failure (Pre‐RELAX‐AHF): a multicentre, randomised, placebo‐controlled, parallel‐group, dose‐finding phase IIb study. Lancet2009;373(9673):1429‐39. [MEDLINE: 19329178] VoorsAA , DavisonBA , FelkerGM , PonikowskiP , UnemoriE , CotterG , et al. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre‐RELAX‐AHF. European Journal of Heart Failure2011;13(9):961‐7. [MEDLINE: 21622980] ">Pre‐RELAX‐AHF 2009</a>; <a href="./references#CD012466-bbs2-0076" title="ClelandJG , ChiswellK , TeerlinkJR , StevensS , FiuzatM , GivertzMM , et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo‐Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Circulation: Heart Failure2014;7(1):76‐87. [MEDLINE: 24281134] CotterG , DittrichHC , WeatherleyBD , BloomfieldDM , O'ConnorCM , MetraM , et al. The PROTECT pilot study: a randomized, placebo‐controlled, dose‐finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. Journal of Cardiac Failure2008;14(8):631‐40. [MEDLINE: 18926433] GivertzMM , PostmusD , HillegeHL , MansoorGA , MassieBM , DavisonBA , et al. Renal function trajectories and clinical outcomes in acute heart failure. Circulation: Heart Failure2014;7(1):59‐67. [MEDLINE: 24281137] MassieBM , O'ConnorCM , MetraM , PonikowskiP , TeerlinkJR , CotterG , et al. Rolofylline, an adenosine A1‐receptor antagonist, in acute heart failure. New England Journal of Medicine2010;363(15):1419‐28. [MEDLINE: 20925544] MetraM , ClelandJG , WeatherleyBD , DittrichHC , GivertzMM , MassieBM , et al. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60‐day outcomes in the PROTECT pilot study. European Journal of Heart Failure2010;12(5):499‐507. [MEDLINE: 20228387] MetraM , O'ConnorCM , DavisonBA , ClelandJG , PonikowskiP , TeerlinkJR , et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. European Heart Journal2011;32(12):1519‐34. [MEDLINE: 21388992] TeerlinkJR , IraguiVJ , MohrJP , CarsonPE , HauptmanPJ , LovettDH , et al. The safety of an adenosine A(1)‐receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Safety2012;35(3):233‐44. [MEDLINE: 22339573] VoorsAA , DittrichHC , MassieBM , DeLuccaP , MansoorGA , MetraM , et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo‐Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). Journal of the American College of Cardiology2011;57(19):1899‐907. [MEDLINE: 21545947] WeatherleyBD , CotterG , DittrichHC , DeLuccaP , MansoorGA , BloomfieldDM , et al. Design and rationale of the PROTECT study: a placebo‐controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. Journal of Cardiac Failure2010;16(1):25‐35. [MEDLINE: 20123315] ">PROTECT 2008</a>; <a href="./references#CD012466-bbs2-0079" title="LiuLC , VoorsAA , TeerlinkJR , CotterG , DavisonBA , FelkerGM , et al. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX‐AHF. Clinical Research in Cardiology2016;105(9):727‐37. [MEDLINE: 27017514] MetraM , CotterG , DavisonBA , FelkerGM , FilippatosG , GreenbergBH , et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX‐AHF) development program: correlation with outcomes. Journal of the American College of Cardiology2013;61(2):196‐206. [MEDLINE: 23273292] MetraM , PonikowskiP , CotterG , DavisonBA , FelkerGM , FilippatosG , et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX‐AHF. European Heart Journal2013;34(40):3128‐36. [MEDLINE: 23999454] PangPS , TeerlinkJR , VoorsAA , PonikowskiP , GreenbergBH , FilippatosG , et al. Use of high‐sensitivity troponin t to identify patients with acute heart failure at lower risk for adverse outcomes: an exploratory analysis from the RELAX‐AHF trial. JACC Heart Failure2016;4(7):591‐9. [MEDLINE: 27039129] PonikowskiP , MetraM , TeerlinkJR , UnemoriE , FelkerGM , VoorsAA , et al. Design of the RELAXin in acute heart failure study. American Heart Journal2012;163(2):149‐55. [MEDLINE: 22305830] TeerlinkJR , CotterG , DavisonBA , FelkerGM , FilippatosG , GreenbergBH , et al. Serelaxin, recombinant human relaxin‐2, for treatment of acute heart failure (RELAX‐AHF): a randomised, placebo‐controlled trial. Lancet2013;381(9860):29‐39. [MEDLINE: 23141816] ">RELAX‐AHF 2012</a>; <a href="./references#CD012466-bbs2-0080" title="PangPS , MehraM , MaggioniAP , FilippatosG , MiddlebrooksJ , TurlapatyP , et al. Rationale, design, and results from RENO‐DEFEND 1: a randomized, dose‐finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. American Heart Journal2011;161(6):1012‐23. [MEDLINE: 21641345] ">RENO‐DEFEND 1 2011</a>; <a href="./references#CD012466-bbs2-0082" title="ChenHH , AbouEzzeddineOF , AnstromKJ , GivertzMM , BartBA , FelkerGM , et al. Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circulation: Heart Failure2013;6(5):1087‐94. [MEDLINE: 24046475] ChenHH , AnstromKJ , GivertzMM , StevensonLW , SemigranMJ , GoldsmithSR , et al. Low‐dose dopamine or low‐dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA2013;310(23):2533‐43. [MEDLINE: 24247300] GrodinJL , LalaA , StevensSR , DeVoreAD , CooperLB , AbouEzzeddineOF , et al. Clinical Implications of serum albumin levels in acute heart failure: insights from DOSE‐AHF and ROSE‐AHF. Journal of Cardiac Failure2016;22(11):884‐90. [MEDLINE: 26844764] GrodinJL , SunJL , AnstromKJ , ChenHH , StarlingRC , TestaniJM , et al. Implications of serum chloride homeostasis in acute heart failure (from ROSE‐AHF). American Journal of Cardiology2017;119(1):78‐83. [MEDLINE: 27816115] WanSH , StevensSR , BorlaugBA , AnstromKJ , DeswalA , FelkerGM , et al. Differential response to low‐dose dopamine or low‐dose nesiritide in acute heart failure with reduced or preserved ejection fraction: results from the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circulation: Heart Failure2016;9(8):1. [MEDLINE: 27512103] ">ROSE AHF 2013</a>). Studies in chronic HF (25) included patients with HFrEF (<a href="./references#CD012466-bbs2-0003" title="AnandIS , TamSW , RectorTS , TaylorAL , SabolinskiML , ArchambaultWT , et al. Influence of blood pressure on the effectiveness of a fixed‐dose combination of isosorbide dinitrate and hydralazine in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2007;49(1):32‐9. [MEDLINE: 17207719] AnandIS , WinS , RectorTS , CohnJN , TaylorAL . Effect of fixed‐dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30‐day readmission rates in patients with heart failure: results from the African‐American Heart Failure Trial. Circulation: Heart Failure2014;7(5):759‐65. [MEDLINE: 24970468] CarsonP , TamSW , GhaliJK , ArchambaultWT , TaylorA , CohnJN , et al. Relationship of quality of life scores with baseline characteristics and outcomes in the African‐American heart failure trial. Journal of Cardiac Failure2009;15(10):835‐42. [MEDLINE: 19944359] ChangKW , BeriN , NguyenNH , ArbitB , FoxS , MojaverS , et al. Heart failure with recovered ejection fraction in African Americans: results from the African‐American Heart Failure Trial. Journal of Cardiac Failure2018;24(5):303‐9. [MEDLINE: 28918108] CohnJN , TamSW , AnandIS , TaylorAL , SabolinskiML , WorcelM , et al. Isosorbide dinitrate and hydralazine in a fixed‐dose combination produces further regression of left ventricular remodeling in a well‐treated black population with heart failure: results from A‐HeFT. Journal of Cardiac Failure2007;13(5):331‐9. [MEDLINE: 17602978] FranciosaJA , TaylorAL , CohnJN , YancyCW , ZiescheS , OlukotunA , et al. African‐American Heart Failure Trial (A‐HeFT): rationale, design, and methodology. Journal of Cardiac Failure2002;8(3):128‐35. [MEDLINE: 12140804] GhaliJK , TamSW , FerdinandKC , LindenfeldJ , SabolinskiML , TaylorAL , et al. Effects of ACE inhibitors or beta‐blockers in patients treated with the fixed‐dose combination of isosorbide dinitrate/hydralazine in the African‐American Heart Failure Trial. American Journal of Cardiovascular Drugs2007;7(5):373‐80. [MEDLINE: 18041162] GhaliJK , TamSW , SabolinskiML , TaylorAL , LindenfeldJ , CohnJN , et al. Exploring the potential synergistic action of spironolactone on nitric oxide‐enhancing therapy: insights from the African‐American Heart Failure Trial. Journal of Cardiac Failure2008;14(9):718‐23. [MEDLINE: 18995175] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , TaylorAL , et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A‐HeFT Trial. Journal of the American College of Cardiology2006;48(6):1277‐82. [MEDLINE: 16979018] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , VenkitachalamL , et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A‐HeFT trial. Journal of Cardiac Failure2009;15(3):191‐8. [MEDLINE: 19327620] McNamaraDM , TaylorAL , TamSW , WorcelM , YancyCW , Hanley‐YanezK , et al. G‐protein beta‐3 subunit genotype predicts enhanced benefit of fixed‐dose isosorbide dinitrate and hydralazine: results of A‐HeFT. JACC Heart Failure2014;2(6):551‐7. [MEDLINE: 25306451] MitchellJE , TamSW , TrivediK , TaylorAL , O'NealW , CohnJN , et al. Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A‐HeFT). American Heart Journal2011;162(1):154‐9. [MEDLINE: 21742102] TaylorAL . The African‐American Heart Failure Trial (A‐HeFT): rationale and methodology.[Erratum appears in J Card Fail. 2003 Dec;9(6):481 Note: Dosage error in article text]. Journal of Cardiac Failure2003;9(5 Suppl Nitric Oxide):S216‐9. [MEDLINE: 14583892] TaylorAL , CohnJN , WorcelM , FranciosaJA , A‐HeFT Investigators.African‐American Heart Failure Trial. The African‐American Heart Failure Trial: background, rationale and significance. Journal of the National Medical Association2002;94(9):762‐9. [MEDLINE: 12392039] TaylorAL , LindenfeldJ , ZiescheS , WalshMN , MitchellJE , AdamsK , et al. Outcomes by gender in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2006;48(11):2263‐7. [MEDLINE: 17161257] TaylorAL , SabolinskiML , TamSW , ZiescheS , GhaliJK , ArchambaultWT , et al. Effect of fixed‐dose combined isosorbide dinitrate/hydralazine in elderly patients in the African‐American heart failure trial. Journal of Cardiac Failure2012;18(8):600‐6. [MEDLINE: 22858074] TaylorAL , ZiescheS , YancyC , CarsonP , D'AgostinoRJr , FerdinandK , et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.[Erratum appears in N Engl J Med. 2005 Mar 24;352(12):1276]. New England Journal of Medicine2004;351(20):2049‐57. [MEDLINE: 15533851] TaylorAL , ZiescheS , YancyCW , CarsonP , FerdinandK , TaylorM , et al. Early and sustained benefit on event‐free survival and heart failure hospitalization from fixed‐dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African‐American Heart Failure Trial. Circulation2007;115(13):1747‐53. [MEDLINE: 17372175] YancyCW , GhaliJK , BramanVM , SabolinskiML , WorcelM , ArchambaultWT , et al. Evidence for the continued safety and tolerability of fixed‐dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African‐American Heart Failure Trial). American Journal of Cardiology2007;100(4):684‐9. [MEDLINE: 17697829] ">A‐HeFT 2002</a>; <a href="./references#CD012466-bbs2-0009" title="SchrotenNF , DammanK , HemmelderMH , VoorsAA , NavisG , GaillardCA , et al. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). American Heart Journal2015;169(5):693‐701. [MEDLINE: 25965717] ">ARIANA‐CHF‐RD 2016</a>; <a href="./references#CD012466-bbs2-0029" title='Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. Fundamental &amp; Clinical Pharmacology1997;11(2):138‐42. [MEDLINE: 9107560] Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS‐II). European Heart Journal2001;22(12):1021‐31. [MEDLINE: 11428837] The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): a randomised trial. Lancet1999;353(9146):9‐13. [MEDLINE: 10023943] BohmM , MaackC , Wehrlen‐GrandjeanM , ErdmannE . Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardiac Insufficiency Bisoprolol Study II (CIBIS II)). Zeitschrift fur Kardiologie2003;92(8):668‐76. [MEDLINE: 12955414] CastagnoD , JhundPS , McMurrayJJ , LewseyJD , ErdmannE , ZannadF , et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS‐II) trial. European Journal of Heart Failure2010;12(6):607‐16. [MEDLINE: 20354032] EkmanM , ZethraeusN , JonssonB . Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics2001;19(9):901‐16. [MEDLINE: 11700777] ErdmannE , LechatP , VerkenneP , WiemannH . Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure. European Journal of Heart Failure2001;3(4):469‐79. [MEDLINE: 11511434] GallanaghS , CastagnoD , WilsonB , ErdmannE , ZannadF , RemmeWJ , et al. Evaluation of the functional status questionnaire in heart failure: a sub‐study of the second cardiac insufficiency bisoprolol survival study (CIBIS‐II). Cardiovascular Drugs &amp; Therapy2011;25(1):77‐85. [MEDLINE: 21287410] KrumH , BaileyM , MeyerW , VerkenneP , DargieH , LechatP , et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta‐blocker use: results of CIBIS II. Cardiology2007;108(1):28‐34. [MEDLINE: 16960445] KrumH , HareD . "Bisoprolol dose‐response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II)," by Simon T. European Heart Journal2004;25(3):277. [MEDLINE: 14972430] LechatP , HulotJS , EscolanoS , MalletA , LeizoroviczA , Werhlen‐GrandjeanM , et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation2001;103(10):1428‐33. [MEDLINE: 11245648] SimonT , Mary‐KrauseM , Funck‐BrentanoC , JaillonP . Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation2001;103(3):375‐80. [MEDLINE: 11157688] SimonT , Mary‐KrauseM , Funck‐BrentanoC , LechatP , JaillonP . Bisoprolol dose‐response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). European Heart Journal2003;24(6):552‐9. [MEDLINE: 12643888] '>CIBIS II 1997</a>; <a href="./references#CD012466-bbs2-0032" title="CiceG , FerraraL , D'AndreaA , D'IsaS , DiBenedettoA , CittadiniA , et al. Carvedilol increases two‐year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo‐controlled trial. Journal of the American College of Cardiology2003;41(9):1438‐44. [MEDLINE: 12742278] CiceG , FerraraL , DiBenedettoA , RussoPE , MarinelliG , PaveseF , et al. Dilated cardiomyopathy in dialysis patients‐‐beneficial effects of carvedilol: a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2001;37(2):407‐11. [MEDLINE: 11216954] ">Cice 2001</a>; <a href="./references#CD012466-bbs2-0033" title="CiceG , DiBenedettoA , D'AndreaA , D'IsaS , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on left ventricular structure and function in hemodialyzed patients with chronic heart failure: a double‐blind placebo‐controlled multicenter study [abstract no: MP434]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv446. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on mortality and morbidity in haemodialysis patients with chronic heart failure: a double‐blind placebo‐controlled trial [abstract no: MO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v187. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , DeGregoriaP , CalabroR . Effect of telmisartan added to angiotensin converting enzyme inhibitors in reducing morbidity and mortality in haemodialysis patients with chronic heart failure [abstract no: P1.19]. Journal of Hypertension ‐ Supplement2006;24(Suppl):S56. [CENTRAL: CN‐00793137] CiceG , DiBenedettoA , D'IsaS , D'AndreaA , MarcelliD , GattiE , et al. Effects of telmisartan added to angiotensin‐converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2010;56(21):1701‐8. [MEDLINE: 21070920] ">Cice 2010</a>; <a href="./references#CD012466-bbs2-0040" title="BrendorpB , ElmingH , JunL , KoberL , MalikM , JensenGB , et al. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation2001;103(10):1422‐7. [MEDLINE: 11245647] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group.Danish Investigations Of Arrhythmia and Mortality On Dofetilide. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. European Journal of Heart Failure2002;4(2):201‐6. [MEDLINE: 11959050] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group. The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide. Clinical Cardiology2003;26(5):219‐25. [MEDLINE: 12769249] MollerM , Torp‐PedersenCT , KoberL . Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congestive Heart Failure2001;7(3):146‐50. [MEDLINE: 11828153] PedersenHS , ElmingH , SeibaekM , BurchardtH , BrendorpB , Torp‐PedersenC , et al. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. American Journal of Cardiology2007;100(5):876‐80. [MEDLINE: 17719337] Torp‐PedersenC , MollerM , Bloch‐ThomsenPE , KoberL , SandoeE , EgstrupK , et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. New England Journal of Medicine1999;341(12):857‐65. [MEDLINE: 10486417] ">DIAMOND 1999</a>; <a href="./references#CD012466-bbs2-0041" title="Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long‐term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clinical Trials1996;17(1):77‐97. [MEDLINE: 8721804] AhmedA . Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. Journals of Gerontology Series A‐Biological Sciences &amp; Medical Sciences2007;62(3):323‐9. [MEDLINE: 17389731] AhmedA , AronowWS , FlegJL . Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. American Journal of Therapeutics2006;13(4):325‐31. [MEDLINE: 16858168] AhmedA , LoveTE , SuiX , RichMW . Effects of angiotensin‐converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. Journal of Cardiac Failure2006;12(7):499‐506. [MEDLINE: 16952782] AhmedA , RichMW , SandersPW , PerryGJ , BakrisGL , ZileMR , et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. American Journal of Cardiology2007;99(3):393‐8. [MEDLINE: 17261405] BowlingCB , PittB , AhmedMI , AbanIB , SandersPW , MujibM , et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity‐matched studies. Circulation: Heart Failure2010;3(2):353‐60. [MEDLINE: 20103777] CampbellRC , SuiX , FilippatosG , LoveTE , WahleC , SandersPW , et al. Association of chronic kidney disease with outcomes in chronic heart failure: a propensity‐matched study. Nephrology Dialysis Transplantation2009;24(1):186‐93. [MEDLINE: 18711222] Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine1997;336(8):525‐33. [MEDLINE: 9036306] EkundayoOJ , MuchimbaM , AbanIB , RitchieC , CampbellRC , AhmedA . Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. American Journal of Cardiology2009;103(1):88‐92. [MEDLINE: 19101236] RitchieC , EkundayoOJ , MuchimbaM , CampbellRC , FrankSJ , LiuB , et al. Effects of diabetes mellitus in patients with heart failure and chronic kidney disease: a propensity‐matched study of multimorbidity in chronic heart failure.[Erratum appears in Int J Cardiol. 2010 Jan 7;138(1):106]. International Journal of Cardiology2009;134(3):330‐5. [MEDLINE: 19178965] ShlipakMG , SmithGL , RathoreSS , MassieBM , KrumholzHM . Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. Journal of the American Society of Nephrology2004;15(8):2195‐203. [MEDLINE: 15284305] TestaniJM , BriscoMA , TangWH , KimmelSE , Tiku‐OwensA , ForfiaPR , et al. Potential effects of digoxin on long‐term renal and clinical outcomes in chronic heart failure. Journal of Cardiac Failure2013;19(5):295‐302. [MEDLINE: 23663810] ">DIG 1996</a>; <a href="./references#CD012466-bbs2-0044" title="EschalierR , McMurrayJJ , SwedbergK , vanVeldhuisenDJ , KrumH , PocockSJ , et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS‐HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Journal of the American College of Cardiology2013;62(17):1585‐93. [MEDLINE: 23810881] KrumH , ShiH , PittB , McMurrayJ , SwedbergK , vanVeldhuisenDJ , et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS‐HF study. Circulation: Heart Failure2013;6(4):711‐8. [MEDLINE: 23625945] RogersJK , McMurrayJJ , PocockSJ , ZannadF , KrumH , vanVeldhuisenDJ , et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation2012;126(19):2317‐23. [MEDLINE: 23042980] RossignolP , DobreD , McMurrayJJ , SwedbergK , KrumH , vanVeldhuisenDJ , et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF). Circulation: Heart Failure2014;7(1):51‐8. [MEDLINE: 24297687] ZannadF , McMurrayJJ , DrexlerH , KrumH , vanVeldhuisenDJ , SwedbergK , et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF). European Journal of Heart Failure2010;12(6):617‐22. [MEDLINE: 20388647] ZannadF , McMurrayJJ , KrumH , vanVeldhuisenDJ , SwedbergK , ShiH , et al. Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine2011;364(1):11‐21. [MEDLINE: 21073363] ">EMPHASIS‐HF 2010</a>; <a href="./references#CD012466-bbs2-0046" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJC , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJC , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD012466-bbs2-0050" title="O'ConnorCM , FiuzatM , LindenfeldJ , MillerA , LombardiC , CarsonP , et al. Mode of death and hospitalization from the Second Follow‐up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. American Journal of Cardiology2011;108(10):1449‐57. [MEDLINE: 21890092] YancyCW , KrumH , MassieBM , SilverMA , StevensonLW , ChengM , et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow‐Up Serial Infusions of Nesiritide (FUSION II) trial. Circulation: Heart Failure2008;1(1):9‐16. [MEDLINE: 19808265] YancyCW , KrumH , MassieBM , SilverMA , StevensonLW , ChengM , et al. The Second Follow‐up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. American Heart Journal2007;153(4):478‐84. [MEDLINE: 17383282] ">FUSION II 2008</a>; <a href="./references#CD012466-bbs2-0053" title="HuDY , HuangJ , CaiNS , ZhuWL , LiYS , MassaadR , et al. A multi‐center, double‐blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment. Chinese Medical Journal2012;125(21):3868‐74. [MEDLINE: 23106890] KiernanMS , GregoryD , SarnakMJ , RossignolP , MassaroJ , KociolR , et al. Early and late effects of high‐ versus low‐dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.[Erratum appears in JACC Heart Fail. 2015 Jun;3(6):510‐1]. JACC Heart Failure2015;3(3):214‐23. [MEDLINE: 25742759] KiernanMS , WentworthD , FrancisG , MartinezFA , DicksteinK , KomajdaM , et al. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. European Journal of Heart Failure2012;14(12):1401‐9. [MEDLINE: 23187648] KonstamMA , NeatonJD , DicksteinK , DrexlerH , KomajdaM , MartinezFA , et al. Effects of high‐dose versus low‐dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double‐blind trial.[Erratum appears in Lancet. 2009 Dec 5;374(9705):1888]. Lancet2009;374(9704):1840‐8. [MEDLINE: 19922995] KonstamMA , Poole‐WilsonPA , DicksteinK , DrexlerH , JusticeSJ , KomajdaM , et al. Design of the heart failure endpoint evaluation of AII‐antagonist losartan (HEAAL) study in patients intolerant to ACE‐inhibitor. European Journal of Heart Failure2008;10(9):899‐906. [MEDLINE: 18768350] RossignolP , DobreD , GregoryD , MassaroJ , KiernanM , KonstamMA , et al. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2014;173(3):380‐7. [MEDLINE: 24726210] RossignolP , GirerdN , GregoryD , MassaroJ , KonstamMA , ZannadF . Increased visit‐to‐visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2015;187:183‐9. [MEDLINE: 25828348] UpshawJN , KonstamMA , KlaverenD , NoubaryF , HugginsGS , KentDM . Multistate model to predict heart failure hospitalizations and all‐cause mortality in outpatients with heart failure with reduced ejection fraction: model derivation and external validation. Circulation: Heart Failure2016;9(8):e003146. [MEDLINE: 27514751] ">HEAAL 2008</a>; <a href="./references#CD012466-bbs2-0059" title="Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Lancet1999;353(9169):2001‐7. [MEDLINE: 10376614] Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT‐HF). The International Steering Committee. American Journal of Cardiology1997;80(9B):54‐8J. [MEDLINE: 9375952] BattyJA , HallAS , WhiteHL , WikstrandJ , deBoerRA , vanVeldhuisenDJ , et al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT‐HF substudy. Clinical Pharmacology &amp; Therapeutics2014;95(3):321‐30. [MEDLINE: 24193112] CaroJJ , Migliaccio‐WalleK , O'BrienJA , NovaW , KimJ , HauchO , et al. Economic implications of extended‐release metoprolol succinate for heart failure in the MERIT‐HF trial: a US perspective of the MERIT‐HF trial. Journal of Cardiac Failure2005;11(9):647‐56. [MEDLINE: 16360958] DeedwaniaPC , GilesTD , KlibanerM , GhaliJK , HerlitzJ , HildebrandtP , et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT‐HF. American Heart Journal2005;149(1):159‐67. [MEDLINE: 15660048] FagerbergB . Screening, endpoint classification, and safety monitoring in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). European Journal of Heart Failure2000;2(3):315‐24. [MEDLINE: 10938494] GhaliJK , PinaIL , GottliebSS , DeedwaniaPC , WikstrandJC , MERIT‐HF Study Group. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended‐Release Randomized Intervention Trial in Heart Failure (MERIT‐HF). Circulation2002;105(13):1585‐91. [MEDLINE: 11927527] GhaliJK , WikstrandJ , vanVeldhuisenDJ , FagerbergB , GoldsteinS , HjalmarsonA , et al. The influence of renal function on clinical outcome and response to beta‐blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT‐HF). Journal of Cardiac Failure2009;15(4):310‐8. [MEDLINE: 19398079] GoldsteinS , HjalmarsonA . The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT‐HF Trial. Clinical Cardiology1999;22(Suppl 5):V30‐5. [MEDLINE: 10526701] GottliebSS , FisherML , KjekshusJ , DeedwaniaP , GullestadL , VitovecJ , et al. Tolerability of beta‐blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT‐HF). Circulation2002;105(10):1182‐8. [MEDLINE: 11889011] GullestadL , ManhenkeC , AarslandT , SkardalR , FagertunH , WikstrandJ , et al. Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure ‐ a substudy to the MERIT‐HF trial. European Journal of Heart Failure2001;3(4):463‐8. [MEDLINE: 11511433] GullestadL , UelandT , BrunsvigA , KjekshusJ , SimonsenS , FrolandSS , et al. Effect of metoprolol on cytokine levels in chronic heart failure‐‐a substudy in the Metoprolol Controlled‐Release Randomised Intervention Trial in Heart Failure (MERIT‐HF). American Heart Journal2001;141(3):418‐21. [MEDLINE: 11231439] GullestadL , WikstrandJ , DeedwaniaP , HjalmarsonA , EgstrupK , ElkayamU , et al. What resting heart rate should one aim for when treating patients with heart failure with a beta‐blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT‐HF). Journal of the American College of Cardiology2005;45(2):252‐9. [MEDLINE: 15653024] HjalmarsonA , GoldsteinS , FagerbergB , WedelH , WaagsteinF , KjekshusJ , et al. Effects of controlled‐release metoprolol on total mortality, hospitalizations, and well‐being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT‐HF). MERIT‐HF Study Group. JAMA2000;283(10):1295‐302. [MEDLINE: 10714728] SavvaJ , MaqboolA , WhiteHL , GallowaySL , YuldashevaNY , BallSG , et al. Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT‐HF substudy. Journal of Cardiac Failure2009;15(5):435‐41. [MEDLINE: 19477404] TepperD . Frontiers in congestive heart failure: effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Congestive Heart Failure1999;5(4):184‐5. [MEDLINE: 12189311] WhiteHL , deBoerRA , MaqboolA , GreenwoodD , vanVeldhuisenDJ , CuthbertR , et al. An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study. European Journal of Heart Failure2003;5(4):463‐8. [MEDLINE: 12921807] WikstrandJ , HjalmarsonA , WaagsteinF , FagerbergB , GoldsteinS , KjekshusJ , et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT‐HF). Journal of the American College of Cardiology2002;40(3):491‐8. [MEDLINE: 12142116] vanVeldhuisenDJ , AassH , ElAllafD , DunselmanPH , GullestadL , HalinenM , et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT‐HF Study. European Journal of Heart Failure2006;8(5):539‐46. [MEDLINE: 16567126] van derMeerP , DeBoerRA , WhiteHL , van derSteegeG , HallAS , VoorsAA , et al. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT‐HF substudy. Journal of Cardiac Failure2005;11(4):279‐84. [MEDLINE: 15880336] ">MERIT‐HF 1997</a>; <a href="./references#CD012466-bbs2-0075" title="EichhornEJ , TandonPK , DiBiancoR , TimmisGC , FensterPE , ShannonJ , et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. Journal of the American College of Cardiology1993;21(3):634‐40. [MEDLINE: 8436744] PackerM . Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. American Journal of Cardiology1989;63(2):41‐5A. [MEDLINE: 2642629] PackerM , CarverJR , RodehefferRJ , IvanhoeRJ , DiBiancoR , ZeldisSM , et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. New England Journal of Medicine1991;325(21):1468‐75. [MEDLINE: 1944425] TeerlinkJR , JalaluddinM , AndersonS , KukinML , EichhornEJ , FrancisG , et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation2000;101(1):40‐6. [MEDLINE: 10618302] ">PROMISE 1989</a>; <a href="./references#CD012466-bbs2-0077" title="Effectiveness of spironolactone added to an angiotensin‐converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). American Journal of Cardiology1996;78(8):902‐7. [MEDLINE: 8888663] GlickHA , OrzolSM , TooleyJF , RemmeWJ , SasayamaS , PittB . Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovascular Drugs &amp; Therapy2002;16(1):53‐9. [MEDLINE: 12085979] HaubenM , ReichL , GerritsCM , MadiganD . Detection of spironolactone‐associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Safety2007;30(12):1143‐9. [MEDLINE: 18035866] PittB , ZannadF , RemmeWJ , CodyR , CastaigneA , PerezA , et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine1999;341(10):709‐17. [MEDLINE: 10471456] PittD . ACE inhibitor co‐therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). European Heart Journal1995;16 Suppl N:107‐10. [MEDLINE: 8682055] RousseauMF , GurneO , DuprezD , VanMieghemW , RobertA , AhnS , et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.[Erratum appears in J Am Coll Cardiol. 2003 Nov 19;42(10):1865]. Journal of the American College of Cardiology2002;40(9):1596‐601. [MEDLINE: 12427411] SchwingerRH . The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study [Der Aldosteronantagonist Spironolacton verlangert das Uberleben chronisch herzinsuffizienter Patienten. Ergebnisse der RALES‐Studie]. Deutsche Medizinische Wochenschrift1999;124(34‐5):987‐8. [MEDLINE: 10488324] VardenyO , WuDH , DesaiA , RossignolP , ZannadF , PittB , et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure. Journal of the American College of Cardiology2012;60(20):2082‐9. [MEDLINE: 23083787] WittesJ , PalenskyJ , AsnerD , JulianD , BoisselJP , FurbergCD , et al. Experience collecting interim data on mortality: an example from the RALES study. Current Controlled Trials in Cardiovascular Medicine2001;2(1):59‐62. [MEDLINE: 11806773] ZannadF , AllaF , DoussetB , PerezA , PittB . Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.[Erratum appears in Circulation 2001 Jan 23;103(3):476]. Circulation2000;102(22):2700‐6. [MEDLINE: 11094035] ">RALES 1995</a>; <a href="./references#CD012466-bbs2-0084" title="HagerWD , DavisBR , RibaA , MoyeLA , WunCC , RouleauJL , et al. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. American Heart Journal1998;135(3):406‐13. [MEDLINE: 9506325] JoseP , SkaliH , AnavekarN , TomsonC , KrumholzHM , RouleauJL , et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. Journal of the American Society of Nephrology2006;17(10):2886‐91. [MEDLINE: 16928807] LamasGA , PfefferMA , HammP , WertheimerJ , RouleauJL , BraunwaldE . Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? the SAVE Investigators. New England Journal of Medicine1992;327(4):241‐7. [MEDLINE: 1535419] MitchellGF , MoyeLA , BraunwaldE , RouleauJL , BernsteinV , GeltmanEM , et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation1997;96(12):4254‐60. [MEDLINE: 9416890] MoyeLA , PfefferMA , BraunwaldE . Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. SAVE Investigators. American Journal of Cardiology1991;68(14):70‐9D. [MEDLINE: 1836100] PfefferMA , BraunwaldE , MoyeLA , BastaL , BrownEJJr , CuddyTE , et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. New England Journal of Medicine1992;327(10):669‐77. [MEDLINE: 1386652] PfefferMA , MoyeLA , BraunwaldE , BastaL , BrownEJJr , CuddyTE , et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA1991;266(4):528‐32. [MEDLINE: 2061979] RouleauJL , MoyeLA , PfefferMA , ArnoldJM , BernsteinV , CuddyTE , et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. New England Journal of Medicine1993;328(11):779‐84. [MEDLINE: 8123063] RutherfordJD , PfefferMA , MoyeLA , DavisBR , FlakerGC , KoweyPR , et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation1994;90(4):1731‐8. [MEDLINE: 7923656] TokmakovaMP , SkaliH , KenchaiahS , BraunwaldE , RouleauJL , PackerM , et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin‐converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation2004;110(24):3667‐73. [MEDLINE: 15569840] UrenaPE , LamasGA , MitchellG , FlakerGC , SmithSCJr , WackersFJ , et al. Ejection fraction by radionuclide ventriculography and contrast left ventriculogram. A tale of two techniques. SAVE Investigators. Survival and Ventricular Enlargement. Journal of the American College of Cardiology1999;33(1):180‐5. [MEDLINE: 9935027] VantrimpontP , RouleauJL , WunCC , CiampiA , KleinM , SussexB , et al. Additive beneficial effects of beta‐blockers to angiotensin‐converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. Journal of the American College of Cardiology1997;29(2):229‐36. [MEDLINE: 9014971] ">SAVE 1991</a>; <a href="./references#CD012466-bbs2-0085" title="Cohen‐SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872‐80. [MEDLINE: 19648605] FlatherMD , ShibataMC , CoatsAJ , VanVeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomised trial to determine the effect of nebivolol on mortality and hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26(3):215‐25. [MEDLINE: 15642700] ShibataMC , FlatherMD , BöhmM , BorbolaJ , Cohen‐SolalA , DumitrascuD , et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisations in Seniors with Heart Failure (SENIORS): rationale and design. International Journal of Cardiology2002;86(1):77‐85. [MEDLINE: 12243852] vanVeldhuisenDJ , Cohen‐SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta‐blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150‐8. [MEDLINE: 19497441] ">SENIORS 2002</a>; <a href="./references#CD012466-bbs2-0086" title="BocchiEA , BohmM , BorerJS , FordI , KomajdaM , SwedbergK , et al. Effect of combining ivabradine and beta‐blockers: focus on the use of carvedilol in the SHIFT population. Cardiology2015;131(4):218‐24. [MEDLINE: 25968495] BohmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20(2):373‐81. [MEDLINE: 29027329] BohmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost‐BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo‐controlled trial. Lancet2010;376(9744):886‐94. [MEDLINE: 20801495] BorerJS , BohmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33(22):2813‐20. [MEDLINE: 22927555] BorerJS , BohmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497‐503. [MEDLINE: 24332674] FordI , RobertsonM , KomajdaM , BohmM , BorerJS , TavazziL , et al. Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: the SHIFT risk model. International Journal of Cardiology2015;184:163‐9. [MEDLINE: 25703424] KomajdaM , BohmM , BorerJS , FordI , RobertsonM , ManolisAJ , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. European Journal of Heart Failure2014;16(7):810‐6. [MEDLINE: 24961493] KomajdaM , TavazziL , FrancqBG , BohmM , BorerJS , FordI , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. European Journal of Heart Failure2015;17(12):1294‐301. [MEDLINE: 26377342] KomajdaM , TavazziL , SwedbergK , BohmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of SHIFT. European Journal of Heart Failure2016;18(9):1182‐9. [MEDLINE: 27210035] SwedbergK , KomajdaM , BohmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta‐blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. Journal of the American College of Cardiology2012;59(22):1938‐45. [MEDLINE: 22617188] SwedbergK , KomajdaM , BohmM , BorerJS , FordI , Dubost‐BramaA , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo‐controlled study.[Erratum appears in Lancet. 2010 Dec 11;376(9757):1988 Note: Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadan, I Roldan]; Leva, M [corrected to Ieva, M]]. Lancet2010;376(9744):875‐85. [MEDLINE: 20801500] SwedbergK , KomajdaM , BöhmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). European Journal of Heart Failure2010;12(1):75‐81. [MEDLINE: 19892778] TardifJC , O'MearaE , KomajdaM , BohmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507‐15. [MEDLINE: 21875858] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182‐8. [MEDLINE: 24225201] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. European Journal of Heart Failure2013;15(11):1296‐303. [MEDLINE: 23803951] VoorsAA , vanVeldhuisenDJ , RobertsonM , FordI , BorerJS , BohmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure2014;16(4):426‐34. [MEDLINE: 24504937] ">SHIFT 2010</a>; <a href="./references#CD012466-bbs2-0089" title="Al‐AhmadA , LeveyA , RandW , MajunathG , SalemD , GregoryD , et al. Anemia and renal insufficiency as risk factors for mortality in patients with left ventricular dysfunction [abstract no: A0739]. Journal of the American Society of Nephrology2000;11(Sept):137A. [CENTRAL: CN‐00550523] Al‐AhmadAM , SarnakMJ , RandW , GregoryD , KonstamMA , SalemDN , et al. Level of renal function as an independent predictor of mortality in patients with left ventricular dysfunction [abstract no: A0783]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):152A. [CENTRAL: CN‐00550524] Alsheikh‐AliAA , TrikalinosTA , RuthazerR , TerrinN , WongJB , SarnakMJ , et al. Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease. American Heart Journal2011;161(1):204‐9. [MEDLINE: 21167355] BansalN , TighiouartH , WeinerD , GriffithJ , VlagopoulosP , SalemD , et al. Anemia as a risk factor for kidney function decline in heart failure [abstract no: TH‐PO928]. Journal of the American Society of Nephrology2005;16(Oct):322A. [CENTRAL: CN‐01658120] BansalN , TighiouartH , WeinerD , GriffithJ , VlagopoulosP , SalemD , et al. Anemia as a risk factor for kidney function decline in individuals with heart failure. American Journal of Cardiology2007;99(8):1137‐42. [MEDLINE: 17437743] BowlingCB , SandersPW , AllmanRM , RogersWJ , PatelK , AbanIB , et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. International Journal of Cardiology2013;167(1):151‐6. [MEDLINE: 22257685] CapesSE , GersteinHC , NegassaA , YusufS . Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care2000;23(3):377‐80. [MEDLINE: 10868869] GregoryDD , SarnakMJ , KonstamMA , PereiraB , SalemD . Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction. American Journal of Cardiology2003;92(11):1300‐5. [MEDLINE: 14636907] KnightEL , GlynnRJ , McIntyreKM , MogunH , AvornJ . Predictors of decreased renal function in patients with heart failure during angiotensin‐converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). American Heart Journal1999;138(5 (Pt 1)):849‐55. [MEDLINE: 10539815] RiedingerMS , DracupKA , BrechtML , SOLVD Investigators. Studies of Left Ventricular Dysfunction. Quality of life in women with heart failure, normative groups, and patients with other chronic conditions. American Journal of Critical Care2002;11(3):211‐9. [MEDLINE: 12022484] SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New England Journal of Medicine1991;325(5):293‐302. [MEDLINE: 2057034] SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD)‐‐rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction.[Erratum appears in Am J Cardiol 1990 Oct 15;66(12):1026]. American Journal of Cardiology1990;66(3):315‐22. [MEDLINE: 2195865] TestaniJM , KimmelSE , DriesDL , CocaSG . Prognostic importance of early worsening renal function after initiation of angiotensin‐converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circulation: Heart Failure2011;4(6):685‐91. [MEDLINE: 21903907] ">SOLVD (Treatment) 1992</a>; <a href="./references#CD012466-bbs2-0093" title="NajafabadiMM , TaheriS , SeyrafianS , AlipoorZ , KarimiS , PoormodhadasA , et al. Spironolactone in continuous ambulatory peritoneal dialysis patients, improves cardiac function [abstract no: SU475]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. TaheriS , MortazaviM , PourmoghadasA , SeyrafianS , AlipourZ , KarimiS . A prospective double‐blind randomized placebo‐controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi Journal of Kidney Diseases &amp; Transplantation2012;23(3):507‐12. [MEDLINE: 22569436] ">Taheri CAPD 2012</a>; <a href="./references#CD012466-bbs2-0094" title="MortazaviM , TaheriS , ShahidiS , PourmoghaddasA , YaraghiMG , SeyrafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: FP379]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi145. [CENTRAL: CN‐00716090] TaheriS , MortazaviM , ShahidiS , PourmoghadasA , GarakyaraghiM , SeirafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):392‐7. [MEDLINE: 19414940] TaheriS , MortazaviM , ShahidiS , PourmoghadasA , GarakyaraghiM , SeirafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: S‐PO‐0370]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:148. ">Taheri HD 2009</a>; <a href="./references#CD012466-bbs2-0100" title="AnandIS , BishuK , RectorTS , IshaniA , KuskowskiMA , CohnJN . Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin‐converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation2009;120(16):1577‐84. [MEDLINE: 19805651] AnandIS , RectorTS , KuskowskiM , AdourianA , MuntendamP , CohnJN . Baseline and serial measurements of galectin‐3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val‐HeFT. European Journal of Heart Failure2013;15(5):511‐8. [MEDLINE: 23291728] CohnJN . Improving outcomes in congestive heart failure: Val‐HeFT. Valsartan in Heart Failure Trial. Cardiology1999;91 Suppl 1:19‐22. [MEDLINE: 10449891] CohnJN , TognoniG , Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure.[Summary for patients in J Card Fail. 2002 Apr;8(2):56‐8; PMID: 12016625]. New England Journal of Medicine2001;345(23):1667‐75. [MEDLINE: 11759645] LesogorA , CohnJN , LatiniR , TognoniG , KrumH , MassieB , et al. Interaction between baseline and early worsening of renal function and efficacy of renin‐angiotensin‐aldosterone system blockade in patients with heart failure: insights from the Val‐HeFT study. European Journal of Heart Failure2013;15(11):1236‐44. [MEDLINE: 23787721] WongM , StaszewskyL , VolpiA , LatiniR , BarleraS , HoglundC . Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val‐HeFT). Journal of the American Society of Echocardiography2002;15(4):293‐301. [MEDLINE: 11944005] ">Val‐HeFT 1999</a>), HFpEF (<a href="./references#CD012466-bbs2-0031" title="CiceG , TagliamonteE , FerraraL , DiBenedettoA , SoriceP , IaconoA . Efficacy of diltiazem in uremic hemodialyzed patients with isolated diastolic dysfunction and dialysis hypotensive crisis [Efficacia del diltiazem in pazienti uremici emodializzati con disfunzione diastolica isolata e crisi ipotensive intradialitiche]. Cardiologia1999;44(3):289‐94. [MEDLINE: 10327731] ">Cice 1999a</a>), or with no prespecified ejection fraction criteria for inclusion (<a href="./references#CD012466-bbs2-0006" title="JacksonCE , MacDonaldMR , PetrieMC , SolomonSD , PittB , LatiniR , et al. Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure2011;13(7):746‐54. [MEDLINE: 21459891] MaggioniAP , McMurrayJJ , LatiniR , SolomonSD , SmithBA , BushC , et al. Safety and tolerability profile of aliskiren added to optimized therapy in patients with heart failure and renal impairment [abstract no: SA‐PO2247]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):616A. [CENTRAL: CN‐00776176] McMurrayJJ , PittB , LatiniR , MaggioniAP , SolomonSD , KeefeDL , et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure2008;1(1):17‐24. [MEDLINE: 19808266] ">ALOFT 2008</a>; <a href="./references#CD012466-bbs2-0008" title='MatsueY , SuzukiM , NagahoriW , YoshidaK , OnishiY , SatohY , et al. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. Cardiovascular Drugs &amp; Therapy2014;28(1):73‐7. [MEDLINE: 24048511] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction.[Erratum appears in J Card Fail. 2016 Nov;22(11):941; PMID: 27481596]. Journal of Cardiac Failure2016;22(6):423‐32. [MEDLINE: 26915749] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423‐432.[Erratum for J Card Fail. 2016 Jun;22(6):423‐32; PMID: 26915749]. Journal of Cardiac Failure2016;22(11):941. [MEDLINE: 27481596] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. International Journal of Cardiology2016;221:188‐93. [MEDLINE: 27404673] MatsueY , Ter MaatenJM , SuzukiM , ToriiS , YamaguchiS , FukamizuS , et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology2017;106(10):802‐12. [MEDLINE: 28540483] '>AQUAMARINE 2014</a>; <a href="./references#CD012466-bbs2-0070" title="Pita‐FernandezS , Choucino‐FernandezT , Juega‐PuigJ , Seoane‐PilladoT , Lopez‐CalvinoB , Pertega‐DiazS , et al. A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia. International Journal of Clinical Practice2014;68(10):1231‐8. [MEDLINE: 25040146] ">Pita‐Fernandez 2015</a>). </p> </section> <section id="CD012466-sec-0091"> <h5 class="title">Interventions</h5> <p>Studies in acute HF evaluated adenosine A1‐receptor antagonists (<a href="./references#CD012466-bbs2-0076" title="ClelandJG , ChiswellK , TeerlinkJR , StevensS , FiuzatM , GivertzMM , et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo‐Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Circulation: Heart Failure2014;7(1):76‐87. [MEDLINE: 24281134] CotterG , DittrichHC , WeatherleyBD , BloomfieldDM , O'ConnorCM , MetraM , et al. The PROTECT pilot study: a randomized, placebo‐controlled, dose‐finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. Journal of Cardiac Failure2008;14(8):631‐40. [MEDLINE: 18926433] GivertzMM , PostmusD , HillegeHL , MansoorGA , MassieBM , DavisonBA , et al. Renal function trajectories and clinical outcomes in acute heart failure. Circulation: Heart Failure2014;7(1):59‐67. [MEDLINE: 24281137] MassieBM , O'ConnorCM , MetraM , PonikowskiP , TeerlinkJR , CotterG , et al. Rolofylline, an adenosine A1‐receptor antagonist, in acute heart failure. New England Journal of Medicine2010;363(15):1419‐28. [MEDLINE: 20925544] MetraM , ClelandJG , WeatherleyBD , DittrichHC , GivertzMM , MassieBM , et al. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60‐day outcomes in the PROTECT pilot study. European Journal of Heart Failure2010;12(5):499‐507. [MEDLINE: 20228387] MetraM , O'ConnorCM , DavisonBA , ClelandJG , PonikowskiP , TeerlinkJR , et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. European Heart Journal2011;32(12):1519‐34. [MEDLINE: 21388992] TeerlinkJR , IraguiVJ , MohrJP , CarsonPE , HauptmanPJ , LovettDH , et al. The safety of an adenosine A(1)‐receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Safety2012;35(3):233‐44. [MEDLINE: 22339573] VoorsAA , DittrichHC , MassieBM , DeLuccaP , MansoorGA , MetraM , et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo‐Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). Journal of the American College of Cardiology2011;57(19):1899‐907. [MEDLINE: 21545947] WeatherleyBD , CotterG , DittrichHC , DeLuccaP , MansoorGA , BloomfieldDM , et al. Design and rationale of the PROTECT study: a placebo‐controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. Journal of Cardiac Failure2010;16(1):25‐35. [MEDLINE: 20123315] ">PROTECT 2008</a>; <a href="./references#CD012466-bbs2-0080" title="PangPS , MehraM , MaggioniAP , FilippatosG , MiddlebrooksJ , TurlapatyP , et al. Rationale, design, and results from RENO‐DEFEND 1: a randomized, dose‐finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. American Heart Journal2011;161(6):1012‐23. [MEDLINE: 21641345] ">RENO‐DEFEND 1 2011</a>), diuretics (<a href="./references#CD012466-bbs2-0067" title="PalazzuoliA , PellegriniM , FranciB , BeltramiM , RuoccoG , GonnelliS , et al. Short and long‐term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction. Internal &amp; Emergency Medicine2015;10(1):41‐49. [MEDLINE: 25087085] PalazzuoliA , PellegriniM , RuoccoG , MartiniG , FranciB , CampagnaMS , et al. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Critical Care (London, England)2014;18(3):R132. [MEDLINE: 24974232] ">Palazzuoli 2014</a>), dopamine and nesiritide (<a href="./references#CD012466-bbs2-0082" title="ChenHH , AbouEzzeddineOF , AnstromKJ , GivertzMM , BartBA , FelkerGM , et al. Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circulation: Heart Failure2013;6(5):1087‐94. [MEDLINE: 24046475] ChenHH , AnstromKJ , GivertzMM , StevensonLW , SemigranMJ , GoldsmithSR , et al. Low‐dose dopamine or low‐dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA2013;310(23):2533‐43. [MEDLINE: 24247300] GrodinJL , LalaA , StevensSR , DeVoreAD , CooperLB , AbouEzzeddineOF , et al. Clinical Implications of serum albumin levels in acute heart failure: insights from DOSE‐AHF and ROSE‐AHF. Journal of Cardiac Failure2016;22(11):884‐90. [MEDLINE: 26844764] GrodinJL , SunJL , AnstromKJ , ChenHH , StarlingRC , TestaniJM , et al. Implications of serum chloride homeostasis in acute heart failure (from ROSE‐AHF). American Journal of Cardiology2017;119(1):78‐83. [MEDLINE: 27816115] WanSH , StevensSR , BorlaugBA , AnstromKJ , DeswalA , FelkerGM , et al. Differential response to low‐dose dopamine or low‐dose nesiritide in acute heart failure with reduced or preserved ejection fraction: results from the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circulation: Heart Failure2016;9(8):1. [MEDLINE: 27512103] ">ROSE AHF 2013</a>), and serelaxin (<a href="./references#CD012466-bbs2-0072" title="DavisonBA , CotterG , SunH , ChenL , TeerlinkJR , MetraM , et al. Permutation criteria to evaluate multiple clinical endpoints in a proof‐of‐concept study: lessons from Pre‐RELAX‐AHF. Clinical Research in Cardiology2011;100(9):745‐53. [MEDLINE: 21416190] MetraM , TeerlinkJR , FelkerGM , GreenbergBH , FilippatosG , PonikowskiP , et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre‐RELAX‐AHF study. European Journal of Heart Failure2010;12(10):1130‐9. [MEDLINE: 20732868] Milo‐CotterO , TeerlinkJR , MetraM , FelkerGM , PonikowskiP , VoorsAA , et al. Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre‐RELAX‐AHF study. Cardiology2010;117(3):190‐6. [MEDLINE: 21088400] TeerlinkJR , MetraM , FelkerGM , PonikowskiP , VoorsAA , WeatherleyBD , et al. Relaxin for the treatment of patients with acute heart failure (Pre‐RELAX‐AHF): a multicentre, randomised, placebo‐controlled, parallel‐group, dose‐finding phase IIb study. Lancet2009;373(9673):1429‐39. [MEDLINE: 19329178] VoorsAA , DavisonBA , FelkerGM , PonikowskiP , UnemoriE , CotterG , et al. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre‐RELAX‐AHF. European Journal of Heart Failure2011;13(9):961‐7. [MEDLINE: 21622980] ">Pre‐RELAX‐AHF 2009</a>; <a href="./references#CD012466-bbs2-0079" title="LiuLC , VoorsAA , TeerlinkJR , CotterG , DavisonBA , FelkerGM , et al. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX‐AHF. Clinical Research in Cardiology2016;105(9):727‐37. [MEDLINE: 27017514] MetraM , CotterG , DavisonBA , FelkerGM , FilippatosG , GreenbergBH , et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX‐AHF) development program: correlation with outcomes. Journal of the American College of Cardiology2013;61(2):196‐206. [MEDLINE: 23273292] MetraM , PonikowskiP , CotterG , DavisonBA , FelkerGM , FilippatosG , et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX‐AHF. European Heart Journal2013;34(40):3128‐36. [MEDLINE: 23999454] PangPS , TeerlinkJR , VoorsAA , PonikowskiP , GreenbergBH , FilippatosG , et al. Use of high‐sensitivity troponin t to identify patients with acute heart failure at lower risk for adverse outcomes: an exploratory analysis from the RELAX‐AHF trial. JACC Heart Failure2016;4(7):591‐9. [MEDLINE: 27039129] PonikowskiP , MetraM , TeerlinkJR , UnemoriE , FelkerGM , VoorsAA , et al. Design of the RELAXin in acute heart failure study. American Heart Journal2012;163(2):149‐55. [MEDLINE: 22305830] TeerlinkJR , CotterG , DavisonBA , FelkerGM , FilippatosG , GreenbergBH , et al. Serelaxin, recombinant human relaxin‐2, for treatment of acute heart failure (RELAX‐AHF): a randomised, placebo‐controlled trial. Lancet2013;381(9860):29‐39. [MEDLINE: 23141816] ">RELAX‐AHF 2012</a>). </p> <p>In chronic settings, studies evaluated ARB (<a href="./references#CD012466-bbs2-0033" title="CiceG , DiBenedettoA , D'AndreaA , D'IsaS , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on left ventricular structure and function in hemodialyzed patients with chronic heart failure: a double‐blind placebo‐controlled multicenter study [abstract no: MP434]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv446. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on mortality and morbidity in haemodialysis patients with chronic heart failure: a double‐blind placebo‐controlled trial [abstract no: MO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v187. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , DeGregoriaP , CalabroR . Effect of telmisartan added to angiotensin converting enzyme inhibitors in reducing morbidity and mortality in haemodialysis patients with chronic heart failure [abstract no: P1.19]. Journal of Hypertension ‐ Supplement2006;24(Suppl):S56. [CENTRAL: CN‐00793137] CiceG , DiBenedettoA , D'IsaS , D'AndreaA , MarcelliD , GattiE , et al. Effects of telmisartan added to angiotensin‐converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2010;56(21):1701‐8. [MEDLINE: 21070920] ">Cice 2010</a>; <a href="./references#CD012466-bbs2-0053" title="HuDY , HuangJ , CaiNS , ZhuWL , LiYS , MassaadR , et al. A multi‐center, double‐blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment. Chinese Medical Journal2012;125(21):3868‐74. [MEDLINE: 23106890] KiernanMS , GregoryD , SarnakMJ , RossignolP , MassaroJ , KociolR , et al. Early and late effects of high‐ versus low‐dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.[Erratum appears in JACC Heart Fail. 2015 Jun;3(6):510‐1]. JACC Heart Failure2015;3(3):214‐23. [MEDLINE: 25742759] KiernanMS , WentworthD , FrancisG , MartinezFA , DicksteinK , KomajdaM , et al. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. European Journal of Heart Failure2012;14(12):1401‐9. [MEDLINE: 23187648] KonstamMA , NeatonJD , DicksteinK , DrexlerH , KomajdaM , MartinezFA , et al. Effects of high‐dose versus low‐dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double‐blind trial.[Erratum appears in Lancet. 2009 Dec 5;374(9705):1888]. Lancet2009;374(9704):1840‐8. [MEDLINE: 19922995] KonstamMA , Poole‐WilsonPA , DicksteinK , DrexlerH , JusticeSJ , KomajdaM , et al. Design of the heart failure endpoint evaluation of AII‐antagonist losartan (HEAAL) study in patients intolerant to ACE‐inhibitor. European Journal of Heart Failure2008;10(9):899‐906. [MEDLINE: 18768350] RossignolP , DobreD , GregoryD , MassaroJ , KiernanM , KonstamMA , et al. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2014;173(3):380‐7. [MEDLINE: 24726210] RossignolP , GirerdN , GregoryD , MassaroJ , KonstamMA , ZannadF . Increased visit‐to‐visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2015;187:183‐9. [MEDLINE: 25828348] UpshawJN , KonstamMA , KlaverenD , NoubaryF , HugginsGS , KentDM . Multistate model to predict heart failure hospitalizations and all‐cause mortality in outpatients with heart failure with reduced ejection fraction: model derivation and external validation. Circulation: Heart Failure2016;9(8):e003146. [MEDLINE: 27514751] ">HEAAL 2008</a>; <a href="./references#CD012466-bbs2-0070" title="Pita‐FernandezS , Choucino‐FernandezT , Juega‐PuigJ , Seoane‐PilladoT , Lopez‐CalvinoB , Pertega‐DiazS , et al. A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia. International Journal of Clinical Practice2014;68(10):1231‐8. [MEDLINE: 25040146] ">Pita‐Fernandez 2015</a>; <a href="./references#CD012466-bbs2-0100" title="AnandIS , BishuK , RectorTS , IshaniA , KuskowskiMA , CohnJN . Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin‐converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation2009;120(16):1577‐84. [MEDLINE: 19805651] AnandIS , RectorTS , KuskowskiM , AdourianA , MuntendamP , CohnJN . Baseline and serial measurements of galectin‐3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val‐HeFT. European Journal of Heart Failure2013;15(5):511‐8. [MEDLINE: 23291728] CohnJN . Improving outcomes in congestive heart failure: Val‐HeFT. Valsartan in Heart Failure Trial. Cardiology1999;91 Suppl 1:19‐22. [MEDLINE: 10449891] CohnJN , TognoniG , Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure.[Summary for patients in J Card Fail. 2002 Apr;8(2):56‐8; PMID: 12016625]. New England Journal of Medicine2001;345(23):1667‐75. [MEDLINE: 11759645] LesogorA , CohnJN , LatiniR , TognoniG , KrumH , MassieB , et al. Interaction between baseline and early worsening of renal function and efficacy of renin‐angiotensin‐aldosterone system blockade in patients with heart failure: insights from the Val‐HeFT study. European Journal of Heart Failure2013;15(11):1236‐44. [MEDLINE: 23787721] WongM , StaszewskyL , VolpiA , LatiniR , BarleraS , HoglundC . Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val‐HeFT). Journal of the American Society of Echocardiography2002;15(4):293‐301. [MEDLINE: 11944005] ">Val‐HeFT 1999</a>), beta‐blockers (<a href="./references#CD012466-bbs2-0029" title='Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. Fundamental &amp; Clinical Pharmacology1997;11(2):138‐42. [MEDLINE: 9107560] Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS‐II). European Heart Journal2001;22(12):1021‐31. [MEDLINE: 11428837] The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): a randomised trial. Lancet1999;353(9146):9‐13. [MEDLINE: 10023943] BohmM , MaackC , Wehrlen‐GrandjeanM , ErdmannE . Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardiac Insufficiency Bisoprolol Study II (CIBIS II)). Zeitschrift fur Kardiologie2003;92(8):668‐76. [MEDLINE: 12955414] CastagnoD , JhundPS , McMurrayJJ , LewseyJD , ErdmannE , ZannadF , et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS‐II) trial. European Journal of Heart Failure2010;12(6):607‐16. [MEDLINE: 20354032] EkmanM , ZethraeusN , JonssonB . Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics2001;19(9):901‐16. [MEDLINE: 11700777] ErdmannE , LechatP , VerkenneP , WiemannH . Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure. European Journal of Heart Failure2001;3(4):469‐79. [MEDLINE: 11511434] GallanaghS , CastagnoD , WilsonB , ErdmannE , ZannadF , RemmeWJ , et al. Evaluation of the functional status questionnaire in heart failure: a sub‐study of the second cardiac insufficiency bisoprolol survival study (CIBIS‐II). Cardiovascular Drugs &amp; Therapy2011;25(1):77‐85. [MEDLINE: 21287410] KrumH , BaileyM , MeyerW , VerkenneP , DargieH , LechatP , et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta‐blocker use: results of CIBIS II. Cardiology2007;108(1):28‐34. [MEDLINE: 16960445] KrumH , HareD . "Bisoprolol dose‐response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II)," by Simon T. European Heart Journal2004;25(3):277. [MEDLINE: 14972430] LechatP , HulotJS , EscolanoS , MalletA , LeizoroviczA , Werhlen‐GrandjeanM , et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation2001;103(10):1428‐33. [MEDLINE: 11245648] SimonT , Mary‐KrauseM , Funck‐BrentanoC , JaillonP . Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation2001;103(3):375‐80. [MEDLINE: 11157688] SimonT , Mary‐KrauseM , Funck‐BrentanoC , LechatP , JaillonP . Bisoprolol dose‐response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). European Heart Journal2003;24(6):552‐9. [MEDLINE: 12643888] '>CIBIS II 1997</a>; <a href="./references#CD012466-bbs2-0032" title="CiceG , FerraraL , D'AndreaA , D'IsaS , DiBenedettoA , CittadiniA , et al. Carvedilol increases two‐year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo‐controlled trial. Journal of the American College of Cardiology2003;41(9):1438‐44. [MEDLINE: 12742278] CiceG , FerraraL , DiBenedettoA , RussoPE , MarinelliG , PaveseF , et al. Dilated cardiomyopathy in dialysis patients‐‐beneficial effects of carvedilol: a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2001;37(2):407‐11. [MEDLINE: 11216954] ">Cice 2001</a>; <a href="./references#CD012466-bbs2-0059" title="Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Lancet1999;353(9169):2001‐7. [MEDLINE: 10376614] Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT‐HF). The International Steering Committee. American Journal of Cardiology1997;80(9B):54‐8J. [MEDLINE: 9375952] BattyJA , HallAS , WhiteHL , WikstrandJ , deBoerRA , vanVeldhuisenDJ , et al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT‐HF substudy. Clinical Pharmacology &amp; Therapeutics2014;95(3):321‐30. [MEDLINE: 24193112] CaroJJ , Migliaccio‐WalleK , O'BrienJA , NovaW , KimJ , HauchO , et al. Economic implications of extended‐release metoprolol succinate for heart failure in the MERIT‐HF trial: a US perspective of the MERIT‐HF trial. Journal of Cardiac Failure2005;11(9):647‐56. [MEDLINE: 16360958] DeedwaniaPC , GilesTD , KlibanerM , GhaliJK , HerlitzJ , HildebrandtP , et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT‐HF. American Heart Journal2005;149(1):159‐67. [MEDLINE: 15660048] FagerbergB . Screening, endpoint classification, and safety monitoring in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). European Journal of Heart Failure2000;2(3):315‐24. [MEDLINE: 10938494] GhaliJK , PinaIL , GottliebSS , DeedwaniaPC , WikstrandJC , MERIT‐HF Study Group. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended‐Release Randomized Intervention Trial in Heart Failure (MERIT‐HF). Circulation2002;105(13):1585‐91. [MEDLINE: 11927527] GhaliJK , WikstrandJ , vanVeldhuisenDJ , FagerbergB , GoldsteinS , HjalmarsonA , et al. The influence of renal function on clinical outcome and response to beta‐blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT‐HF). Journal of Cardiac Failure2009;15(4):310‐8. [MEDLINE: 19398079] GoldsteinS , HjalmarsonA . The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT‐HF Trial. Clinical Cardiology1999;22(Suppl 5):V30‐5. [MEDLINE: 10526701] GottliebSS , FisherML , KjekshusJ , DeedwaniaP , GullestadL , VitovecJ , et al. Tolerability of beta‐blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT‐HF). Circulation2002;105(10):1182‐8. [MEDLINE: 11889011] GullestadL , ManhenkeC , AarslandT , SkardalR , FagertunH , WikstrandJ , et al. Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure ‐ a substudy to the MERIT‐HF trial. European Journal of Heart Failure2001;3(4):463‐8. [MEDLINE: 11511433] GullestadL , UelandT , BrunsvigA , KjekshusJ , SimonsenS , FrolandSS , et al. Effect of metoprolol on cytokine levels in chronic heart failure‐‐a substudy in the Metoprolol Controlled‐Release Randomised Intervention Trial in Heart Failure (MERIT‐HF). American Heart Journal2001;141(3):418‐21. [MEDLINE: 11231439] GullestadL , WikstrandJ , DeedwaniaP , HjalmarsonA , EgstrupK , ElkayamU , et al. What resting heart rate should one aim for when treating patients with heart failure with a beta‐blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT‐HF). Journal of the American College of Cardiology2005;45(2):252‐9. [MEDLINE: 15653024] HjalmarsonA , GoldsteinS , FagerbergB , WedelH , WaagsteinF , KjekshusJ , et al. Effects of controlled‐release metoprolol on total mortality, hospitalizations, and well‐being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT‐HF). MERIT‐HF Study Group. JAMA2000;283(10):1295‐302. [MEDLINE: 10714728] SavvaJ , MaqboolA , WhiteHL , GallowaySL , YuldashevaNY , BallSG , et al. Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT‐HF substudy. Journal of Cardiac Failure2009;15(5):435‐41. [MEDLINE: 19477404] TepperD . Frontiers in congestive heart failure: effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Congestive Heart Failure1999;5(4):184‐5. [MEDLINE: 12189311] WhiteHL , deBoerRA , MaqboolA , GreenwoodD , vanVeldhuisenDJ , CuthbertR , et al. An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study. European Journal of Heart Failure2003;5(4):463‐8. [MEDLINE: 12921807] WikstrandJ , HjalmarsonA , WaagsteinF , FagerbergB , GoldsteinS , KjekshusJ , et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT‐HF). Journal of the American College of Cardiology2002;40(3):491‐8. [MEDLINE: 12142116] vanVeldhuisenDJ , AassH , ElAllafD , DunselmanPH , GullestadL , HalinenM , et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT‐HF Study. European Journal of Heart Failure2006;8(5):539‐46. [MEDLINE: 16567126] van derMeerP , DeBoerRA , WhiteHL , van derSteegeG , HallAS , VoorsAA , et al. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT‐HF substudy. Journal of Cardiac Failure2005;11(4):279‐84. [MEDLINE: 15880336] ">MERIT‐HF 1997</a>; <a href="./references#CD012466-bbs2-0085" title="Cohen‐SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872‐80. [MEDLINE: 19648605] FlatherMD , ShibataMC , CoatsAJ , VanVeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomised trial to determine the effect of nebivolol on mortality and hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26(3):215‐25. [MEDLINE: 15642700] ShibataMC , FlatherMD , BöhmM , BorbolaJ , Cohen‐SolalA , DumitrascuD , et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisations in Seniors with Heart Failure (SENIORS): rationale and design. International Journal of Cardiology2002;86(1):77‐85. [MEDLINE: 12243852] vanVeldhuisenDJ , Cohen‐SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta‐blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150‐8. [MEDLINE: 19497441] ">SENIORS 2002</a>), ACEi (<a href="./references#CD012466-bbs2-0033" title="CiceG , DiBenedettoA , D'AndreaA , D'IsaS , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on left ventricular structure and function in hemodialyzed patients with chronic heart failure: a double‐blind placebo‐controlled multicenter study [abstract no: MP434]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv446. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on mortality and morbidity in haemodialysis patients with chronic heart failure: a double‐blind placebo‐controlled trial [abstract no: MO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v187. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , DeGregoriaP , CalabroR . Effect of telmisartan added to angiotensin converting enzyme inhibitors in reducing morbidity and mortality in haemodialysis patients with chronic heart failure [abstract no: P1.19]. Journal of Hypertension ‐ Supplement2006;24(Suppl):S56. [CENTRAL: CN‐00793137] CiceG , DiBenedettoA , D'IsaS , D'AndreaA , MarcelliD , GattiE , et al. Effects of telmisartan added to angiotensin‐converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2010;56(21):1701‐8. [MEDLINE: 21070920] ">Cice 2010</a>; <a href="./references#CD012466-bbs2-0084" title="HagerWD , DavisBR , RibaA , MoyeLA , WunCC , RouleauJL , et al. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. American Heart Journal1998;135(3):406‐13. [MEDLINE: 9506325] JoseP , SkaliH , AnavekarN , TomsonC , KrumholzHM , RouleauJL , et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. Journal of the American Society of Nephrology2006;17(10):2886‐91. [MEDLINE: 16928807] LamasGA , PfefferMA , HammP , WertheimerJ , RouleauJL , BraunwaldE . Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? the SAVE Investigators. New England Journal of Medicine1992;327(4):241‐7. [MEDLINE: 1535419] MitchellGF , MoyeLA , BraunwaldE , RouleauJL , BernsteinV , GeltmanEM , et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation1997;96(12):4254‐60. [MEDLINE: 9416890] MoyeLA , PfefferMA , BraunwaldE . Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. SAVE Investigators. American Journal of Cardiology1991;68(14):70‐9D. [MEDLINE: 1836100] PfefferMA , BraunwaldE , MoyeLA , BastaL , BrownEJJr , CuddyTE , et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. New England Journal of Medicine1992;327(10):669‐77. [MEDLINE: 1386652] PfefferMA , MoyeLA , BraunwaldE , BastaL , BrownEJJr , CuddyTE , et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA1991;266(4):528‐32. [MEDLINE: 2061979] RouleauJL , MoyeLA , PfefferMA , ArnoldJM , BernsteinV , CuddyTE , et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. New England Journal of Medicine1993;328(11):779‐84. [MEDLINE: 8123063] RutherfordJD , PfefferMA , MoyeLA , DavisBR , FlakerGC , KoweyPR , et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation1994;90(4):1731‐8. [MEDLINE: 7923656] TokmakovaMP , SkaliH , KenchaiahS , BraunwaldE , RouleauJL , PackerM , et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin‐converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation2004;110(24):3667‐73. [MEDLINE: 15569840] UrenaPE , LamasGA , MitchellG , FlakerGC , SmithSCJr , WackersFJ , et al. Ejection fraction by radionuclide ventriculography and contrast left ventriculogram. A tale of two techniques. SAVE Investigators. Survival and Ventricular Enlargement. Journal of the American College of Cardiology1999;33(1):180‐5. [MEDLINE: 9935027] VantrimpontP , RouleauJL , WunCC , CiampiA , KleinM , SussexB , et al. Additive beneficial effects of beta‐blockers to angiotensin‐converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. Journal of the American College of Cardiology1997;29(2):229‐36. [MEDLINE: 9014971] ">SAVE 1991</a>; <a href="./references#CD012466-bbs2-0089" title="Al‐AhmadA , LeveyA , RandW , MajunathG , SalemD , GregoryD , et al. Anemia and renal insufficiency as risk factors for mortality in patients with left ventricular dysfunction [abstract no: A0739]. Journal of the American Society of Nephrology2000;11(Sept):137A. [CENTRAL: CN‐00550523] Al‐AhmadAM , SarnakMJ , RandW , GregoryD , KonstamMA , SalemDN , et al. Level of renal function as an independent predictor of mortality in patients with left ventricular dysfunction [abstract no: A0783]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):152A. [CENTRAL: CN‐00550524] Alsheikh‐AliAA , TrikalinosTA , RuthazerR , TerrinN , WongJB , SarnakMJ , et al. Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease. American Heart Journal2011;161(1):204‐9. [MEDLINE: 21167355] BansalN , TighiouartH , WeinerD , GriffithJ , VlagopoulosP , SalemD , et al. Anemia as a risk factor for kidney function decline in heart failure [abstract no: TH‐PO928]. Journal of the American Society of Nephrology2005;16(Oct):322A. [CENTRAL: CN‐01658120] BansalN , TighiouartH , WeinerD , GriffithJ , VlagopoulosP , SalemD , et al. Anemia as a risk factor for kidney function decline in individuals with heart failure. American Journal of Cardiology2007;99(8):1137‐42. [MEDLINE: 17437743] BowlingCB , SandersPW , AllmanRM , RogersWJ , PatelK , AbanIB , et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. International Journal of Cardiology2013;167(1):151‐6. [MEDLINE: 22257685] CapesSE , GersteinHC , NegassaA , YusufS . Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care2000;23(3):377‐80. [MEDLINE: 10868869] GregoryDD , SarnakMJ , KonstamMA , PereiraB , SalemD . Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction. American Journal of Cardiology2003;92(11):1300‐5. [MEDLINE: 14636907] KnightEL , GlynnRJ , McIntyreKM , MogunH , AvornJ . Predictors of decreased renal function in patients with heart failure during angiotensin‐converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). American Heart Journal1999;138(5 (Pt 1)):849‐55. [MEDLINE: 10539815] RiedingerMS , DracupKA , BrechtML , SOLVD Investigators. Studies of Left Ventricular Dysfunction. Quality of life in women with heart failure, normative groups, and patients with other chronic conditions. American Journal of Critical Care2002;11(3):211‐9. [MEDLINE: 12022484] SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New England Journal of Medicine1991;325(5):293‐302. [MEDLINE: 2057034] SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD)‐‐rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction.[Erratum appears in Am J Cardiol 1990 Oct 15;66(12):1026]. American Journal of Cardiology1990;66(3):315‐22. [MEDLINE: 2195865] TestaniJM , KimmelSE , DriesDL , CocaSG . Prognostic importance of early worsening renal function after initiation of angiotensin‐converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circulation: Heart Failure2011;4(6):685‐91. [MEDLINE: 21903907] ">SOLVD (Treatment) 1992</a>), aldosterone antagonists (<a href="./references#CD012466-bbs2-0044" title="EschalierR , McMurrayJJ , SwedbergK , vanVeldhuisenDJ , KrumH , PocockSJ , et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS‐HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Journal of the American College of Cardiology2013;62(17):1585‐93. [MEDLINE: 23810881] KrumH , ShiH , PittB , McMurrayJ , SwedbergK , vanVeldhuisenDJ , et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS‐HF study. Circulation: Heart Failure2013;6(4):711‐8. [MEDLINE: 23625945] RogersJK , McMurrayJJ , PocockSJ , ZannadF , KrumH , vanVeldhuisenDJ , et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation2012;126(19):2317‐23. [MEDLINE: 23042980] RossignolP , DobreD , McMurrayJJ , SwedbergK , KrumH , vanVeldhuisenDJ , et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF). Circulation: Heart Failure2014;7(1):51‐8. [MEDLINE: 24297687] ZannadF , McMurrayJJ , DrexlerH , KrumH , vanVeldhuisenDJ , SwedbergK , et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF). European Journal of Heart Failure2010;12(6):617‐22. [MEDLINE: 20388647] ZannadF , McMurrayJJ , KrumH , vanVeldhuisenDJ , SwedbergK , ShiH , et al. Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine2011;364(1):11‐21. [MEDLINE: 21073363] ">EMPHASIS‐HF 2010</a>; <a href="./references#CD012466-bbs2-0077" title="Effectiveness of spironolactone added to an angiotensin‐converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). American Journal of Cardiology1996;78(8):902‐7. [MEDLINE: 8888663] GlickHA , OrzolSM , TooleyJF , RemmeWJ , SasayamaS , PittB . Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovascular Drugs &amp; Therapy2002;16(1):53‐9. [MEDLINE: 12085979] HaubenM , ReichL , GerritsCM , MadiganD . Detection of spironolactone‐associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Safety2007;30(12):1143‐9. [MEDLINE: 18035866] PittB , ZannadF , RemmeWJ , CodyR , CastaigneA , PerezA , et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine1999;341(10):709‐17. [MEDLINE: 10471456] PittD . ACE inhibitor co‐therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). European Heart Journal1995;16 Suppl N:107‐10. [MEDLINE: 8682055] RousseauMF , GurneO , DuprezD , VanMieghemW , RobertA , AhnS , et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.[Erratum appears in J Am Coll Cardiol. 2003 Nov 19;42(10):1865]. Journal of the American College of Cardiology2002;40(9):1596‐601. [MEDLINE: 12427411] SchwingerRH . The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study [Der Aldosteronantagonist Spironolacton verlangert das Uberleben chronisch herzinsuffizienter Patienten. Ergebnisse der RALES‐Studie]. Deutsche Medizinische Wochenschrift1999;124(34‐5):987‐8. [MEDLINE: 10488324] VardenyO , WuDH , DesaiA , RossignolP , ZannadF , PittB , et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure. Journal of the American College of Cardiology2012;60(20):2082‐9. [MEDLINE: 23083787] WittesJ , PalenskyJ , AsnerD , JulianD , BoisselJP , FurbergCD , et al. Experience collecting interim data on mortality: an example from the RALES study. Current Controlled Trials in Cardiovascular Medicine2001;2(1):59‐62. [MEDLINE: 11806773] ZannadF , AllaF , DoussetB , PerezA , PittB . Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.[Erratum appears in Circulation 2001 Jan 23;103(3):476]. Circulation2000;102(22):2700‐6. [MEDLINE: 11094035] ">RALES 1995</a>; <a href="./references#CD012466-bbs2-0093" title="NajafabadiMM , TaheriS , SeyrafianS , AlipoorZ , KarimiS , PoormodhadasA , et al. Spironolactone in continuous ambulatory peritoneal dialysis patients, improves cardiac function [abstract no: SU475]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. TaheriS , MortazaviM , PourmoghadasA , SeyrafianS , AlipourZ , KarimiS . A prospective double‐blind randomized placebo‐controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi Journal of Kidney Diseases &amp; Transplantation2012;23(3):507‐12. [MEDLINE: 22569436] ">Taheri CAPD 2012</a>; <a href="./references#CD012466-bbs2-0094" title="MortazaviM , TaheriS , ShahidiS , PourmoghaddasA , YaraghiMG , SeyrafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: FP379]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi145. [CENTRAL: CN‐00716090] TaheriS , MortazaviM , ShahidiS , PourmoghadasA , GarakyaraghiM , SeirafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):392‐7. [MEDLINE: 19414940] TaheriS , MortazaviM , ShahidiS , PourmoghadasA , GarakyaraghiM , SeirafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: S‐PO‐0370]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:148. ">Taheri HD 2009</a>), nesiritide (<a href="./references#CD012466-bbs2-0050" title="O'ConnorCM , FiuzatM , LindenfeldJ , MillerA , LombardiC , CarsonP , et al. Mode of death and hospitalization from the Second Follow‐up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. American Journal of Cardiology2011;108(10):1449‐57. [MEDLINE: 21890092] YancyCW , KrumH , MassieBM , SilverMA , StevensonLW , ChengM , et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow‐Up Serial Infusions of Nesiritide (FUSION II) trial. Circulation: Heart Failure2008;1(1):9‐16. [MEDLINE: 19808265] YancyCW , KrumH , MassieBM , SilverMA , StevensonLW , ChengM , et al. The Second Follow‐up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. American Heart Journal2007;153(4):478‐84. [MEDLINE: 17383282] ">FUSION II 2008</a>), calcium‐channel blockers (<a href="./references#CD012466-bbs2-0031" title="CiceG , TagliamonteE , FerraraL , DiBenedettoA , SoriceP , IaconoA . Efficacy of diltiazem in uremic hemodialyzed patients with isolated diastolic dysfunction and dialysis hypotensive crisis [Efficacia del diltiazem in pazienti uremici emodializzati con disfunzione diastolica isolata e crisi ipotensive intradialitiche]. Cardiologia1999;44(3):289‐94. [MEDLINE: 10327731] ">Cice 1999a</a>), renin inhibitors (<a href="./references#CD012466-bbs2-0006" title="JacksonCE , MacDonaldMR , PetrieMC , SolomonSD , PittB , LatiniR , et al. Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure2011;13(7):746‐54. [MEDLINE: 21459891] MaggioniAP , McMurrayJJ , LatiniR , SolomonSD , SmithBA , BushC , et al. Safety and tolerability profile of aliskiren added to optimized therapy in patients with heart failure and renal impairment [abstract no: SA‐PO2247]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):616A. [CENTRAL: CN‐00776176] McMurrayJJ , PittB , LatiniR , MaggioniAP , SolomonSD , KeefeDL , et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure2008;1(1):17‐24. [MEDLINE: 19808266] ">ALOFT 2008</a>; <a href="./references#CD012466-bbs2-0009" title="SchrotenNF , DammanK , HemmelderMH , VoorsAA , NavisG , GaillardCA , et al. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). American Heart Journal2015;169(5):693‐701. [MEDLINE: 25965717] ">ARIANA‐CHF‐RD 2016</a>), vasopressin receptor antagonists (<a href="./references#CD012466-bbs2-0008" title='MatsueY , SuzukiM , NagahoriW , YoshidaK , OnishiY , SatohY , et al. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. Cardiovascular Drugs &amp; Therapy2014;28(1):73‐7. [MEDLINE: 24048511] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction.[Erratum appears in J Card Fail. 2016 Nov;22(11):941; PMID: 27481596]. Journal of Cardiac Failure2016;22(6):423‐32. [MEDLINE: 26915749] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423‐432.[Erratum for J Card Fail. 2016 Jun;22(6):423‐32; PMID: 26915749]. Journal of Cardiac Failure2016;22(11):941. [MEDLINE: 27481596] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. International Journal of Cardiology2016;221:188‐93. [MEDLINE: 27404673] MatsueY , Ter MaatenJM , SuzukiM , ToriiS , YamaguchiS , FukamizuS , et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology2017;106(10):802‐12. [MEDLINE: 28540483] '>AQUAMARINE 2014</a>; <a href="./references#CD012466-bbs2-0046" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJC , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJC , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>), anti‐arrhythmics (<a href="./references#CD012466-bbs2-0040" title="BrendorpB , ElmingH , JunL , KoberL , MalikM , JensenGB , et al. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation2001;103(10):1422‐7. [MEDLINE: 11245647] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group.Danish Investigations Of Arrhythmia and Mortality On Dofetilide. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. European Journal of Heart Failure2002;4(2):201‐6. [MEDLINE: 11959050] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group. The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide. Clinical Cardiology2003;26(5):219‐25. [MEDLINE: 12769249] MollerM , Torp‐PedersenCT , KoberL . Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congestive Heart Failure2001;7(3):146‐50. [MEDLINE: 11828153] PedersenHS , ElmingH , SeibaekM , BurchardtH , BrendorpB , Torp‐PedersenC , et al. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. American Journal of Cardiology2007;100(5):876‐80. [MEDLINE: 17719337] Torp‐PedersenC , MollerM , Bloch‐ThomsenPE , KoberL , SandoeE , EgstrupK , et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. New England Journal of Medicine1999;341(12):857‐65. [MEDLINE: 10486417] ">DIAMOND 1999</a>), digitalis glycoside (<a href="./references#CD012466-bbs2-0041" title="Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long‐term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clinical Trials1996;17(1):77‐97. [MEDLINE: 8721804] AhmedA . Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. Journals of Gerontology Series A‐Biological Sciences &amp; Medical Sciences2007;62(3):323‐9. [MEDLINE: 17389731] AhmedA , AronowWS , FlegJL . Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. American Journal of Therapeutics2006;13(4):325‐31. [MEDLINE: 16858168] AhmedA , LoveTE , SuiX , RichMW . Effects of angiotensin‐converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. Journal of Cardiac Failure2006;12(7):499‐506. [MEDLINE: 16952782] AhmedA , RichMW , SandersPW , PerryGJ , BakrisGL , ZileMR , et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. American Journal of Cardiology2007;99(3):393‐8. [MEDLINE: 17261405] BowlingCB , PittB , AhmedMI , AbanIB , SandersPW , MujibM , et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity‐matched studies. Circulation: Heart Failure2010;3(2):353‐60. [MEDLINE: 20103777] CampbellRC , SuiX , FilippatosG , LoveTE , WahleC , SandersPW , et al. Association of chronic kidney disease with outcomes in chronic heart failure: a propensity‐matched study. Nephrology Dialysis Transplantation2009;24(1):186‐93. [MEDLINE: 18711222] Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine1997;336(8):525‐33. [MEDLINE: 9036306] EkundayoOJ , MuchimbaM , AbanIB , RitchieC , CampbellRC , AhmedA . Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. American Journal of Cardiology2009;103(1):88‐92. [MEDLINE: 19101236] RitchieC , EkundayoOJ , MuchimbaM , CampbellRC , FrankSJ , LiuB , et al. Effects of diabetes mellitus in patients with heart failure and chronic kidney disease: a propensity‐matched study of multimorbidity in chronic heart failure.[Erratum appears in Int J Cardiol. 2010 Jan 7;138(1):106]. International Journal of Cardiology2009;134(3):330‐5. [MEDLINE: 19178965] ShlipakMG , SmithGL , RathoreSS , MassieBM , KrumholzHM . Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. Journal of the American Society of Nephrology2004;15(8):2195‐203. [MEDLINE: 15284305] TestaniJM , BriscoMA , TangWH , KimmelSE , Tiku‐OwensA , ForfiaPR , et al. Potential effects of digoxin on long‐term renal and clinical outcomes in chronic heart failure. Journal of Cardiac Failure2013;19(5):295‐302. [MEDLINE: 23663810] ">DIG 1996</a>), phosphodiesterase inhibitors (<a href="./references#CD012466-bbs2-0075" title="EichhornEJ , TandonPK , DiBiancoR , TimmisGC , FensterPE , ShannonJ , et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. Journal of the American College of Cardiology1993;21(3):634‐40. [MEDLINE: 8436744] PackerM . Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. American Journal of Cardiology1989;63(2):41‐5A. [MEDLINE: 2642629] PackerM , CarverJR , RodehefferRJ , IvanhoeRJ , DiBiancoR , ZeldisSM , et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. New England Journal of Medicine1991;325(21):1468‐75. [MEDLINE: 1944425] TeerlinkJR , JalaluddinM , AndersonS , KukinML , EichhornEJ , FrancisG , et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation2000;101(1):40‐6. [MEDLINE: 10618302] ">PROMISE 1989</a>), sinus node inhibitors (<a href="./references#CD012466-bbs2-0086" title="BocchiEA , BohmM , BorerJS , FordI , KomajdaM , SwedbergK , et al. Effect of combining ivabradine and beta‐blockers: focus on the use of carvedilol in the SHIFT population. Cardiology2015;131(4):218‐24. [MEDLINE: 25968495] BohmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20(2):373‐81. [MEDLINE: 29027329] BohmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost‐BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo‐controlled trial. Lancet2010;376(9744):886‐94. [MEDLINE: 20801495] BorerJS , BohmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33(22):2813‐20. [MEDLINE: 22927555] BorerJS , BohmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497‐503. [MEDLINE: 24332674] FordI , RobertsonM , KomajdaM , BohmM , BorerJS , TavazziL , et al. Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: the SHIFT risk model. International Journal of Cardiology2015;184:163‐9. [MEDLINE: 25703424] KomajdaM , BohmM , BorerJS , FordI , RobertsonM , ManolisAJ , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. European Journal of Heart Failure2014;16(7):810‐6. [MEDLINE: 24961493] KomajdaM , TavazziL , FrancqBG , BohmM , BorerJS , FordI , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. European Journal of Heart Failure2015;17(12):1294‐301. [MEDLINE: 26377342] KomajdaM , TavazziL , SwedbergK , BohmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of SHIFT. European Journal of Heart Failure2016;18(9):1182‐9. [MEDLINE: 27210035] SwedbergK , KomajdaM , BohmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta‐blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. Journal of the American College of Cardiology2012;59(22):1938‐45. [MEDLINE: 22617188] SwedbergK , KomajdaM , BohmM , BorerJS , FordI , Dubost‐BramaA , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo‐controlled study.[Erratum appears in Lancet. 2010 Dec 11;376(9757):1988 Note: Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadan, I Roldan]; Leva, M [corrected to Ieva, M]]. Lancet2010;376(9744):875‐85. [MEDLINE: 20801500] SwedbergK , KomajdaM , BöhmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). European Journal of Heart Failure2010;12(1):75‐81. [MEDLINE: 19892778] TardifJC , O'MearaE , KomajdaM , BohmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507‐15. [MEDLINE: 21875858] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182‐8. [MEDLINE: 24225201] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. European Journal of Heart Failure2013;15(11):1296‐303. [MEDLINE: 23803951] VoorsAA , vanVeldhuisenDJ , RobertsonM , FordI , BorerJS , BohmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure2014;16(4):426‐34. [MEDLINE: 24504937] ">SHIFT 2010</a>), and vasodilators (<a href="./references#CD012466-bbs2-0003" title="AnandIS , TamSW , RectorTS , TaylorAL , SabolinskiML , ArchambaultWT , et al. Influence of blood pressure on the effectiveness of a fixed‐dose combination of isosorbide dinitrate and hydralazine in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2007;49(1):32‐9. [MEDLINE: 17207719] AnandIS , WinS , RectorTS , CohnJN , TaylorAL . Effect of fixed‐dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30‐day readmission rates in patients with heart failure: results from the African‐American Heart Failure Trial. Circulation: Heart Failure2014;7(5):759‐65. [MEDLINE: 24970468] CarsonP , TamSW , GhaliJK , ArchambaultWT , TaylorA , CohnJN , et al. Relationship of quality of life scores with baseline characteristics and outcomes in the African‐American heart failure trial. Journal of Cardiac Failure2009;15(10):835‐42. [MEDLINE: 19944359] ChangKW , BeriN , NguyenNH , ArbitB , FoxS , MojaverS , et al. Heart failure with recovered ejection fraction in African Americans: results from the African‐American Heart Failure Trial. Journal of Cardiac Failure2018;24(5):303‐9. [MEDLINE: 28918108] CohnJN , TamSW , AnandIS , TaylorAL , SabolinskiML , WorcelM , et al. Isosorbide dinitrate and hydralazine in a fixed‐dose combination produces further regression of left ventricular remodeling in a well‐treated black population with heart failure: results from A‐HeFT. Journal of Cardiac Failure2007;13(5):331‐9. [MEDLINE: 17602978] FranciosaJA , TaylorAL , CohnJN , YancyCW , ZiescheS , OlukotunA , et al. African‐American Heart Failure Trial (A‐HeFT): rationale, design, and methodology. Journal of Cardiac Failure2002;8(3):128‐35. [MEDLINE: 12140804] GhaliJK , TamSW , FerdinandKC , LindenfeldJ , SabolinskiML , TaylorAL , et al. Effects of ACE inhibitors or beta‐blockers in patients treated with the fixed‐dose combination of isosorbide dinitrate/hydralazine in the African‐American Heart Failure Trial. American Journal of Cardiovascular Drugs2007;7(5):373‐80. [MEDLINE: 18041162] GhaliJK , TamSW , SabolinskiML , TaylorAL , LindenfeldJ , CohnJN , et al. Exploring the potential synergistic action of spironolactone on nitric oxide‐enhancing therapy: insights from the African‐American Heart Failure Trial. Journal of Cardiac Failure2008;14(9):718‐23. [MEDLINE: 18995175] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , TaylorAL , et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A‐HeFT Trial. Journal of the American College of Cardiology2006;48(6):1277‐82. [MEDLINE: 16979018] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , VenkitachalamL , et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A‐HeFT trial. Journal of Cardiac Failure2009;15(3):191‐8. [MEDLINE: 19327620] McNamaraDM , TaylorAL , TamSW , WorcelM , YancyCW , Hanley‐YanezK , et al. G‐protein beta‐3 subunit genotype predicts enhanced benefit of fixed‐dose isosorbide dinitrate and hydralazine: results of A‐HeFT. JACC Heart Failure2014;2(6):551‐7. [MEDLINE: 25306451] MitchellJE , TamSW , TrivediK , TaylorAL , O'NealW , CohnJN , et al. Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A‐HeFT). American Heart Journal2011;162(1):154‐9. [MEDLINE: 21742102] TaylorAL . The African‐American Heart Failure Trial (A‐HeFT): rationale and methodology.[Erratum appears in J Card Fail. 2003 Dec;9(6):481 Note: Dosage error in article text]. Journal of Cardiac Failure2003;9(5 Suppl Nitric Oxide):S216‐9. [MEDLINE: 14583892] TaylorAL , CohnJN , WorcelM , FranciosaJA , A‐HeFT Investigators.African‐American Heart Failure Trial. The African‐American Heart Failure Trial: background, rationale and significance. Journal of the National Medical Association2002;94(9):762‐9. [MEDLINE: 12392039] TaylorAL , LindenfeldJ , ZiescheS , WalshMN , MitchellJE , AdamsK , et al. Outcomes by gender in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2006;48(11):2263‐7. [MEDLINE: 17161257] TaylorAL , SabolinskiML , TamSW , ZiescheS , GhaliJK , ArchambaultWT , et al. Effect of fixed‐dose combined isosorbide dinitrate/hydralazine in elderly patients in the African‐American heart failure trial. Journal of Cardiac Failure2012;18(8):600‐6. [MEDLINE: 22858074] TaylorAL , ZiescheS , YancyC , CarsonP , D'AgostinoRJr , FerdinandK , et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.[Erratum appears in N Engl J Med. 2005 Mar 24;352(12):1276]. New England Journal of Medicine2004;351(20):2049‐57. [MEDLINE: 15533851] TaylorAL , ZiescheS , YancyCW , CarsonP , FerdinandK , TaylorM , et al. Early and sustained benefit on event‐free survival and heart failure hospitalization from fixed‐dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African‐American Heart Failure Trial. Circulation2007;115(13):1747‐53. [MEDLINE: 17372175] YancyCW , GhaliJK , BramanVM , SabolinskiML , WorcelM , ArchambaultWT , et al. Evidence for the continued safety and tolerability of fixed‐dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African‐American Heart Failure Trial). American Journal of Cardiology2007;100(4):684‐9. [MEDLINE: 17697829] ">A‐HeFT 2002</a>). </p> <p>Of the 31 studies, 28 studies (90%) including a total of 22,893 CKD patients, the intervention was compared with placebo or standard care. Of the remaining studies, two compared different doses of the same drug (<a href="./references#CD012466-bbs2-0053" title="HuDY , HuangJ , CaiNS , ZhuWL , LiYS , MassaadR , et al. A multi‐center, double‐blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment. Chinese Medical Journal2012;125(21):3868‐74. [MEDLINE: 23106890] KiernanMS , GregoryD , SarnakMJ , RossignolP , MassaroJ , KociolR , et al. Early and late effects of high‐ versus low‐dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.[Erratum appears in JACC Heart Fail. 2015 Jun;3(6):510‐1]. JACC Heart Failure2015;3(3):214‐23. [MEDLINE: 25742759] KiernanMS , WentworthD , FrancisG , MartinezFA , DicksteinK , KomajdaM , et al. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. European Journal of Heart Failure2012;14(12):1401‐9. [MEDLINE: 23187648] KonstamMA , NeatonJD , DicksteinK , DrexlerH , KomajdaM , MartinezFA , et al. Effects of high‐dose versus low‐dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double‐blind trial.[Erratum appears in Lancet. 2009 Dec 5;374(9705):1888]. Lancet2009;374(9704):1840‐8. [MEDLINE: 19922995] KonstamMA , Poole‐WilsonPA , DicksteinK , DrexlerH , JusticeSJ , KomajdaM , et al. Design of the heart failure endpoint evaluation of AII‐antagonist losartan (HEAAL) study in patients intolerant to ACE‐inhibitor. European Journal of Heart Failure2008;10(9):899‐906. [MEDLINE: 18768350] RossignolP , DobreD , GregoryD , MassaroJ , KiernanM , KonstamMA , et al. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2014;173(3):380‐7. [MEDLINE: 24726210] RossignolP , GirerdN , GregoryD , MassaroJ , KonstamMA , ZannadF . Increased visit‐to‐visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2015;187:183‐9. [MEDLINE: 25828348] UpshawJN , KonstamMA , KlaverenD , NoubaryF , HugginsGS , KentDM . Multistate model to predict heart failure hospitalizations and all‐cause mortality in outpatients with heart failure with reduced ejection fraction: model derivation and external validation. Circulation: Heart Failure2016;9(8):e003146. [MEDLINE: 27514751] ">HEAAL 2008</a>; <a href="./references#CD012466-bbs2-0070" title="Pita‐FernandezS , Choucino‐FernandezT , Juega‐PuigJ , Seoane‐PilladoT , Lopez‐CalvinoB , Pertega‐DiazS , et al. A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia. International Journal of Clinical Practice2014;68(10):1231‐8. [MEDLINE: 25040146] ">Pita‐Fernandez 2015</a>) and one compared different IV infusion strategies (continuous versus bolus) of furosemide (<a href="./references#CD012466-bbs2-0067" title="PalazzuoliA , PellegriniM , FranciB , BeltramiM , RuoccoG , GonnelliS , et al. Short and long‐term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction. Internal &amp; Emergency Medicine2015;10(1):41‐49. [MEDLINE: 25087085] PalazzuoliA , PellegriniM , RuoccoG , MartiniG , FranciB , CampagnaMS , et al. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Critical Care (London, England)2014;18(3):R132. [MEDLINE: 24974232] ">Palazzuoli 2014</a>). </p> </section> <section id="CD012466-sec-0092"> <h5 class="title">Outcomes</h5> <p>Study outcomes included death, hospitalisation, worsening HF, progression of kidney disease, quality of life, and adverse events such as hyperkalaemia and hypotension. Of the 31 studies, nine reported data in a form that could not be extracted for meta‐analysis. We contacted the authors of these nine studies and two (22%) were able to provide data (<a href="./references#CD012466-bbs2-0008" title='MatsueY , SuzukiM , NagahoriW , YoshidaK , OnishiY , SatohY , et al. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. Cardiovascular Drugs &amp; Therapy2014;28(1):73‐7. [MEDLINE: 24048511] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction.[Erratum appears in J Card Fail. 2016 Nov;22(11):941; PMID: 27481596]. Journal of Cardiac Failure2016;22(6):423‐32. [MEDLINE: 26915749] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423‐432.[Erratum for J Card Fail. 2016 Jun;22(6):423‐32; PMID: 26915749]. Journal of Cardiac Failure2016;22(11):941. [MEDLINE: 27481596] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. International Journal of Cardiology2016;221:188‐93. [MEDLINE: 27404673] MatsueY , Ter MaatenJM , SuzukiM , ToriiS , YamaguchiS , FukamizuS , et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology2017;106(10):802‐12. [MEDLINE: 28540483] '>AQUAMARINE 2014</a>; <a href="./references#CD012466-bbs2-0086" title="BocchiEA , BohmM , BorerJS , FordI , KomajdaM , SwedbergK , et al. Effect of combining ivabradine and beta‐blockers: focus on the use of carvedilol in the SHIFT population. Cardiology2015;131(4):218‐24. [MEDLINE: 25968495] BohmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20(2):373‐81. [MEDLINE: 29027329] BohmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost‐BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo‐controlled trial. Lancet2010;376(9744):886‐94. [MEDLINE: 20801495] BorerJS , BohmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33(22):2813‐20. [MEDLINE: 22927555] BorerJS , BohmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497‐503. [MEDLINE: 24332674] FordI , RobertsonM , KomajdaM , BohmM , BorerJS , TavazziL , et al. Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: the SHIFT risk model. International Journal of Cardiology2015;184:163‐9. [MEDLINE: 25703424] KomajdaM , BohmM , BorerJS , FordI , RobertsonM , ManolisAJ , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. European Journal of Heart Failure2014;16(7):810‐6. [MEDLINE: 24961493] KomajdaM , TavazziL , FrancqBG , BohmM , BorerJS , FordI , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. European Journal of Heart Failure2015;17(12):1294‐301. [MEDLINE: 26377342] KomajdaM , TavazziL , SwedbergK , BohmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of SHIFT. European Journal of Heart Failure2016;18(9):1182‐9. [MEDLINE: 27210035] SwedbergK , KomajdaM , BohmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta‐blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. Journal of the American College of Cardiology2012;59(22):1938‐45. [MEDLINE: 22617188] SwedbergK , KomajdaM , BohmM , BorerJS , FordI , Dubost‐BramaA , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo‐controlled study.[Erratum appears in Lancet. 2010 Dec 11;376(9757):1988 Note: Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadan, I Roldan]; Leva, M [corrected to Ieva, M]]. Lancet2010;376(9744):875‐85. [MEDLINE: 20801500] SwedbergK , KomajdaM , BöhmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). European Journal of Heart Failure2010;12(1):75‐81. [MEDLINE: 19892778] TardifJC , O'MearaE , KomajdaM , BohmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507‐15. [MEDLINE: 21875858] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182‐8. [MEDLINE: 24225201] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. European Journal of Heart Failure2013;15(11):1296‐303. [MEDLINE: 23803951] VoorsAA , vanVeldhuisenDJ , RobertsonM , FordI , BorerJS , BohmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure2014;16(4):426‐34. [MEDLINE: 24504937] ">SHIFT 2010</a>). One study investigating calcium‐channel blockers (<a href="./references#CD012466-bbs2-0031" title="CiceG , TagliamonteE , FerraraL , DiBenedettoA , SoriceP , IaconoA . Efficacy of diltiazem in uremic hemodialyzed patients with isolated diastolic dysfunction and dialysis hypotensive crisis [Efficacia del diltiazem in pazienti uremici emodializzati con disfunzione diastolica isolata e crisi ipotensive intradialitiche]. Cardiologia1999;44(3):289‐94. [MEDLINE: 10327731] ">Cice 1999a</a>) did not report any outcomes of interest and was also not included the in meta‐analysis. At this time, we do not have extractable data for any outcomes for four studies (<a href="./references#CD012466-bbs2-0003" title="AnandIS , TamSW , RectorTS , TaylorAL , SabolinskiML , ArchambaultWT , et al. Influence of blood pressure on the effectiveness of a fixed‐dose combination of isosorbide dinitrate and hydralazine in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2007;49(1):32‐9. [MEDLINE: 17207719] AnandIS , WinS , RectorTS , CohnJN , TaylorAL . Effect of fixed‐dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30‐day readmission rates in patients with heart failure: results from the African‐American Heart Failure Trial. Circulation: Heart Failure2014;7(5):759‐65. [MEDLINE: 24970468] CarsonP , TamSW , GhaliJK , ArchambaultWT , TaylorA , CohnJN , et al. Relationship of quality of life scores with baseline characteristics and outcomes in the African‐American heart failure trial. Journal of Cardiac Failure2009;15(10):835‐42. [MEDLINE: 19944359] ChangKW , BeriN , NguyenNH , ArbitB , FoxS , MojaverS , et al. Heart failure with recovered ejection fraction in African Americans: results from the African‐American Heart Failure Trial. Journal of Cardiac Failure2018;24(5):303‐9. [MEDLINE: 28918108] CohnJN , TamSW , AnandIS , TaylorAL , SabolinskiML , WorcelM , et al. Isosorbide dinitrate and hydralazine in a fixed‐dose combination produces further regression of left ventricular remodeling in a well‐treated black population with heart failure: results from A‐HeFT. Journal of Cardiac Failure2007;13(5):331‐9. [MEDLINE: 17602978] FranciosaJA , TaylorAL , CohnJN , YancyCW , ZiescheS , OlukotunA , et al. African‐American Heart Failure Trial (A‐HeFT): rationale, design, and methodology. Journal of Cardiac Failure2002;8(3):128‐35. [MEDLINE: 12140804] GhaliJK , TamSW , FerdinandKC , LindenfeldJ , SabolinskiML , TaylorAL , et al. Effects of ACE inhibitors or beta‐blockers in patients treated with the fixed‐dose combination of isosorbide dinitrate/hydralazine in the African‐American Heart Failure Trial. American Journal of Cardiovascular Drugs2007;7(5):373‐80. [MEDLINE: 18041162] GhaliJK , TamSW , SabolinskiML , TaylorAL , LindenfeldJ , CohnJN , et al. Exploring the potential synergistic action of spironolactone on nitric oxide‐enhancing therapy: insights from the African‐American Heart Failure Trial. Journal of Cardiac Failure2008;14(9):718‐23. [MEDLINE: 18995175] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , TaylorAL , et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A‐HeFT Trial. Journal of the American College of Cardiology2006;48(6):1277‐82. [MEDLINE: 16979018] McNamaraDM , TamSW , SabolinskiML , TobelmannP , JanoskoK , VenkitachalamL , et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A‐HeFT trial. Journal of Cardiac Failure2009;15(3):191‐8. [MEDLINE: 19327620] McNamaraDM , TaylorAL , TamSW , WorcelM , YancyCW , Hanley‐YanezK , et al. G‐protein beta‐3 subunit genotype predicts enhanced benefit of fixed‐dose isosorbide dinitrate and hydralazine: results of A‐HeFT. JACC Heart Failure2014;2(6):551‐7. [MEDLINE: 25306451] MitchellJE , TamSW , TrivediK , TaylorAL , O'NealW , CohnJN , et al. Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A‐HeFT). American Heart Journal2011;162(1):154‐9. [MEDLINE: 21742102] TaylorAL . The African‐American Heart Failure Trial (A‐HeFT): rationale and methodology.[Erratum appears in J Card Fail. 2003 Dec;9(6):481 Note: Dosage error in article text]. Journal of Cardiac Failure2003;9(5 Suppl Nitric Oxide):S216‐9. [MEDLINE: 14583892] TaylorAL , CohnJN , WorcelM , FranciosaJA , A‐HeFT Investigators.African‐American Heart Failure Trial. The African‐American Heart Failure Trial: background, rationale and significance. Journal of the National Medical Association2002;94(9):762‐9. [MEDLINE: 12392039] TaylorAL , LindenfeldJ , ZiescheS , WalshMN , MitchellJE , AdamsK , et al. Outcomes by gender in the African‐American Heart Failure Trial. Journal of the American College of Cardiology2006;48(11):2263‐7. [MEDLINE: 17161257] TaylorAL , SabolinskiML , TamSW , ZiescheS , GhaliJK , ArchambaultWT , et al. Effect of fixed‐dose combined isosorbide dinitrate/hydralazine in elderly patients in the African‐American heart failure trial. Journal of Cardiac Failure2012;18(8):600‐6. [MEDLINE: 22858074] TaylorAL , ZiescheS , YancyC , CarsonP , D'AgostinoRJr , FerdinandK , et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.[Erratum appears in N Engl J Med. 2005 Mar 24;352(12):1276]. New England Journal of Medicine2004;351(20):2049‐57. [MEDLINE: 15533851] TaylorAL , ZiescheS , YancyCW , CarsonP , FerdinandK , TaylorM , et al. Early and sustained benefit on event‐free survival and heart failure hospitalization from fixed‐dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African‐American Heart Failure Trial. Circulation2007;115(13):1747‐53. [MEDLINE: 17372175] YancyCW , GhaliJK , BramanVM , SabolinskiML , WorcelM , ArchambaultWT , et al. Evidence for the continued safety and tolerability of fixed‐dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African‐American Heart Failure Trial). American Journal of Cardiology2007;100(4):684‐9. [MEDLINE: 17697829] ">A‐HeFT 2002</a>; <a href="./references#CD012466-bbs2-0041" title="Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long‐term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clinical Trials1996;17(1):77‐97. [MEDLINE: 8721804] AhmedA . Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. Journals of Gerontology Series A‐Biological Sciences &amp; Medical Sciences2007;62(3):323‐9. [MEDLINE: 17389731] AhmedA , AronowWS , FlegJL . Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. American Journal of Therapeutics2006;13(4):325‐31. [MEDLINE: 16858168] AhmedA , LoveTE , SuiX , RichMW . Effects of angiotensin‐converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. Journal of Cardiac Failure2006;12(7):499‐506. [MEDLINE: 16952782] AhmedA , RichMW , SandersPW , PerryGJ , BakrisGL , ZileMR , et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. American Journal of Cardiology2007;99(3):393‐8. [MEDLINE: 17261405] BowlingCB , PittB , AhmedMI , AbanIB , SandersPW , MujibM , et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity‐matched studies. Circulation: Heart Failure2010;3(2):353‐60. [MEDLINE: 20103777] CampbellRC , SuiX , FilippatosG , LoveTE , WahleC , SandersPW , et al. Association of chronic kidney disease with outcomes in chronic heart failure: a propensity‐matched study. Nephrology Dialysis Transplantation2009;24(1):186‐93. [MEDLINE: 18711222] Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine1997;336(8):525‐33. [MEDLINE: 9036306] EkundayoOJ , MuchimbaM , AbanIB , RitchieC , CampbellRC , AhmedA . Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. American Journal of Cardiology2009;103(1):88‐92. [MEDLINE: 19101236] RitchieC , EkundayoOJ , MuchimbaM , CampbellRC , FrankSJ , LiuB , et al. Effects of diabetes mellitus in patients with heart failure and chronic kidney disease: a propensity‐matched study of multimorbidity in chronic heart failure.[Erratum appears in Int J Cardiol. 2010 Jan 7;138(1):106]. International Journal of Cardiology2009;134(3):330‐5. [MEDLINE: 19178965] ShlipakMG , SmithGL , RathoreSS , MassieBM , KrumholzHM . Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. Journal of the American Society of Nephrology2004;15(8):2195‐203. [MEDLINE: 15284305] TestaniJM , BriscoMA , TangWH , KimmelSE , Tiku‐OwensA , ForfiaPR , et al. Potential effects of digoxin on long‐term renal and clinical outcomes in chronic heart failure. Journal of Cardiac Failure2013;19(5):295‐302. [MEDLINE: 23663810] ">DIG 1996</a>; <a href="./references#CD012466-bbs2-0044" title="EschalierR , McMurrayJJ , SwedbergK , vanVeldhuisenDJ , KrumH , PocockSJ , et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS‐HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Journal of the American College of Cardiology2013;62(17):1585‐93. [MEDLINE: 23810881] KrumH , ShiH , PittB , McMurrayJ , SwedbergK , vanVeldhuisenDJ , et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS‐HF study. Circulation: Heart Failure2013;6(4):711‐8. [MEDLINE: 23625945] RogersJK , McMurrayJJ , PocockSJ , ZannadF , KrumH , vanVeldhuisenDJ , et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation2012;126(19):2317‐23. [MEDLINE: 23042980] RossignolP , DobreD , McMurrayJJ , SwedbergK , KrumH , vanVeldhuisenDJ , et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF). Circulation: Heart Failure2014;7(1):51‐8. [MEDLINE: 24297687] ZannadF , McMurrayJJ , DrexlerH , KrumH , vanVeldhuisenDJ , SwedbergK , et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF). European Journal of Heart Failure2010;12(6):617‐22. [MEDLINE: 20388647] ZannadF , McMurrayJJ , KrumH , vanVeldhuisenDJ , SwedbergK , ShiH , et al. Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine2011;364(1):11‐21. [MEDLINE: 21073363] ">EMPHASIS‐HF 2010</a>; <a href="./references#CD012466-bbs2-0053" title="HuDY , HuangJ , CaiNS , ZhuWL , LiYS , MassaadR , et al. A multi‐center, double‐blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment. Chinese Medical Journal2012;125(21):3868‐74. [MEDLINE: 23106890] KiernanMS , GregoryD , SarnakMJ , RossignolP , MassaroJ , KociolR , et al. Early and late effects of high‐ versus low‐dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.[Erratum appears in JACC Heart Fail. 2015 Jun;3(6):510‐1]. JACC Heart Failure2015;3(3):214‐23. [MEDLINE: 25742759] KiernanMS , WentworthD , FrancisG , MartinezFA , DicksteinK , KomajdaM , et al. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. European Journal of Heart Failure2012;14(12):1401‐9. [MEDLINE: 23187648] KonstamMA , NeatonJD , DicksteinK , DrexlerH , KomajdaM , MartinezFA , et al. Effects of high‐dose versus low‐dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double‐blind trial.[Erratum appears in Lancet. 2009 Dec 5;374(9705):1888]. Lancet2009;374(9704):1840‐8. [MEDLINE: 19922995] KonstamMA , Poole‐WilsonPA , DicksteinK , DrexlerH , JusticeSJ , KomajdaM , et al. Design of the heart failure endpoint evaluation of AII‐antagonist losartan (HEAAL) study in patients intolerant to ACE‐inhibitor. European Journal of Heart Failure2008;10(9):899‐906. [MEDLINE: 18768350] RossignolP , DobreD , GregoryD , MassaroJ , KiernanM , KonstamMA , et al. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2014;173(3):380‐7. [MEDLINE: 24726210] RossignolP , GirerdN , GregoryD , MassaroJ , KonstamMA , ZannadF . Increased visit‐to‐visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: insights from the HEAAL study. International Journal of Cardiology2015;187:183‐9. [MEDLINE: 25828348] UpshawJN , KonstamMA , KlaverenD , NoubaryF , HugginsGS , KentDM . Multistate model to predict heart failure hospitalizations and all‐cause mortality in outpatients with heart failure with reduced ejection fraction: model derivation and external validation. Circulation: Heart Failure2016;9(8):e003146. [MEDLINE: 27514751] ">HEAAL 2008</a>) and did not include these studies in our meta‐analyses. Of the 81 studies in the general population, 39 had valid author contact information and the authors were emailed to request data on the subset of patients with CKD. No authors have responded to this request, to date. </p> <p>Combining all intervention types:</p> <p> <ul id="CD012466-list-0023"> <li> <p>29 (94%) studies reported on death (any cause), of which 21 provided extractable data and were meta‐analysed </p> </li> <li> <p>25 (81%) on hospitalisations for HF, of which eight provided extractable data and were meta‐analysed </p> </li> <li> <p>18 (58%) on cardiovascular death, of which ten provided extractable data and were meta‐analysed </p> </li> <li> <p>10 (32%) on all‐cause hospitalisation, of which three provided extractable data and were meta‐analysed </p> </li> <li> <p>11 (35%) reported a dichotomous measure of worsening HF, of which seven were extractable and meta‐analysed </p> </li> <li> <p>17 (55%) reported a dichotomous measure of progression of kidney disease, of which eight were extractable and meta‐analysed </p> </li> <li> <p>10 (31%) reported a dichotomous measure of hyperkalaemia, of which seven were extractable and meta‐analysed </p> </li> <li> <p>15 (48%) reported a dichotomous measure of hypotension, of which eight were extractable and meta‐analysed </p> </li> <li> <p>3 (10%) reported a quality of life score, of which one was extractable and analysed</p> </li> </ul> </p> <p>Other secondary outcomes (e.g. dyspnoea, oedema) in CKD populations were not extractable and excluded from analysis. </p> <p>In summary, 26 studies (19,612 participants) reported disaggregated and extractable data on at least one outcome of interest for our review and were included in our meta‐analyses (<a href="./references#CD012466-bbs2-0006" title="JacksonCE , MacDonaldMR , PetrieMC , SolomonSD , PittB , LatiniR , et al. Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure2011;13(7):746‐54. [MEDLINE: 21459891] MaggioniAP , McMurrayJJ , LatiniR , SolomonSD , SmithBA , BushC , et al. Safety and tolerability profile of aliskiren added to optimized therapy in patients with heart failure and renal impairment [abstract no: SA‐PO2247]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):616A. [CENTRAL: CN‐00776176] McMurrayJJ , PittB , LatiniR , MaggioniAP , SolomonSD , KeefeDL , et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure2008;1(1):17‐24. [MEDLINE: 19808266] ">ALOFT 2008</a>; <a href="./references#CD012466-bbs2-0008" title='MatsueY , SuzukiM , NagahoriW , YoshidaK , OnishiY , SatohY , et al. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. Cardiovascular Drugs &amp; Therapy2014;28(1):73‐7. [MEDLINE: 24048511] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction.[Erratum appears in J Card Fail. 2016 Nov;22(11):941; PMID: 27481596]. Journal of Cardiac Failure2016;22(6):423‐32. [MEDLINE: 26915749] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423‐432.[Erratum for J Card Fail. 2016 Jun;22(6):423‐32; PMID: 26915749]. Journal of Cardiac Failure2016;22(11):941. [MEDLINE: 27481596] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. International Journal of Cardiology2016;221:188‐93. [MEDLINE: 27404673] MatsueY , Ter MaatenJM , SuzukiM , ToriiS , YamaguchiS , FukamizuS , et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology2017;106(10):802‐12. [MEDLINE: 28540483] '>AQUAMARINE 2014</a>; <a href="./references#CD012466-bbs2-0009" title="SchrotenNF , DammanK , HemmelderMH , VoorsAA , NavisG , GaillardCA , et al. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). American Heart Journal2015;169(5):693‐701. [MEDLINE: 25965717] ">ARIANA‐CHF‐RD 2016</a>; <a href="./references#CD012466-bbs2-0029" title='Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. Fundamental &amp; Clinical Pharmacology1997;11(2):138‐42. [MEDLINE: 9107560] Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS‐II). European Heart Journal2001;22(12):1021‐31. [MEDLINE: 11428837] The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): a randomised trial. Lancet1999;353(9146):9‐13. [MEDLINE: 10023943] BohmM , MaackC , Wehrlen‐GrandjeanM , ErdmannE . Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardiac Insufficiency Bisoprolol Study II (CIBIS II)). Zeitschrift fur Kardiologie2003;92(8):668‐76. [MEDLINE: 12955414] CastagnoD , JhundPS , McMurrayJJ , LewseyJD , ErdmannE , ZannadF , et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS‐II) trial. European Journal of Heart Failure2010;12(6):607‐16. [MEDLINE: 20354032] EkmanM , ZethraeusN , JonssonB . Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics2001;19(9):901‐16. [MEDLINE: 11700777] ErdmannE , LechatP , VerkenneP , WiemannH . Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure. European Journal of Heart Failure2001;3(4):469‐79. [MEDLINE: 11511434] GallanaghS , CastagnoD , WilsonB , ErdmannE , ZannadF , RemmeWJ , et al. Evaluation of the functional status questionnaire in heart failure: a sub‐study of the second cardiac insufficiency bisoprolol survival study (CIBIS‐II). Cardiovascular Drugs &amp; Therapy2011;25(1):77‐85. [MEDLINE: 21287410] KrumH , BaileyM , MeyerW , VerkenneP , DargieH , LechatP , et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta‐blocker use: results of CIBIS II. Cardiology2007;108(1):28‐34. [MEDLINE: 16960445] KrumH , HareD . "Bisoprolol dose‐response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II)," by Simon T. European Heart Journal2004;25(3):277. [MEDLINE: 14972430] LechatP , HulotJS , EscolanoS , MalletA , LeizoroviczA , Werhlen‐GrandjeanM , et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation2001;103(10):1428‐33. [MEDLINE: 11245648] SimonT , Mary‐KrauseM , Funck‐BrentanoC , JaillonP . Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation2001;103(3):375‐80. [MEDLINE: 11157688] SimonT , Mary‐KrauseM , Funck‐BrentanoC , LechatP , JaillonP . Bisoprolol dose‐response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). European Heart Journal2003;24(6):552‐9. [MEDLINE: 12643888] '>CIBIS II 1997</a>; <a href="./references#CD012466-bbs2-0032" title="CiceG , FerraraL , D'AndreaA , D'IsaS , DiBenedettoA , CittadiniA , et al. Carvedilol increases two‐year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo‐controlled trial. Journal of the American College of Cardiology2003;41(9):1438‐44. [MEDLINE: 12742278] CiceG , FerraraL , DiBenedettoA , RussoPE , MarinelliG , PaveseF , et al. Dilated cardiomyopathy in dialysis patients‐‐beneficial effects of carvedilol: a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2001;37(2):407‐11. [MEDLINE: 11216954] ">Cice 2001</a>; <a href="./references#CD012466-bbs2-0033" title="CiceG , DiBenedettoA , D'AndreaA , D'IsaS , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on left ventricular structure and function in hemodialyzed patients with chronic heart failure: a double‐blind placebo‐controlled multicenter study [abstract no: MP434]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv446. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on mortality and morbidity in haemodialysis patients with chronic heart failure: a double‐blind placebo‐controlled trial [abstract no: MO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v187. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , DeGregoriaP , CalabroR . Effect of telmisartan added to angiotensin converting enzyme inhibitors in reducing morbidity and mortality in haemodialysis patients with chronic heart failure [abstract no: P1.19]. Journal of Hypertension ‐ Supplement2006;24(Suppl):S56. [CENTRAL: CN‐00793137] CiceG , DiBenedettoA , D'IsaS , D'AndreaA , MarcelliD , GattiE , et al. Effects of telmisartan added to angiotensin‐converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2010;56(21):1701‐8. [MEDLINE: 21070920] ">Cice 2010</a>; <a href="./references#CD012466-bbs2-0040" title="BrendorpB , ElmingH , JunL , KoberL , MalikM , JensenGB , et al. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation2001;103(10):1422‐7. [MEDLINE: 11245647] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group.Danish Investigations Of Arrhythmia and Mortality On Dofetilide. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. European Journal of Heart Failure2002;4(2):201‐6. [MEDLINE: 11959050] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group. The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide. Clinical Cardiology2003;26(5):219‐25. [MEDLINE: 12769249] MollerM , Torp‐PedersenCT , KoberL . Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congestive Heart Failure2001;7(3):146‐50. [MEDLINE: 11828153] PedersenHS , ElmingH , SeibaekM , BurchardtH , BrendorpB , Torp‐PedersenC , et al. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. American Journal of Cardiology2007;100(5):876‐80. [MEDLINE: 17719337] Torp‐PedersenC , MollerM , Bloch‐ThomsenPE , KoberL , SandoeE , EgstrupK , et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. New England Journal of Medicine1999;341(12):857‐65. [MEDLINE: 10486417] ">DIAMOND 1999</a>; <a href="./references#CD012466-bbs2-0046" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJC , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJC , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD012466-bbs2-0050" title="O'ConnorCM , FiuzatM , LindenfeldJ , MillerA , LombardiC , CarsonP , et al. Mode of death and hospitalization from the Second Follow‐up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. American Journal of Cardiology2011;108(10):1449‐57. [MEDLINE: 21890092] YancyCW , KrumH , MassieBM , SilverMA , StevensonLW , ChengM , et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow‐Up Serial Infusions of Nesiritide (FUSION II) trial. Circulation: Heart Failure2008;1(1):9‐16. [MEDLINE: 19808265] YancyCW , KrumH , MassieBM , SilverMA , StevensonLW , ChengM , et al. The Second Follow‐up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. American Heart Journal2007;153(4):478‐84. [MEDLINE: 17383282] ">FUSION II 2008</a>; <a href="./references#CD012466-bbs2-0059" title="Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Lancet1999;353(9169):2001‐7. [MEDLINE: 10376614] Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT‐HF). The International Steering Committee. American Journal of Cardiology1997;80(9B):54‐8J. [MEDLINE: 9375952] BattyJA , HallAS , WhiteHL , WikstrandJ , deBoerRA , vanVeldhuisenDJ , et al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT‐HF substudy. Clinical Pharmacology &amp; Therapeutics2014;95(3):321‐30. [MEDLINE: 24193112] CaroJJ , Migliaccio‐WalleK , O'BrienJA , NovaW , KimJ , HauchO , et al. Economic implications of extended‐release metoprolol succinate for heart failure in the MERIT‐HF trial: a US perspective of the MERIT‐HF trial. Journal of Cardiac Failure2005;11(9):647‐56. [MEDLINE: 16360958] DeedwaniaPC , GilesTD , KlibanerM , GhaliJK , HerlitzJ , HildebrandtP , et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT‐HF. American Heart Journal2005;149(1):159‐67. [MEDLINE: 15660048] FagerbergB . Screening, endpoint classification, and safety monitoring in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). European Journal of Heart Failure2000;2(3):315‐24. [MEDLINE: 10938494] GhaliJK , PinaIL , GottliebSS , DeedwaniaPC , WikstrandJC , MERIT‐HF Study Group. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended‐Release Randomized Intervention Trial in Heart Failure (MERIT‐HF). Circulation2002;105(13):1585‐91. [MEDLINE: 11927527] GhaliJK , WikstrandJ , vanVeldhuisenDJ , FagerbergB , GoldsteinS , HjalmarsonA , et al. The influence of renal function on clinical outcome and response to beta‐blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT‐HF). Journal of Cardiac Failure2009;15(4):310‐8. [MEDLINE: 19398079] GoldsteinS , HjalmarsonA . The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT‐HF Trial. Clinical Cardiology1999;22(Suppl 5):V30‐5. [MEDLINE: 10526701] GottliebSS , FisherML , KjekshusJ , DeedwaniaP , GullestadL , VitovecJ , et al. Tolerability of beta‐blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT‐HF). Circulation2002;105(10):1182‐8. [MEDLINE: 11889011] GullestadL , ManhenkeC , AarslandT , SkardalR , FagertunH , WikstrandJ , et al. Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure ‐ a substudy to the MERIT‐HF trial. European Journal of Heart Failure2001;3(4):463‐8. [MEDLINE: 11511433] GullestadL , UelandT , BrunsvigA , KjekshusJ , SimonsenS , FrolandSS , et al. Effect of metoprolol on cytokine levels in chronic heart failure‐‐a substudy in the Metoprolol Controlled‐Release Randomised Intervention Trial in Heart Failure (MERIT‐HF). American Heart Journal2001;141(3):418‐21. [MEDLINE: 11231439] GullestadL , WikstrandJ , DeedwaniaP , HjalmarsonA , EgstrupK , ElkayamU , et al. What resting heart rate should one aim for when treating patients with heart failure with a beta‐blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT‐HF). Journal of the American College of Cardiology2005;45(2):252‐9. [MEDLINE: 15653024] HjalmarsonA , GoldsteinS , FagerbergB , WedelH , WaagsteinF , KjekshusJ , et al. Effects of controlled‐release metoprolol on total mortality, hospitalizations, and well‐being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT‐HF). MERIT‐HF Study Group. JAMA2000;283(10):1295‐302. [MEDLINE: 10714728] SavvaJ , MaqboolA , WhiteHL , GallowaySL , YuldashevaNY , BallSG , et al. Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT‐HF substudy. Journal of Cardiac Failure2009;15(5):435‐41. [MEDLINE: 19477404] TepperD . Frontiers in congestive heart failure: effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Congestive Heart Failure1999;5(4):184‐5. [MEDLINE: 12189311] WhiteHL , deBoerRA , MaqboolA , GreenwoodD , vanVeldhuisenDJ , CuthbertR , et al. An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study. European Journal of Heart Failure2003;5(4):463‐8. [MEDLINE: 12921807] WikstrandJ , HjalmarsonA , WaagsteinF , FagerbergB , GoldsteinS , KjekshusJ , et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT‐HF). Journal of the American College of Cardiology2002;40(3):491‐8. [MEDLINE: 12142116] vanVeldhuisenDJ , AassH , ElAllafD , DunselmanPH , GullestadL , HalinenM , et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT‐HF Study. European Journal of Heart Failure2006;8(5):539‐46. [MEDLINE: 16567126] van derMeerP , DeBoerRA , WhiteHL , van derSteegeG , HallAS , VoorsAA , et al. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT‐HF substudy. Journal of Cardiac Failure2005;11(4):279‐84. [MEDLINE: 15880336] ">MERIT‐HF 1997</a>; <a href="./references#CD012466-bbs2-0067" title="PalazzuoliA , PellegriniM , FranciB , BeltramiM , RuoccoG , GonnelliS , et al. Short and long‐term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction. Internal &amp; Emergency Medicine2015;10(1):41‐49. [MEDLINE: 25087085] PalazzuoliA , PellegriniM , RuoccoG , MartiniG , FranciB , CampagnaMS , et al. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Critical Care (London, England)2014;18(3):R132. [MEDLINE: 24974232] ">Palazzuoli 2014</a>; <a href="./references#CD012466-bbs2-0070" title="Pita‐FernandezS , Choucino‐FernandezT , Juega‐PuigJ , Seoane‐PilladoT , Lopez‐CalvinoB , Pertega‐DiazS , et al. A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia. International Journal of Clinical Practice2014;68(10):1231‐8. [MEDLINE: 25040146] ">Pita‐Fernandez 2015</a>; <a href="./references#CD012466-bbs2-0072" title="DavisonBA , CotterG , SunH , ChenL , TeerlinkJR , MetraM , et al. Permutation criteria to evaluate multiple clinical endpoints in a proof‐of‐concept study: lessons from Pre‐RELAX‐AHF. Clinical Research in Cardiology2011;100(9):745‐53. [MEDLINE: 21416190] MetraM , TeerlinkJR , FelkerGM , GreenbergBH , FilippatosG , PonikowskiP , et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre‐RELAX‐AHF study. European Journal of Heart Failure2010;12(10):1130‐9. [MEDLINE: 20732868] Milo‐CotterO , TeerlinkJR , MetraM , FelkerGM , PonikowskiP , VoorsAA , et al. Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre‐RELAX‐AHF study. Cardiology2010;117(3):190‐6. [MEDLINE: 21088400] TeerlinkJR , MetraM , FelkerGM , PonikowskiP , VoorsAA , WeatherleyBD , et al. Relaxin for the treatment of patients with acute heart failure (Pre‐RELAX‐AHF): a multicentre, randomised, placebo‐controlled, parallel‐group, dose‐finding phase IIb study. Lancet2009;373(9673):1429‐39. [MEDLINE: 19329178] VoorsAA , DavisonBA , FelkerGM , PonikowskiP , UnemoriE , CotterG , et al. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre‐RELAX‐AHF. European Journal of Heart Failure2011;13(9):961‐7. [MEDLINE: 21622980] ">Pre‐RELAX‐AHF 2009</a>; <a href="./references#CD012466-bbs2-0075" title="EichhornEJ , TandonPK , DiBiancoR , TimmisGC , FensterPE , ShannonJ , et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. Journal of the American College of Cardiology1993;21(3):634‐40. [MEDLINE: 8436744] PackerM . Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. American Journal of Cardiology1989;63(2):41‐5A. [MEDLINE: 2642629] PackerM , CarverJR , RodehefferRJ , IvanhoeRJ , DiBiancoR , ZeldisSM , et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. New England Journal of Medicine1991;325(21):1468‐75. [MEDLINE: 1944425] TeerlinkJR , JalaluddinM , AndersonS , KukinML , EichhornEJ , FrancisG , et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation2000;101(1):40‐6. [MEDLINE: 10618302] ">PROMISE 1989</a>; <a href="./references#CD012466-bbs2-0076" title="ClelandJG , ChiswellK , TeerlinkJR , StevensS , FiuzatM , GivertzMM , et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo‐Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Circulation: Heart Failure2014;7(1):76‐87. [MEDLINE: 24281134] CotterG , DittrichHC , WeatherleyBD , BloomfieldDM , O'ConnorCM , MetraM , et al. The PROTECT pilot study: a randomized, placebo‐controlled, dose‐finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. Journal of Cardiac Failure2008;14(8):631‐40. [MEDLINE: 18926433] GivertzMM , PostmusD , HillegeHL , MansoorGA , MassieBM , DavisonBA , et al. Renal function trajectories and clinical outcomes in acute heart failure. Circulation: Heart Failure2014;7(1):59‐67. [MEDLINE: 24281137] MassieBM , O'ConnorCM , MetraM , PonikowskiP , TeerlinkJR , CotterG , et al. Rolofylline, an adenosine A1‐receptor antagonist, in acute heart failure. New England Journal of Medicine2010;363(15):1419‐28. [MEDLINE: 20925544] MetraM , ClelandJG , WeatherleyBD , DittrichHC , GivertzMM , MassieBM , et al. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60‐day outcomes in the PROTECT pilot study. European Journal of Heart Failure2010;12(5):499‐507. [MEDLINE: 20228387] MetraM , O'ConnorCM , DavisonBA , ClelandJG , PonikowskiP , TeerlinkJR , et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. European Heart Journal2011;32(12):1519‐34. [MEDLINE: 21388992] TeerlinkJR , IraguiVJ , MohrJP , CarsonPE , HauptmanPJ , LovettDH , et al. The safety of an adenosine A(1)‐receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Safety2012;35(3):233‐44. [MEDLINE: 22339573] VoorsAA , DittrichHC , MassieBM , DeLuccaP , MansoorGA , MetraM , et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo‐Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). Journal of the American College of Cardiology2011;57(19):1899‐907. [MEDLINE: 21545947] WeatherleyBD , CotterG , DittrichHC , DeLuccaP , MansoorGA , BloomfieldDM , et al. Design and rationale of the PROTECT study: a placebo‐controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. Journal of Cardiac Failure2010;16(1):25‐35. [MEDLINE: 20123315] ">PROTECT 2008</a>; <a href="./references#CD012466-bbs2-0077" title="Effectiveness of spironolactone added to an angiotensin‐converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). American Journal of Cardiology1996;78(8):902‐7. [MEDLINE: 8888663] GlickHA , OrzolSM , TooleyJF , RemmeWJ , SasayamaS , PittB . Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovascular Drugs &amp; Therapy2002;16(1):53‐9. [MEDLINE: 12085979] HaubenM , ReichL , GerritsCM , MadiganD . Detection of spironolactone‐associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Safety2007;30(12):1143‐9. [MEDLINE: 18035866] PittB , ZannadF , RemmeWJ , CodyR , CastaigneA , PerezA , et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine1999;341(10):709‐17. [MEDLINE: 10471456] PittD . ACE inhibitor co‐therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). European Heart Journal1995;16 Suppl N:107‐10. [MEDLINE: 8682055] RousseauMF , GurneO , DuprezD , VanMieghemW , RobertA , AhnS , et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.[Erratum appears in J Am Coll Cardiol. 2003 Nov 19;42(10):1865]. Journal of the American College of Cardiology2002;40(9):1596‐601. [MEDLINE: 12427411] SchwingerRH . The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study [Der Aldosteronantagonist Spironolacton verlangert das Uberleben chronisch herzinsuffizienter Patienten. Ergebnisse der RALES‐Studie]. Deutsche Medizinische Wochenschrift1999;124(34‐5):987‐8. [MEDLINE: 10488324] VardenyO , WuDH , DesaiA , RossignolP , ZannadF , PittB , et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure. Journal of the American College of Cardiology2012;60(20):2082‐9. [MEDLINE: 23083787] WittesJ , PalenskyJ , AsnerD , JulianD , BoisselJP , FurbergCD , et al. Experience collecting interim data on mortality: an example from the RALES study. Current Controlled Trials in Cardiovascular Medicine2001;2(1):59‐62. [MEDLINE: 11806773] ZannadF , AllaF , DoussetB , PerezA , PittB . Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.[Erratum appears in Circulation 2001 Jan 23;103(3):476]. Circulation2000;102(22):2700‐6. [MEDLINE: 11094035] ">RALES 1995</a>; <a href="./references#CD012466-bbs2-0079" title="LiuLC , VoorsAA , TeerlinkJR , CotterG , DavisonBA , FelkerGM , et al. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX‐AHF. Clinical Research in Cardiology2016;105(9):727‐37. [MEDLINE: 27017514] MetraM , CotterG , DavisonBA , FelkerGM , FilippatosG , GreenbergBH , et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX‐AHF) development program: correlation with outcomes. Journal of the American College of Cardiology2013;61(2):196‐206. [MEDLINE: 23273292] MetraM , PonikowskiP , CotterG , DavisonBA , FelkerGM , FilippatosG , et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX‐AHF. European Heart Journal2013;34(40):3128‐36. [MEDLINE: 23999454] PangPS , TeerlinkJR , VoorsAA , PonikowskiP , GreenbergBH , FilippatosG , et al. Use of high‐sensitivity troponin t to identify patients with acute heart failure at lower risk for adverse outcomes: an exploratory analysis from the RELAX‐AHF trial. JACC Heart Failure2016;4(7):591‐9. [MEDLINE: 27039129] PonikowskiP , MetraM , TeerlinkJR , UnemoriE , FelkerGM , VoorsAA , et al. Design of the RELAXin in acute heart failure study. American Heart Journal2012;163(2):149‐55. [MEDLINE: 22305830] TeerlinkJR , CotterG , DavisonBA , FelkerGM , FilippatosG , GreenbergBH , et al. Serelaxin, recombinant human relaxin‐2, for treatment of acute heart failure (RELAX‐AHF): a randomised, placebo‐controlled trial. Lancet2013;381(9860):29‐39. [MEDLINE: 23141816] ">RELAX‐AHF 2012</a>; <a href="./references#CD012466-bbs2-0080" title="PangPS , MehraM , MaggioniAP , FilippatosG , MiddlebrooksJ , TurlapatyP , et al. Rationale, design, and results from RENO‐DEFEND 1: a randomized, dose‐finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. American Heart Journal2011;161(6):1012‐23. [MEDLINE: 21641345] ">RENO‐DEFEND 1 2011</a>; <a href="./references#CD012466-bbs2-0082" title="ChenHH , AbouEzzeddineOF , AnstromKJ , GivertzMM , BartBA , FelkerGM , et al. Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circulation: Heart Failure2013;6(5):1087‐94. [MEDLINE: 24046475] ChenHH , AnstromKJ , GivertzMM , StevensonLW , SemigranMJ , GoldsmithSR , et al. Low‐dose dopamine or low‐dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA2013;310(23):2533‐43. [MEDLINE: 24247300] GrodinJL , LalaA , StevensSR , DeVoreAD , CooperLB , AbouEzzeddineOF , et al. Clinical Implications of serum albumin levels in acute heart failure: insights from DOSE‐AHF and ROSE‐AHF. Journal of Cardiac Failure2016;22(11):884‐90. [MEDLINE: 26844764] GrodinJL , SunJL , AnstromKJ , ChenHH , StarlingRC , TestaniJM , et al. Implications of serum chloride homeostasis in acute heart failure (from ROSE‐AHF). American Journal of Cardiology2017;119(1):78‐83. [MEDLINE: 27816115] WanSH , StevensSR , BorlaugBA , AnstromKJ , DeswalA , FelkerGM , et al. Differential response to low‐dose dopamine or low‐dose nesiritide in acute heart failure with reduced or preserved ejection fraction: results from the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circulation: Heart Failure2016;9(8):1. [MEDLINE: 27512103] ">ROSE AHF 2013</a>; <a href="./references#CD012466-bbs2-0084" title="HagerWD , DavisBR , RibaA , MoyeLA , WunCC , RouleauJL , et al. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. American Heart Journal1998;135(3):406‐13. [MEDLINE: 9506325] JoseP , SkaliH , AnavekarN , TomsonC , KrumholzHM , RouleauJL , et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. Journal of the American Society of Nephrology2006;17(10):2886‐91. [MEDLINE: 16928807] LamasGA , PfefferMA , HammP , WertheimerJ , RouleauJL , BraunwaldE . Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? the SAVE Investigators. New England Journal of Medicine1992;327(4):241‐7. [MEDLINE: 1535419] MitchellGF , MoyeLA , BraunwaldE , RouleauJL , BernsteinV , GeltmanEM , et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation1997;96(12):4254‐60. [MEDLINE: 9416890] MoyeLA , PfefferMA , BraunwaldE . Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. SAVE Investigators. American Journal of Cardiology1991;68(14):70‐9D. [MEDLINE: 1836100] PfefferMA , BraunwaldE , MoyeLA , BastaL , BrownEJJr , CuddyTE , et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. New England Journal of Medicine1992;327(10):669‐77. [MEDLINE: 1386652] PfefferMA , MoyeLA , BraunwaldE , BastaL , BrownEJJr , CuddyTE , et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA1991;266(4):528‐32. [MEDLINE: 2061979] RouleauJL , MoyeLA , PfefferMA , ArnoldJM , BernsteinV , CuddyTE , et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. New England Journal of Medicine1993;328(11):779‐84. [MEDLINE: 8123063] RutherfordJD , PfefferMA , MoyeLA , DavisBR , FlakerGC , KoweyPR , et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation1994;90(4):1731‐8. [MEDLINE: 7923656] TokmakovaMP , SkaliH , KenchaiahS , BraunwaldE , RouleauJL , PackerM , et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin‐converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation2004;110(24):3667‐73. [MEDLINE: 15569840] UrenaPE , LamasGA , MitchellG , FlakerGC , SmithSCJr , WackersFJ , et al. Ejection fraction by radionuclide ventriculography and contrast left ventriculogram. A tale of two techniques. SAVE Investigators. Survival and Ventricular Enlargement. Journal of the American College of Cardiology1999;33(1):180‐5. [MEDLINE: 9935027] VantrimpontP , RouleauJL , WunCC , CiampiA , KleinM , SussexB , et al. Additive beneficial effects of beta‐blockers to angiotensin‐converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. Journal of the American College of Cardiology1997;29(2):229‐36. [MEDLINE: 9014971] ">SAVE 1991</a>; <a href="./references#CD012466-bbs2-0085" title="Cohen‐SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872‐80. [MEDLINE: 19648605] FlatherMD , ShibataMC , CoatsAJ , VanVeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomised trial to determine the effect of nebivolol on mortality and hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26(3):215‐25. [MEDLINE: 15642700] ShibataMC , FlatherMD , BöhmM , BorbolaJ , Cohen‐SolalA , DumitrascuD , et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisations in Seniors with Heart Failure (SENIORS): rationale and design. International Journal of Cardiology2002;86(1):77‐85. [MEDLINE: 12243852] vanVeldhuisenDJ , Cohen‐SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta‐blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150‐8. [MEDLINE: 19497441] ">SENIORS 2002</a>; <a href="./references#CD012466-bbs2-0086" title="BocchiEA , BohmM , BorerJS , FordI , KomajdaM , SwedbergK , et al. Effect of combining ivabradine and beta‐blockers: focus on the use of carvedilol in the SHIFT population. Cardiology2015;131(4):218‐24. [MEDLINE: 25968495] BohmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20(2):373‐81. [MEDLINE: 29027329] BohmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost‐BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo‐controlled trial. Lancet2010;376(9744):886‐94. [MEDLINE: 20801495] BorerJS , BohmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33(22):2813‐20. [MEDLINE: 22927555] BorerJS , BohmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497‐503. [MEDLINE: 24332674] FordI , RobertsonM , KomajdaM , BohmM , BorerJS , TavazziL , et al. Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: the SHIFT risk model. International Journal of Cardiology2015;184:163‐9. [MEDLINE: 25703424] KomajdaM , BohmM , BorerJS , FordI , RobertsonM , ManolisAJ , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. European Journal of Heart Failure2014;16(7):810‐6. [MEDLINE: 24961493] KomajdaM , TavazziL , FrancqBG , BohmM , BorerJS , FordI , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. European Journal of Heart Failure2015;17(12):1294‐301. [MEDLINE: 26377342] KomajdaM , TavazziL , SwedbergK , BohmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of SHIFT. European Journal of Heart Failure2016;18(9):1182‐9. [MEDLINE: 27210035] SwedbergK , KomajdaM , BohmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta‐blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. Journal of the American College of Cardiology2012;59(22):1938‐45. [MEDLINE: 22617188] SwedbergK , KomajdaM , BohmM , BorerJS , FordI , Dubost‐BramaA , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo‐controlled study.[Erratum appears in Lancet. 2010 Dec 11;376(9757):1988 Note: Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadan, I Roldan]; Leva, M [corrected to Ieva, M]]. Lancet2010;376(9744):875‐85. [MEDLINE: 20801500] SwedbergK , KomajdaM , BöhmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). European Journal of Heart Failure2010;12(1):75‐81. [MEDLINE: 19892778] TardifJC , O'MearaE , KomajdaM , BohmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507‐15. [MEDLINE: 21875858] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182‐8. [MEDLINE: 24225201] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. European Journal of Heart Failure2013;15(11):1296‐303. [MEDLINE: 23803951] VoorsAA , vanVeldhuisenDJ , RobertsonM , FordI , BorerJS , BohmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure2014;16(4):426‐34. [MEDLINE: 24504937] ">SHIFT 2010</a>; <a href="./references#CD012466-bbs2-0089" title="Al‐AhmadA , LeveyA , RandW , MajunathG , SalemD , GregoryD , et al. Anemia and renal insufficiency as risk factors for mortality in patients with left ventricular dysfunction [abstract no: A0739]. Journal of the American Society of Nephrology2000;11(Sept):137A. [CENTRAL: CN‐00550523] Al‐AhmadAM , SarnakMJ , RandW , GregoryD , KonstamMA , SalemDN , et al. Level of renal function as an independent predictor of mortality in patients with left ventricular dysfunction [abstract no: A0783]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):152A. [CENTRAL: CN‐00550524] Alsheikh‐AliAA , TrikalinosTA , RuthazerR , TerrinN , WongJB , SarnakMJ , et al. Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease. American Heart Journal2011;161(1):204‐9. [MEDLINE: 21167355] BansalN , TighiouartH , WeinerD , GriffithJ , VlagopoulosP , SalemD , et al. Anemia as a risk factor for kidney function decline in heart failure [abstract no: TH‐PO928]. Journal of the American Society of Nephrology2005;16(Oct):322A. [CENTRAL: CN‐01658120] BansalN , TighiouartH , WeinerD , GriffithJ , VlagopoulosP , SalemD , et al. Anemia as a risk factor for kidney function decline in individuals with heart failure. American Journal of Cardiology2007;99(8):1137‐42. [MEDLINE: 17437743] BowlingCB , SandersPW , AllmanRM , RogersWJ , PatelK , AbanIB , et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. International Journal of Cardiology2013;167(1):151‐6. [MEDLINE: 22257685] CapesSE , GersteinHC , NegassaA , YusufS . Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care2000;23(3):377‐80. [MEDLINE: 10868869] GregoryDD , SarnakMJ , KonstamMA , PereiraB , SalemD . Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction. American Journal of Cardiology2003;92(11):1300‐5. [MEDLINE: 14636907] KnightEL , GlynnRJ , McIntyreKM , MogunH , AvornJ . Predictors of decreased renal function in patients with heart failure during angiotensin‐converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). American Heart Journal1999;138(5 (Pt 1)):849‐55. [MEDLINE: 10539815] RiedingerMS , DracupKA , BrechtML , SOLVD Investigators. Studies of Left Ventricular Dysfunction. Quality of life in women with heart failure, normative groups, and patients with other chronic conditions. American Journal of Critical Care2002;11(3):211‐9. [MEDLINE: 12022484] SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New England Journal of Medicine1991;325(5):293‐302. [MEDLINE: 2057034] SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD)‐‐rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction.[Erratum appears in Am J Cardiol 1990 Oct 15;66(12):1026]. American Journal of Cardiology1990;66(3):315‐22. [MEDLINE: 2195865] TestaniJM , KimmelSE , DriesDL , CocaSG . Prognostic importance of early worsening renal function after initiation of angiotensin‐converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circulation: Heart Failure2011;4(6):685‐91. [MEDLINE: 21903907] ">SOLVD (Treatment) 1992</a>; <a href="./references#CD012466-bbs2-0094" title="MortazaviM , TaheriS , ShahidiS , PourmoghaddasA , YaraghiMG , SeyrafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: FP379]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi145. [CENTRAL: CN‐00716090] TaheriS , MortazaviM , ShahidiS , PourmoghadasA , GarakyaraghiM , SeirafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):392‐7. [MEDLINE: 19414940] TaheriS , MortazaviM , ShahidiS , PourmoghadasA , GarakyaraghiM , SeirafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: S‐PO‐0370]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:148. ">Taheri HD 2009</a>; <a href="./references#CD012466-bbs2-0093" title="NajafabadiMM , TaheriS , SeyrafianS , AlipoorZ , KarimiS , PoormodhadasA , et al. Spironolactone in continuous ambulatory peritoneal dialysis patients, improves cardiac function [abstract no: SU475]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. TaheriS , MortazaviM , PourmoghadasA , SeyrafianS , AlipourZ , KarimiS . A prospective double‐blind randomized placebo‐controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi Journal of Kidney Diseases &amp; Transplantation2012;23(3):507‐12. [MEDLINE: 22569436] ">Taheri CAPD 2012</a>; <a href="./references#CD012466-bbs2-0100" title="AnandIS , BishuK , RectorTS , IshaniA , KuskowskiMA , CohnJN . Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin‐converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation2009;120(16):1577‐84. [MEDLINE: 19805651] AnandIS , RectorTS , KuskowskiM , AdourianA , MuntendamP , CohnJN . Baseline and serial measurements of galectin‐3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val‐HeFT. European Journal of Heart Failure2013;15(5):511‐8. [MEDLINE: 23291728] CohnJN . Improving outcomes in congestive heart failure: Val‐HeFT. Valsartan in Heart Failure Trial. Cardiology1999;91 Suppl 1:19‐22. [MEDLINE: 10449891] CohnJN , TognoniG , Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure.[Summary for patients in J Card Fail. 2002 Apr;8(2):56‐8; PMID: 12016625]. New England Journal of Medicine2001;345(23):1667‐75. [MEDLINE: 11759645] LesogorA , CohnJN , LatiniR , TognoniG , KrumH , MassieB , et al. Interaction between baseline and early worsening of renal function and efficacy of renin‐angiotensin‐aldosterone system blockade in patients with heart failure: insights from the Val‐HeFT study. European Journal of Heart Failure2013;15(11):1236‐44. [MEDLINE: 23787721] WongM , StaszewskyL , VolpiA , LatiniR , BarleraS , HoglundC . Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val‐HeFT). Journal of the American Society of Echocardiography2002;15(4):293‐301. [MEDLINE: 11944005] ">Val‐HeFT 1999</a>). Studies were either exclusively in patients with HF and CKD (14) or in the general HF population, but included patients with CKD and stratified results based on kidney function at baseline (12). </p> </section> </section> <section id="CD012466-sec-0093"> <h4 class="title">Excluded studies</h4> <p>Reasons for exclusion are summarised in the <a href="./references#CD012466-sec-0141" title="">Characteristics of excluded studies</a> table. In 38 studies, the populations studied had conditions other than HF, five evaluated a non‐pharmacological intervention, and 16 measured short‐term outcomes (less than three months follow‐up) </p> </section> </section> <section id="CD012466-sec-0094"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias for all 112 included studies is summarised in <a href="#CD012466-fig-0002">Figure 2</a> and <a href="#CD012466-fig-0003">Figure 3</a>. In general, the risk of bias was unclear in most studies for many domains. Fifty‐four studies (48%) were published after 2005, the year when trial registration became mandatory. Of these, 37 had evidence of registration within a trial registry and 33 reported information on authorship and/or involvement of the study sponsor in data collection, analysis, and interpretation. </p> <div class="figure" id="CD012466-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012466-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012466-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012466-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012466-sec-0095"> <h4 class="title">Allocation</h4> <section id="CD012466-sec-0096"> <h5 class="title">Random sequence generation</h5> <p>Risk of bias was deemed low for 46 studies, high for one study, and unclear for 65 studies. </p> </section> <section id="CD012466-sec-0097"> <h5 class="title">Allocation concealment</h5> <p>Risk of bias was deemed low for 28 studies and unclear for the remaining 84 studies.</p> </section> </section> <section id="CD012466-sec-0098"> <h4 class="title">Blinding</h4> <section id="CD012466-sec-0099"> <h5 class="title">Participants and personnel (performance bias)</h5> <p>Eighty‐six studies were judged to be at low risk of bias, 13 did not blind participants or study personnel, and 13 were judged unclear. </p> </section> <section id="CD012466-sec-0100"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p>Fifty‐four studies were judged to be at low risk of bias, either because outcome assessors were blinded or because the outcome measured was unlikely to be influenced by a lack of blinding. Seven studies were judged to be at high risk of bias, and the remaining 51 were judged to be at unclear risk of bias. </p> </section> </section> <section id="CD012466-sec-0101"> <h4 class="title">Incomplete outcome data</h4> <p>Seventy‐four studies were at low risk of attrition bias as &lt; 10% of patients were lost to follow‐up and analysis followed an intention‐to‐treat design. Thirty‐four studies were at high risk of attrition bias and 14 studies were judged to be at unclear risk of bias. </p> </section> <section id="CD012466-sec-0102"> <h4 class="title">Selective reporting</h4> <p>Ninety‐nine studies were at low risk of bias, either because a protocol was published or because it was clear that the published report included all expected outcomes. Three studies were at high risk of bias and 10 were judged to be at unclear risk of bias. </p> </section> <section id="CD012466-sec-0103"> <h4 class="title">Other potential sources of bias</h4> <p>Twenty‐nine studies appeared to be free of other sources of bias. Forty‐three studies were at high risk of bias, as the study sponsor was involved in the design, data acquisition and/or analysis, or preparation of the manuscript. The remaining 40 studies were deemed to be at unclear risk of bias. </p> </section> </section> <section id="CD012466-sec-0104"> <h3 class="title" id="CD012466-sec-0104">Effects of interventions</h3> <p>See: <a href="./full#CD012466-tbl-0001"><b>Summary of findings for the main comparison</b> ACUTE: Serelaxin versus placebo in patients with heart failure and chronic kidney disease</a>; <a href="./full#CD012466-tbl-0002"><b>Summary of findings 2</b> CHRONIC: ACEi or ARB versus placebo in patients with heart failure and chronic kidney disease</a>; <a href="./full#CD012466-tbl-0003"><b>Summary of findings 3</b> CHRONIC: Beta‐blockers versus placebo in patients with heart failure and chronic kidney disease</a>; <a href="./full#CD012466-tbl-0004"><b>Summary of findings 4</b> CHRONIC: Aldosterone antagonists versus placebo in patients with heart failure and chronic kidney disease</a> </p> <section id="CD012466-sec-0105"> <h4 class="title">Effects in an acute heart failure setting</h4> <p>(See <a href="./full#CD012466-tbl-0001">summary of findings Table for the main comparison</a> and <a href="#CD012466-tbl-0005">Table 1</a>). </p> <div class="table" id="CD012466-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional Summary of Findings</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. participants (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Acute heart failure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Adenosine A1‐receptor antagonist versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.71 (0.39 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2078 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>2,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.85 (0.43 to 1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.93 (0.70 to 1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2033 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.89 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2033 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Diuretic bolus versus continuous infusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.56 (0.15 to 2.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.83 (0.33 to 2.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Dopamine versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.89 (0.41 to 1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>241 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.15 (0.77 to 5.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>241 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.09 (0.01 to 0.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Nesiritide versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (0.28 to 1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.83 (0.26 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.80 (0.94 to 3.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>232 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Chronic heart failure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Anti‐arrhythmics versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.95 (0.83 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>755 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Nesiritide versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.98 (0.64 to 1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>911 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.88 (0.56 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>911 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.80 (1.38 to 2.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>911 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of Life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 1.20 (‐1.85 to 4.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>911 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Phosphodiesterase inhibitors versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.26 (0.98 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>539 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Renin inhibitors versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.26 (0.08 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.52 (0.22 to 10.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.86 (0.49 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.44 (0.62 to 3.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Sinus node inhibitors versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.96 (0.48 to 1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1576 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.83 (0.48 to 1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1576 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.95 (0.71 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1576 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.53 (0.28 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1576 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Vasopressin receptor antagonists versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.26 (0.55 to 2.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1840 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.82 (0.37 to 1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.87 (0.56 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>217 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>MD:</b> Mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Important study limitations due to risks of bias </p> <p><sup>2</sup> The confidence intervals include potential for important benefits and harms </p> <p><sup>3</sup> Important and unexplained heterogeneity present (or insufficient data observations to evaluate) </p> <p><sup>4</sup> Insufficient data observations to evaluate </p> </div> </div> <section id="CD012466-sec-0106"> <h5 class="title">Diuretic bolus versus continuous infusion</h5> <p><a href="./references#CD012466-bbs2-0067" title="PalazzuoliA , PellegriniM , FranciB , BeltramiM , RuoccoG , GonnelliS , et al. Short and long‐term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction. Internal &amp; Emergency Medicine2015;10(1):41‐49. [MEDLINE: 25087085] PalazzuoliA , PellegriniM , RuoccoG , MartiniG , FranciB , CampagnaMS , et al. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Critical Care (London, England)2014;18(3):R132. [MEDLINE: 24974232] ">Palazzuoli 2014</a> compared a bolus diuretic versus infusion. Evidence was very uncertain on whether administering furosemide as a bolus compared to a continuous infusion has any impact on cardiovascular death (<a href="./references#CD012466-fig-0004" title="">Analysis 1.1</a>) or hospitalisation for HF (<a href="./references#CD012466-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD012466-sec-0107"> <h5 class="title">Serelaxin versus placebo</h5> <p>Two studies (<a href="./references#CD012466-bbs2-0072" title="DavisonBA , CotterG , SunH , ChenL , TeerlinkJR , MetraM , et al. Permutation criteria to evaluate multiple clinical endpoints in a proof‐of‐concept study: lessons from Pre‐RELAX‐AHF. Clinical Research in Cardiology2011;100(9):745‐53. [MEDLINE: 21416190] MetraM , TeerlinkJR , FelkerGM , GreenbergBH , FilippatosG , PonikowskiP , et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre‐RELAX‐AHF study. European Journal of Heart Failure2010;12(10):1130‐9. [MEDLINE: 20732868] Milo‐CotterO , TeerlinkJR , MetraM , FelkerGM , PonikowskiP , VoorsAA , et al. Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre‐RELAX‐AHF study. Cardiology2010;117(3):190‐6. [MEDLINE: 21088400] TeerlinkJR , MetraM , FelkerGM , PonikowskiP , VoorsAA , WeatherleyBD , et al. Relaxin for the treatment of patients with acute heart failure (Pre‐RELAX‐AHF): a multicentre, randomised, placebo‐controlled, parallel‐group, dose‐finding phase IIb study. Lancet2009;373(9673):1429‐39. [MEDLINE: 19329178] VoorsAA , DavisonBA , FelkerGM , PonikowskiP , UnemoriE , CotterG , et al. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre‐RELAX‐AHF. European Journal of Heart Failure2011;13(9):961‐7. [MEDLINE: 21622980] ">Pre‐RELAX‐AHF 2009</a>; <a href="./references#CD012466-bbs2-0079" title="LiuLC , VoorsAA , TeerlinkJR , CotterG , DavisonBA , FelkerGM , et al. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX‐AHF. Clinical Research in Cardiology2016;105(9):727‐37. [MEDLINE: 27017514] MetraM , CotterG , DavisonBA , FelkerGM , FilippatosG , GreenbergBH , et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX‐AHF) development program: correlation with outcomes. Journal of the American College of Cardiology2013;61(2):196‐206. [MEDLINE: 23273292] MetraM , PonikowskiP , CotterG , DavisonBA , FelkerGM , FilippatosG , et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX‐AHF. European Heart Journal2013;34(40):3128‐36. [MEDLINE: 23999454] PangPS , TeerlinkJR , VoorsAA , PonikowskiP , GreenbergBH , FilippatosG , et al. Use of high‐sensitivity troponin t to identify patients with acute heart failure at lower risk for adverse outcomes: an exploratory analysis from the RELAX‐AHF trial. JACC Heart Failure2016;4(7):591‐9. [MEDLINE: 27039129] PonikowskiP , MetraM , TeerlinkJR , UnemoriE , FelkerGM , VoorsAA , et al. Design of the RELAXin in acute heart failure study. American Heart Journal2012;163(2):149‐55. [MEDLINE: 22305830] TeerlinkJR , CotterG , DavisonBA , FelkerGM , FilippatosG , GreenbergBH , et al. Serelaxin, recombinant human relaxin‐2, for treatment of acute heart failure (RELAX‐AHF): a randomised, placebo‐controlled trial. Lancet2013;381(9860):29‐39. [MEDLINE: 23141816] ">RELAX‐AHF 2012</a>) compared serelaxin to placebo. Treatment with serelaxin had uncertain effects on the risk of death (any cause) (<a href="./references#CD012466-fig-0006" title="">Analysis 2.1</a> (2 studies, 1395 participants): RR 0.59, 95% CI 0.34 to 1.02; I<sup>2</sup> = 0%; low certainty evidence). Similarly, treatment with serelaxin had uncertain effects on the risk of cardiovascular death (<a href="./references#CD012466-fig-0007" title="">Analysis 2.2</a> (2 studies, 1395 participants): RR 0.47, 95% CI 0.21 to 1.08; I<sup>2</sup> = 55%; low certainty evidence). Treatment with serelaxin may reduce the risk of worsening HF in acute chronic HF (<a href="./references#CD012466-fig-0008" title="">Analysis 2.3</a> (2 studies, 1395 participants): RR 0.71, 95% CI 0.54 to 0.92; I<sup>2</sup> = 0%; low certainty evidence). Treatment with serelaxin had uncertain effects on worsening kidney function (<a href="./references#CD012466-fig-0009" title="">Analysis 2.4</a> (2 studies, 1395 participants): RR 0.86, 95% CI 0.37 to 1.98; I<sup>2</sup> = 58%; low certainty evidence). It is uncertain whether treatment with serelaxin increases the risk of hyperkalaemia (<a href="./references#CD012466-fig-0010" title="">Analysis 2.5</a> (1 study, 234 participants): RR 1.08, 95% CI 0.30 to 3.87; very low certainty evidence) or hypotension in acute settings (<a href="./references#CD012466-fig-0011" title="">Analysis 2.6</a> (2 studies, 1395 participants): RR 1.26, 95% CI 0.81 to 1.96; I<sup>2</sup> = 0%; low certainty evidence). </p> </section> <section id="CD012466-sec-0108"> <h5 class="title">Adenosine A1‐receptor antagonists versus placebo</h5> <p>Two studies (<a href="./references#CD012466-bbs2-0076" title="ClelandJG , ChiswellK , TeerlinkJR , StevensS , FiuzatM , GivertzMM , et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo‐Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Circulation: Heart Failure2014;7(1):76‐87. [MEDLINE: 24281134] CotterG , DittrichHC , WeatherleyBD , BloomfieldDM , O'ConnorCM , MetraM , et al. The PROTECT pilot study: a randomized, placebo‐controlled, dose‐finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. Journal of Cardiac Failure2008;14(8):631‐40. [MEDLINE: 18926433] GivertzMM , PostmusD , HillegeHL , MansoorGA , MassieBM , DavisonBA , et al. Renal function trajectories and clinical outcomes in acute heart failure. Circulation: Heart Failure2014;7(1):59‐67. [MEDLINE: 24281137] MassieBM , O'ConnorCM , MetraM , PonikowskiP , TeerlinkJR , CotterG , et al. Rolofylline, an adenosine A1‐receptor antagonist, in acute heart failure. New England Journal of Medicine2010;363(15):1419‐28. [MEDLINE: 20925544] MetraM , ClelandJG , WeatherleyBD , DittrichHC , GivertzMM , MassieBM , et al. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60‐day outcomes in the PROTECT pilot study. European Journal of Heart Failure2010;12(5):499‐507. [MEDLINE: 20228387] MetraM , O'ConnorCM , DavisonBA , ClelandJG , PonikowskiP , TeerlinkJR , et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. European Heart Journal2011;32(12):1519‐34. [MEDLINE: 21388992] TeerlinkJR , IraguiVJ , MohrJP , CarsonPE , HauptmanPJ , LovettDH , et al. The safety of an adenosine A(1)‐receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Safety2012;35(3):233‐44. [MEDLINE: 22339573] VoorsAA , DittrichHC , MassieBM , DeLuccaP , MansoorGA , MetraM , et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo‐Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). Journal of the American College of Cardiology2011;57(19):1899‐907. [MEDLINE: 21545947] WeatherleyBD , CotterG , DittrichHC , DeLuccaP , MansoorGA , BloomfieldDM , et al. Design and rationale of the PROTECT study: a placebo‐controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. Journal of Cardiac Failure2010;16(1):25‐35. [MEDLINE: 20123315] ">PROTECT 2008</a>; <a href="./references#CD012466-bbs2-0080" title="PangPS , MehraM , MaggioniAP , FilippatosG , MiddlebrooksJ , TurlapatyP , et al. Rationale, design, and results from RENO‐DEFEND 1: a randomized, dose‐finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. American Heart Journal2011;161(6):1012‐23. [MEDLINE: 21641345] ">RENO‐DEFEND 1 2011</a>) compared adenosine A1 receptor antagonists to placebo. Treatment with adenosine A1‐receptor antagonists had uncertain effects on the risk of death (any cause) (<a href="./references#CD012466-fig-0012" title="">Analysis 3.1</a> (2 studies, 2078 participants): RR 0.71, 95% CI 0.39 to 1.26; I<sup>2</sup> = 0%; low certainty evidence). </p> <p>Evidence was very uncertain on whether adenosine A1 receptor antagonists have any impact on hospitalisation (any cause) (<a href="./references#CD012466-fig-0013" title="">Analysis 3.2</a>), worsening HF (<a href="./references#CD012466-fig-0014" title="">Analysis 3.3</a>), or worsening kidney function (<a href="./references#CD012466-fig-0015" title="">Analysis 3.4</a>) as only single studies reported these three outcomes. </p> </section> <section id="CD012466-sec-0109"> <h5 class="title">Dopamine versus placebo</h5> <p><a href="./references#CD012466-bbs2-0082" title="ChenHH , AbouEzzeddineOF , AnstromKJ , GivertzMM , BartBA , FelkerGM , et al. Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circulation: Heart Failure2013;6(5):1087‐94. [MEDLINE: 24046475] ChenHH , AnstromKJ , GivertzMM , StevensonLW , SemigranMJ , GoldsmithSR , et al. Low‐dose dopamine or low‐dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA2013;310(23):2533‐43. [MEDLINE: 24247300] GrodinJL , LalaA , StevensSR , DeVoreAD , CooperLB , AbouEzzeddineOF , et al. Clinical Implications of serum albumin levels in acute heart failure: insights from DOSE‐AHF and ROSE‐AHF. Journal of Cardiac Failure2016;22(11):884‐90. [MEDLINE: 26844764] GrodinJL , SunJL , AnstromKJ , ChenHH , StarlingRC , TestaniJM , et al. Implications of serum chloride homeostasis in acute heart failure (from ROSE‐AHF). American Journal of Cardiology2017;119(1):78‐83. [MEDLINE: 27816115] WanSH , StevensSR , BorlaugBA , AnstromKJ , DeswalA , FelkerGM , et al. Differential response to low‐dose dopamine or low‐dose nesiritide in acute heart failure with reduced or preserved ejection fraction: results from the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circulation: Heart Failure2016;9(8):1. [MEDLINE: 27512103] ">ROSE AHF 2013</a> compared dopamine to placebo. Evidence was very uncertain on whether dopamine has any impact on death (any cause) (<a href="./references#CD012466-fig-0016" title="">Analysis 4.1</a>), worsening HF (<a href="./references#CD012466-fig-0017" title="">Analysis 4.2</a>), or hypotension (<a href="./references#CD012466-fig-0018" title="">Analysis 4.3</a>). </p> </section> <section id="CD012466-sec-0110"> <h5 class="title">Nesiritide versus placebo</h5> <p><a href="./references#CD012466-bbs2-0082" title="ChenHH , AbouEzzeddineOF , AnstromKJ , GivertzMM , BartBA , FelkerGM , et al. Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circulation: Heart Failure2013;6(5):1087‐94. [MEDLINE: 24046475] ChenHH , AnstromKJ , GivertzMM , StevensonLW , SemigranMJ , GoldsmithSR , et al. Low‐dose dopamine or low‐dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA2013;310(23):2533‐43. [MEDLINE: 24247300] GrodinJL , LalaA , StevensSR , DeVoreAD , CooperLB , AbouEzzeddineOF , et al. Clinical Implications of serum albumin levels in acute heart failure: insights from DOSE‐AHF and ROSE‐AHF. Journal of Cardiac Failure2016;22(11):884‐90. [MEDLINE: 26844764] GrodinJL , SunJL , AnstromKJ , ChenHH , StarlingRC , TestaniJM , et al. Implications of serum chloride homeostasis in acute heart failure (from ROSE‐AHF). American Journal of Cardiology2017;119(1):78‐83. [MEDLINE: 27816115] WanSH , StevensSR , BorlaugBA , AnstromKJ , DeswalA , FelkerGM , et al. Differential response to low‐dose dopamine or low‐dose nesiritide in acute heart failure with reduced or preserved ejection fraction: results from the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circulation: Heart Failure2016;9(8):1. [MEDLINE: 27512103] ">ROSE AHF 2013</a> compared nesiritide to placebo. Evidence was very uncertain on whether nesiritide has any impact on death (any cause) (<a href="./references#CD012466-fig-0019" title="">Analysis 5.1</a>), worsening HF (<a href="./references#CD012466-fig-0020" title="">Analysis 5.2</a>), or hypotension (<a href="./references#CD012466-fig-0021" title="">Analysis 5.3</a>). </p> </section> </section> <section id="CD012466-sec-0111"> <h4 class="title">Effects in a chronic heart failure setting</h4> <p>(See <a href="./full#CD012466-tbl-0002">summary of findings Table 2</a><i>;</i><a href="./full#CD012466-tbl-0003">summary of findings Table 3</a><i>;</i><a href="./full#CD012466-tbl-0004">summary of findings Table 4</a>; and <a href="#CD012466-tbl-0005">Table 1</a>). </p> <section id="CD012466-sec-0112"> <h5 class="title">Angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers versus placebo</h5> <p>Four studies (<a href="./references#CD012466-bbs2-0033" title="CiceG , DiBenedettoA , D'AndreaA , D'IsaS , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on left ventricular structure and function in hemodialyzed patients with chronic heart failure: a double‐blind placebo‐controlled multicenter study [abstract no: MP434]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv446. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on mortality and morbidity in haemodialysis patients with chronic heart failure: a double‐blind placebo‐controlled trial [abstract no: MO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v187. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , DeGregoriaP , CalabroR . Effect of telmisartan added to angiotensin converting enzyme inhibitors in reducing morbidity and mortality in haemodialysis patients with chronic heart failure [abstract no: P1.19]. Journal of Hypertension ‐ Supplement2006;24(Suppl):S56. [CENTRAL: CN‐00793137] CiceG , DiBenedettoA , D'IsaS , D'AndreaA , MarcelliD , GattiE , et al. Effects of telmisartan added to angiotensin‐converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2010;56(21):1701‐8. [MEDLINE: 21070920] ">Cice 2010</a>; <a href="./references#CD012466-bbs2-0084" title="HagerWD , DavisBR , RibaA , MoyeLA , WunCC , RouleauJL , et al. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. American Heart Journal1998;135(3):406‐13. [MEDLINE: 9506325] JoseP , SkaliH , AnavekarN , TomsonC , KrumholzHM , RouleauJL , et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. Journal of the American Society of Nephrology2006;17(10):2886‐91. [MEDLINE: 16928807] LamasGA , PfefferMA , HammP , WertheimerJ , RouleauJL , BraunwaldE . Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? the SAVE Investigators. New England Journal of Medicine1992;327(4):241‐7. [MEDLINE: 1535419] MitchellGF , MoyeLA , BraunwaldE , RouleauJL , BernsteinV , GeltmanEM , et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation1997;96(12):4254‐60. [MEDLINE: 9416890] MoyeLA , PfefferMA , BraunwaldE . Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. SAVE Investigators. American Journal of Cardiology1991;68(14):70‐9D. [MEDLINE: 1836100] PfefferMA , BraunwaldE , MoyeLA , BastaL , BrownEJJr , CuddyTE , et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. New England Journal of Medicine1992;327(10):669‐77. [MEDLINE: 1386652] PfefferMA , MoyeLA , BraunwaldE , BastaL , BrownEJJr , CuddyTE , et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA1991;266(4):528‐32. [MEDLINE: 2061979] RouleauJL , MoyeLA , PfefferMA , ArnoldJM , BernsteinV , CuddyTE , et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. New England Journal of Medicine1993;328(11):779‐84. [MEDLINE: 8123063] RutherfordJD , PfefferMA , MoyeLA , DavisBR , FlakerGC , KoweyPR , et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation1994;90(4):1731‐8. [MEDLINE: 7923656] TokmakovaMP , SkaliH , KenchaiahS , BraunwaldE , RouleauJL , PackerM , et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin‐converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation2004;110(24):3667‐73. [MEDLINE: 15569840] UrenaPE , LamasGA , MitchellG , FlakerGC , SmithSCJr , WackersFJ , et al. Ejection fraction by radionuclide ventriculography and contrast left ventriculogram. A tale of two techniques. SAVE Investigators. Survival and Ventricular Enlargement. Journal of the American College of Cardiology1999;33(1):180‐5. [MEDLINE: 9935027] VantrimpontP , RouleauJL , WunCC , CiampiA , KleinM , SussexB , et al. Additive beneficial effects of beta‐blockers to angiotensin‐converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. Journal of the American College of Cardiology1997;29(2):229‐36. [MEDLINE: 9014971] ">SAVE 1991</a>; <a href="./references#CD012466-bbs2-0089" title="Al‐AhmadA , LeveyA , RandW , MajunathG , SalemD , GregoryD , et al. Anemia and renal insufficiency as risk factors for mortality in patients with left ventricular dysfunction [abstract no: A0739]. Journal of the American Society of Nephrology2000;11(Sept):137A. [CENTRAL: CN‐00550523] Al‐AhmadAM , SarnakMJ , RandW , GregoryD , KonstamMA , SalemDN , et al. Level of renal function as an independent predictor of mortality in patients with left ventricular dysfunction [abstract no: A0783]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):152A. [CENTRAL: CN‐00550524] Alsheikh‐AliAA , TrikalinosTA , RuthazerR , TerrinN , WongJB , SarnakMJ , et al. Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease. American Heart Journal2011;161(1):204‐9. [MEDLINE: 21167355] BansalN , TighiouartH , WeinerD , GriffithJ , VlagopoulosP , SalemD , et al. Anemia as a risk factor for kidney function decline in heart failure [abstract no: TH‐PO928]. Journal of the American Society of Nephrology2005;16(Oct):322A. [CENTRAL: CN‐01658120] BansalN , TighiouartH , WeinerD , GriffithJ , VlagopoulosP , SalemD , et al. Anemia as a risk factor for kidney function decline in individuals with heart failure. American Journal of Cardiology2007;99(8):1137‐42. [MEDLINE: 17437743] BowlingCB , SandersPW , AllmanRM , RogersWJ , PatelK , AbanIB , et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. International Journal of Cardiology2013;167(1):151‐6. [MEDLINE: 22257685] CapesSE , GersteinHC , NegassaA , YusufS . Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care2000;23(3):377‐80. [MEDLINE: 10868869] GregoryDD , SarnakMJ , KonstamMA , PereiraB , SalemD . Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction. American Journal of Cardiology2003;92(11):1300‐5. [MEDLINE: 14636907] KnightEL , GlynnRJ , McIntyreKM , MogunH , AvornJ . Predictors of decreased renal function in patients with heart failure during angiotensin‐converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). American Heart Journal1999;138(5 (Pt 1)):849‐55. [MEDLINE: 10539815] RiedingerMS , DracupKA , BrechtML , SOLVD Investigators. Studies of Left Ventricular Dysfunction. Quality of life in women with heart failure, normative groups, and patients with other chronic conditions. American Journal of Critical Care2002;11(3):211‐9. [MEDLINE: 12022484] SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New England Journal of Medicine1991;325(5):293‐302. [MEDLINE: 2057034] SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD)‐‐rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction.[Erratum appears in Am J Cardiol 1990 Oct 15;66(12):1026]. American Journal of Cardiology1990;66(3):315‐22. [MEDLINE: 2195865] TestaniJM , KimmelSE , DriesDL , CocaSG . Prognostic importance of early worsening renal function after initiation of angiotensin‐converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circulation: Heart Failure2011;4(6):685‐91. [MEDLINE: 21903907] ">SOLVD (Treatment) 1992</a>; <a href="./references#CD012466-bbs2-0100" title="AnandIS , BishuK , RectorTS , IshaniA , KuskowskiMA , CohnJN . Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin‐converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation2009;120(16):1577‐84. [MEDLINE: 19805651] AnandIS , RectorTS , KuskowskiM , AdourianA , MuntendamP , CohnJN . Baseline and serial measurements of galectin‐3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val‐HeFT. European Journal of Heart Failure2013;15(5):511‐8. [MEDLINE: 23291728] CohnJN . Improving outcomes in congestive heart failure: Val‐HeFT. Valsartan in Heart Failure Trial. Cardiology1999;91 Suppl 1:19‐22. [MEDLINE: 10449891] CohnJN , TognoniG , Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure.[Summary for patients in J Card Fail. 2002 Apr;8(2):56‐8; PMID: 12016625]. New England Journal of Medicine2001;345(23):1667‐75. [MEDLINE: 11759645] LesogorA , CohnJN , LatiniR , TognoniG , KrumH , MassieB , et al. Interaction between baseline and early worsening of renal function and efficacy of renin‐angiotensin‐aldosterone system blockade in patients with heart failure: insights from the Val‐HeFT study. European Journal of Heart Failure2013;15(11):1236‐44. [MEDLINE: 23787721] WongM , StaszewskyL , VolpiA , LatiniR , BarleraS , HoglundC . Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val‐HeFT). Journal of the American Society of Echocardiography2002;15(4):293‐301. [MEDLINE: 11944005] ">Val‐HeFT 1999</a>) compared ACEi or ARB with placebo. Treatment with ACEi or ARB had uncertain effects on death (any cause) (<a href="./references#CD012466-fig-0022" title="">Analysis 6.1</a> (4 studies, 4003 participants): RR 0.85, 95% CI 0.70 to 1.02; I<sup>2</sup> = 78%; low certainty evidence). In subgroup analysis, there was no evidence that ACEi or ARB had different effects (P for subgroup interaction = 0.91). Treatment with either ACEi or ARB may decrease the risk of cardiovascular death compared to placebo or no treatment (<a href="./references#CD012466-fig-0023" title="">Analysis 6.2</a> (2 studies, 1368 participants): RR 0.81, 95% CI 0.64 to 1.01; I<sup>2</sup> = 51%; low certainty evidence). Treatment with either ACEi or ARB had uncertain effects on hospitalisation for HF (<a href="./references#CD012466-fig-0024" title="">Analysis 6.3</a> (2 studies, 1368 participants): RR 0.90, 95% CI 0.43 to 1.90; I<sup>2</sup> = 97%; very low certainty evidence). </p> </section> <section id="CD012466-sec-0113"> <h5 class="title">Angiotensin receptor blockers (ARB): 50% reduction versus full dose</h5> <p>It was not possible to ascertain the effect of different doses on death (any cause) as only <a href="./references#CD012466-bbs2-0070" title="Pita‐FernandezS , Choucino‐FernandezT , Juega‐PuigJ , Seoane‐PilladoT , Lopez‐CalvinoB , Pertega‐DiazS , et al. A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia. International Journal of Clinical Practice2014;68(10):1231‐8. [MEDLINE: 25040146] ">Pita‐Fernandez 2015</a> was designed to examine drug dosing (<a href="./references#CD012466-fig-0026" title="">Analysis 7.1</a>). </p> </section> <section id="CD012466-sec-0114"> <h5 class="title">Beta‐blockers versus placebo</h5> <p>Four studies (<a href="./references#CD012466-bbs2-0029" title='Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. Fundamental &amp; Clinical Pharmacology1997;11(2):138‐42. [MEDLINE: 9107560] Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS‐II). European Heart Journal2001;22(12):1021‐31. [MEDLINE: 11428837] The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): a randomised trial. Lancet1999;353(9146):9‐13. [MEDLINE: 10023943] BohmM , MaackC , Wehrlen‐GrandjeanM , ErdmannE . Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardiac Insufficiency Bisoprolol Study II (CIBIS II)). Zeitschrift fur Kardiologie2003;92(8):668‐76. [MEDLINE: 12955414] CastagnoD , JhundPS , McMurrayJJ , LewseyJD , ErdmannE , ZannadF , et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS‐II) trial. European Journal of Heart Failure2010;12(6):607‐16. [MEDLINE: 20354032] EkmanM , ZethraeusN , JonssonB . Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics2001;19(9):901‐16. [MEDLINE: 11700777] ErdmannE , LechatP , VerkenneP , WiemannH . Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure. European Journal of Heart Failure2001;3(4):469‐79. [MEDLINE: 11511434] GallanaghS , CastagnoD , WilsonB , ErdmannE , ZannadF , RemmeWJ , et al. Evaluation of the functional status questionnaire in heart failure: a sub‐study of the second cardiac insufficiency bisoprolol survival study (CIBIS‐II). Cardiovascular Drugs &amp; Therapy2011;25(1):77‐85. [MEDLINE: 21287410] KrumH , BaileyM , MeyerW , VerkenneP , DargieH , LechatP , et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta‐blocker use: results of CIBIS II. Cardiology2007;108(1):28‐34. [MEDLINE: 16960445] KrumH , HareD . "Bisoprolol dose‐response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II)," by Simon T. European Heart Journal2004;25(3):277. [MEDLINE: 14972430] LechatP , HulotJS , EscolanoS , MalletA , LeizoroviczA , Werhlen‐GrandjeanM , et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation2001;103(10):1428‐33. [MEDLINE: 11245648] SimonT , Mary‐KrauseM , Funck‐BrentanoC , JaillonP . Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation2001;103(3):375‐80. [MEDLINE: 11157688] SimonT , Mary‐KrauseM , Funck‐BrentanoC , LechatP , JaillonP . Bisoprolol dose‐response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). European Heart Journal2003;24(6):552‐9. [MEDLINE: 12643888] '>CIBIS II 1997</a>; <a href="./references#CD012466-bbs2-0032" title="CiceG , FerraraL , D'AndreaA , D'IsaS , DiBenedettoA , CittadiniA , et al. Carvedilol increases two‐year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo‐controlled trial. Journal of the American College of Cardiology2003;41(9):1438‐44. [MEDLINE: 12742278] CiceG , FerraraL , DiBenedettoA , RussoPE , MarinelliG , PaveseF , et al. Dilated cardiomyopathy in dialysis patients‐‐beneficial effects of carvedilol: a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2001;37(2):407‐11. [MEDLINE: 11216954] ">Cice 2001</a>; <a href="./references#CD012466-bbs2-0059" title="Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Lancet1999;353(9169):2001‐7. [MEDLINE: 10376614] Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT‐HF). The International Steering Committee. American Journal of Cardiology1997;80(9B):54‐8J. [MEDLINE: 9375952] BattyJA , HallAS , WhiteHL , WikstrandJ , deBoerRA , vanVeldhuisenDJ , et al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT‐HF substudy. Clinical Pharmacology &amp; Therapeutics2014;95(3):321‐30. [MEDLINE: 24193112] CaroJJ , Migliaccio‐WalleK , O'BrienJA , NovaW , KimJ , HauchO , et al. Economic implications of extended‐release metoprolol succinate for heart failure in the MERIT‐HF trial: a US perspective of the MERIT‐HF trial. Journal of Cardiac Failure2005;11(9):647‐56. [MEDLINE: 16360958] DeedwaniaPC , GilesTD , KlibanerM , GhaliJK , HerlitzJ , HildebrandtP , et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT‐HF. American Heart Journal2005;149(1):159‐67. [MEDLINE: 15660048] FagerbergB . Screening, endpoint classification, and safety monitoring in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). European Journal of Heart Failure2000;2(3):315‐24. [MEDLINE: 10938494] GhaliJK , PinaIL , GottliebSS , DeedwaniaPC , WikstrandJC , MERIT‐HF Study Group. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended‐Release Randomized Intervention Trial in Heart Failure (MERIT‐HF). Circulation2002;105(13):1585‐91. [MEDLINE: 11927527] GhaliJK , WikstrandJ , vanVeldhuisenDJ , FagerbergB , GoldsteinS , HjalmarsonA , et al. The influence of renal function on clinical outcome and response to beta‐blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT‐HF). Journal of Cardiac Failure2009;15(4):310‐8. [MEDLINE: 19398079] GoldsteinS , HjalmarsonA . The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT‐HF Trial. Clinical Cardiology1999;22(Suppl 5):V30‐5. [MEDLINE: 10526701] GottliebSS , FisherML , KjekshusJ , DeedwaniaP , GullestadL , VitovecJ , et al. Tolerability of beta‐blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT‐HF). Circulation2002;105(10):1182‐8. [MEDLINE: 11889011] GullestadL , ManhenkeC , AarslandT , SkardalR , FagertunH , WikstrandJ , et al. Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure ‐ a substudy to the MERIT‐HF trial. European Journal of Heart Failure2001;3(4):463‐8. [MEDLINE: 11511433] GullestadL , UelandT , BrunsvigA , KjekshusJ , SimonsenS , FrolandSS , et al. Effect of metoprolol on cytokine levels in chronic heart failure‐‐a substudy in the Metoprolol Controlled‐Release Randomised Intervention Trial in Heart Failure (MERIT‐HF). American Heart Journal2001;141(3):418‐21. [MEDLINE: 11231439] GullestadL , WikstrandJ , DeedwaniaP , HjalmarsonA , EgstrupK , ElkayamU , et al. What resting heart rate should one aim for when treating patients with heart failure with a beta‐blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT‐HF). Journal of the American College of Cardiology2005;45(2):252‐9. [MEDLINE: 15653024] HjalmarsonA , GoldsteinS , FagerbergB , WedelH , WaagsteinF , KjekshusJ , et al. Effects of controlled‐release metoprolol on total mortality, hospitalizations, and well‐being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT‐HF). MERIT‐HF Study Group. JAMA2000;283(10):1295‐302. [MEDLINE: 10714728] SavvaJ , MaqboolA , WhiteHL , GallowaySL , YuldashevaNY , BallSG , et al. Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT‐HF substudy. Journal of Cardiac Failure2009;15(5):435‐41. [MEDLINE: 19477404] TepperD . Frontiers in congestive heart failure: effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‐HF). Congestive Heart Failure1999;5(4):184‐5. [MEDLINE: 12189311] WhiteHL , deBoerRA , MaqboolA , GreenwoodD , vanVeldhuisenDJ , CuthbertR , et al. An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study. European Journal of Heart Failure2003;5(4):463‐8. [MEDLINE: 12921807] WikstrandJ , HjalmarsonA , WaagsteinF , FagerbergB , GoldsteinS , KjekshusJ , et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT‐HF). Journal of the American College of Cardiology2002;40(3):491‐8. [MEDLINE: 12142116] vanVeldhuisenDJ , AassH , ElAllafD , DunselmanPH , GullestadL , HalinenM , et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT‐HF Study. European Journal of Heart Failure2006;8(5):539‐46. [MEDLINE: 16567126] van derMeerP , DeBoerRA , WhiteHL , van derSteegeG , HallAS , VoorsAA , et al. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT‐HF substudy. Journal of Cardiac Failure2005;11(4):279‐84. [MEDLINE: 15880336] ">MERIT‐HF 1997</a>; <a href="./references#CD012466-bbs2-0085" title="Cohen‐SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872‐80. [MEDLINE: 19648605] FlatherMD , ShibataMC , CoatsAJ , VanVeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomised trial to determine the effect of nebivolol on mortality and hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26(3):215‐25. [MEDLINE: 15642700] ShibataMC , FlatherMD , BöhmM , BorbolaJ , Cohen‐SolalA , DumitrascuD , et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisations in Seniors with Heart Failure (SENIORS): rationale and design. International Journal of Cardiology2002;86(1):77‐85. [MEDLINE: 12243852] vanVeldhuisenDJ , Cohen‐SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta‐blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150‐8. [MEDLINE: 19497441] ">SENIORS 2002</a>) compared beta‐blockers with placebo. Treatment with beta‐blockers may reduce the risk of death (any cause) (<a href="./references#CD012466-fig-0027" title="">Analysis 8.1</a> (4 studies, 3136 participants): RR 0.69, 95% CI 0.60 to 0.79; I<sup>2</sup> = 0%; moderate certainty evidence) compared with placebo. Treatment with beta‐blockers may decrease cardiovascular death (<a href="./references#CD012466-fig-0028" title="">Analysis 8.2</a> (3 studies, 2287 participants): RR 0.53, 95% CI 0.35 to 0.81; I<sup>2</sup> = 61%; low certainty evidence) or hospitalisation (any cause) (<a href="./references#CD012466-fig-0029" title="">Analysis 8.3</a> (2 studies, 1583 participants): RR 0.75, 95% CI 0.52 to 1.08; I<sup>2</sup> = 67%; low certainty evidence). Treatment with beta‐blockers may decrease hospitalisation for HF (<a href="./references#CD012466-fig-0030" title="">Analysis 8.4</a> (3 studies, 2287 participants): RR 0.67, 95% CI 0.43 to 1.05; I<sup>2</sup>= 87%; low certainty evidence). Potential causes of high heterogeneity include differences in study year, sample size, location, or use of contaminant ACEi. </p> <p>Evidence was very uncertain on whether beta‐blockers have any impact on worsening HF (<a href="./references#CD012466-fig-0031" title="">Analysis 8.5</a>), worsening kidney function (<a href="./references#CD012466-fig-0032" title="">Analysis 8.6</a>), or hypotension (<a href="./references#CD012466-fig-0033" title="">Analysis 8.7</a>) as only <a href="./references#CD012466-bbs2-0085" title="Cohen‐SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872‐80. [MEDLINE: 19648605] FlatherMD , ShibataMC , CoatsAJ , VanVeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomised trial to determine the effect of nebivolol on mortality and hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26(3):215‐25. [MEDLINE: 15642700] ShibataMC , FlatherMD , BöhmM , BorbolaJ , Cohen‐SolalA , DumitrascuD , et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisations in Seniors with Heart Failure (SENIORS): rationale and design. International Journal of Cardiology2002;86(1):77‐85. [MEDLINE: 12243852] vanVeldhuisenDJ , Cohen‐SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta‐blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150‐8. [MEDLINE: 19497441] ">SENIORS 2002</a> reported these three outcomes. </p> </section> <section id="CD012466-sec-0115"> <h5 class="title">Aldosterone antagonists versus placebo</h5> <p>Three studies (<a href="./references#CD012466-bbs2-0077" title="Effectiveness of spironolactone added to an angiotensin‐converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). American Journal of Cardiology1996;78(8):902‐7. [MEDLINE: 8888663] GlickHA , OrzolSM , TooleyJF , RemmeWJ , SasayamaS , PittB . Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovascular Drugs &amp; Therapy2002;16(1):53‐9. [MEDLINE: 12085979] HaubenM , ReichL , GerritsCM , MadiganD . Detection of spironolactone‐associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Safety2007;30(12):1143‐9. [MEDLINE: 18035866] PittB , ZannadF , RemmeWJ , CodyR , CastaigneA , PerezA , et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine1999;341(10):709‐17. [MEDLINE: 10471456] PittD . ACE inhibitor co‐therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). European Heart Journal1995;16 Suppl N:107‐10. [MEDLINE: 8682055] RousseauMF , GurneO , DuprezD , VanMieghemW , RobertA , AhnS , et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.[Erratum appears in J Am Coll Cardiol. 2003 Nov 19;42(10):1865]. Journal of the American College of Cardiology2002;40(9):1596‐601. [MEDLINE: 12427411] SchwingerRH . The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study [Der Aldosteronantagonist Spironolacton verlangert das Uberleben chronisch herzinsuffizienter Patienten. Ergebnisse der RALES‐Studie]. Deutsche Medizinische Wochenschrift1999;124(34‐5):987‐8. [MEDLINE: 10488324] VardenyO , WuDH , DesaiA , RossignolP , ZannadF , PittB , et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure. Journal of the American College of Cardiology2012;60(20):2082‐9. [MEDLINE: 23083787] WittesJ , PalenskyJ , AsnerD , JulianD , BoisselJP , FurbergCD , et al. Experience collecting interim data on mortality: an example from the RALES study. Current Controlled Trials in Cardiovascular Medicine2001;2(1):59‐62. [MEDLINE: 11806773] ZannadF , AllaF , DoussetB , PerezA , PittB . Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.[Erratum appears in Circulation 2001 Jan 23;103(3):476]. Circulation2000;102(22):2700‐6. [MEDLINE: 11094035] ">RALES 1995</a>; <a href="./references#CD012466-bbs2-0093" title="NajafabadiMM , TaheriS , SeyrafianS , AlipoorZ , KarimiS , PoormodhadasA , et al. Spironolactone in continuous ambulatory peritoneal dialysis patients, improves cardiac function [abstract no: SU475]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. TaheriS , MortazaviM , PourmoghadasA , SeyrafianS , AlipourZ , KarimiS . A prospective double‐blind randomized placebo‐controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi Journal of Kidney Diseases &amp; Transplantation2012;23(3):507‐12. [MEDLINE: 22569436] ">Taheri CAPD 2012</a>; <a href="./references#CD012466-bbs2-0094" title="MortazaviM , TaheriS , ShahidiS , PourmoghaddasA , YaraghiMG , SeyrafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: FP379]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi145. [CENTRAL: CN‐00716090] TaheriS , MortazaviM , ShahidiS , PourmoghadasA , GarakyaraghiM , SeirafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases &amp; Transplantation2009;20(3):392‐7. [MEDLINE: 19414940] TaheriS , MortazaviM , ShahidiS , PourmoghadasA , GarakyaraghiM , SeirafianS , et al. Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: S‐PO‐0370]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:148. ">Taheri HD 2009</a>) compared aldosterone antagonists to placebo. Aldosterone antagonists had uncertain effects on death (any cause) compared with placebo (<a href="./references#CD012466-fig-0034" title="">Analysis 9.1</a> ( 2 studies, 34 participants): RR 0.61, 95% CI 0.06 to 6.59; I<sup>2</sup> = 57%; very low certainty evidence). Aldosterone antagonists may increase the risk of hyperkalaemia in people with HF and CKD (<a href="./references#CD012466-fig-0035" title="">Analysis 9.2</a> (3 studies, 826 participants): RR 2.91, 95% CI 2.03 to 4.17; I<sup>2</sup>= 0%, low certainty evidence). </p> </section> <section id="CD012466-sec-0116"> <h5 class="title">Anti‐arrhythmics versus placebo</h5> <p><a href="./references#CD012466-bbs2-0040" title="BrendorpB , ElmingH , JunL , KoberL , MalikM , JensenGB , et al. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation2001;103(10):1422‐7. [MEDLINE: 11245647] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group.Danish Investigations Of Arrhythmia and Mortality On Dofetilide. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. European Journal of Heart Failure2002;4(2):201‐6. [MEDLINE: 11959050] BrendorpB , ElmingH , JunL , KoberL , Torp‐PedersenC , DIAMOND Study Group. The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide. Clinical Cardiology2003;26(5):219‐25. [MEDLINE: 12769249] MollerM , Torp‐PedersenCT , KoberL . Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congestive Heart Failure2001;7(3):146‐50. [MEDLINE: 11828153] PedersenHS , ElmingH , SeibaekM , BurchardtH , BrendorpB , Torp‐PedersenC , et al. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. American Journal of Cardiology2007;100(5):876‐80. [MEDLINE: 17719337] Torp‐PedersenC , MollerM , Bloch‐ThomsenPE , KoberL , SandoeE , EgstrupK , et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. New England Journal of Medicine1999;341(12):857‐65. [MEDLINE: 10486417] ">DIAMOND 1999</a> compared anti‐arrhythmics to placebo. Evidence was very uncertain on whether anti‐arrhythmics have any impact on death (any cause) (<a href="./references#CD012466-fig-0036" title="">Analysis 10.1</a>). </p> </section> <section id="CD012466-sec-0117"> <h5 class="title">Nesiritide versus placebo</h5> <p>One study <a href="./references#CD012466-bbs2-0050" title="O'ConnorCM , FiuzatM , LindenfeldJ , MillerA , LombardiC , CarsonP , et al. Mode of death and hospitalization from the Second Follow‐up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. American Journal of Cardiology2011;108(10):1449‐57. [MEDLINE: 21890092] YancyCW , KrumH , MassieBM , SilverMA , StevensonLW , ChengM , et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow‐Up Serial Infusions of Nesiritide (FUSION II) trial. Circulation: Heart Failure2008;1(1):9‐16. [MEDLINE: 19808265] YancyCW , KrumH , MassieBM , SilverMA , StevensonLW , ChengM , et al. The Second Follow‐up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. American Heart Journal2007;153(4):478‐84. [MEDLINE: 17383282] ">FUSION II 2008</a> compared nesiritide to placebo in a chronic setting. Evidence was very uncertain on whether nesiritide has any impact on death (any cause) (<a href="./references#CD012466-fig-0037" title="">Analysis 11.1</a>), cardiovascular death (<a href="./references#CD012466-fig-0038" title="">Analysis 11.2</a>), or quality of life (<a href="./references#CD012466-fig-0040" title="">Analysis 11.4</a>). There were 196/605 patients with at least one episode of hypotension in the nesiritide group and 55/306 in the placebo group (<a href="./references#CD012466-fig-0039" title="">Analysis 11.3</a>). </p> </section> <section id="CD012466-sec-0118"> <h5 class="title">Phosphodiesterase inhibitors versus placebo</h5> <p><a href="./references#CD012466-bbs2-0075" title="EichhornEJ , TandonPK , DiBiancoR , TimmisGC , FensterPE , ShannonJ , et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. Journal of the American College of Cardiology1993;21(3):634‐40. [MEDLINE: 8436744] PackerM . Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. American Journal of Cardiology1989;63(2):41‐5A. [MEDLINE: 2642629] PackerM , CarverJR , RodehefferRJ , IvanhoeRJ , DiBiancoR , ZeldisSM , et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. New England Journal of Medicine1991;325(21):1468‐75. [MEDLINE: 1944425] TeerlinkJR , JalaluddinM , AndersonS , KukinML , EichhornEJ , FrancisG , et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation2000;101(1):40‐6. [MEDLINE: 10618302] ">PROMISE 1989</a> compared phosphodiesterase inhibitors to placebo. Evidence was very uncertain on whether phosphodiesterase inhibitors have any impact on death (any cause) (<a href="./references#CD012466-fig-0041" title="">Analysis 12.1</a>). </p> </section> <section id="CD012466-sec-0119"> <h5 class="title">Renin inhibitors versus placebo</h5> <p>Two studies (<a href="./references#CD012466-bbs2-0006" title="JacksonCE , MacDonaldMR , PetrieMC , SolomonSD , PittB , LatiniR , et al. Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure2011;13(7):746‐54. [MEDLINE: 21459891] MaggioniAP , McMurrayJJ , LatiniR , SolomonSD , SmithBA , BushC , et al. Safety and tolerability profile of aliskiren added to optimized therapy in patients with heart failure and renal impairment [abstract no: SA‐PO2247]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):616A. [CENTRAL: CN‐00776176] McMurrayJJ , PittB , LatiniR , MaggioniAP , SolomonSD , KeefeDL , et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure2008;1(1):17‐24. [MEDLINE: 19808266] ">ALOFT 2008</a>; <a href="./references#CD012466-bbs2-0009" title="SchrotenNF , DammanK , HemmelderMH , VoorsAA , NavisG , GaillardCA , et al. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). American Heart Journal2015;169(5):693‐701. [MEDLINE: 25965717] ">ARIANA‐CHF‐RD 2016</a>) compared renin inhibitors to placebo. Evidence was very uncertain on whether renin inhibitors have any impact on worsening HF (<a href="./references#CD012466-fig-0042" title="">Analysis 13.1</a>) as only <a href="./references#CD012466-bbs2-0009" title="SchrotenNF , DammanK , HemmelderMH , VoorsAA , NavisG , GaillardCA , et al. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). American Heart Journal2015;169(5):693‐701. [MEDLINE: 25965717] ">ARIANA‐CHF‐RD 2016</a> reported this outcome. Treatment with renin inhibitors had uncertain effects on worsening kidney function (<a href="./references#CD012466-fig-0043" title="">Analysis 13.2</a> (2 studies, 142 participants): RR 1.52, 95% CI 0.22 to 10.33; I<sup>2</sup> = 36%; very low certainty evidence). The risk of hyperkalaemia was uncertain with renin inhibitors (<a href="./references#CD012466-fig-0044" title="">Analysis 13.3</a> (2 studies, 142 participants): RR 0.86, 95% CI 0.49 to 1.49; I<sup>2</sup> = 0%; very low certainty evidence). The risk of hypotension was uncertain with renin inhibitors (<a href="./references#CD012466-fig-0045" title="">Analysis 13.4</a> (2 studies, 142 participants):RR 1.44, 95% CI 0.62 to 3.31; I<sup>2</sup> = 0%; very low certainty evidence). </p> </section> <section id="CD012466-sec-0120"> <h5 class="title">Sinus node inhibitors versus placebo</h5> <p>One study (<a href="./references#CD012466-bbs2-0086" title="BocchiEA , BohmM , BorerJS , FordI , KomajdaM , SwedbergK , et al. Effect of combining ivabradine and beta‐blockers: focus on the use of carvedilol in the SHIFT population. Cardiology2015;131(4):218‐24. [MEDLINE: 25968495] BohmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20(2):373‐81. [MEDLINE: 29027329] BohmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost‐BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo‐controlled trial. Lancet2010;376(9744):886‐94. [MEDLINE: 20801495] BorerJS , BohmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33(22):2813‐20. [MEDLINE: 22927555] BorerJS , BohmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497‐503. [MEDLINE: 24332674] FordI , RobertsonM , KomajdaM , BohmM , BorerJS , TavazziL , et al. Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: the SHIFT risk model. International Journal of Cardiology2015;184:163‐9. [MEDLINE: 25703424] KomajdaM , BohmM , BorerJS , FordI , RobertsonM , ManolisAJ , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. European Journal of Heart Failure2014;16(7):810‐6. [MEDLINE: 24961493] KomajdaM , TavazziL , FrancqBG , BohmM , BorerJS , FordI , et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. European Journal of Heart Failure2015;17(12):1294‐301. [MEDLINE: 26377342] KomajdaM , TavazziL , SwedbergK , BohmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of SHIFT. European Journal of Heart Failure2016;18(9):1182‐9. [MEDLINE: 27210035] SwedbergK , KomajdaM , BohmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta‐blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. Journal of the American College of Cardiology2012;59(22):1938‐45. [MEDLINE: 22617188] SwedbergK , KomajdaM , BohmM , BorerJS , FordI , Dubost‐BramaA , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo‐controlled study.[Erratum appears in Lancet. 2010 Dec 11;376(9757):1988 Note: Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadan, I Roldan]; Leva, M [corrected to Ieva, M]]. Lancet2010;376(9744):875‐85. [MEDLINE: 20801500] SwedbergK , KomajdaM , BöhmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). European Journal of Heart Failure2010;12(1):75‐81. [MEDLINE: 19892778] TardifJC , O'MearaE , KomajdaM , BohmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507‐15. [MEDLINE: 21875858] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182‐8. [MEDLINE: 24225201] TavazziL , SwedbergK , KomajdaM , BohmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. European Journal of Heart Failure2013;15(11):1296‐303. [MEDLINE: 23803951] VoorsAA , vanVeldhuisenDJ , RobertsonM , FordI , BorerJS , BohmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure2014;16(4):426‐34. [MEDLINE: 24504937] ">SHIFT 2010</a>) compared sinus node inhibitors to placebo. Evidence was very uncertain on whether sinus node inhibitors have any impact on cardiovascular death (<a href="./references#CD012466-fig-0046" title="">Analysis 14.1</a>), hospitalisation for HF (<a href="./references#CD012466-fig-0047" title="">Analysis 14.2</a>), or worsening kidney function (<a href="./references#CD012466-fig-0048" title="">Analysis 14.3</a>). There were 14/780 patients with at least one episode of hyperkalaemia in the sinus node inhibitor group and 27/799 in the placebo group (<a href="./references#CD012466-fig-0049" title="">Analysis 14.4</a>). </p> </section> <section id="CD012466-sec-0121"> <h5 class="title">Vasopressin receptor antagonists versus placebo</h5> <p>Two studies (<a href="./references#CD012466-bbs2-0008" title='MatsueY , SuzukiM , NagahoriW , YoshidaK , OnishiY , SatohY , et al. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. Cardiovascular Drugs &amp; Therapy2014;28(1):73‐7. [MEDLINE: 24048511] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction.[Erratum appears in J Card Fail. 2016 Nov;22(11):941; PMID: 27481596]. Journal of Cardiac Failure2016;22(6):423‐32. [MEDLINE: 26915749] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423‐432.[Erratum for J Card Fail. 2016 Jun;22(6):423‐32; PMID: 26915749]. Journal of Cardiac Failure2016;22(11):941. [MEDLINE: 27481596] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. International Journal of Cardiology2016;221:188‐93. [MEDLINE: 27404673] MatsueY , Ter MaatenJM , SuzukiM , ToriiS , YamaguchiS , FukamizuS , et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology2017;106(10):802‐12. [MEDLINE: 28540483] '>AQUAMARINE 2014</a>; <a href="./references#CD012466-bbs2-0046" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJC , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJC , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>) compared vasopressin receptor antagonists to placebo. Vasopressin receptor antagonists had uncertain effects on death (any cause) (<a href="./references#CD012466-fig-0050" title="">Analysis 15.1</a> (2 studies, 1840 participants): RR 1.26, 95% CI 0.55 to 2.89; I<sup>2</sup> = 41%; low certainty evidence). Evidence was very uncertain on whether vasopressin receptor antagonists have any impact on HF hospitalisations (<a href="./references#CD012466-fig-0051" title="">Analysis 15.2</a>) or worsening kidney function (<a href="./references#CD012466-fig-0052" title="">Analysis 15.3</a>), as only <a href="./references#CD012466-bbs2-0008" title='MatsueY , SuzukiM , NagahoriW , YoshidaK , OnishiY , SatohY , et al. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. Cardiovascular Drugs &amp; Therapy2014;28(1):73‐7. [MEDLINE: 24048511] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction.[Erratum appears in J Card Fail. 2016 Nov;22(11):941; PMID: 27481596]. Journal of Cardiac Failure2016;22(6):423‐32. [MEDLINE: 26915749] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423‐432.[Erratum for J Card Fail. 2016 Jun;22(6):423‐32; PMID: 26915749]. Journal of Cardiac Failure2016;22(11):941. [MEDLINE: 27481596] MatsueY , SuzukiM , ToriiS , YamaguchiS , FukamizuS , OnoY , et al. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. International Journal of Cardiology2016;221:188‐93. [MEDLINE: 27404673] MatsueY , Ter MaatenJM , SuzukiM , ToriiS , YamaguchiS , FukamizuS , et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology2017;106(10):802‐12. [MEDLINE: 28540483] '>AQUAMARINE 2014</a> reported these two outcomes. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012466-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012466-sec-0122"></div> <section id="CD012466-sec-0123"> <h3 class="title" id="CD012466-sec-0123">Summary of main results</h3> <p>In this systematic review of HF therapies in people with CKD, we identified 112 studies: 15 studies reported data on CKD patients only; 16 studies included both people with and without CKD, and provided stratified data for CKD patients; and 81 studies included people with and without CKD, however data for those with CKD was not available. Twenty‐six studies with disaggregated and extractable data in people with CKD were included in our meta‐analyses. In acute settings, six studies investigated dopamine, nesiritide, furosemide (dose reduction), serelaxin, and adenosine A1 receptor antagonists. Based on the level of evidence available, it is uncertain whether these therapies make any difference to death, hospitalisations, or adverse effects including worsening kidney function, hyperkalaemia, or hypotension. In chronic settings, 18 studies investigated ACEi, ARB, aldosterone antagonists, anti‐arrhythmic, beta‐blockers, digoxin, phosphodiesterase inhibitors, renin inhibitors, sinus node inhibitors, vasodilators, and vasopressin receptor antagonists. It is uncertain whether these interventions make any difference to death, hospitalisations, or harms, as the number of studies available was low. Due to few data observations, studies with zero events in both arms, and situations where only single studies were available for clinical outcomes, meta‐analysis was not possible for most of the review outcomes, particularly for harms. </p> <p>Considering that CKD is a significant independent predictor of worse outcome in acute or chronic HF (<a href="./references#CD012466-bbs2-0183" title="GrandeD , GioiaMI , TerlizzeseP , IacovielloM . Heart failure and kidney disease. Advances in Experimental Medicine and Biology2017;1067:219‐38. [EMBASE: 622227520] ">Grande 2017</a>; <a href="./references#CD012466-bbs2-0206" title="SmithGL , LichtmanJH , BrackenMB , ShlipakMG , PhillipsCO , DiCapuaP , et al. Renal impairment and outcomes in heart failure: systematic review and meta‐analysis. Journal of the American College of Cardiology2006;47(10):1987‐96. [CENTRAL: 16697315] ">Smith 2006</a>), knowledge about benefits and harms of recommended interventions for HF in this patient population is important. Insufficient evidence is available to inform decision‐making. </p> </section> <section id="CD012466-sec-0124"> <h3 class="title" id="CD012466-sec-0124">Overall completeness and applicability of evidence</h3> <p>Of the 112 included studies, quantitative data on CKD patients could be extracted in only 23% of studies. In total, 26 studies were eligible for meta‐analysis. Due to the diversity of drug classes and outcomes available, few summary estimates of the effects were possible. Meta‐analysis in acute settings was not performed. Meta‐analysis for death (any cause) was only possible for ACEi/ARB, anti‐aldosterone, beta‐blockers, and vasopressin receptor antagonists. Meta‐analysis for cardiovascular death was only possible for ACEi/ARs and beta‐blockers. Re‐hospitalisation for HF was meta‐analysed only for ACEi/ARB and beta‐blockers. Analyses for harms were only possible for renin inhibitors (worsening kidney function and hyperkalaemia) and aldosterone antagonists (hyperkalaemia). Overall, the certainty of the evidence across most interventions and outcomes was very low due to the limited number of studies. Treatment with beta‐blockers may reduce risk of all‐cause or cardiovascular death; however, the certainty was moderate and low, respectively. Furthermore, due to the few number of studies in each meta‐analysis, sub‐group analyses by type of HF (systolic or diastolic) or level of kidney failure were not possible. </p> </section> <section id="CD012466-sec-0125"> <h3 class="title" id="CD012466-sec-0125">Quality of the evidence</h3> <p>Of the 112 studies, the risks of bias were generally high, or unclear. The risk of selection bias was unclear in the majority of studies due to unclear randomisation methods or allocation concealment. Over three‐quarters of studies blinded participants and nearly half blinded outcome assessors. The majority reported on outcomes as per a pre‐specified protocol. Over 70% of studies followed an intention‐to‐treat approach. Nearly one‐third were at high risk of attrition bias. In most studies, the study sponsor was involved in the study or their role was unclear. </p> </section> <section id="CD012466-sec-0126"> <h3 class="title" id="CD012466-sec-0126">Potential biases in the review process</h3> <p>Although based on a peer‐reviewed protocol and conducted using methods developed by Cochrane, our review has limitations mostly related to lack of data availability. Data for CKD populations that could be extracted for meta‐analysis were only available in 23% of studies. Considering that our review was broad in scope and included a variety of pharmacological interventions and outcomes, availability of more data on interventions and outcome would be key to obtaining summary measures of effect. Of the studies in the CKD population (or subgroup analyses), the definition of CKD varied and ranged from having eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> to being on dialysis. Many of the studies did not specify the stage of CKD among patients with an eGFR &lt; 60 mL/min/1.73 m<sup>2</sup>, which may be problematic as the effect or safety of these interventions likely differs based on early versus advanced CKD, Further, many of these studies defined CKD by a baseline eGFR, which may not represent a true CKD diagnosis if not confirmed with a second measure three months apart. Generalisation of findings to people with HF and CKD requires additional data, some of which could be made available from studies already completed. </p> </section> <section id="CD012466-sec-0127"> <h3 class="title" id="CD012466-sec-0127">Agreements and disagreements with other studies or reviews</h3> <p>Our review only identified six studies that assessed interventions for acute HF with a follow‐up of at least three months: investigating dopamine or nesiritide (1 study), serelaxin (2), adenosine A1 receptor antagonists (2) and diuretics (1). We were unable to estimate risk of any outcome for studies investigating diuretics, nesiritide, or dopamine in an acute setting. No significant reduction in risk of death (any cause) was found for adenosine A1 receptor antagonists; however, the certainty of the evidence was low. No other analyses could be performed for this intervention due to limited data. Serelaxin did not significantly reduce risk of all‐cause or cardiovascular death nor increase the risk of worsening kidney function or hypotension. There appeared to be a decrease in risk of worsening HF; however, the certainty of evidence for all analyses in this intervention group was very low. Previous research has suggested that kidney impairment may affect the response to interventions for acute decompensated HF, such as tolvaptan (<a href="./references#CD012466-bbs2-0189" title="IkedaS , OhshimaK , MiyazakiS , KadotaH , ShimizuH , OgimotoA , et al. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure. ESC heart failure2017;4(4):614‐22. [MEDLINE: 29154417] ">Ikeda 2017</a>). Further data are needed to clarify whether reduced kidney function hampers the efficacy of the interventions for HF or leads to excess harm. While we acknowledge that MI and HF often are physiopathologically related and overlap, to address the specific question of this review, we excluded studies that examined pharmacological interventions in people with acute MI without HF. </p> <p>The ACC/AHA Clinical Practice Guidelines for people with HF (<a href="./references#CD012466-bbs2-0208" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDEJr , ColvinMM , DraznerMH , et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology2017;70(6):776‐803. [MEDLINE: 28461007] ">Yancy 2017</a>) recommend the use of renin‐angiotensin system inhibition (with ACEi or ARB) in conjunction with beta‐blockers and aldosterone antagonists, in selected patients with chronic HFrEF. Of note, the guidelines mention that treatment with ACEi and ARBs should be administered with caution to people with HFrEF renal insufficiency, and further, that aldosterone antagonists may be beneficial for people with HFpEF only if their eGFR &gt; 30 mL/min/17.3 m<sup>2</sup> (<a href="./references#CD012466-bbs2-0208" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDEJr , ColvinMM , DraznerMH , et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology2017;70(6):776‐803. [MEDLINE: 28461007] ">Yancy 2017</a>). Further, a 2014 review exploring the efficacy of HF interventions suggested a benefit among people with moderate CKD (i.e. stage 3), but the evidence in those with more advanced CKD (stage 4 to 5) is unknown (<a href="./references#CD012466-bbs2-0179" title="DammanK , TangWH , FelkerGM , LassusJ , ZannadF , KrumH , et al. Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. Journal of the American College of Cardiology2014;63(9):853‐71. [MEDLINE: 24334210] ">Damman 2014b</a>). Our review was unable to differentiate CKD stage due to limited data accessibility. However, we found that beta‐blockers may reduce risk of all‐cause and cardiovascular death in people with HF who also have CKD. Pooling studies administering ARB or ACEi found no significant risk reduction in the CKD population for any outcome; however, one study (<a href="./references#CD012466-bbs2-0033" title="CiceG , DiBenedettoA , D'AndreaA , D'IsaS , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on left ventricular structure and function in hemodialyzed patients with chronic heart failure: a double‐blind placebo‐controlled multicenter study [abstract no: MP434]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv446. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , BonannoD , PacchianoG , et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on mortality and morbidity in haemodialysis patients with chronic heart failure: a double‐blind placebo‐controlled trial [abstract no: MO01]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v187. CiceG , DiBenedettoA , D'IsaS , D'AndreaA , DeGregoriaP , CalabroR . Effect of telmisartan added to angiotensin converting enzyme inhibitors in reducing morbidity and mortality in haemodialysis patients with chronic heart failure [abstract no: P1.19]. Journal of Hypertension ‐ Supplement2006;24(Suppl):S56. [CENTRAL: CN‐00793137] CiceG , DiBenedettoA , D'IsaS , D'AndreaA , MarcelliD , GattiE , et al. Effects of telmisartan added to angiotensin‐converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double‐blind, placebo‐controlled trial. Journal of the American College of Cardiology2010;56(21):1701‐8. [MEDLINE: 21070920] ">Cice 2010</a>) reported that treatment with ARB significantly reduced the risk of cardiovascular death as well as hospitalisation for HF. We searched the OVID database and found three reviews that evaluated the combination of ARB and ACEi versus a single agent (<a href="./references#CD012466-bbs2-0186" title="HeranBS , MusiniVM , BassettK , TaylorRS , WrightJM . Angiotensin receptor blockers for heart failure. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003040.pub2] ">Heran 2012</a>; <a href="./references#CD012466-bbs2-0191" title="KuenzliA , BucherHC , AnandI , ArutiunovG , KumLC , McKelvieR , et al. Meta‐analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS One [Electronic Resource]2010;5(4):e9946. [MEDLINE: 20376345] ">Kuenzli 2010</a>; <a href="./references#CD012466-bbs2-0192" title="LeeVC , RhewDC , DylanM , BadamgaravE , BraunsteinGD , WeingartenSR . Meta‐analysis: angiotensin‐receptor blockers in chronic heart failure and high‐risk acute myocardial infarction.[Erratum appears in: Ann Intern Med. 2005 Mar 1;42(5):391 Note: Dosage error in article text]. Annals of Internal Medicine2004;141(9):693‐704. [MEDLINE: 15520426] ">Lee 2004</a>). While reviews have shown a significant benefit of ARB versus placebo (<a href="./references#CD012466-bbs2-0186" title="HeranBS , MusiniVM , BassettK , TaylorRS , WrightJM . Angiotensin receptor blockers for heart failure. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003040.pub2] ">Heran 2012</a>; <a href="./references#CD012466-bbs2-0192" title="LeeVC , RhewDC , DylanM , BadamgaravE , BraunsteinGD , WeingartenSR . Meta‐analysis: angiotensin‐receptor blockers in chronic heart failure and high‐risk acute myocardial infarction.[Erratum appears in: Ann Intern Med. 2005 Mar 1;42(5):391 Note: Dosage error in article text]. Annals of Internal Medicine2004;141(9):693‐704. [MEDLINE: 15520426] ">Lee 2004</a>) and a similar effect of ARB versus ACE inhibitors (<a href="./references#CD012466-bbs2-0186" title="HeranBS , MusiniVM , BassettK , TaylorRS , WrightJM . Angiotensin receptor blockers for heart failure. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003040.pub2] ">Heran 2012</a>; <a href="./references#CD012466-bbs2-0191" title="KuenzliA , BucherHC , AnandI , ArutiunovG , KumLC , McKelvieR , et al. Meta‐analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS One [Electronic Resource]2010;5(4):e9946. [MEDLINE: 20376345] ">Kuenzli 2010</a>; <a href="./references#CD012466-bbs2-0192" title="LeeVC , RhewDC , DylanM , BadamgaravE , BraunsteinGD , WeingartenSR . Meta‐analysis: angiotensin‐receptor blockers in chronic heart failure and high‐risk acute myocardial infarction.[Erratum appears in: Ann Intern Med. 2005 Mar 1;42(5):391 Note: Dosage error in article text]. Annals of Internal Medicine2004;141(9):693‐704. [MEDLINE: 15520426] ">Lee 2004</a>), we were unable to find any published reviews of studies comparing the effects of ACEi versus placebo. The Cochrane Database of Systematic Reviews reports protocols currently investigating a number of interventions: ACEi or ARB (<a href="http://www.cochrane.org/CD003040/VASC_are-angiotensin-receptor-blockers-arbs-an-effective-treatment-for-heart-failure" target="_blank">http://www.cochrane.org/CD003040/VASC_are‐angiotensin‐receptor‐blockers‐arbs‐an‐effective‐treatment‐for‐heart‐failure</a>) and beta‐blockers (<a href="http://www.cochrane.org/CD012897/VASC_beta-blockers-heart-failure" target="_blank">http://www.cochrane.org/CD012897/VASC_beta‐blockers‐heart‐failure</a>). This research will be important to ensure guidelines are based on high quality systematic reviews of RCTs. </p> <p>Following appropriate ACEi/ARB dose‐adjustment based on eGFR may be important for people with HF and impaired kidney function (<a href="./references#CD012466-bbs2-0183" title="GrandeD , GioiaMI , TerlizzeseP , IacovielloM . Heart failure and kidney disease. Advances in Experimental Medicine and Biology2017;1067:219‐38. [EMBASE: 622227520] ">Grande 2017</a>). This was addressed in only one study (<a href="./references#CD012466-bbs2-0070" title="Pita‐FernandezS , Choucino‐FernandezT , Juega‐PuigJ , Seoane‐PilladoT , Lopez‐CalvinoB , Pertega‐DiazS , et al. A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia. International Journal of Clinical Practice2014;68(10):1231‐8. [MEDLINE: 25040146] ">Pita‐Fernandez 2015</a>), which found that reducing the dose of ACEi by 50% in people with HF and CKD resulted in an improvement in anaemia and kidney function, decreased protein C, and improved survival. Further research into dose‐adjustment for people with CKD may be important for preventing the progression of kidney failure. </p> <p>The effect of beta‐blockers did not significantly reduce the risk of all‐cause or cardiovascular death in a study including people over 70 years of age (<a href="./references#CD012466-bbs2-0085" title="Cohen‐SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872‐80. [MEDLINE: 19648605] FlatherMD , ShibataMC , CoatsAJ , VanVeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomised trial to determine the effect of nebivolol on mortality and hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26(3):215‐25. [MEDLINE: 15642700] ShibataMC , FlatherMD , BöhmM , BorbolaJ , Cohen‐SolalA , DumitrascuD , et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisations in Seniors with Heart Failure (SENIORS): rationale and design. International Journal of Cardiology2002;86(1):77‐85. [MEDLINE: 12243852] vanVeldhuisenDJ , Cohen‐SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta‐blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150‐8. [MEDLINE: 19497441] ">SENIORS 2002</a>), which is consistent with findings from the general population (<a href="./references#CD012466-bbs2-0184" title="GrossmanE , MesserliFH . Why beta‐blockers are not cardioprotective in elderly patients with hypertension. Current Cardiology Reports2002;4(6):468‐73. [MEDLINE: 12379165] ">Grossman 2002</a>). While that study appears to show a trend toward an increased risk of worsening HF with beta‐blockers, the estimate of this effect was imprecise. An observational study reported that beta‐blocker use in patients with HF and CKD was safe and effective in reducing risk of death or hospitalisations (<a href="./references#CD012466-bbs2-0175" title="ChangTI , YangJ , FreemanJV , HlatkyMA , GoAS . Effectiveness of beta‐blockers in heart failure with left ventricular systolic dysfunction and chronic kidney disease. Journal of Cardiac Failure2013;19(3):176‐82. [MEDLINE: 23482078] ">Chang 2013</a>), but RCTs in this population are warranted (<a href="./references#CD012466-bbs2-0180" title="Franco PeláezJA , Cortés GarcíaM , Romero DazaAM , Martín MariscalML , García RoperoÁ , López CastilloM , et al. Relationship between different doses of beta‐blockers and prognosis in elderly patients with reduced ejection fraction. International Journal of Cardiology2016;220:219‐25. [MEDLINE: 27389445] ">Franco Peláez 2016</a>). Insufficient data are available on potential harms, including hypotension and acute kidney injury in people with CKD. </p> <p>Our review reported an uncertain effect of aldosterone antagonists on death (any cause). Other research investigating the use of aldosterone antagonists in people on dialysis (with or without HF) reported a protective effect with respect to all‐cause and cardiovascular death (<a href="./references#CD012466-bbs2-0200" title="QuachK , LvtvynL , BaigentC , BuetiJ , GargAX , HawleyC , et al. The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta‐analysis. American Journal of Kidney Diseases2016;68(4):591‐8. [MEDLINE: 27265777] ">Quach 2016</a>). However, hyperkalaemia may be a concern in this patient population. The authors of the same review were unable to provide any recommendations due to insufficient sample size and the quality of the study. Due to the potential risk of hyperkalaemia in CKD patients who also have HF (as we found pooling the results of three studies), further work investigating the safety and efficacy of aldosterone antagonists, and other agents that block the renin‐angiotensin system, is warranted. </p> <p>Our review found a significant protective effect of aliskiren on reducing the risk of worsening HF in one study (<a href="./references#CD012466-bbs2-0009" title="SchrotenNF , DammanK , HemmelderMH , VoorsAA , NavisG , GaillardCA , et al. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). American Heart Journal2015;169(5):693‐701. [MEDLINE: 25965717] ">ARIANA‐CHF‐RD 2016</a>). However, while not significant, a trend suggesting a potential harmful effect on kidney function with administration of aliskiren was reported in two studies (<a href="./references#CD012466-bbs2-0006" title="JacksonCE , MacDonaldMR , PetrieMC , SolomonSD , PittB , LatiniR , et al. Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure2011;13(7):746‐54. [MEDLINE: 21459891] MaggioniAP , McMurrayJJ , LatiniR , SolomonSD , SmithBA , BushC , et al. Safety and tolerability profile of aliskiren added to optimized therapy in patients with heart failure and renal impairment [abstract no: SA‐PO2247]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):616A. [CENTRAL: CN‐00776176] McMurrayJJ , PittB , LatiniR , MaggioniAP , SolomonSD , KeefeDL , et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure2008;1(1):17‐24. [MEDLINE: 19808266] ">ALOFT 2008</a>; <a href="./references#CD012466-bbs2-0009" title="SchrotenNF , DammanK , HemmelderMH , VoorsAA , NavisG , GaillardCA , et al. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). American Heart Journal2015;169(5):693‐701. [MEDLINE: 25965717] ">ARIANA‐CHF‐RD 2016</a>). Other research has suggested that aliskiren is safe for use in people with CKD due to its anti‐proteinuric effect (<a href="./references#CD012466-bbs2-0198" title="PerssonF , RossingP , ParvingHH . Direct renin inhibition in chronic kidney disease. British Journal of Clinical Pharmacology2013;76(4):580‐6. [MEDLINE: 23278708] ">Persson 2013</a>). However, much of the research done pertains to the treatment of hypertension and findings may not necessarily apply to HF populations. Furthermore, risks of hyperkalaemia with this intervention could be of concern for patients with CKD (<a href="./references#CD012466-bbs2-0196" title="MorishitaY , KusanoE . Direct renin inhibitor: aliskiren in chronic kidney disease. Nephrourology Monthly2013;5(1):668‐72. [MEDLINE: 23577328] ">Morishita 2013</a>). </p> <p>There are a number of additional therapies for the treatment of HF (<a href="./references#CD012466-bbs2-0194" title="LotherA , HeinL . Pharmacology of heart failure: From basic science to novel therapies. Pharmacology &amp; Therapeutics2016;166:136‐49. [MEDLINE: 27456554] ">Lother 2016</a>). Our review identified studies investigating anti‐arrhythmics (dofetilide), digoxin, phosphodiesterase inhibitors (milrinone), sinus node inhibitors (ivabradine), and vasopressin receptor antagonists (tolvaptan). Evidence on the safety and efficacy of these interventions in people with CKD is limited and further research is needed before any conclusions may be drawn about their use in this patient population. As the co‐occurrence of HF and CKD appears to be increasing (<a href="./references#CD012466-bbs2-0177" title="ConradN , JudgeA , TranJ , MohseniH , HedgecottD , CrespilloAP , et al. Temporal trends and patterns in heart failure incidence: a population‐based study of 4 million individuals. Lancet2018;391(10120):572‐80. [MEDLINE: 29174292] ">Conrad 2018</a>), a better understanding of how to manage this patient population, particularly with a focus on the potential harms of conventional therapies, is important. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012466-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012466-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012466-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012466-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ACUTE: Diuretic bolus versus continuous infusion, Outcome 1 Cardiovascular death." data-id="CD012466-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 ACUTE: Diuretic bolus versus continuous infusion, Outcome 1 Cardiovascular death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ACUTE: Diuretic bolus versus continuous infusion, Outcome 2 Hospitalisation for heart failure." data-id="CD012466-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 ACUTE: Diuretic bolus versus continuous infusion, Outcome 2 Hospitalisation for heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 1 Death (any cause)." data-id="CD012466-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 1 Death (any cause).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 2 Cardiovascular death." data-id="CD012466-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 2 Cardiovascular death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 3 Worsening heart failure." data-id="CD012466-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 3 Worsening heart failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 4 Worsening kidney function." data-id="CD012466-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 4 Worsening kidney function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 5 Hyperkalaemia." data-id="CD012466-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 5 Hyperkalaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 6 Hypotension." data-id="CD012466-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 ACUTE: Serelaxin versus placebo, Outcome 6 Hypotension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ACUTE: Adenosine A1‐receptor antagonist versus placebo, Outcome 1 Death (any cause)." data-id="CD012466-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 ACUTE: Adenosine A1‐receptor antagonist versus placebo, Outcome 1 Death (any cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ACUTE: Adenosine A1‐receptor antagonist versus placebo, Outcome 2 Hospitalisation (any cause)." data-id="CD012466-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 ACUTE: Adenosine A1‐receptor antagonist versus placebo, Outcome 2 Hospitalisation (any cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ACUTE: Adenosine A1‐receptor antagonist versus placebo, Outcome 3 Worsening heart failure." data-id="CD012466-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 ACUTE: Adenosine A1‐receptor antagonist versus placebo, Outcome 3 Worsening heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ACUTE: Adenosine A1‐receptor antagonist versus placebo, Outcome 4 Worsening kidney function." data-id="CD012466-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 ACUTE: Adenosine A1‐receptor antagonist versus placebo, Outcome 4 Worsening kidney function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 ACUTE: Dopamine versus placebo, Outcome 1 Death (any cause)." data-id="CD012466-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 ACUTE: Dopamine versus placebo, Outcome 1 Death (any cause).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 ACUTE: Dopamine versus placebo, Outcome 2 Worsening heart failure." data-id="CD012466-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 ACUTE: Dopamine versus placebo, Outcome 2 Worsening heart failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 ACUTE: Dopamine versus placebo, Outcome 3 Hypotension." data-id="CD012466-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 ACUTE: Dopamine versus placebo, Outcome 3 Hypotension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 ACUTE: Nesiritide versus placebo, Outcome 1 Death (any cause)." data-id="CD012466-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 ACUTE: Nesiritide versus placebo, Outcome 1 Death (any cause).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 ACUTE: Nesiritide versus placebo, Outcome 2 Worsening heart failure." data-id="CD012466-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 ACUTE: Nesiritide versus placebo, Outcome 2 Worsening heart failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 ACUTE: Nesiritide versus placebo, Outcome 3 Hypotension." data-id="CD012466-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 ACUTE: Nesiritide versus placebo, Outcome 3 Hypotension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CHRONIC: ACEi OR ARB versus placebo, Outcome 1 Death (any cause)." data-id="CD012466-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 CHRONIC: ACEi OR ARB versus placebo, Outcome 1 Death (any cause).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CHRONIC: ACEi OR ARB versus placebo, Outcome 2 Cardiovascular death." data-id="CD012466-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 CHRONIC: ACEi OR ARB versus placebo, Outcome 2 Cardiovascular death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CHRONIC: ACEi OR ARB versus placebo, Outcome 3 Hospitalisation for heart failure." data-id="CD012466-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 CHRONIC: ACEi OR ARB versus placebo, Outcome 3 Hospitalisation for heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CHRONIC: ACEi OR ARB versus placebo, Outcome 4 Hypotension." data-id="CD012466-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 CHRONIC: ACEi OR ARB versus placebo, Outcome 4 Hypotension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 CHRONIC: 50% ARB dose reduction versus full dose, Outcome 1 Death (any cause)." data-id="CD012466-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 CHRONIC: 50% ARB dose reduction versus full dose, Outcome 1 Death (any cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 1 Death (any cause)." data-id="CD012466-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 1 Death (any cause).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 2 Cardiovascular death." data-id="CD012466-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 2 Cardiovascular death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 3 Hospitalisation (any cause)." data-id="CD012466-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 3 Hospitalisation (any cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 4 Hospitalisation for heart failure." data-id="CD012466-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 4 Hospitalisation for heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 5 Worsening heart failure." data-id="CD012466-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 5 Worsening heart failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 6 Worsening kidney function." data-id="CD012466-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 6 Worsening kidney function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 7 Hypotension." data-id="CD012466-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 CHRONIC: Beta‐blockers versus placebo, Outcome 7 Hypotension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 CHRONIC: Aldosterone antagonists versus placebo, Outcome 1 Death (any cause)." data-id="CD012466-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 CHRONIC: Aldosterone antagonists versus placebo, Outcome 1 Death (any cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 CHRONIC: Aldosterone antagonists versus placebo, Outcome 2 Hyperkalaemia." data-id="CD012466-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 CHRONIC: Aldosterone antagonists versus placebo, Outcome 2 Hyperkalaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 CHRONIC: Anti‐arrhythmics versus placebo, Outcome 1 Death (any cause)." data-id="CD012466-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 CHRONIC: Anti‐arrhythmics versus placebo, Outcome 1 Death (any cause).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 CHRONIC: Nesiritide versus placebo, Outcome 1 Death (any cause)." data-id="CD012466-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 CHRONIC: Nesiritide versus placebo, Outcome 1 Death (any cause).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 CHRONIC: Nesiritide versus placebo, Outcome 2 Cardiovascular death." data-id="CD012466-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 CHRONIC: Nesiritide versus placebo, Outcome 2 Cardiovascular death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 CHRONIC: Nesiritide versus placebo, Outcome 3 Hypotension." data-id="CD012466-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 CHRONIC: Nesiritide versus placebo, Outcome 3 Hypotension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 CHRONIC: Nesiritide versus placebo, Outcome 4 Quality of Life." data-id="CD012466-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 CHRONIC: Nesiritide versus placebo, Outcome 4 Quality of Life.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 CHRONIC: Phosphodiesterase inhibitors versus placebo, Outcome 1 Death (any cause)." data-id="CD012466-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 CHRONIC: Phosphodiesterase inhibitors versus placebo, Outcome 1 Death (any cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 CHRONIC: Renin inhibitors versus placebo, Outcome 1 Worsening heart failure." data-id="CD012466-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 CHRONIC: Renin inhibitors versus placebo, Outcome 1 Worsening heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 CHRONIC: Renin inhibitors versus placebo, Outcome 2 Worsening kidney function." data-id="CD012466-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 CHRONIC: Renin inhibitors versus placebo, Outcome 2 Worsening kidney function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 CHRONIC: Renin inhibitors versus placebo, Outcome 3 Hyperkalaemia." data-id="CD012466-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 CHRONIC: Renin inhibitors versus placebo, Outcome 3 Hyperkalaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 CHRONIC: Renin inhibitors versus placebo, Outcome 4 Hypotension." data-id="CD012466-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 CHRONIC: Renin inhibitors versus placebo, Outcome 4 Hypotension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 CHRONIC: Sinus node inhibitors versus placebo, Outcome 1 Cardiovascular death." data-id="CD012466-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 CHRONIC: Sinus node inhibitors versus placebo, Outcome 1 Cardiovascular death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 CHRONIC: Sinus node inhibitors versus placebo, Outcome 2 Hospitalisation for heart failure." data-id="CD012466-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 CHRONIC: Sinus node inhibitors versus placebo, Outcome 2 Hospitalisation for heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 CHRONIC: Sinus node inhibitors versus placebo, Outcome 3 Worsening kidney function." data-id="CD012466-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 CHRONIC: Sinus node inhibitors versus placebo, Outcome 3 Worsening kidney function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-014-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-014-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 CHRONIC: Sinus node inhibitors versus placebo, Outcome 4 Hyperkalaemia." data-id="CD012466-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-014-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14 CHRONIC: Sinus node inhibitors versus placebo, Outcome 4 Hyperkalaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-014-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 CHRONIC: Vasopressin receptor antagonists versus placebo, Outcome 1 Death (any cause)." data-id="CD012466-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 CHRONIC: Vasopressin receptor antagonists versus placebo, Outcome 1 Death (any cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 CHRONIC: Vasopressin receptor antagonists versus placebo, Outcome 2 Hospitalisation for heart failure." data-id="CD012466-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 CHRONIC: Vasopressin receptor antagonists versus placebo, Outcome 2 Hospitalisation for heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012466-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/urn:x-wiley:14651858:media:CD012466:CD012466-CMP-015-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_t/tCD012466-CMP-015-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 CHRONIC: Vasopressin receptor antagonists versus placebo, Outcome 3 Worsening kidney function." data-id="CD012466-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-015-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15 CHRONIC: Vasopressin receptor antagonists versus placebo, Outcome 3 Worsening kidney function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/media/CDSR/CD012466/image_n/nCD012466-CMP-015-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012466-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ACUTE: Serelaxin versus placebo in patients with heart failure and chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ACUTE: Serelaxin versus placebo in patients with heart failure and chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> heart failure with chronic kidney disease </p> <p><b>Settings:</b> acute, inpatient </p> <p><b>Intervention:</b> serelaxin </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Serelaxin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death (any cause)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> <p>(14 to 43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> </p> <p>(0.34 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1395 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>97 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> </p> <p>(20 to 105)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b> (0.21 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1395 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation (any cause)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heart failure hospitalisation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening heart failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>162 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>115 per 1000</b> </p> <p>(87 to 149)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.71</b> (0.54 to 0.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1395 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening kidney function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>86 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>74 per 1000</b> </p> <p>(32 to 170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.86</b> (0.37 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1395 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> <p>(39 to 94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> (0.81 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1395 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hyperkalaemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>48 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>52 per 1000</p> <p>(15 to 187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.08 (0.30 to 3.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Important study limitations due to risks of bias </p> <p><sup>2</sup> The confidence intervals include potential for important benefits and harms </p> <p><sup>3</sup> Important and unexplained heterogeneity present (or insufficient data observations to evaluate) </p> <p><sup>4</sup> Insufficient data observations to evaluate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ACUTE: Serelaxin versus placebo in patients with heart failure and chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012466-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CHRONIC: ACEi or ARB versus placebo in patients with heart failure and chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CHRONIC: ACEi or ARB versus placebo in patients with heart failure and chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> heart failure with chronic kidney disease </p> <p><b>Settings:</b> chronic, outpatient </p> <p><b>Intervention:</b> ACEi or ARB </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ACEi or ARB</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death (any cause)</b> </p> <p>(follow‐up 2 to 3.5 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>320 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b><br/> (224 to 326) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> (0.70 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5003 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> <p>(follow‐up 3 to 4 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>411 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b><br/> (263 to 415) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.81</b> (0.64 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1368 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation (any cause)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heart failure hospitalisation</b> </p> <p>(follow‐up 2 to 3.5 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>546 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>491 per 1000</b><br/> (235 to 1037) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> (0.43 to 1.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1368 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2</sup> </b><sup>,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Worsening heart failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Worsening kidney function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension (ARB; withdrawn from study)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> </p> <p>(47 to 254</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.60</b> (1.12 to 6.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>332 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hyperkalaemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The <b>assumed risk</b> (e.g. the median control group risk across studies) was calculated by dividing the number of participants in the control group that experienced an event by the total number of participants in the control group. The <b>corresponding risk</b> was calculated by multiplying the assumed risk with the <b>relative effect</b> from the meta‐analysis. The 95% CI for the corresponding risk was calculated by multiplying the assumed risk with the lower and upper CI of the risk ratio estimate from the meta‐analysis. </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>ACEi</b> : angiotensin‐converting enzyme inhibitor; <b>ARB</b>: angiotensin receptor blocker </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Important study limitations due to risks of bias </p> <p><sup>2</sup> The confidence intervals include potential for important benefits and harms </p> <p><sup>3</sup> Important and unexplained heterogeneity present (or insufficient data observations to evaluate) </p> <p><sup>4</sup> Insufficient data observations to evaluate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CHRONIC: ACEi or ARB versus placebo in patients with heart failure and chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012466-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CHRONIC: Beta‐blockers versus placebo in patients with heart failure and chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CHRONIC: Beta‐blockers versus placebo in patients with heart failure and chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> heart failure with chronic kidney disease </p> <p><b>Settings:</b> chronic, outpatient </p> <p><b>Intervention:</b> beta‐blockers </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Beta‐blockers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death (any cause)</b> </p> <p>(follow‐up 1 to 2.5 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>215 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b><br/> (129to 170) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b> </p> <p>(0.60 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3136 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>moderate</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> <p>(follow‐up 1 to 2.5 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><br/> (43 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b> (0.35 to 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2287 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation (any cause)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>432 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>324 per 1000</b><br/> (225 to 467) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.75</b> (0.52 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1583 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heart failure hospitalisation</b> </p> <p>(follow‐up 1 to 2.5 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>318 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>213 per 1000</b><br/> (137 to 334) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.67</b> (0.43 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2287 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening heart failure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> </p> <p>(0.58 to 3.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>704 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening kidney function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>no events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>no events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>704 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>no events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2/356**</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.11</b> </p> <p>(0.25 to 106.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>704 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hyperkalaemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The <b>assumed risk</b> (e.g. the median control group risk across studies) was calculated by dividing the number of participants in the control group that experienced an event by the total number of participants in the control group. The <b>corresponding risk</b> was calculated by multiplying the assumed risk with the <b>relative effect</b> from the meta‐analysis. The 95% CI for the corresponding risk was calculated by multiplying the assumed risk with the lower and upper CI of the risk ratio estimate from the meta‐analysis. </p> <p>** Event rate derived from the raw data. A 'per thousand' rate is non‐informative in view of the scarcity of evidence and zero events in the control group </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Important study limitations due to risks of bias </p> <p><sup>2</sup> The confidence intervals include potential for important benefits and harms </p> <p><sup>3</sup> Important and unexplained heterogeneity present (or insufficient data observations to evaluate) </p> <p><sup>4</sup> Insufficient data observations to evaluate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CHRONIC: Beta‐blockers versus placebo in patients with heart failure and chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012466-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">CHRONIC: Aldosterone antagonists versus placebo in patients with heart failure and chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CHRONIC: Aldosterone antagonists versus placebo in patients with heart failure and chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> heart failure with chronic kidney disease </p> <p><b>Settings:</b> chronic, outpatient </p> <p><b>Intervention:</b> aldosterone antagonists </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐aldosterone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death (any cause)</b> </p> <p>(follow‐up 6 to 21 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b><br/> (17 to 1,938) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.61</b> (0.06 to 6.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular death</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation (any cause)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heart failure hospitalisation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening heart failure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Worsening kidney function</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypotension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hyperkalaemia</b> </p> <p>follow‐up 6‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>243 per 1000</b><br/> (170 to 350) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.91</b> (2.03 to 4.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>826 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The <b>assumed risk</b> (e.g. the median control group risk across studies) was calculated by dividing the number of participants in the control group that experienced an event by the total number of participants in the control group. The <b>corresponding risk</b> was calculated by multiplying the assumed risk with the <b>relative effect</b> from the meta‐analysis. The 95% CI for the corresponding risk was calculated by multiplying the assumed risk with the lower and upper CI of the risk ratio estimate from the meta‐analysis. </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Important study limitations due to risks of bias </p> <p><sup>2</sup> The confidence intervals include potential for important benefits and harms </p> <p><sup>3</sup> Important and unexplained heterogeneity present (or insufficient data observations to evaluate) </p> <p><sup>4</sup> Insufficient data observations to evaluate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">CHRONIC: Aldosterone antagonists versus placebo in patients with heart failure and chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012466-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional Summary of Findings</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. participants (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Acute heart failure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Adenosine A1‐receptor antagonist versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.71 (0.39 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2078 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>2,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.85 (0.43 to 1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.93 (0.70 to 1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2033 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.89 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2033 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,3,4</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Diuretic bolus versus continuous infusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.56 (0.15 to 2.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.83 (0.33 to 2.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Dopamine versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.89 (0.41 to 1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>241 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.15 (0.77 to 5.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>241 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.09 (0.01 to 0.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Nesiritide versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (0.28 to 1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.83 (0.26 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.80 (0.94 to 3.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>232 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Chronic heart failure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Anti‐arrhythmics versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.95 (0.83 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>755 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Nesiritide versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.98 (0.64 to 1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>911 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.88 (0.56 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>911 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.80 (1.38 to 2.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>911 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of Life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 1.20 (‐1.85 to 4.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>911 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Phosphodiesterase inhibitors versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.26 (0.98 to 1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>539 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Renin inhibitors versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.26 (0.08 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.52 (0.22 to 10.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.86 (0.49 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.44 (0.62 to 3.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Sinus node inhibitors versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.96 (0.48 to 1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1576 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.83 (0.48 to 1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1576 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.95 (0.71 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1576 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.53 (0.28 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1576 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Vasopressin receptor antagonists versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.26 (0.55 to 2.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1840 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular death</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.82 (0.37 to 1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening kidney function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.87 (0.56 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>217 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>MD:</b> Mean difference </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup> Important study limitations due to risks of bias </p> <p><sup>2</sup> The confidence intervals include potential for important benefits and harms </p> <p><sup>3</sup> Important and unexplained heterogeneity present (or insufficient data observations to evaluate) </p> <p><sup>4</sup> Insufficient data observations to evaluate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional Summary of Findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/full#CD012466-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ACUTE: Diuretic bolus versus continuous infusion</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospitalisation for heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ACUTE: Diuretic bolus versus continuous infusion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ACUTE: Serelaxin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.34, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.21, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Worsening heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.54, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Worsening kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.37, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.81, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ACUTE: Serelaxin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ACUTE: Adenosine A1‐receptor antagonist versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.39, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospitalisation (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Worsening heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Worsening kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ACUTE: Adenosine A1‐receptor antagonist versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">ACUTE: Dopamine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Worsening heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">ACUTE: Dopamine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">ACUTE: Nesiritide versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Worsening heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">ACUTE: Nesiritide versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">CHRONIC: ACEi OR ARB versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ACEi versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 ARB versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.52, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.64, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ACEi versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.75, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 ARB versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.52, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hospitalisation for heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.43, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ACEi versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.18, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ARB versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 ARB versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">CHRONIC: ACEi OR ARB versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">CHRONIC: 50% ARB dose reduction versus full dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">CHRONIC: 50% ARB dose reduction versus full dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">CHRONIC: Beta‐blockers versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.60, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.35, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hospitalisation (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.52, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hospitalisation for heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.43, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Worsening heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Worsening kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">CHRONIC: Beta‐blockers versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">CHRONIC: Aldosterone antagonists versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.06, 6.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [2.03, 4.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">CHRONIC: Aldosterone antagonists versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">CHRONIC: Anti‐arrhythmics versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">CHRONIC: Anti‐arrhythmics versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">CHRONIC: Nesiritide versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of Life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">CHRONIC: Nesiritide versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">CHRONIC: Phosphodiesterase inhibitors versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">CHRONIC: Phosphodiesterase inhibitors versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">CHRONIC: Renin inhibitors versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Worsening heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Worsening kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.22, 10.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.49, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.62, 3.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">CHRONIC: Renin inhibitors versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">CHRONIC: Sinus node inhibitors versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospitalisation for heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Worsening kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">CHRONIC: Sinus node inhibitors versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012466-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">CHRONIC: Vasopressin receptor antagonists versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.55, 2.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospitalisation for heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Worsening kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">CHRONIC: Vasopressin receptor antagonists versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012466.pub2/references#CD012466-tbl-0020">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012466.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012466-note-0018">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012466-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012466-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012466-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD012466-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012466-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012466-note-0010">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012466-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012466-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012466-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012466-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012466\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012466\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012466\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012466\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012466\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012466.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012466.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012466.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012466.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012466.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729171063"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012466.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729171066"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012466.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed653bd17f55b',t:'MTc0MDcyOTE3MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 